"Entry ID","Ligand","PDB ID","Structure Title","EC Number","Ligand Name",
"1ETS","MID","1ETS","REFINED 2.3 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF BOVINE THROMBIN COMPLEXES FORMED WITH THE BENZAMIDINE AND ARGININE-BASED THROMBIN INHIBITORS NAPAP, 4-TAPAP AND MQPA: A STARTING POINT FOR IMPROVING ANTITHROMBOTICS","3.4.21.5","1-[N-(naphthalen-2-ylsulfonyl)glycyl-4-carbamimidoyl-D-phenylalanyl]piperidine",
,"MID",,,"3.4.21.5",,
,"MID",,,,,
,"MID",,,,,
,"MID",,,,,
,"MID",,,,,
,"MID",,,,,
,"MID",,,,,
,"MID",,,,,
,"MID",,,,,
"1ETR",,"1ETR","REFINED 2.3 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF BOVINE THROMBIN COMPLEXES FORMED WITH THE BENZAMIDINE AND ARGININE-BASED THROMBIN INHIBITORS NAPAP, 4-TAPAP AND MQPA: A STARTING POINT FOR IMPROVING ANTITHROMBOTICS","3.4.21.5","amino{[(4S)-5-[(2R,4R)-2-carboxy-4-methylpiperidin-1-yl]-4-({[(3R)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonyl}amino)-5-oxopentyl]amino}methaniminium",
,,,,"3.4.21.5",,
"1TBR",,"1TBR","CRYSTAL STRUCTURE OF INSECT DERIVED DOUBLE DOMAIN KAZAL INHIBITOR RHODNIIN IN COMPLEX WITH THROMBIN","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1TBQ",,"1TBQ","CRYSTAL STRUCTURE OF INSECT DERIVED DOUBLE DOMAIN KAZAL INHIBITOR RHODNIIN IN COMPLEX WITH THROMBIN","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"148D",,"148D","THREE-DIMENSIONAL SOLUTION STRUCTURE OF THE THROMBIN BINDING DNA APTAMER D(GGTTGGTGTGGTTGG)",
"1QDI",,"1QDI","THE NMR STUDY OF DNA QUADRUPLEX STRUCTURE, (12MER) DNA",
"1QDF",,"1QDF","THE NMR STUDY OF DNA QUADRUPLEX STRUCTURE, APTAMER (15MER) DNA",
"1UCY",,"1UCY","THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A ALPHA (RESIDUES 7-19). THREE COMPLEXES, ONE WITH EPSILON-THROMBIN AND TWO WITH ALPHA-THROMBIN","3.4.21.5",
,,,,"3.4.21.5",
,,,,"3.4.21.5",
,,,,,
,,,,"3.4.21.5",
"1RDE",,"1RDE","NMR structure of the thrombin-binding DNA aptamer stabilized by Sr2+",
"3PMB",,"3PMB","2.9 Angstrom crystal structure of bovine thrombin in tetragonal spacegroup","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5",,
"1VIT",,"1VIT","THROMBIN:HIRUDIN 51-65 COMPLEX","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5",,
,,,,,,
,,,,"3.4.21.5",,
,,,,"3.4.21.5",,
"1AVG",,"1AVG","THROMBIN INHIBITOR FROM TRIATOMA PALLIDIPENNIS","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1MKX",,"1MKX","THE CO-CRYSTAL STRUCTURE OF UNLIGANDED BOVINE ALPHA-THROMBIN AND PRETHROMBIN-2: MOVEMENT OF THE YPPW SEGMENT AND ACTIVE SITE RESIDUES UPON LIGAND BINDING","3.4.21.5",
,,,,"3.4.21.5",
,,,,"3.4.21.5",
"1MKW",,"1MKW","THE CO-CRYSTAL STRUCTURE OF UNLIGANDED BOVINE ALPHA-THROMBIN AND PRETHROMBIN-2: MOVEMENT OF THE YPPW SEGMENT AND ACTIVE SITE RESIDUES UPON LIGAND BINDING","3.4.21.5",
,,,,"3.4.21.5",
,,,,"3.4.21.5",
"1NRS",,"1NRS","CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
,,,,,
"1ID5",,"1ID5","CRYSTAL STRUCTURE OF BOVINE THROMBIN COMPLEX WITH PROTEASE INHIBITOR ECOTIN","3.4.21.5","CALCIUM ION",
,,,,"3.4.21.5","2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL",
,,,,,,
"1TOC",,"1TOC","STRUCTURE OF SERINE PROTEINASE","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1EGT",,"1EGT","THROMBIN-BOUND STRUCTURE OF AN EGF SUBDOMAIN FROM HUMAN THROMBOMODULIN DETERMINED BY TRANSFERRED NUCLEAR OVERHAUSER EFFECTS",
"1HRT",,"1HRT","THE STRUCTURE OF A COMPLEX OF BOVINE ALPHA-THROMBIN AND RECOMBINANT HIRUDIN AT 2.8 ANGSTROMS RESOLUTION","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"3PMA","SCR","3PMA","2.2 Angstrom crystal structure of the complex between Bovine Thrombin and Sucrose Octasulfate","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","CITRIC ACID",
"2HNT",,"2HNT","CRYSTALLOGRAPHIC STRUCTURE OF HUMAN GAMMA-THROMBIN","3.4.21.5",
,,,,"3.4.21.5",
,,,,"3.4.21.5",
,,,,"3.4.21.5",
"1QDK",,"1QDK","THE NMR STUDY OF DNA QUADRUPLEX STRUCTURE, (12MER) DNA",,"MANGANESE (II) ION",
"1QDH",,"1QDH","THE NMR STUDY OF DNA QUADRUPLEX STRUCTURE, APTAMER (15MER) DNA",,"MANGANESE (II) ION",
"1BBR",,"1BBR","THE STRUCTURE OF RESIDUES 7-16 OF THE A ALPHA CHAIN OF HUMAN FIBRINOGEN BOUND TO BOVINE THROMBIN AT 2.3 ANGSTROMS RESOLUTION","3.4.21.5",
,,,,"3.4.21.5",
,,,,"3.4.21.5",
,,,,,
,,,,"3.4.21.5",
"1PPB",,"1PPB","THE REFINED 1.9 ANGSTROMS CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN: INTERACTION WITH D-PHE-PRO-ARG CHLOROMETHYLKETONE AND SIGNIFICANCE OF THE TYR-PRO-PRO-TRP INSERTION SEGMENT","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5",,
"1YCP",,"1YCP","THE CRYSTAL STRUCTURE OF FIBRINOGEN-AA PEPTIDE 1-23 (F8Y) BOUND TO BOVINE THROMBIN EXPLAINS WHY THE MUTATION OF PHE-8 TO TYROSINE STRONGLY INHIBITS NORMAL CLEAVAGE AT ARGININE-16","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
,,,,"3.4.21.5",
,,,,"3.4.21.5",
"1UVU","DCH","1UVU","BOVINE THROMBIN--BM12.1700 COMPLEX","3.4.21.5","3-(7-DIAMINOMETHYL-NAPHTHALEN-2-YL)-PROPIONIC ACID ETHYL ESTER",
,,,,"3.4.21.5",,
"1UVT","I48","1UVT","BOVINE THROMBIN--BM14.1248 COMPLEX","3.4.21.5","N-{3-METHYL-5-[2-(PYRIDIN-4-YLAMINO)-ETHOXY]-PHENYL}-BENZENESULFONAMIDE",
,"I48",,,"3.4.21.5",,
"1PPC","MID","1PPC","GEOMETRY OF BINDING OF THE BENZAMIDINE-AND ARGININE-BASED INHIBITORS N-ALPHA-(2-NAPHTHYL-SULPHONYL-GLYCYL)-DL-P-AMIDINOPHENYLALANYL-PIPERIDINE (NAPAP) AND (2R,4R)-4-METHYL-1-[N-ALPHA-(3-METHYL-1,2,3,4-TETRAHYDRO-8-QUINOLINESULPHONYL)-L-ARGINYL]-2-PIPERIDINE CARBOXYLIC ACID (MQPA) TO HUMAN ALPHA-THROMBIN: X-RAY CRYSTALLOGRAPHIC DETERMINATION OF THE NAPAP-TRYPSIN COMPLEX AND MODELING OF NAPAP-THROMBIN AND MQPA-THROMBIN","3.4.21.4","1-[N-(naphthalen-2-ylsulfonyl)glycyl-4-carbamimidoyl-D-phenylalanyl]piperidine",
,"MID",,,,"CALCIUM ION",
,"MID",,,,,
"2PUX",,"2PUX","Crystal structure of murine thrombin in complex with the extracellular fragment of murine PAR3","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5",,
,,,,,,
"2PV9",,"2PV9","Crystal structure of murine thrombin in complex with the extracellular fragment of murine PAR4","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5",,
,,,,,,
"1BTH",,"1BTH","STRUCTURE OF THROMBIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"2A1D",,"2A1D","Staphylocoagulase bound to bovine thrombin","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
"1NRR",,"1NRR","Crystallographic structures of Thrombin complexed with Thrombin receptor peptides: Existence of expected and novel binding modes","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5",,
,,,,,,
"1NRP",,"1NRP","CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1NRO",,"1NRO","CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1NRN",,"1NRN","CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1VR1",,"1VR1","Specifity for Plasminogen Activator Inhibitor-1","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1HXF",,"1HXF","HUMAN THROMBIN COMPLEX WITH HIRUDIN VARIANT","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1DWC","MIT","1DWC","CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS","3.4.21.5","amino{[(4S)-5-[(2R,4R)-2-carboxy-4-methylpiperidin-1-yl]-4-({[(3R)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonyl}amino)-5-oxopentyl]amino}methaniminium",
,,,,"3.4.21.5",,
,,,,,,
"1DWB",,"1DWB","CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS","3.4.21.5","BENZAMIDINE",
,,,,"3.4.21.5",,
,,,,,,
"1DWE",,"1DWE","Crystallographic analysis at 3.0-Angstroms resolution of the binding to human thrombin of four active site-directed inhibitors","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5",,
,,,,,,
"1DWD","MID","1DWD","CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS","3.4.21.5","1-[N-(naphthalen-2-ylsulfonyl)glycyl-4-carbamimidoyl-D-phenylalanyl]piperidine",
,"MID",,,"3.4.21.5",,
,"MID",,,,,
,"MID",,,,,
,"MID",,,,,
,"MID",,,,,
,"MID",,,,,
,"MID",,,,,
,"MID",,,,,
,"MID",,,,,
"1NRQ",,"1NRQ","CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1PPH","0ZG","1PPH","GEOMETRY OF BINDING OF THE NALPHA-TOSYLATED PIPERIDIDES OF M-AMIDINO-, P-AMIDINO-AND P-GUANIDINO PHENYLALANINE TO THROMBIN AND TRYPSIN: X-RAY CRYSTAL STRUCTURES OF THEIR TRYPSIN COMPLEXES AND MODELING OF THEIR THROMBIN COMPLEXES","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"3-[(2S)-2-{[(4-methylphenyl)sulfonyl]amino}-3-oxo-3-piperidin-1-ylpropyl]benzenecarboximidamide",
"1NY2",,"1NY2","Human alpha thrombin inhibited by RPPGF and hirugen","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
,,,,,
"2IDN",,"2IDN","NMR structure of a new modified Thrombin Binding Aptamer containing a 5'-5' inversion of polarity site",
"1DX5",,"1DX5","Crystal structure of the thrombin-thrombomodulin complex","3.4.21.5","FORMIC ACID",
,,,,,"CALCIUM ION",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"L-alpha-glutamyl-N-{(1S)-4-{[amino(iminio)methyl]amino}-1-[(1S)-2-chloro-1-hydroxyethyl]butyl}glycinamide",
"1E0F",,"1E0F","Crystal structure of the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"2HGT",,"2HGT","STRUCTURE OF THE HIRUGEN AND HIRULOG 1 COMPLEXES OF ALPHA-THROMBIN","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
,,,,,
"1DE7",,"1DE7","INTERACTION OF FACTOR XIII ACTIVATION PEPTIDE WITH ALPHA-THROMBIN: CRYSTAL STRUCTURE OF THE ENZYME-SUBSTRATE COMPLEX","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5",,
,,,,,,
"1DIT",,"1DIT","COMPLEX OF A DIVALENT INHIBITOR WITH THROMBIN","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1ABI",,"1ABI","STRUCTURE OF THE HIRULOG 3-THROMBIN COMPLEX AND NATURE OF THE S' SUBSITES OF SUBSTRATES AND INHIBITORS","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1ABJ",,"1ABJ","STRUCTURE OF THE HIRULOG 3-THROMBIN COMPLEX AND NATURE OF THE S' SUBSITES OF SUBSTRATES AND INHIBITORS","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5",,
"1HAI",,"1HAI","THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
"1HAH",,"1HAH","THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5",,
,,,,,,
"1HLT",,"1HLT","THE STRUCTURE OF A NONADECAPEPTIDE OF THE FIFTH EGF DOMAIN OF THROMBOMODULIN COMPLEXED WITH THROMBIN","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5",,
,,,,,,
"3HK6",,"3HK6","Crystal structure of murine thrombin mutant W215A/E217A (two molecules in the asymmetric unit)","3.4.21.5",
,,,,"3.4.21.5",
"3PO1","MKY","3PO1","Thrombin in complex with Benzothiazole Guanidine","3.4.21.5","ethyl [(2Z)-2-(carbamimidoylimino)-6-hydroxy-1,3-benzothiazol-3(2H)-yl]acetate",
,"MKY",,,"3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","ACETATE ION",
,,,,,,
"3B23",,"3B23","Crystal structure of thrombin-variegin complex: Insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1HXE",,"1HXE","SERINE PROTEASE","3.4.21.5","RUBIDIUM ION",
,,,,"3.4.21.5",,
,,,,,,
"1A3B",,"1A3B","COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG1","3.4.21.5","TRI166 (BIFUNCTIONAL BORONATE INHIBITOR)",
,,,,"3.4.21.5",,
,,,,,,
"1A3E",,"1A3E","COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG2","3.4.21.5","BOROLOG2",
,,,,"3.4.21.5",,
,,,,,,
"1AWH","GR3","1AWH","NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT","3.4.21.5","3-ACETOXY-17-(1-FORMYL-5-METHYL-3-OXO-HEX-4-ENYL)-16-HYDROXY-4,10,13,14-TETRAMETHYL-2,3,4,5,6,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHRENE-4-CARBOXYLIC ACID",
,,,,"3.4.21.5",,
"1BHX","R56","1BHX","X-RAY STRUCTURE OF THE COMPLEX OF HUMAN ALPHA THROMBIN WITH THE INHIBITOR SDZ 229-357","3.4.21.5","5-OXO-6-PHENYLMETHANESULFONYLAMINO-HEXAHYDRO-THIAZOLO[3,2-A]PYRIDINE-3-CARBOXYLIC ACID (3-GUANIDINO-PROPYL)-AMIDE",
,"R56",,,"3.4.21.5",,
,,,,"3.4.21.5",,
,,,,"3.4.21.5",,
"2OCV",,"2OCV","Structural basis of Na+ activation mimicry in murine thrombin","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5",,
"3HK3",,"3HK3","Crystal structure of murine thrombin mutant W215A/E217A (one molecule in the asymmetric unit)","3.4.21.5",
,,,,"3.4.21.5",
"1MTS",,"1MTS","FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN","3.4.21.4","CALCIUM ION",
,,,,,"(+)-2-[4-[(-1-ACETIMIDOYL-4-PIPERIDINYL)OXY]-3-(7-AMIDINO-2-NAPHTHYL)PROPIONIC ACID",
"1A4W","QWE","1A4W","CRYSTAL STRUCTURES OF THROMBIN WITH THIAZOLE-CONTAINING INHIBITORS: PROBES OF THE S1' BINDING SITE","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","amino{[(4S)-4-({[5-(dimethylamino)naphthalen-1-yl]sulfonyl}amino)-5-oxo-5-{(2R)-2-[3-oxo-3-(1,3-thiazol-2-yl)propyl]pip
eridin-1-yl}pentyl]amino}methaniminium",
,,,,,,
"1TBZ",,"1TBZ","HUMAN THROMBIN WITH ACTIVE SITE N-METHYL-D PHENYLALANYL-N-[5-(AMINOIMINOMETHYL)AMINO]-1-{{BENZOTHIAZOLYL)CARBONYL] BUTYL]-L-PROLINAMIDE TRIFLUROACETATE AND EXOSITE-HIRUGEN","3.4.21.5","D-phenylalanyl-N-{(1S)-1-[(S)-1,3-benzothiazol-2-yl(hydroxy)methyl]-4-carbamimidamidobutyl}-L-prolinamide",
,,,,"3.4.21.5","SODIUM ION",
,,,,,,
"1HBT",,"1HBT","Human alpha-thrombin complexed with a peptidyl pyridinium methyl ketone containing bivalent inhibitor","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1A0H",,"1A0H","THE X-RAY CRYSTAL STRUCTURE OF PPACK-MEIZOTHROMBIN DESF1: KRINGLE/THROMBIN AND CARBOHYDRATE/KRINGLE/THROMBIN INTERACTIONS AND LOCATION OF THE LINKER CHAIN","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5",,
"4BOH",,"4BOH","Madanins (MEROPS I53) are cleaved by thrombin and factor Xa","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"SULFATE ION",
"1AD8","MDL","1AD8","COMPLEX OF THROMBIN WITH AND INHIBITOR CONTAINING A NOVEL P1 MOIETY","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","[DEHYDROXY-N-METHYL-TYROSYL-PROLINYL]-[4,4,5,5,5-PENTAFLUORO-3-OXY-1-[3-INDOLYL]-PENT-2-YL]AMINE",
,,,,,,
"1AI8",,"1AI8","HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH THE EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA-PRO-BOROMPG","3.4.21.5","MORPHOLINO-DIPHENYLALANINE-METHOXYPROPYLBORONIC ACID",
,,,,"3.4.21.5",,
,,,,"3.4.21.5",,
"1TMT",,"1TMT","CHANGES IN INTERACTIONS IN COMPLEXES OF HIRUDIN DERIVATIVES AND HUMAN ALPHA-THROMBIN DUE TO DIFFERENT CRYSTAL FORMS","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5",,
,,,,,,
,,,,,,
"2PKS","G44","2PKS","Thrombin in complex with inhibitor","3.4.21.5","SODIUM ION",
,"G44",,,"3.4.21.5","4-({[4-(3-METHYLBENZOYL)PYRIDIN-2-YL]AMINO}METHYL)BENZENECARBOXIMIDAMIDE",
,,,,"3.4.21.5",,
,,,,,,
"2HPQ","0G7","2HPQ","Structures of the noncovalent complexes of human and bovine prothrombin fragment 2 with human ppack-thrombin","3.4.21.5","D-phenylalanyl-N-[(3S)-6-carbamimidamido-1-chloro-2-oxohexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5",,
,,,,"3.4.21.5",,
"1QHR","157","1QHR","NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS","3.4.21.5","6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE",
,,,,"3.4.21.5",,
,,,,,,
"1QJ1","166","1QJ1","Novel Covalent Active Site Thrombin Inhibitors","3.4.21.5","6-CARBAMIMIDOYL-2-[2-HYDROXY-6-(4-HYDROXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID",
,,,,"3.4.21.5",,
,,,,,,
"1QJ7","GR1","1QJ7","Novel Covalent Active Site Thrombin Inhibitors","3.4.21.5","6-CARBAMIMIDOYL-2-[5-(3-DIETHYLCARBAMOYL-PHENYL)-2-HYDROXY-INDAN-1-YL]-HEXANOIC ACID",
,,,,"3.4.21.5",,
,,,,,,
"1QJ6","167","1QJ6","Novel Covalent Active Site Thrombin Inhibitors","3.4.21.5","6-CARBAMIMIDOYL-2-[2-HYDROXY-5-(3-METHOXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID",
,,,,"3.4.21.5",,
,,,,,,
"5GIM",,"5GIM","Crystal structure of thrombin-avathrin complex","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
,,,,,
"1A61",,"1A61","THROMBIN COMPLEXED WITH A BETA-MIMETIC THIAZOLE-CONTAINING INHIBITOR","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","(1S,7S)-7-amino-7-benzyl-N-{(1S)-4-carbamimidamido-1-[(S)-hydroxy(1,3-thiazol-2-yl)methyl]butyl}-8-oxohexahydro-1H-pyra
zolo[1,2-a]pyridazine-1-carboxamide",
,,,,,,
"1THR",,"1THR","STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1HDT",,"1HDT","STRUCTURE OF A RETRO-BINDING PEPTIDE INHIBITOR COMPLEXED WITH HUMAN ALPHA-THROMBIN","3.4.21.5","methyl N-(4-carbamimidamidobutanoyl)-L-phenylalanyl-L-allothreonyl-L-phenylalaninate",
,,,,"3.4.21.5",,
,,,,,,
"1HGT",,"1HGT","STRUCTURE OF THE HIRUGEN AND HIRULOG 1 COMPLEXES OF ALPHA-THROMBIN","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1HUT","0G7","1HUT","THE STRUCTURE OF ALPHA-THROMBIN INHIBITED BY A 15-MER SINGLE-STRANDED DNA APTAMER",,"D-phenylalanyl-N-[(3S)-6-carbamimidamido-1-chloro-2-oxohexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5",,
,,,,"3.4.21.5",,
"4DII",,"4DII","X-ray structure of the complex between human alpha thrombin and thrombin binding aptamer in the presence of potassium ions","3.4.21.5","ZINC ION",
,,,,"3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
,,,,,"CHLORIDE ION",
,,,,,"POTASSIUM ION",
"4DIH",,"4DIH","X-ray structure of the complex between human alpha thrombin and thrombin binding aptamer in the presence of sodium ions","3.4.21.5","ZINC ION",
,,,,"3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
,,,,,"CHLORIDE ION",
"4E05",,"4E05","Anophelin from the malaria vector inhibits thrombin through a novel reverse-binding mechanism","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SODIUM ION",
,,,,,,
"4E06",,"4E06","Anophelin from the malaria vector inhibits thrombin through a novel reverse-binding mechanism","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SODIUM ION",
,,,,,,
"1AIX",,"1AIX","HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA-PRO-BOROVAL","3.4.21.5","PHENYLMETHYLENECARBOXY-(METHYLENEAMINO-FORMYL-DIPHENYLMETHYL)METHY-PRO-BOROVAL",
,,,,"3.4.21.5",,
,,,,,,
"1TMU",,"1TMU","Changes in interactions in complexes of hirudin derivatives and human alpha-thrombin due to different crystal forms","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,,
"4HTC",,"4HTC","THE REFINED STRUCTURE OF THE HIRUDIN-THROMBIN COMPLEX","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5",,
,,,,,,
"1A46",,"1A46","THROMBIN COMPLEXED WITH HIRUGEN AND A BETA-STRAND MIMETIC INHIBITOR","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","(1S,7S)-7-amino-N-[(2R,3S)-7-amino-1-(cyclohexylamino)-2-hydroxy-1-oxoheptan-3-yl]-7-benzyl-8-oxohexahydro-1H-pyrazolo[1,2-a]pyridazine-1-carboxamide",
,,,,,,
"1THS",,"1THS","STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1SGI",,"1SGI","Crystal structure of the anticoagulant slow form of thrombin","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5",,
"1QBV","PPX","1QBV","CRYSTAL STRUCTURE OF THROMBIN COMPLEXED WITH AN GUANIDINE-MIMETIC INHIBITOR","3.4.21.5","[PHENYLALANINYL-PROLINYL]-[2-(PYRIDIN-4-YLAMINO)-ETHYL]-AMINE",
,"PPX",,,"3.4.21.5",,
,"PPX",,,,,
"2OD3",,"2OD3","Human thrombin chimera with human residues 184a, 186, 186a, 186b, 186c and 222 replaced by murine thrombin equivalents.","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
"3QLP",,"3QLP","X-ray structure of the complex between human alpha thrombin and a modified thrombin binding aptamer (mTBA)","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
,,,,,"POTASSIUM ION",
"4THN",,"4THN","THE CRYSTAL STRUCTURE OF ALPHA-THROMBIN-HIRUNORM IV COMPLEX REVEALS A NOVEL SPECIFICITY SITE RECOGNITION MODE.","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5",,
,,,,,,
"4LZ4",,"4LZ4","X-ray structure of the complex between human thrombin and the TBA deletion mutant lacking thymine 3 nucleobase","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,,"SODIUM ION",
,,,,,"POTASSIUM ION",
"4LZ1",,"4LZ1","X-ray structure of the complex between human thrombin and the TBA deletion mutant lacking thymine 12 nucleobase","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","POTASSIUM ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
"5GDS",,"5GDS","HIRUNORMS ARE TRUE HIRUDIN MIMETICS. THE CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN:HIRUNORM V COMPLEX","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5",,
,,,,,,
"1AWF","GR4","1AWF","NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT","3.4.21.5","R3-ACETOXY-17-(1-FORMYL-5-METHYL-3-OXO-HEX-4-ENYL)-12,16-DIHYDROXY-14-HYDROXYMETHYL-4,10,13-TRIMETHYL-2,3,4,5,6,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHRENE-4-CARBOXYLIC ACID IDOPYRANOSYL ESTER",
,,,,"3.4.21.5",,
,,,,,,
"1AHT","APA","1AHT","CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND P-AMIDINOPHENYLPYRUVATE AT 1.6 ANGSTROMS RESOLUTION","3.4.21.5","(2S)-3-(4-carbamimidoylphenyl)-2-hydroxypropanoic acid",
,,,,"3.4.21.5",,
,,,,,,
"2HPP","0G7","2HPP","Structures of the noncovalent complexes of human and bovine prothrombin fragment 2 with human ppack-thrombin","3.4.21.5","D-phenylalanyl-N-[(3S)-6-carbamimidamido-1-chloro-2-oxohexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5",,
,,,,"3.4.21.5",,
"1D3T","BT1","1D3T","CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 1","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"{2-[4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYL]-BENZO[B]THIOPHEN-3-YL}-[4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYL]-METHANONE",
"1D3Q","BT2","1D3Q","CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 2","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"3-[4-(2-PYRROLIDIN-1-YL-ETHOXY)-BENZYL]-2-4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYL] -BENZO[B]THIOPHENE",
"1D3P","BT3","1D3P","CRYSTAL STRUCTURE OF HUMAN APLHA-THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 3","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"BT3",,,"3.4.21.5","SODIUM ION",
,,,,,"3-[4-(2-PYRROLIDIN-1-YL-ETHOXY)-BENZYL]-2-4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYL] -BENZO[B]THIOPHEN-6-OL",
"1D3D","BZT","1D3D","CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZOTHIOPHENE INHIBITOR 4","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"BZT",,,"3.4.21.5","SODIUM ION",
,"BZT",,,,"3-(3-BROMO-4-PYRROLIDIN-1-YLMETHYL-BENZYL)-2-[4-PYRROLIDIN-1-YL-ETHOXY)-PHENYL]-BENZO[B]THIOPHEN-6-OL",
"3GIC",,"3GIC","Structure of thrombin mutant delta(146-149e) in the free form","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5",,
"4AYV","9MQ","4AYV","Human thrombin - inhibitor complex","3.4.21.5","{Benzyl-[(S)-3-[((S)-1-carbamimidoyl-piperidin-3-ylmethyl)-carbamoyl]-2-(naphthalene-2-sulfonylamino)-propionyl]-amino}-acetic acid",
,"9MQ",,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
"4AYY","9MX","4AYY","Human thrombin - inhibitor complex","3.4.21.5","(R)-1-[(S)-3-[((S)-1-Carbamimidoyl-piperidin-3-ylmethyl)-carbamoyl]-2-(naphthalene-2-sulfonylamino)-propionyl]-4-methyl-piperidine-2-carboxylic acid",
,"9MX",,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
"4AZ2","9MU","4AZ2","Human thrombin - inhibitor complex","3.4.21.5","(R)-N-((S)-1-CARBAMIMIDOYL-PIPERIDIN-3-YLMETHYL)-2-(NAPHTHALENE-2-SULFONYLAMINO)-3-PHENYL-PROPIONAMIDE",
,"9MU",,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"9MU",,,,,
"3HTC",,"3HTC","THE STRUCTURE OF A COMPLEX OF RECOMBINANT HIRUDIN AND HUMAN ALPHA-THROMBIN","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1EB1",,"1EB1","Complex structure of human thrombin with N-methyl-arginine inhibitor",
,,,,3.4.21.5,
,,,,3.4.21.5,
,,,,
"1A5G",,"1A5G","HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","(1S,7S)-7-amino-7-benzyl-N-[(1S)-4-carbamimidamido-1-{(1S)-1-hydroxy-2-oxo-2-[(2-phenylethyl)amino]ethyl}butyl]-8-oxohexahydro-1H-pyrazolo[1,2-a]pyridazine-1-carboxamide",
,,,,,,
"1YPM","RA4","1YPM","X-ray crystal structure of thrombin inhibited by synthetic cyanopeptide analogue RA-1014","3.4.21.5","N-(4-NITROBENZOYL)-L-LEUCYL-N-(4-{[AMINO(IMINO)METHYL]AMINO}BUTYL)-L-PROLINAMIDE",
,,,,"3.4.21.5",,
,,,,,,
"6V64",,"6V64","Crystal structure of human thrombin bound to ppack with tryptophans replaced by 5-F-tryptophan","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
"1KTT","C02","1KTT","Thrombin inhibitor complex","3.4.21.5","4-(5-BENZENESULFONYLAMINO-1-METHYL-1H-BENZOIMIDAZOL-2-YLMETHYL)-BENZAMIDINE",
,"C02",,,"3.4.21.5",,
,"C02",,,,,
"1KTS","C24","1KTS","Thrombin Inhibitor Complex","3.4.21.5","3-({2-[(4-CARBAMIMIDOYL-PHENYLAMINO)-METHYL]-3-METHYL-3H-BENZOIMIDAZOLE-5-CARBONYL}-PYRIDIN-2-YL-AMINO)-PROPIONIC ACID ETHYL ESTER",
,,,,"3.4.21.5",,
,,,,,,
"2ODY",,"2ODY","Thrombin-bound boophilin displays a functional and accessible reactive-site loop","3.4.21.5","PHOSPHATE ION",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"1MTW","DX9","1MTW","FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN","3.4.21.4","CALCIUM ION",
,"DX9",,,,"(2S)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-({(3R)-1-[(1Z)-ethanimidoyl]pyrrolidin-3-yl}oxy)phenyl]propanoic acid",
"1MTV",,"1MTV","FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN","3.4.21.4","CALCIUM ION",
,,,,,"(+)-2-[4-[(-1-ACETIMIDOYL-4-PIPERIDINYL)OXY]-3-(7-AMIDINO-2-NAPHTHYL)PROPIONIC ACID",
"1MTU",,"1MTU","FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN","3.4.21.4","CALCIUM ION",
,,,,,"(+)-2-[4-[(-1-ACETIMIDOYL-4-PIPERIDINYL)OXY]-3-(7-AMIDINO-2-NAPHTHYL)PROPIONIC ACID",
"1FGD",,"1FGD","EPIDERMAL GROWTH FACTOR (EGF) SUBDOMAIN OF HUMAN THROMBOMODULIN (NMR, 11 STRUCTURES)",
"4DT7",,"4DT7","Crystal structure of thrombin bound to the activation domain QEDQVDPRLIDGKMTRRGDS of protein C","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","DI(HYDROXYETHYL)ETHER",
,,,,"3.4.21.69","ACETATE ION",
"3VXF",,"3VXF","X/N Joint refinement of Human alpha-thrombin-Bivalirudin complex PD5","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5",,
,,,,,,
,,,,,,
"1AE8",,"1AE8","HUMAN ALPHA-THROMBIN INHIBITION BY EOC-D-PHE-PRO-AZALYS-ONP","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","1-ETHOXYCARBONYL-D-PHE-PRO-2(4-AMINOBUTYL)HYDRAZINE",
,,,,,,
"1AFE",,"1AFE","HUMAN ALPHA-THROMBIN INHIBITION BY CBZ-PRO-AZALYS-ONP","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","2-[N'-(4-AMINO-BUTYL)-HYDRAZINOCARBONYL]-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER",
,,,,,,
"1SG8",,"1SG8","Crystal structure of the procoagulant fast form of thrombin","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SODIUM ION",
"1HAG",,"1HAG","THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2, HIRUGEN-AND PPACK-THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,,
"1UMA",,"1UMA","ALPHA-THROMBIN (HIRUGEN) COMPLEXED WITH NA-(N,N-DIMETHYLCARBAMOYL)-ALPHA-AZALYSINE","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","N,N-DIMETHYLCARBAMOYL-ALPHA-AZALYSINE",
,,,,,,
"3R3G",,"3R3G","Structure of human thrombin with residues 145-150 of murine thrombin.","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SODIUM ION",
"2A0Q",,"2A0Q","Structure of thrombin in 400 mM potassium chloride","3.4.21.5","2-acetamido-2-deoxy-alpha-D-glucopyranose",
,,,,"3.4.21.5","POTASSIUM ION",
,,,,,"CHLORIDE ION",
"6TKJ",,"6TKJ","Tsetse thrombin inhibitor in complex with human alpha-thrombin - tetragonal form at 7keV","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5",,
,,,,,,
"6TKI",,"6TKI","Tsetse thrombin inhibitor in complex with human alpha-thrombin - tetragonal form at 12.7keV","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SODIUM ION",
,,,,,,
"1EOL",,"1EOL","Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures","3.4.21.5",
,,,,,
"1EOJ",,"1EOJ","Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures","3.4.21.5",
,,,,,
"1B5G",,"1B5G","HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN","3.4.21.5","[[[(4S,5S)-4-[[(3S,6S,8aR)-6-azanyl-5-oxo-6-(phenylmethyl)-1,2,3,7,8,8a-hexahydroindolizin-3-yl]carbonylamino]-5-(1,3-b
enzothiazol-2-yl)-5-hydroxy-pentyl]amino]-azanyl-methylidene]azanium",
,,,,"3.4.21.5","SODIUM ION",
,,,,,,
"1W7G","MIU","1W7G","Alpha-thrombin complex with sulfated hirudin (residues 54-65) and L- Arginine template inhibitor CS107","3.4.21.5","N-{(1S)-1-{[4-(3-AMINOPROPYL)PIPERAZIN-1-YL]CARBONYL}-4-[(DIAMINOMETHYLENE)AMINO]BUTYL}-3-(TRIFLUOROMETHYL)BENZENESULFONAMIDE",
,"MIU",,,,,
,"MIU",,,"3.4.21.5",,
"1C4U","IH1","1C4U","SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES.","3.4.21.5","SODIUM ION",
,"IH1",,,"3.4.21.5","2-[2-(4-BROMO-BENZENESULFONYL)-ETHYL]-1-3-DIOXO-2,3,5,8-TETRAHYDRO-1H-[1,2,4]TRIAZOLO[1,2-A]PYRIDAZINE-5-CARBOXYLIC ACID(4-CARBAMIMIDOYL-CYCLOHEXYLMETHYL)-AMIDE",
,,,,,,
"1BMN","BM9","1BMN","HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R*,R*)]-1-(AMINOIMINOMETHYL)-N-[[1-[N-[(2-NAPHTHALENYLSULFONYL)-L-SERYL]-PYRROLIDINYL]METHYL]-3-PIPERIDENECARBOXAMIDE (BMS-189090)","3.4.21.5","[S-(R*,R*)]-1-(AMINOIMINOMETHYL)-N-[[1-[N-[(2-NAPHTHALENYLSULFONYL)-L-SERYL]-3-PYRROLIDINYL]METHYL]-3-PIPERIDENECARBOXA
MIDE",
,,,,"3.4.21.5",,
,,,,,,
"1BMM","BM2","1BMM","HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R*,R*)]-4-[(AMINOIMINOMETHYL)AMINO]-N-[[1-[3-HYDROXY-2-[(2-NAPHTHALENYLSULFONYL)AMINO]-1-OXOPROPYL]-2-PYRROLIDINYL] METHYL]BUTANAMIDE (BMS-186282)","3.4.21.5","S-(R*,R*)]-4-[AMINOIMINOMETHYL)AMINO]-N-[[1-[3-HYDROXY -2-[(2-NAPHTHALENYLSULFONYL)AMINO]-1-OXOPROPYL]-2-PYRROLIDINYL]
METHYL]BUTANAMIDE",
,,,,"3.4.21.5",,
,,,,,,
"8KME",,"8KME","CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2770.","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5",,
,,,,,,
,,,,,,
"4GSO",,"4GSO","structure of Jararacussin-I","3.4.21",
"3S69",,"3S69","Crystal structure of saxthrombin","3.4.21","CALCIUM ION",
"1ZZZ",,"1ZZZ","Trypsin inhibitors with rigid tripeptidyl aldehydes","3.4.21.4","2-{(3S)-3-[(benzylsulfonyl)amino]-2-oxopiperidin-1-yl}-N-{(2S)-1-[(3R)-1-carbamimidoylpiperidin-3-yl]-3-oxopropan-2-yl}acetamide",
,,,,,"CALCIUM ION",
"1YYY",,"1YYY","Trypsin inhibitors with rigid tripeptidyl aldehydes","3.4.21.4","CALCIUM ION",
,,,,,"2-{(3S)-3-[(benzylsulfonyl)amino]-2-oxopiperidin-1-yl}-N-{(2S)-1-[(3S)-1-carbamimidoylpiperidin-3-yl]-3-oxopropan-2-yl}acetamide",
"3GIS",,"3GIS","Crystal Structure of Na-free Thrombin in Complex with Thrombomodulin","3.4.21.5","SULFATE ION",
,,,,"3.4.21.5","CALCIUM ION",
,,,,,,
"5EW2",,"5EW2","Human thrombin sandwiched between two DNA aptamers: HD22 and HD1-deltaT12","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,,"SODIUM ION",
,,,,,,
"5EW1",,"5EW1","Human thrombin sandwiched between two DNA aptamers: HD22 and HD1-deltaT3","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,,"SODIUM ION",
,,,,,,
"1OOK",,"1OOK","Crystal Structure of the Complex of Platelet Receptor GPIb-alpha and Human alpha-Thrombin","3.4.21.5","CHLORIDE ION",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,,
,,,,,,
"1SFQ",,"1SFQ","Fast form of thrombin mutant R(77a)A bound to PPACK","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
"1SHH",,"1SHH","Slow form of Thrombin Bound with PPACK","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
"1JMO",,"1JMO","Crystal Structure of the Heparin Cofactor II-S195A Thrombin Complex","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","(4S)-2-METHYL-2,4-PENTANEDIOL",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"1FGE",,"1FGE","EPIDERMAL GROWTH FACTOR (EGF) SUBDOMAIN OF HUMAN THROMBOMODULIN (NMR, 14 STRUCTURES)",
"5INW",,"5INW","Structure of reaction loop cleaved lamprey angiotensinogen",,"SULFATE ION",
,,,,,,
"2H9T","SVR","2H9T","Crystal structure of human alpha-thrombin in complex with suramin","3.4.21.5","8,8'-[CARBONYLBIS[IMINO-3,1-PHENYLENECARBONYLIMINO(4-METHYL-3,1-PHENYLENE)CARBONYLIMINO]]BIS-1,3,5-NAPHTHALENETRISULFON
IC ACID",
,,,,"3.4.21.5",,
,,,,,,
"3QGN",,"3QGN","The allosteric E*-E equilibrium is a key property of the trypsin fold","3.4.21.5","IODIDE ION",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"CHLORIDE ION",
"5CMX",,"5CMX","X-ray structure of the complex between human alpha thrombin and a duplex/quadruplex 31-mer DNA aptamer","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","POTASSIUM ION",
,,,,,,
"1UVS","I11","1UVS","BOVINE THROMBIN--BM51.1011 COMPLEX","3.4.21.5","[[CYCLOHEXANESULFONYL-GLYCYL]-3[PYRIDIN-4-YL-AMINOMETHYL]ALANYL]PIPERIDINE",
,,,,"3.4.21.5",,
"1H8D",,"1H8D","X-ray structure of the human alpha-thrombin complex with a tripeptide phosphonate inhibitor.","3.4.21.5","N-[(benzyloxy)carbonyl]-beta-phenyl-D-phenylalanyl-N-{(1S,3E)-1-[dihydroxy(diphenoxy)-lambda~5~-phosphanyl]-4-methoxybut-3-en-1-yl}-L-prolinamide",
,,,,,,
,,,,"3.4.21.5",,
"1H8I",,"1H8I","X-ray crystal structure of human alpha-thrombin with a tripeptide phosphonate inhibitor.","3.4.21.5","N-[(benzyloxy)carbonyl]-beta-phenyl-D-phenylalanyl-N-[(1S)-4-methoxy-1-phosphonobutyl]-L-prolinamide",
,,,,,,
,,,,"3.4.21.5",,
"7KME",,"7KME","CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2711.","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5",,
,,,,,,
,,,,,,
"3U8O",,"3U8O","Human thrombin complexed with D-Phe-Pro-D-Arg-D-Thr","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"IODIDE ION",
,,,,,"CHLORIDE ION",
,,,,,"(4R)-2-METHYLPENTANE-2,4-DIOL",
"1BB0",,"1BB0","THROMBIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","2-{(3S)-3-[(benzylsulfonyl)amino]-2-oxopiperidin-1-yl}-N-{(2S)-1-[(3R)-1-carbamimidoylpiperidin-3-yl]-3-oxopropan-2-yl}acetamide",
,,,,,,
"1BA8",,"1BA8","THROMBIN INHIBITOR WITH A RIGID TRIPEPTIDYL ALDEHYDES","3.4.21.5","amino({(4S)-4-[({(3S)-3-[(benzylsulfonyl)amino]-2-oxopiperidin-1-yl}acetyl)amino]-5-oxopentyl}amino)methaniminium",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,,
"1TMB",,"1TMB","MOLECULAR BASIS FOR THE INHIBITION OF HUMAN ALPHA-THROMBIN BY THE MACROCYCLIC PEPTIDE CYCLOTHEONAMIDE A","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
,,,,,
"1CA8",,"1CA8","Thrombin inhibitors with rigid tripeptidyl aldehydes","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","2-{(3S)-3-[(benzylsulfonyl)amino]-2-oxopiperidin-1-yl}-N-{(2S)-1-[(3S)-1-carbamimidoylpiperidin-3-yl]-3-oxopropan-2-yl}acetamide",
,,,,,,
"4AX9","N5N","4AX9","Human thrombin complexed with Napsagatran, RO0466240","3.4.21.5","SODIUM ION",
,"N5N",,,,"2-[[(2S)-4-[[(3S)-1-carbamimidoylpiperidin-3-yl]methylamino]-2-(naphthalen-2-ylsulfonylamino)-4-oxidanylidene-butanoyl]
-cyclopropyl-amino]ethanoic acid",
,"N5N",,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"N5N",,,,,
"2CF9","348","2CF9","Complex of recombinant human thrombin with an inhibitor","3.4.21.5","4-[(1R,3AS,4R,8AS,8BR)-1-ISOPROPYL-2-(4-METHOXYBENZYL)-3-OXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZENECARBOXIMIDAMIDE",
,"348",,,,"SODIUM ION",
,,,,"3.4.21.5","CALCIUM ION",
"2CF8","ESH","2CF8","Complex of recombinant human thrombin with an inhibitor","3.4.21.5","4- [(1R,3AS,4R,8AS,8BR)- 2- (4-CHLOROBENZYL)- 1- ISOPROPYL- 3- OXODECAHYDROPYRROLO[3,4- A]PYRROLIZIN- 4- YL]BENZENECARBOXIMIDAMIDE",
,"ESH",,,,"SODIUM ION",
,,,,"3.4.21.5","CALCIUM ION",
"1NZQ","162","1NZQ","D-Phe-Pro-Arg-Type Thrombin Inhibitor","3.4.21.5","(2-{2-[(5-CARBAMIMIDOYL-1-METHYL-1H-PYRROL-3-YLMETHYL)-CARBAMOYL]-PYRROL-1-YL} -1-CYCLOHEXYLMETHYL-2-OXO-ETHYLAMINO)-ACETIC ACID",
,"162",,,"3.4.21.5",,
,,,,,,
"2R2M","I50","2R2M","2-(2-Chloro-6-Fluorophenyl)Acetamides as Potent Thrombin Inhibitors","3.4.21.5","N-[2-({[amino(imino)methyl]amino}oxy)ethyl]-2-{6-chloro-3-[(2,2-difluoro-2-phenylethyl)amino]-2-fluorophenyl}acetamide",
,"I50",,,"3.4.21.5",,
,,,,,,
"2C8Z","C2A","2C8Z","thrombin inhibitors","3.4.21.5","SODIUM ION",
,"C2A",,,"3.4.21.5","DIMETHYL SULFOXIDE",
,,,,,"1-(3-CHLOROPHENYL)METHANAMINE",
"2C8W","C7M","2C8W","thrombin inhibitors","3.4.21.5","SODIUM ION",
,"C7M",,,"3.4.21.5","(2S,3R)-N-[5-CHLORO-2-(2,3-DIHYDRO-1H-TETRAZOL-1-YL)BENZYL]-3-HYDROXY-4-{[(4-METHOXYPHENYL)SULFONYL]AMINO}-1-PHENYLBUTA
N-2-AMINIUM",
,,,,,,
"1G37","110","1G37","CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH BCH-10556 AND EXOSITE-DIRECTED PEPTIDE","3.4.21.5","3-(4-AMINO-CYCLOHEXYL)-2-HYDROXY-3-[(4-OXO-2-PHENYLMETHANESULFONYL-1,2,3,4-TETRAHYDRO-PYRROLO[1,2-A]PYRAZINE-6-CARBONYL)-AMINO]-PROPIONIC ACID BUTYL ESTER",
,,,,,,
"5L6N",,"5L6N","Disulfated madanin-thrombin complex","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SODIUM ION",
,,,,,,
"1BCU","PRL","1BCU","ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND PROFLAVIN","3.4.21.5","PROFLAVIN",
,"PRL",,,"3.4.21.5",,
,,,,,,
"1LHD","DI2","1LHD","HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROLYS-OH","3.4.21.5","AC-(D)PHE-PRO-BOROLYS-OH",
,"DI2",,,"3.4.21.5",,
,"DI2",,,,,
"1LHC","DP7","1LHC","HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROARG-OH","3.4.21.5","AC-(D)PHE-PRO-BOROARG-OH",
,"DP7",,,"3.4.21.5",,
,"DP7",,,,,
,"DP7",,,,,
"1LHG","DI5","1LHG","HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROORNITHINE-OH","3.4.21.5","AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH",
,,,,"3.4.21.5",,
,,,,,,
"1LHF","DI4","1LHF","HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO-HOMOLYS-OH","3.4.21.5","AC-(D)PHE-PRO-BOROHOMOLYS-OH",
,,,,"3.4.21.5",,
,,,,,,
"1LHE","DI3","1LHE","HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO-N-BUTYL-AMIDINO-GLYCINE-OH","3.4.21.5","AC-(D)PHE-PRO-BORO-N-BUTYL-AMIDINO-GLYCINE-OH",
,,,,"3.4.21.5",,
,,,,,,
"1MU8","CDB","1MU8","thrombin-hirugen_l-378,650","3.4.21.5","2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-3-METHYL-6-PYRIDINYL)METHYL]ACETAMIDE",
,"CDB",,,"3.4.21.5",,
,,,,,,
"1C5O","BAM","1C5O","STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR","3.4.21.5","SODIUM ION",
,"BAM",,,"3.4.21.5","BENZAMIDINE",
,,,,,,
"3P70",,"3P70","Structural basis of thrombin-mediated factor V activation: essential role of the hirudin-like sequence Glu666-Glu672 for processing at the heavy chain-B domain junction","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","BENZAMIDINE",
,,,,,"SODIUM ION",
,,,,,"beta-D-glucopyranose",
"1AY6",,"1AY6","THROMBIN INHIBITOR FROM THEONALLA, CYCLOTHEANAMIDE-BASED MACROCYCLIC TRIPEPTIDE MOTIF","3.4.21.5","amino({3-[(3R,5R,14S,16S,21aR)-5,14-dihydroxy-1,4,17-trioxo-16-(2-phenylethyl)icosahydro-1H-pyrrolo[1,2-d][1,4,7,11]tetraazacyclononadecin-3-yl]propyl}amino)methaniminium",
,,,,"3.4.21.5",,
,,,,,,
"3HKI",,"3HKI","Crystal structure of murine thrombin mutant W215A/E217A in complex with the extracellular fragment of human PAR1","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5",,
,,,,,,
"1FPH",,"1FPH","THE INTERACTION OF THROMBIN WITH FIBRINOGEN: A STRUCTURAL BASIS FOR ITS SPECIFICITY","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
,,,,,
"3UTU","1TS","3UTU","High affinity inhibitor of human thrombin","3.4.21.5","(2S)-N-[(4-carbamimidoylphenyl)methyl]-1-[(2S)-2-[(3-chloro-4-methoxybenzene)sulfonamido]-3-{[(4-cyanophenyl)methyl]carbamoyl}propanoyl]pyrrolidine-2-carboxamide",
,"1TS",,,"3.4.21.5","SODIUM ION",
,,,,,,
"3DUX","64U","3DUX","Understanding Thrombin Inhibition","3.4.21.5","3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide",
,"64U",,,"3.4.21.5","SODIUM ION",
,"64U",,,,,
,"64U",,,,,
,"64U",,,,,
,"64U",,,,,
,"64U",,,,,
,"64U",,,,,
,"64U",,,,,
,"64U",,,,,
"3VXE",,"3VXE","Human alpha-thrombin-Bivalirudin complex at PD5.0","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5",,
,,,,,,
,,,,,,
"2ZC9","22U","2ZC9","Thrombin in complex with Inhibitor","3.4.21.5","SODIUM ION",
,"22U",,,"3.4.21.5","D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide",
,"22U",,,,,
,"22U",,,,,
,"22U",,,,,
"2ZDA","32U","2ZDA","Exploring Thrombin S1 pocket","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","PHOSPHATE ION",
,,,,,"D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide",
"2ZFP","19U","2ZFP","Thrombin Inibition","3.4.21.5","SODIUM ION",
,"19U",,,"3.4.21.5","1-[(2R)-2-aminobutanoyl]-N-(3-chlorobenzyl)-L-prolinamide",
,"19U",,,,,
,"19U",,,,,
"2ZGX","29U","2ZGX","Thrombin Inhibition","3.4.21.5","SODIUM ION",
,"29U",,,"3.4.21.5","1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide",
,"29U",,,,,
,"29U",,,,,
,"29U",,,,,
"2ZO3","33U","2ZO3","Bisphenylic Thrombin Inhibitors","3.4.21.5","beta-phenyl-D-phenylalanyl-N-(4-carbamimidoylbenzyl)-L-prolinamide",
,"33U",,,"3.4.21.5","SODIUM ION",
,"33U",,,,,
"4BAH","MEL","4BAH","Thrombin in complex with inhibitor","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"MEL",,,"3.4.21.5","[((1R)-2-{(2S)-2-[({4-[AMINO(IMINO)METHYL]BENZYL}AMINO)CARBONYL]AZETIDINYL}-1-CYCLOHEXYL-2-OXOETHYL)AMINO]ACETIC ACID",
,,,,,"SODIUM ION",
"4LOY",,"4LOY","Crystal Structure Analysis of thrombin in complex with compound D57, 5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2- oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1- yl)-3-oxopropyl]amide (SAR107375)","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
,,,,"3.4.21.5","5-Chloro-thiophene-2-carboxylic acid [(S)-2-[2-chloro-5-fluoro-3-(2-oxo-piperidin-1-yl)-benzenesulfonylamino]-3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]-amide",
"4LXB","7R9","4LXB","Crystal Structure Analysis of thrombin in complex with compound D58","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
,,,,"3.4.21.5","5-Chloro-thiophene-2-carboxylic acid [(S)-2-[2-difluoromethoxy-3-(2-oxo-piperidin-1-yl)-benzenesulfonylamino]-3-((S)-3-dimethylamino-pyrrolidin-1-yl)-3-oxo-propyl]-amide",
"1O0D","163","1O0D","Human Thrombin complexed with a d-Phe-Pro-Arg-type Inhibitor and a C-terminal Hirudin derived exo-site inhibitor","3.4.21.5","(2-{2-[(5-CARBAMIMIDOYL-1-METHYL-1H-PYRROL-2-YLMETHYL)-CARBAMOYL]-PYRROL-1-YL}- 1-CYCLOHEXYLMETHYL-2-OXO-ETHYLAMINO)-ACETIC ACID",
,"163",,,"3.4.21.5",,
,,,,,,
"1NO9","4ND","1NO9","Design of weakly basic thrombin inhibitors incorporating novel P1 binding functions: molecular and X-ray crystallographic studies.","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","N4-(N,N-DIPHENYLCARBAMOYL)-AMINOGUANIDINE",
,,,,,,
"1D6W","00R","1D6W","STRUCTURE OF THROMBIN COMPLEXED WITH SELECTIVE NON-ELECTROPHILIC INHIBITORS HAVING CYCLOHEXYL MOIETIES AT P1","3.4.21.5","SODIUM ION",
,,,,,"(5S)-N-[trans-4-(2-amino-1H-imidazol-5-yl)cyclohexyl]-1,3-dioxo-2-[2-(phenylsulfonyl)ethyl]-2,3,5,8-tetrahydro-1H-[1,2,4]triazolo[1,2-a]pyridazine-5-carboxamide",
"4I7Y",,"4I7Y","Crystal Structure of Human Alpha Thrombin in Complex with a 27-mer Aptamer Bound to Exosite II","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"2PW8",,"2PW8","Crystal structure of sulfo-hirudin complexed to thrombin","3.4.21.5","NICKEL (II) ION",
,,,,"3.4.21.5","SODIUM ION",
,,,,,,
"3DA9","44U","3DA9","Crystal structure of thrombin in complex with inhibitor","3.4.21.5","SODIUM ION",
,"44U",,,"3.4.21.5","beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide",
,"44U",,,,,
,"44U",,,,,
"3F68","91U","3F68","Thrombin Inhibition","3.4.21.5","N-acetyl-3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide",
,"91U",,,"3.4.21.5","SODIUM ION",
,,,,,,
"2C8Y","C3M","2C8Y","thrombin inhibitors","3.4.21.5","DIMETHYL SULFOXIDE",
,"C3M",,,"3.4.21.5","SODIUM ION",
,,,,,"N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]NAPHTHALENE-2-SULFONAMIDE",
"2C8X","C5M","2C8X","thrombin inhibitors","3.4.21.5","DIMETHYL SULFOXIDE",
,"C5M",,,"3.4.21.5","SODIUM ION",
,"C5M",,,,"N-{(2R,3S)-3-[(3-CHLOROBENZYL)AMINO]-2-HYDROXY-4-PHENYLBUTYL}-4-METHOXY-2,3,6-TRIMETHYLBENZENESULFONAMIDE",
"2C93","C4M","2C93","thrombin inhibitors","3.4.21.5","DIMETHYL SULFOXIDE",
,"C4M",,,"3.4.21.5","SODIUM ION",
,"C4M",,,,"N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]-4-METHOXY-2,3,6-TRIMETHYLBENZENESULFONAMIDE",
"2C90","C1M","2C90","thrombin inhibitors","3.4.21.5","DIMETHYL SULFOXIDE",
,"C1M",,,"3.4.21.5","SODIUM ION",
,"C1M",,,,"1-(4-CHLOROPHENYL)-1H-TETRAZOLE",
"1MU6","CDA","1MU6","Crystal Structure of Thrombin in Complex with L-378,622","3.4.21.5","2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-6-PYRIDINYL)METHYL]ACETAMIDE",
,"CDA",,,"3.4.21.5",,
,"CDA",,,,,
"1C5N","ESI","1C5N","STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR","3.4.21.5","SODIUM ION",
,"ESI",,,"3.4.21.5","CALCIUM ION",
,,,,,"4-IODOBENZO[B]THIOPHENE-2-CARBOXAMIDINE",
"1MUE","CDD","1MUE","Thrombin-Hirugen-L405,426","3.4.21.5","2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(1-OXIDO-2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUOROPHENYL)METHYL]ACETAMIDE",
,"CDD",,,"3.4.21.5",,
,"CDD",,,,,
"4CH2",,"4CH2","Low-salt crystal structure of a thrombin-GpIbalpha peptide complex","3.4.21.5","GLYCEROL",
,,,,"3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,,"SODIUM ION",
"4CH8",,"4CH8","High-salt crystal structure of a thrombin-GpIbalpha peptide complex","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,,"GLYCEROL",
"3U8R",,"3U8R","Human thrombin complexed with D-Phe-Pro-D-Arg-Ile","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"IODIDE ION",
,,,,,"CHLORIDE ION",
,,,,,"(4S)-2-METHYL-2,4-PENTANEDIOL",
,,,,,"(4R)-2-METHYLPENTANE-2,4-DIOL",
"4DY7",,"4DY7","Crystal structures of protease nexin-1 in complex with S195A thrombin","3.4.21.5","ACETATE ION",
,,,,"3.4.21.5","CALCIUM ION",
,,,,,"SODIUM ION",
"3DHK","23U","3DHK","Bisphenylic Thrombin Inhibitors","3.4.21.5","beta-phenyl-D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide",
,"23U",,,"3.4.21.5","SODIUM ION",
,"23U",,,,,
"3P17","99P","3P17","Thrombin Inhibition by Pyridin Derivatives","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"99P",,,"3.4.21.5","D-phenylalanyl-N-(pyridin-3-ylmethyl)-L-prolinamide",
,,,,,"PHOSPHATE ION",
,,,,,"SODIUM ION",
"4BAK","M67","4BAK","Thrombin in complex with inhibitor","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"M67",,,"3.4.21.5","(2S)-N-(4-CARBAMIMIDOYLBENZYL)-1-[(2R)-2-CYCLOHEXYL-2-{[2-OXO-2-(PROPYLAMINO)ETHYL]AMINO}ACETYL]AZETIDINE-2-CARBOXAMIDE",
,,,,,"SODIUM ION",
"4BAM","MM9","4BAM","Thrombin in complex with inhibitor","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"MM9",,,"3.4.21.5","(2S)-N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-2-cyclohexyl-2-[[2-(dimethylamino)-2-oxidanylidene-ethyl]amino]ethanoyl]azetidine-2-carboxamide",
,,,,,"SODIUM ION",
"4BAN","M6S","4BAN","Thrombin in complex with inhibitor","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"M6S",,,"3.4.21.5","(2S)-N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-2-cyclohexyl-2-[[2-(methylamino)-2-oxidanylidene-ethyl]amino]ethanoyl]azetidine-2-carboxamide",
,,,,,"SODIUM ION",
"4BAO","MVF","4BAO","Thrombin in complex with inhibitor","3.4.21.5","(2S)-1-[(2R)-2-[(2-azanyl-2-oxidanylidene-ethyl)amino]-2-cyclohexyl-ethanoyl]-N-[(4-carbamimidoylphenyl)methyl]azetidine-2-carboxamide",
,"MVF",,,"3.4.21.5","SODIUM ION",
,,,,,,
"4BAQ","M4Z","4BAQ","Thrombin in complex with inhibitor","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"M4Z",,,"3.4.21.5","(2S)-N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-2-cyclohexyl-2-[[2-(ethylamino)-2-oxidanylidene-ethyl]amino]ethanoyl]azetidine-2-carboxamide",
,,,,,"SODIUM ION",
"3SHC","B01","3SHC","Human Thrombin In Complex With UBTHR101","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"B01",,,"3.4.21.5","SODIUM ION",
,,,,,"D-phenylalanyl-N-[(4-chloropyridin-2-yl)methyl]-L-prolinamide",
"2UUK",,"2UUK","Thrombin-hirugen-gw420128 ternary complex at 1.39A resolution","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","CALCIUM ION",
,,,,,"N-[3-(TERT-BUTYLAMINO)-3-OXOPROPYL]-N-ISOPROPYL-3-METHYL-5-{[(2S)-2-(PYRIDIN-4-YLAMINO)PROPYL]OXY}BENZAMIDE",
"2UUF",,"2UUF","Thrombin-hirugen binary complex at 1.26A resolution","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","CALCIUM ION",
,,,,,,
"1GHY","121","1GHY","A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE","3.4.21.5","ZINC ION",
,"121",,,"3.4.21.5","SODIUM ION",
,,,,,"CALCIUM ION",
,,,,,"2-(3-HYDROXY-PYRIDIN-2-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE",
"1GHX","122","1GHX","A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE","3.4.21.5","ZINC ION",
,"122",,,"3.4.21.5","CALCIUM ION",
,"122",,,,"SODIUM ION",
,"122",,,,"2-(2-HYDROXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE",
"1GHW","BMZ","1GHW","A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE","3.4.21.5","SODIUM ION",
,"122",,,"3.4.21.5","2-(2-HYDROXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE",
,"122",,,,,
,"122",,,,,
,"BMZ",,,,,
,"122",,,,,
"1GHV","120","1GHV","A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE","3.4.21.5","SODIUM ION",
,"120",,,"3.4.21.5","2-(2-OXO-1,2-DIHYDRO-PYRIDIN-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE",
,,,,,,
"5NHU",,"5NHU","HUMAN ALPHA THROMBIN COMPLEXED WITH ANOPHELES GAMBIAE cE5 ANTICOAGULANT","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SODIUM ION",
,,,,,,
"1P8V",,"1P8V","CRYSTAL STRUCTURE OF THE COMPLEX OF PLATELET RECEPTOR GPIB-ALPHA AND ALPHA-THROMBIN AT 2.6A",,"2-(N-MORPHOLINO)-ETHANESULFONIC ACID",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","DIISOPROPYL PHOSPHONATE",
"1C5L",,"1C5L","STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","CALCIUM ION",
,,,,,,
"1D4P","BPP","1D4P","CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH 5-AMIDINOINDOLE-4-BENZYLPIPERIDINE INHIBITOR","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"BPP",,,"3.4.21.5","SODIUM ION",
,,,,,"(4-BENZYL-PIPERIDIN-1-YL)-(5-AMIDINOMETHYL-3AH-INDOL-2-YL-METHANONE",
"1XMN",,"1XMN","Crystal structure of thrombin bound to heparin","3.4.21.5","GLYCEROL",
,,,,"3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,,"SODIUM ION",
"2ZGB","21U","2ZGB","Thrombin Inhibition","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","D-leucyl-N-(3-chlorobenzyl)-L-prolinamide",
,,,,,,
"2ZHQ","27U","2ZHQ","Thrombin Inhibition","3.4.21.5","SODIUM ION",
,"27U",,,"3.4.21.5","N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-L-prolinamide",
,"27U",,,,,
,"27U",,,,,
"2ZI2","24U","2ZI2","Thrombin Inhibition","3.4.21.5","SODIUM ION",
,"24U",,,"3.4.21.5","1-butanoyl-N-(4-carbamimidoylbenzyl)-L-prolinamide",
,"24U",,,,"BENZAMIDINE",
"2ZNK","31U","2ZNK","Thrombin Inhibition","3.4.21.5","D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide",
,,,,"3.4.21.5","SODIUM ION",
,,,,,,
"3HAT",,"3HAT","ACTIVE SITE MIMETIC INHIBITION OF THROMBIN","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
,,,,,
"3S7K",,"3S7K","Structure of thrombin mutant Y225P in the E form","3.4.21.5","POTASSIUM ION",
,,,,"3.4.21.5","2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL",
"3BF6","SVR","3BF6","Thrombin:suramin complex","3.4.21.5","8,8'-[CARBONYLBIS[IMINO-3,1-PHENYLENECARBONYLIMINO(4-METHYL-3,1-PHENYLENE)CARBONYLIMINO]]BIS-1,3,5-NAPHTHALENETRISULFON
IC ACID",
,,,,"3.4.21.5",,
,,,,,,
"1FPC","0ZI","1FPC","ACTIVE SITE MIMETIC INHIBITION OF THROMBIN","3.4.21.5","amino{[(4S)-4-({[5-(dimethylamino)naphthalen-1-yl]sulfonyl}amino)-5-(4-ethylpiperidin-1-yl)-5-oxopentyl]amino}methaniminium",
,,,,"3.4.21.5",,
,,,,,,
"2GDE","SN3","2GDE","Thrombin in complex with inhibitor","3.4.21.5","SODIUM ION",
,"SN3",,,"3.4.21.5","(R)-3-((2S,3R)-1-((2S,3AR,5S,6S,7AS)-2-(2-(1-CARBAMIMIDOYL-2,5-DIHYDRO-1H-PYRROL-3-YL)ETHYLCARBAMOYL)-5,6-DIHYDROXYOCTA
HYDRO-1H-INDOL-1-YL)-3-CHLORO-4-METHYL-1-OXOPENTAN-2-YLAMINO)-2-METHOXY-3-OXOPROPYL HYDROGEN SULFATE",
,,,,,,
"1SL3","170","1SL3","crystal structue of Thrombin in complex with a potent P1 heterocycle-Aryl based inhibitor","3.4.21.5","(2-[6-CHLORO-3-{[2,2-DIFLUORO-2-(1-OXIDOPYRIDIN-2-YL)ETHYL]AMINO}-2-OXOPYRAZIN-1(2H)-YL]-N-[5-CHLORO-2-(1H-TETRAZOL-1-YL)BENZYL]ACETAMIDE",
,"170",,,,,
,"170",,,,,
,"170",,,,,
"1ZRB","062","1ZRB","Thrombin in complex with an azafluorenyl inhibitor 23b","3.4.21.5","3-AZA-9-HYDROXY-9-FLUORENYLCARBONYL-L-PROLYL-2-AMINOMETHYL-5-CHLOROBENZYLAMIDE, N-OXIDE",
,,,,,,
"1C4Y","IH3","1C4Y","SELECTIVE NON-ELECTROPHILIC THROMBIN INHIBITORS","3.4.21.5","2-(2,2-DIPHENYL-ETHYL)-7-METHYL-1,3-DIOXO-2,3,5,8-TETRAHYDRO-1H-[1,2,4] TRIAZOLO[1,2-A]PYRIDAZINE-5-CARBOXYLIC ACID [4-(2-AMINO-3H-IMIDAZOL-4-YL)-CYCLOHEXYL]-AMIDE",
,,,,"3.4.21.5",,
,,,,,,
"1C4V","IH2","1C4V","SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES.","3.4.21.5","SODIUM ION",
,"IH2",,,"3.4.21.5","2-(2,2-DIPHENYL-ETHYL)-7-METHYL-1,3-DIOXO-2,3,5,8-TETRAHYDRO-1H-[1,2,4]TRIAZOLO [1,2-A]PYRIDAZINE-5-CARBOXYLIC ACID(4-CARBAMIMIDOYL-CYCLOHEXYLMETHYL)-AMIDE",
,,,,,,
"6T0P",,"6T0P","Cationic Trypsin in Complex with a D-Phe-Pro-2-aminopyridine derivative","3.4.21.4","CALCIUM ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"(2~{S})-1-[(2~{R})-2-azanyl-3-phenyl-propanoyl]-~{N}-[(2-azanylpyridin-4-yl)methyl]pyrrolidine-2-carboxamide",
,,,,,"SULFATE ION",
"6T5W",,"6T5W","Cationic Trypsin in Complex with a D-Phe-Pro-p-aminopyridine Derivative (cocrystallizaton at 291 K)","3.4.21.4","CALCIUM ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"SULFATE ION",
,,,,,"(2~{S})-1-[(2~{R})-2-azanyl-3-phenyl-propanoyl]-~{N}-[(6-azanylpyridin-3-yl)methyl]pyrrolidine-2-carboxamide",
"6SY3",,"6SY3","Cationic Trypsin in Complex with a D-DiPhe-Pro-pyridine derivative","3.4.21.4","CALCIUM ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"(2~{S})-1-[(2~{R})-2-azanyl-3,3-diphenyl-propanoyl]-~{N}-(pyridin-4-ylmethyl)pyrrolidine-2-carboxamide",
"3PMH","0G7","3PMH","Mechanism of Sulfotyrosine-Mediated Glycoprotein Ib Interaction with Two Distinct alpha-Thrombin Sites","3.4.21.5","D-phenylalanyl-N-[(3S)-6-carbamimidamido-1-chloro-2-oxohexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,,
"3P6Z",,"3P6Z","Structural basis of thrombin mediated factor V activation: essential role of the hirudin-like sequence Glu666-Glu672 for processing at the heavy chain-B domain junction","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"CHLORIDE ION",
,,,,,"(4S)-2-METHYL-2,4-PENTANEDIOL",
"1IHT",,"1IHT","CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN ALPHA-THROMBIN AND NON-HYDROLYZABLE BIFUNCTIONAL INHIBITORS, HIRUTONIN-2 AND HIRUTONIN-6","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1IHS",,"1IHS","CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN ALPHA-THROMBIN AND NON-HYDROLYZABLE BIFUNCTIONAL INHIBITORS, HIRUTONIN-2 AND HIRUTONIN-6","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"3EDX",,"3EDX","Crystal structure of the W215A/E217A mutant of murine thrombin","3.4.21.5","SULFATE ION",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
"4UFE",,"4UFE","Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-(2-((4- carbamimidoylphenyl)methylamino)-2-oxo-butyl)-3-phenyl-propanamide","3.4.21.5","SODIUM ION",
,,,,,"(2R)-N-[(2S)-1-[(4-carbamimidoylphenyl)methylamino]-1-oxidanylidene-propan-2-yl]-3-phenyl-2-[(phenylmethyl)sulfonylamino]propanamide",
,,,,"3.4.21.5","PHOSPHATE ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"4UFF",,"4UFF","Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-(2-((4- carbamimidoylphenyl)methylamino)-2-oxo-ethyl)-N-methyl-3-phenyl- propanamide","3.4.21.5","SODIUM ION",
,,,,,"(2R)-2-(benzylsulfonylamino)-N-(2-((4-carbamimidoylphenyl)methylamino)-2-oxo-ethyl)-N-methyl-3-phenyl-propanamide",
,,,,"3.4.21.5","PHOSPHATE ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"4UFG",,"4UFG","Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-((1S)-2-((4- carbamimidoylphenyl)methylamino)-1-methyl-2-oxo-ethyl)-N-methyl-3- phenyl-propanamide ethane","3.4.21.5","SODIUM ION",
,,,,,"(2S)-N-[(4-carbamimidoylphenyl)methyl]-2-[methyl-[(2R)-3-phenyl-2-[(phenylmethyl)sulfonylamino]propanoyl]amino]butanamide",
,,,,"3.4.21.5","PHOSPHATE ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"1DOJ",,"1DOJ","Crystal structure of human alpha-thrombin*RWJ-51438 complex at 1.7 A","3.4.21.5","N-methyl-D-phenylalanyl-N-{(1S)-4-carbamimidamido-1-[(6-carboxy-1,3-benzothiazol-2-yl)carbonyl]butyl}-L-prolinamide",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
"6EO7",,"6EO7","X-ray structure of the complex between human alpha-thrombin and modified 15-mer DNA aptamer containing 5-(3-(acetamide-N-yl)-1-propen-1-yl)-2'-deoxyuridine residue",,"POTASSIUM ION",
,,,,"3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"1NU7",,"1NU7","Staphylocoagulase-Thrombin Complex","3.4.21.5","N-(sulfanylacetyl)-D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","MERCURY (II) ION",
,,,,,"IMIDAZOLE",
"1OYT","FSN","1OYT","COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A DESIGNED FLUORINATED INHIBITOR","3.4.21.5","SODIUM ION",
,"FSN",,,"3.4.21.5","CALCIUM ION",
,,,,,"(3ASR,4RS,8ASR,8BRS)-4-(2-(4-FLUOROBENZYL)-1,3-DIOXODEACAHYDROPYRROLO[3,4-A] PYRROLIZIN-4-YL)BENZAMIDINE",
"1D9I","00P","1D9I","STRUCTURE OF THROMBIN COMPLEXED WITH SELECTIVE NON-ELECTOPHILIC INHIBITORS HAVING CYCLOHEXYL MOIETIES AT P1","3.4.21.5","SODIUM ION",
,,,,,"(5S)-N-[(trans-4-aminocyclohexyl)methyl]-1,3-dioxo-2-[2-(phenylsulfonyl)ethyl]-2,3,5,8-tetrahydro-1H-[1,2,4]triazolo[1,2-a]pyridazine-5-carboxamide",
"2A45",,"2A45","Crystal structure of the complex between thrombin and the central ""E"" region of fibrin","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","PHOSPHATE ION",
,,,,,,
,,,,,,
,,,,,,
"4BTT","VYR","4BTT","factor Xa in complex with the dual thrombin-FXa inhibitor 31.","3.4.21.6","CALCIUM ION",
,"VYR",,,"3.4.21.6","N-[(S)-1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(4-methoxy-piperidin-1-yl)-2-oxo-ethyl]-2-ethyl-3-(3-oxo-morpholin-4-yl)-benzenesulfonamide",
"4BTU","6XS","4BTU","Factor Xa in complex with the dual thrombin-FXa inhibitor 57.","3.4.21.6","CALCIUM ION",
,"6XS",,,"3.4.21.6","5-Chloro-thiophene-2-carboxylic acid [(S)-2-[2-chloro-5-fluoro-3-(2-oxo-piperidin-1-yl)-benzenesulfonylamino]-3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]-amide",
,"6XS",,,,,
"4BTI","7R9","4BTI","factor Xa in complex with the dual thrombin-FXa inhibitor 58.","3.4.21.6","CALCIUM ION",
,"7R9",,,"3.4.21.6","5-Chloro-thiophene-2-carboxylic acid [(S)-2-[2-difluoromethoxy-3-(2-oxo-piperidin-1-yl)-benzenesulfonylamino]-3-((S)-3-dimethylamino-pyrrolidin-1-yl)-3-oxo-propyl]-amide",
,"7R9",,,,,
"2THF",,"2THF","STRUCTURE OF HUMAN ALPHA-THROMBIN Y225F MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","SODIUM ION",
"1QUR",,"1QUR","HUMAN ALPHA-THROMBIN IN COMPLEX WITH BIVALENT, BENZAMIDINE-BASED SYNTHETIC INHIBITOR","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1G32","R11","1G32","THROMBIN INHIBITOR COMPLEX","3.4.21.5","4-{[1-METHYL-5-(2-METHYL-BENZOIMIDAZOL-1-YLMETHYL)-1H-BENZOIMIDAZOL-2-YLMETHYL]-AMINO}-BENZAMIDINE",
,"R11",,,"3.4.21.5",,
,"R11",,,,,
"1G30","T87","1G30","THROMBIN INHIBITOR COMPLEX","3.4.21.5","[(1-{2[(4-CARBAMIMIDOYL-PHENYLAMINO)-METHYL]-1-METHYL-1H-BENZOIMIDAZOL-5-YL}-CYCLOPROPYL)-PYRIDIN-2-YL-METHYLENEAMINOOXY]-ACETIC ACID ETHYL ESTER",
,"T87",,,"3.4.21.5",,
,"T87",,,,,
"3C1K","T15","3C1K","Crystal structure of thrombin in complex with inhibitor 15","3.4.21.5","2-{3-[(benzylsulfonyl)amino]-6-methyl-2-oxopyridin-1(2H)-yl}-N-({1-[2-(tert-butylamino)-2-oxoethyl]-4-methyl-1H-imidazol-5-yl}methyl)acetamide",
,"T15",,,,,
"1A2C",,"1A2C","Structure of thrombin inhibited by AERUGINOSIN298-A from a BLUE-GREEN ALGA","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5",,
,,,,,,
,,,,,,
"1B7X",,"1B7X","STRUCTURE OF HUMAN ALPHA-THROMBIN Y225I MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"1TA2","176","1TA2","Crystal structure of thrombin in complex with compound 1","3.4.21.5","1-(2-AMINO-3,3-DIPHENYL-PROPIONYL)-PYRROLIDINE-3-CARBOXYLIC ACID 2,5-DICHLORO-BENZYLAMIDE",
,"176",,,,,
,"176",,,,,
"1TA6","177","1TA6","Crystal structure of thrombin in complex with compound 14b","3.4.21.5","1-[2-AMINO-2-CYCLOHEXYL-ACETYL]-PYRROLIDINE-3-CARBOXYLIC ACID 5-CHLORO-2-(2-ETHYLCARBAMOYL-ETHOXY)-BENZYLAMIDE",
,"177",,,,,
,"177",,,,,
"1THP",,"1THP","STRUCTURE OF HUMAN ALPHA-THROMBIN Y225P MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5",,
"1TQ0",,"1TQ0","Crystal structure of the potent anticoagulant thrombin mutant W215A/E217A in free form","3.4.21.5",
,,,,"3.4.21.5",
"1NM6","L86","1NM6","thrombin in complex with selective macrocyclic inhibitor at 1.8A","3.4.21.5","(11S)-11-BENZYL-6-CHLORO-1,2,10,11,12,13,14,15,16,17,18,19-DODECAHYDRO-5,9-METHANO-2,5,8,10,13,17-BENZOHEXAAZACYCLOHENI
COSINE-3,24-DIONE",
,"L86",,,,,
,"L86",,,,,
"1NT1","T76","1NT1","thrombin in complex with selective macrocyclic inhibitor","3.4.21.5","(6R,21AS)-17-CHLORO-6-CYCLOHEXYL-2,3,6,7,10,11,19,20-OCTAHYDRO-1H,5H-PYRROLO[1,2-K][1,4,8,11,14]BENZOXATETRAAZA-CYCLOHEPTADECINE-5,8,12,21(9H,13H,21AH)-TETRONE",
,"T76",,,,,
,"T76",,,,,
,"T76",,,,,
"1SB1","165","1SB1","Novel Non-Covalent Thrombin Inhibitors Incorporating P1 4,5,6,7-Tetrahydrobenzothiazole Arginine Side Chain Mimetics","3.4.21.5","SODIUM ION",
,"165",,,"3.4.21.5","N-(BENZYLSULFONYL)-3-CYCLOHEXYLALANYL-N-(2-AMINO-1,3-BENZOTHIAZOL-6-YL)PROLINAMIDE",
,,,,,,
"1HAP",,"1HAP","COMPLEX OF HUMAN ALPHA-THROMBIN WITH A 15MER OLIGONUCLEOTIDE GGTTGGTGTGGTTGG (BASED ON X-RAY MODEL OF DNA)",,"D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5",,
,,,,"3.4.21.5",,
"1HAO",,"1HAO","COMPLEX OF HUMAN ALPHA-THROMBIN WITH A 15MER OLIGONUCLEOTIDE GGTTGGTGTGGTTGG (BASED ON NMR MODEL OF DNA)",,"D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5",,
,,,,"3.4.21.5",,
"3DD2",,"3DD2","Crystal structure of an RNA aptamer bound to human thrombin","3.4.21.5","DI(HYDROXYETHYL)ETHER",
,,,,"3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,,"MAGNESIUM ION",
,,,,,"HEXAETHYLENE GLYCOL",
,,,,,"ACETIC ACID",
"3U8T",,"3U8T","Human thrombin complexed with D-Phe-Pro-D-Arg-Cys","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"IODIDE ION",
,,,,,"CHLORIDE ION",
,,,,,"(4S)-2-METHYL-2,4-PENTANEDIOL",
"3HKJ",,"3HKJ","Crystal structure of human thrombin mutant W215A/E217A in complex with the extracellular fragment of human PAR1","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5",,
,,,,,,
"5MJX",,"5MJX","2'F-ANA/DNA Chimeric TBA Quadruplex structure",
"5HVF",,"5HVF","Crystal Structure of Thrombin-activatable Fibrinolysis Inhibitor in Complex with an Inhibitory Nanobody (VHH-i83)","3.4.17.20","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"ZINC ION",
,,,,,"CITRATE ANION",
"5HVH",,"5HVH","Crystal Structure of Thrombin-activatable Fibrinolysis Inhibitor in Complex with two Inhibitory Nanobodies","3.4.17.20","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"ZINC ION",
,,,,,,
"5HVG",,"5HVG","Crystal Structure of Thrombin-activatable Fibrinolysis Inhibitor in Complex with an Inhibitory Nanobody (VHH-a204)","3.4.17.20","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"ZINC ION",
,,,,,"ACETATE ION",
"2F3C",,"2F3C","Crystal structure of infestin 1, a Kazal-type serineprotease inhibitor, in complex with trypsin","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
"6T0M",,"6T0M","Cationic Trypsin in Complex with a D-Phe-Pro-diaminopyridine derivative","3.4.21.4","DIMETHYL SULFOXIDE",
,,,,,"CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"(2~{S})-1-[(2~{R})-2-azanyl-3-phenyl-propanoyl]-~{N}-[[2,6-bis(azanyl)pyridin-4-yl]methyl]pyrrolidine-2-carboxamide",
"1TB6",,"1TB6","2.5A Crystal Structure of the Antithrombin-Thrombin-Heparin Ternary Complex","3.4.21.5","(4S)-2-METHYL-2,4-PENTANEDIOL",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,,
"2FES","3SP","2FES","Orally active thrombin inhibitors","3.4.21.5","N-(CARBOXYMETHYL)-3-CYCLOHEXYL-D-ALANYL-N-({5-[(E)-AMINO(IMINO)METHYL]THIEN-2-YL}METHYL)-L-PROLINAMIDE",
,"3SP",,,"3.4.21.5",,
,"3SP",,,,,
"2FEQ","34P","2FEQ","orally active thrombin inhibitors","3.4.21.5","N-(CARBOXYMETHYL)-3-CYCLOHEXYL-D-ALANYL-N-({4-[(E)-AMINO(IMINO)METHYL]-1,3-THIAZOL-2-YL}METHYL)-L-PROLINAMIDE",
,"34P",,,"3.4.21.5",,
,,,,,,
"3UWJ","TIF","3UWJ","Human Thrombin In Complex With MI353","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","N-(benzylsulfonyl)-D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide",
,,,,,"PHOSPHATE ION",
,,,,,"SODIUM ION",
"3TU7","0BM","3TU7","Human alpha-thrombin complexed with N-(methylsulfonyl)-D-phenylalanyl-N-((1-carbamimidoyl-4-piperidinyl)methyl)-l-prolinamide (BMS-189664)","3.4.21.5","N-(methylsulfonyl)-D-phenylalanyl-N-[(1-carbamimidoylpiperidin-4-yl)methyl]-L-prolinamide",
,"0BM",,,"3.4.21.5",,
,"0BM",,,,,
,"0BM",,,,,
"3BIU",,"3BIU","Human thrombin-in complex with UB-THR10","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide",
"3BIV","11U","3BIV","Human thrombin-in complex with UB-THR11","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"11U",,,"3.4.21.5","(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide",
,,,,,,
"2UUJ",,"2UUJ","Thrombin-hirugen-gw473178 ternary complex at 1.32A resolution","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","CALCIUM ION",
,,,,,"N-ETHYL-N-ISOPROPYL-3-METHYL-5-{[(2S)-2-(PYRIDIN-4-YLAMINO)PROPYL]OXY}BENZAMIDE",
"6TDT",,"6TDT","Thrombin in Complex with a D-DiPhe-Pro-p-pyridine derivative","3.4.21.5","PHOSPHATE ION",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"(2~{S})-1-[(2~{R})-2-azanyl-3,3-diphenyl-propanoyl]-~{N}-(pyridin-4-ylmethyl)pyrrolidine-2-carboxamide",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"1WBG","L03","1WBG","Active site thrombin inhibitors","3.4.21.5","3-(4-CHLOROPHENYL)-5-(METHYLTHIO)-4H-1,2,4-TRIAZOLE",
,"L03",,,"3.4.21.5","DIMETHYL SULFOXIDE",
,,,,,,
"1K22","MEL","1K22","HUMAN THROMBIN-INHIBITOR COMPLEX","3.4.21.5","SODIUM ION",
,"MEL",,,"3.4.21.5","[((1R)-2-{(2S)-2-[({4-[AMINO(IMINO)METHYL]BENZYL}AMINO)CARBONYL]AZETIDINYL}-1-CYCLOHEXYL-2-OXOETHYL)AMINO]ACETIC ACID",
,"MEL",,,,,
,"MEL",,,,,
,"MEL",,,,,
,"MEL",,,,,
,"MEL",,,,,
,"MEL",,,,,
,"MEL",,,,,
"1P9A",,"1P9A","Crystal Structure of N-Terminal Domain of Human Platelet Receptor Glycoprotein Ib-alpha at 1.7 Angstrom Resolution",
"2GP9",,"2GP9","Crystal structure of the slow form of thrombin in a self-inhibited conformation","3.4.21.5","4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID",
,,,,"3.4.21.5",,
"2BDY","UNB","2BDY","thrombin in complex with inhibitor","3.4.21.5","SODIUM ION",
,"UNB",,,,"N-(4-CARBAMIMIDOYL-BENZYL)-2-[2-HYDROXY-6-METHYL-3-(NAPHTHALENE-1-SULFONYLAMINO)-PHENYL]-ACETAMIDE",
,"UNB",,,,,
"1YPG","UIR","1YPG","Thrombin Inhibitor Complex","3.4.21.5","(1R,3AS,4R,8AS,8BR)-4-(2-BENZO[1,3]DIOXOL-5-YL-1-CYCLOPROPYL-3-OXO-DECAHYDRO-PYRROLO[3,4-A]PYRROLIZIN-4-YL)-BENZAMIDINE",
,"UIR",,,"3.4.21.5",,
,,,,,,
"1YPJ","UIB","1YPJ","Thrombin Inhibitor Complex","3.4.21.5","(1R,3AS,4R,8AS,8BR)-4-{5-(PHENYL[1,3]DIOXOL-5-YLMETHYL)-4-ETHYL-2,3,3-TRIMETHYL-6-OXO-OCTAHYDRO-PYRROLO[3,4-C]PYRROL-1-YL}-BENZAMIDINE",
,"UIB",,,"3.4.21.5",,
,,,,,,
"1MH0",,"1MH0","Crystal structure of the anticoagulant slow form of thrombin","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
"3LU9",,"3LU9","Crystal structure of human thrombin mutant S195A in complex with the extracellular fragment of human PAR1","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"GLYCEROL",
"1KMA",,"1KMA","NMR Structure of the Domain-I of the Kazal-type Thrombin Inhibitor Dipetalin",
"5AFZ","UET","5AFZ","Thrombin in complex with (2R)-2-(benzylsulfonylamino)-N-(2-((4- carbamimidoylphenyl)methylamino)-2-oxo-propyl)-3-phenyl-propanamide","3.4.21.5","SODIUM ION",
,"UET",,,,"N-(BENZYLSULFONYL)-D-PHENYLALANYL-N-(4-CARBAMIMIDOYLBENZYL)GLYCINAMIDE",
,"UET",,,"3.4.21.5","PHOSPHATE ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"O-SULFO-L-TYROSINE",
"6PXQ",,"6PXQ","Crystal structure of human thrombin mutant D194A","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5",,
"6EO6",,"6EO6","X-ray structure of the complex between human alpha-thrombin and modified 15-mer DNA aptamer containing 5-(3-(2-(1H-indol-3-yl)acetamide-N-yl)-1-propen-1-yl)-2'-deoxyuridine residue",,"POTASSIUM ION",
,,,,"3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"1TQ7",,"1TQ7","Crystal structure of the anticoagulant thrombin mutant W215A/E217A bound to PPACK","3.4.21.5","ZINC ION",
,,,,"3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"1O2G","696","1O2G","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.5","SODIUM ION",
,"696",,,"3.4.21.5","3-{5-[AMINO(IMINIO)METHYL]-1H-INDOL-2-YL}-1,1'-BIPHENYL-2-OLATE",
,"696",,,,,
,"696",,,,,
"1K21","IGN","1K21","HUMAN THROMBIN-INHIBITOR COMPLEX","3.4.21.5","SODIUM ION",
,"IGN",,,"3.4.21.5","{[(1R)-2-((2S)-2-{[(3-{[AMINO(IMINO)METHYL]AMINO}PROPYL)AMINO]CARBONYL}PIPERIDINYL)-1-(CYCLOHEXYLMETHYL)-2-OXOETHYL]AMINO}ACETIC ACID",
,"IGN",,,,,
,"IGN",,,,,
,"IGN",,,,,
,"IGN",,,,,
,"IGN",,,,,
"1GI2",,"1GI2","A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"2-(2-HYDROXY-PHENYL)-3H-BENZOIMIDAZOLE-5-CARBOXAMIDINE",
"1GI1","122","1GI1","A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE","3.4.21.4","CALCIUM ION",
,"122",,,,"SULFATE ION",
,"BMZ",,,,"2-(2-HYDROXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE",
,"122",,,,,
,"BMZ",,,,,
,"122",,,,,
"1GI0","122","1GI0","A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE","3.4.21.4","CALCIUM ION",
,"122",,,,"MAGNESIUM ION",
,"122",,,,"SULFATE ION",
,"122",,,,"2-(2-HYDROXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE",
"1GI6","124","1GI6","A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE","3.4.21.4","CALCIUM ION",
,"124",,,,"CHLORIDE ION",
,"124",,,,"SULFATE ION",
,,,,,"2-(2-HYDROXY-PHENYL)-1H-INDOLE-5-CARBOXAMIDINE",
"1GI5",,"1GI5","A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"2-(2-HYDROXY-5-METHOXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE",
"1GI4","122","1GI4","A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE","3.4.21.4","CALCIUM ION",
,"122",,,,"ZINC ION",
,,,,,"SULFATE ION",
,,,,,"2-(2-HYDROXY-PHENYL)-3H-BENZOIMIDAZOLE-5-CARBOXAMIDINE",
"1GI3","122","1GI3","A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE","3.4.21.4","CALCIUM ION",
,"122",,,,"2-(2-HYDROXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE",
,"122",,,,,
,"122",,,,,
"1GHZ","120","1GHZ","A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE","3.4.21.4","CALCIUM ION",
,"120",,,,"MAGNESIUM ION",
,,,,,"SULFATE ION",
,,,,,"2-(2-OXO-1,2-DIHYDRO-PYRIDIN-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE",
"1FIE",,"1FIE","RECOMBINANT HUMAN COAGULATION FACTOR XIII","2.3.2.13",
"1K1P","MEL","1K1P","BOVINE TRYPSIN-INHIBITOR COMPLEX","3.4.21.4","CALCIUM ION",
,"MEL",,,,"[((1R)-2-{(2S)-2-[({4-[AMINO(IMINO)METHYL]BENZYL}AMINO)CARBONYL]AZETIDINYL}-1-CYCLOHEXYL-2-OXOETHYL)AMINO]ACETIC ACID",
"4H6S",,"4H6S","Crystal structure of thrombin mutant E14eA/D14lA/E18A/S195A","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5",,
"3K65",,"3K65","Crystal Structure of Prethombin-2/Fragment-2 Complex","3.4.21.5","1,4-BUTANEDIOL",
,,,,"3.4.21.5",,
"2ANM","CDO","2ANM","Ternary complex of an orally active thrombin inhibitor with human thrombin and a c-terminal hirudin derived exo-sit inhibitor","3.4.21.5","2-((R)-1-((S)-2-(N-(6-CARBAMIMIDOYLPYRIDIN-3-YL)METHYLCARBAMOYL)-2H-PYRROL-1(5H)-YL)-3-CYCLOHEXYL-1-OXOPROPAN-2-YLAMINO)ACETIC ACID",
,"CDO",,,"3.4.21.5",,
,"CDO",,,,,
,"CDO",,,,,
"5E8E",,"5E8E","Crystal structure of thrombin bound to an exosite 1-specific IgA Fab",,"SODIUM ION",
,,,,,"D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","DI(HYDROXYETHYL)ETHER",
,,,,"3.4.21.5","PHOSPHATE ION",
,,,,,"CITRIC ACID",
"1YPL","RA8","1YPL","X-ray crystal structure of thrombin inhibited by synthetic cyanopeptide analogue RA-1008","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","N-(BENZYLSULFONYL)-L-LEUCYL-N-(4-{[AMINO(IMINO)METHYL]AMINO}BUTYL)-L-PROLINAMIDE",
,,,,,"GLYCEROL",
"3QDZ",,"3QDZ","Crystal structure of the human thrombin mutant D102N in complex with the extracellular fragment of human PAR4.","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"2ANK","N12","2ANK","orally active thrombin inhibitors in complex with thrombin and an exosite decapeptide","3.4.21.5","N-[(1R)-2-[(1-{[({6-[AMINO(IMINO)METHYL]PYRIDIN-3-YL}METHYL)AMINO]CARBONYL}CYCLOPENTYL)AMINO]-1-(CYCLOHEXYLMETHYL)-2-OXOETHYL]GLYCINE",
,"N12",,,"3.4.21.5",,
,"N12",,,,,
"2A2X","NA9","2A2X","Orally Active Thrombin Inhibitors in Complex with Thrombin Inh12","3.4.21.5","N-(CARBOXYMETHYL)-3-CYCLOHEXYL-D-ALANYL-N-({6-[AMINO(IMINO)METHYL]PYRIDIN-3-YL}METHYL)-N~2~-METHYL-L-ALANINAMIDE",
,"NA9",,,"3.4.21.5",,
,"NA9",,,,,
"1Z8J",,"1Z8J","Crystal structure of the thrombin mutant G193P bound to PPACK","3.4.21.5","ZINC ION",
,,,,"3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
"1WAY","L02","1WAY","Active site thrombin inhibitors","3.4.21.5","4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE",
,"L02",,,"3.4.21.5","DIMETHYL SULFOXIDE",
,,,,,,
"1DQB",,"1DQB","NMR STRUCTURE OF THROMBOMODULIN EGF(4-5)",,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"1AUJ","PPB","1AUJ","BOVINE TRYPSIN COMPLEXED TO META-CYANO-BENZYLIC INHIBITOR","3.4.21.4","CALCIUM ION",
,,,,,"1-{[1-(2-AMINO-3-PHENYL-PROPIONYL)-PYRROLIDINE-2-CARBONYL]-AMINO}-2-(3-CYANO-PHENYL)-ETHANEBORONIC ACID",
"1JOU",,"1JOU","Crystal Structure of Native S195A Thrombin with an Unoccupied Active Site","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"GLYCEROL",
,,,,,"ACETIC ACID",
"3BEF",,"3BEF","Crystal structure of thrombin bound to the extracellular fragment of PAR1","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5",,
,,,,,,
"6TKH",,"6TKH","Tsetse thrombin inhibitor in complex with human alpha-thrombin - orthorhombic form at 7keV","3.4.21.5","GLYCEROL",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
"1JMJ",,"1JMJ","Crystal Structure of Native Heparin Cofactor II",,"CALCIUM ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"2JH6","894","2JH6","Human Thrombin Hirugen Inhibitor complex","3.4.21.5","CALCIUM ION",
,"894",,,"3.4.21.5","SODIUM ION",
,"894",,,,"2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHANESULFONAMIDE",
"2JH5","895","2JH5","Human Thrombin Hirugen Inhibitor complex","3.4.21.5","CALCIUM ION",
,"895",,,"3.4.21.5","SODIUM ION",
,"895",,,,"2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHENESULFONAMIDE",
"2JH0","701","2JH0","Human Thrombin Hirugen Inhibitor complex","3.4.21.5","(2R)-2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}PROPENE-1-SULFONAMIDE",
,"701",,,"3.4.21.5","CALCIUM ION",
,"701",,,,"SODIUM ION",
"3DT0",,"3DT0","Understanding Thrombin Inhibition","3.4.21.5","N-(3-chlorobenzyl)-1-(4-methylpentanoyl)-L-prolinamide",
,,,,"3.4.21.5","SODIUM ION",
,,,,,,
"3EE0",,"3EE0","Crystal Structure of the W215A/E217A Mutant of Human Thrombin (space group P2(1)2(1)2(1))","3.4.21.5",
,,,,"3.4.21.5",
"2ZDV",,"2ZDV","Exploring Thrombin S1 pocket","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","PHOSPHATE ION",
,,,,,"D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide",
"2ZF0",,"2ZF0","Exploring Thrombin S1 Pocket","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide",
,,,,,,
"2ZG0","50U","2ZG0","Exploring thrombin S3 pocket","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide",
,,,,,,
"2ZFF","53U","2ZFF","Exploring Thrombin S1-pocket","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","D-phenylalanyl-N-benzyl-L-prolinamide",
,,,,,,
"2ZHW",,"2ZHW","Exploring thrombin S3 pocket","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide",
,,,,,,
"2ZHE",,"2ZHE","Exploring thrombin S3 pocket","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide",
,,,,,,
"2ZIQ",,"2ZIQ","Thrombin Inhibition","3.4.21.5","N-(4-carbamimidoylbenzyl)-1-(4-methylpentanoyl)-L-prolinamide",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"BENZAMIDINE",
"4HFP","15U","4HFP","Structure of thrombin mutant S195a bound to the active site inhibitor argatroban","3.4.21.5","SODIUM ION",
,"15U",,,"3.4.21.5","(2R,4R)-4-methyl-1-(N~2~-{[(3S)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonyl}-L-arginyl)piperidine-2-carboxylic
acid",
"3U98","BJA","3U98","Human Thrombin In Complex With MI001","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"BJA",,,"3.4.21.5","(2S)-1-[(2R)-2-(benzylsulfonylamino)-5-guanidino-pentanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide",
,,,,,"PHOSPHATE ION",
,,,,,"SODIUM ION",
"3EQ0","2TS","3EQ0","Thrombin Inhibitor","3.4.21.5","(2S)-N-[[2-(aminomethyl)-5-chloro-phenyl]methyl]-1-[(2R)-5-carbamimidamido-2-(phenylmethylsulfonylamino)pentanoyl]pyrrolidine-2-carboxamide",
,,,,"3.4.21.5","SODIUM ION",
,,,,,,
"3C27","DKK","3C27","Cyanofluorophenylacetamides as Orally Efficacious Thrombin Inhibitors","3.4.21.5","N-[2-(carbamimidamidooxy)ethyl]-2-{6-cyano-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-2-fluorophenyl}acetamide",
,,,,"3.4.21.5",,
,,,,,,
"1NU9",,"1NU9","Staphylocoagulase-Prethrombin-2 complex","3.4.21.5","N-(sulfanylacetyl)-D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,,"MERCURY (II) ION",
,,,,,"IMIDAZOLE",
"1ZGV","501","1ZGV","Thrombin in complex with an oxazolopyridine inhibitor 2","3.4.21.5","N7-BUTYL-N2-(5-CHLORO-2-METHYLPHENYL)-5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE-2,7-DIAMINE",
,"501",,,,,
,"501",,,,,
"1ZGI","382","1ZGI","thrombin in complex with an oxazolopyridine inhibitor 21","3.4.21.5","(R)-2-(2-(1H-1,2,4-TRIAZOL-1-YL)BENZYL)-N-(2,2-DIFLUORO-2-(PIPERIDIN-2-YL)ETHYL)OXAZOLO[4,5-C]PYRIDIN-4-AMINE",
,"382",,,,,
,"382",,,,,
"1VZQ","SHY","1VZQ","Complex of thrombin with designed inhibitor 7165","3.4.21.5","4-[(3AS,4R,7R,8AS,8BR)-2-(1,3-BENZODIOXOL-5-YLMETHYL)-7-HYDROXY-1,3-DIOXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZENECARBOXIMIDAMIDE",
,"SHY",,,,"SODIUM ION",
,,,,"3.4.21.5","CALCIUM ION",
"1TWX",,"1TWX","Crystal structure of the thrombin mutant D221A/D222K","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5",,
,,,,,,
"1C1V","BAB","1C1V","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.5","ZINC ION",
,"BAB",,,"3.4.21.5","SODIUM ION",
,,,,,"BIS(5-AMIDINO-BENZIMIDAZOLYL)METHANE",
"1C1U","BAI","1C1U","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.5","ZINC ION",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"(5-AMIDINO-2-BENZIMIDAZOLYL)(2-BENZIMIDAZOLYL)METHANE",
"1C1W",,"1C1W","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.5","ZINC ION",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"BIS(5-AMIDINO-2-BENZIMIDAZOLYL)METHANE KETONE HYDRATE",
"1HIC",,"1HIC","THE NMR SOLUTION STRUCTURE OF HIRUDIN(1-51) AND COMPARISON WITH CORRESPONDING THREE-DIMENSIONAL STRUCTURES DETERMINED USING THE COMPLETE 65-RESIDUE HIRUDIN POLYPEPTIDE CHAIN",
"3B9F",,"3B9F","1.6 A structure of the PCI-thrombin-heparin complex","3.4.21.5","SULFATE ION",
,,,,"3.4.21.5","GLYCEROL",
,,,,,,
"2PGQ",,"2PGQ","Human thrombin mutant C191A-C220A in complex with the inhibitor PPACK","3.4.21.5","ZINC ION",
,,,,"3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"1Z8I",,"1Z8I","Crystal structure of the thrombin mutant G193A bound to PPACK","3.4.21.5","ZINC ION",
,,,,"3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
"1RIW","OSC","1RIW","Thrombin in complex with natural product inhibitor Oscillarin","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"OSC",,,"3.4.21.5","SODIUM ION",
,"OSC",,,"3.4.21.5","(2R,3AS,6R,7AS)-N-(2-{1-[AMINO(IMINO)METHYL]-2,5-DIHYDRO-1H-PYRROL-3-YL}ETHYL)-6-HYDROXY-1-{N-[(2S)-2-HYDROXY-3-PHENYLPROPANOYL]PHENYLALANYL}OCTAHYDRO-1H-INDOLE-2-CARBOXAMIDE",
,,,,,,
"1K1N","CCR","1K1N","BOVINE TRYPSIN-INHIBITOR COMPLEX","3.4.21.4","CALCIUM ION",
,"CCR",,,,"[N-[N-(4-METHOXY-2,3,6-TRIMETHYLPHENYLSULFONYL)-L-ASPARTYL]-D-(4-AMIDINO-PHENYLALANYL)]-PIPERIDINE",
"1K1M","FD4","1K1M","BOVINE TRYPSIN-INHIBITOR COMPLEX","3.4.21.4","CALCIUM ION",
,"FD4",,,,"SULFATE ION",
,,,,,"N-ALPHA-(2-NAPHTHYLSULFONYL)-N(3-AMIDINO-L-PHENYLALANINYL)-4-ACETYL-PIPERAZINE",
"1K1L","FD3","1K1L","BOVINE TRYPSIN-INHIBITOR COMPLEX","3.4.21.4","SULFATE ION",
,"FD3",,,,"CALCIUM ION",
,"FD3",,,,"N-ALPHA-(2-NAPHTHYLSULFONYL)-3-AMIDINO-L-PHENYLALANINE PIPERAZIDE",
"1K1J","FD2","1K1J","BOVINE TRYPSIN-INHIBITOR COMPLEX","3.4.21.4","CALCIUM ION",
,"FD2",,,,"SULFATE ION",
,"FD2",,,,"N-ALPHA-(2-NAPHTHYLSULFONYL)-N(3-AMIDINO-L-PHENYLALANINYL)ISOPIPECOLINIC ACID METHYL ESTER",
"1K1I","FD1","1K1I","BOVINE TRYPSIN-INHIBITOR COMPLEX","3.4.21.4","CALCIUM ION",
,"FD1",,,,"N-ALPHA-(2-NAPHTHYLSULFONYL)-N-(3-AMIDINO-L-PHENYLALANINYL)-D-PIPECOLINIC ACID",
"1K1O","IGN","1K1O","BOVINE TRYPSIN-INHIBITOR COMPLEX","3.4.21.4","CALCIUM ION",
,"IGN",,,,"{[(1R)-2-((2S)-2-{[(3-{[AMINO(IMINO)METHYL]AMINO}PROPYL)AMINO]CARBONYL}PIPERIDINYL)-1-(CYCLOHEXYLMETHYL)-2-OXOETHYL]AMINO}ACETIC ACID",
"3JZ1",,"3JZ1","Crystal structure of human thrombin mutant N143P in E:Na+ form","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","NITRATE ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"GLYCEROL",
"3JZ2",,"3JZ2","Crystal structure of human thrombin mutant N143P in E* form","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","GLYCEROL",
"2AFQ",,"2AFQ","1.9 angstrom crystal structure of wild-type human thrombin in the sodium free state","3.4.21.5","GLYCEROL",
,,,,"3.4.21.5",,
"3LDX",,"3LDX","Discovery and Clinical Evaluation of RWJ-671818, a Thrombin Inhibitor with an Oxyguanidine P1 Motif","3.4.21.5","N-[2-(carbamimidamidooxy)ethyl]-2-{3-[(2,2-difluoro-2-phenylethyl)amino]-6-methyl-2-oxopyrazin-1(2H)-yl}acetamide",
,,,,"3.4.21.5",,
,,,,,,
"3D49",,"3D49","Thrombin Inhibition","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","BENZAMIDINE",
,,,,,,
"4RN6",,"4RN6","Structure of prethrombin-2 mutant s195a bound to the active site inhibitor argatroban","3.4.21.5","(2R,4R)-4-methyl-1-(N~2~-{[(3S)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]sulfonyl}-L-arginyl)piperidine-2-carboxylic
acid",
"6P9U",,"6P9U","Crystal structure of human thrombin mutant W215A","3.4.21.5","ZINC ION",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
"1TOM","MIN","1TOM","ALPHA-THROMBIN COMPLEXED WITH HIRUGEN","3.4.21.5","METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE",
,"MIN",,,"3.4.21.5",,
,"MIN",,,,,
,"MIN",,,,,
,"MIN",,,,,
"1YPK",,"1YPK","Thrombin Inhibitor Complex","3.4.21.5","[N-[N-(4-METHOXY-2,3,6-TRIMETHYLPHENYLSULFONYL)-L-ASPARTYL]-D-(4-AMIDINO-PHENYLALANYL)]-PIPERIDINE",
,,,,"3.4.21.5",,
,,,,,,
"1G36","R11","1G36","TRYPSIN INHIBITOR COMPLEX","3.4.21.4","CALCIUM ION",
,"R11",,,,"SULFATE ION",
,"R11",,,,"4-{[1-METHYL-5-(2-METHYL-BENZOIMIDAZOL-1-YLMETHYL)-1H-BENZOIMIDAZOL-2-YLMETHYL]-AMINO}-BENZAMIDINE",
"1OYQ","T87","1OYQ","TRYPSIN INHIBITOR COMPLEX","3.4.21.4","CALCIUM ION",
,"T87",,,,"SULFATE ION",
,"T87",,,,"[(1-{2[(4-CARBAMIMIDOYL-PHENYLAMINO)-METHYL]-1-METHYL-1H-BENZOIMIDAZOL-5-YL}-CYCLOPROPYL)-PYRIDIN-2-YL-METHYLENEAMINOOXY]-ACETIC ACID ETHYL ESTER",
"1MAY",,"1MAY","BETA-TRYPSIN PHOSPHONATE INHIBITED","3.4.21.4","CALCIUM ION",
,,,,,"[N-(BENZYLOXYCARBONYL)AMINO](4-AMIDINOPHENYL)METHANE-PHOSPHONATE",
"1MAX",,"1MAX","BETA-TRYPSIN PHOSPHONATE INHIBITED","3.4.21.4","CALCIUM ION",
,,,,,"[N-(BENZYLOXYCARBONYL)AMINO](4-AMIDINOPHENYL)METHANE-PHOSPHONATE",
"3QTO","10P","3QTO","Thrombin Inhibition by Pyridin Derivatives","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"10P",,,"3.4.21.5","D-phenylalanyl-N-[(1-methylpyridinium-3-yl)methyl]-L-prolinamide",
,,,,,"GLYCEROL",
,,,,,"PHOSPHATE ION",
,,,,,"SODIUM ION",
"3QTV","06P","3QTV","Thrombin Inhibition by Pyridin Derivatives","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"06P",,,"3.4.21.5","D-phenylalanyl-N-[(1-methylpyridinium-4-yl)methyl]-L-prolinamide",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"SODIUM ION",
"3QX5","02P","3QX5","Thrombin Inhibition by Pyridin Derivatives","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"02P",,,"3.4.21.5","SODIUM ION",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"D-phenylalanyl-N-[(4-chloro-1-methylpyridinium-2-yl)methyl]-L-prolinamide",
"3QWC","98P","3QWC","Thrombin Inhibition by Pyridin Derivatives","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"98P",,,"3.4.21.5","SODIUM ION",
,,,,,"GLYCEROL",
,,,,,"D-phenylalanyl-N-[(4-chloro-1-methylpyridinium-3-yl)methyl]-L-prolinamide",
"3SHA","P97","3SHA","Human Thrombin In Complex With UBTHR97","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"P97",,,"3.4.21.5","D-phenylalanyl-N-[(4-chloropyridin-3-yl)methyl]-L-prolinamide",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"SODIUM ION",
"3SI3","B03","3SI3","Human Thrombin In Complex With UBTHR103","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"B03",,,"3.4.21.5","SODIUM ION",
,,,,,"GLYCEROL",
,,,,,"PHOSPHATE ION",
,,,,,"D-phenylalanyl-N-(pyridin-2-ylmethyl)-L-prolinamide",
"3SI4","B04","3SI4","Human Thrombin In Complex With UBTHR104","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"B04",,,"3.4.21.5","D-phenylalanyl-N-[(1-methylpyridinium-2-yl)methyl]-L-prolinamide",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"SODIUM ION",
"2PGB",,"2PGB","Inhibitor-free human thrombin mutant C191A-C220A","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SULFATE ION",
"3U69",,"3U69","Unliganded wild-type human thrombin","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","BICINE",
,,,,,"SODIUM ION",
,,,,,"IODIDE ION",
,,,,,"CHLORIDE ION",
,,,,,"(4R)-2-METHYLPENTANE-2,4-DIOL",
,,,,,"(4S)-2-METHYL-2,4-PENTANEDIOL",
"1RD3",,"1RD3","2.5A Structure of Anticoagulant Thrombin Variant E217K","3.4.21.5","PHOSPHATE ION",
,,,,"3.4.21.5","GLYCEROL",
"2UWL","895","2UWL","Selective and Dual Action Orally Active Inhibitors of Thrombin and Factor Xa","3.4.21.6","2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHENESULFONAMIDE",
,"895",,,"3.4.21.6",,
,"895",,,,,
"2UWO","701","2UWO","Selective and Dual Action Orally Active Inhibitors of Thrombin and Factor Xa","3.4.21.6","(2R)-2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}PROPENE-1-SULFONAMIDE",
,"701",,,"3.4.21.6",,
,"701",,,,,
"1HCG",,"1HCG","STRUCTURE OF HUMAN DES(1-45) FACTOR XA AT 2.2 ANGSTROMS RESOLUTION","3.4.21.6",
,,,,"3.4.21.6",
"2HWL",,"2HWL","Crystal structure of thrombin in complex with fibrinogen gamma' peptide","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,,
"1DM4",,"1DM4","SER195ALA MUTANT OF HUMAN THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A (7-16)","3.4.21.5",
,,,,"3.4.21.5",
,,,,,
"5Z5X",,"5Z5X","HVF18 in complex with LPS micelles","3.4.21.5",
"5Z5W",,"5Z5W","VFR12 in complex with LPS micelles","3.4.21.5",
"2ERW",,"2ERW","Crystal Structure of Infestin 4, a factor XIIa inhibitor",
"4UDW","N6L","4UDW","Thrombin in complex with 1-(2R)-2-amino-3-phenyl-propanoyl-N-(2, 5dichlorophenyl)methylpyrrolidine-2-carboxamide","3.4.21.5","SODIUM ION",
,"N6L",,,,"D-phenylalanyl-N-(2,5-dichlorobenzyl)-L-prolinamide",
,,,,"3.4.21.5","PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"4UFD",,"4UFD","Thrombin in complex with 4-(((1-((2S)-1-((2R)-2-(benzylsulfonylamino)- 3-phenyl-propanoyl)pyrrolidin-2-yl)-1-oxo-ethyl)amino)methyl) benzamidine","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
,,,,"3.4.21.5","GLYCEROL",
,,,,,"(2S)-N-[(4-carbamimidoylphenyl)methyl]-1-[(2R)-3-phenyl-2-[(phenylmethyl)sulfonylamino]propanoyl]pyrrolidine-2-carboxamide",
,,,,,"PHOSPHATE ION",
"4UEH","BEN","4UEH","Thrombin in complex with benzamidine","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
,,,,"3.4.21.5","BENZAMIDINE",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
"4RKJ",,"4RKJ","Crystal structure of thrombin mutant S195T (free form)","3.4.21.5","POTASSIUM ION",
,,,,"3.4.21.5","GLYCEROL",
"3SV2","P05","3SV2","Human Thrombin In Complex With UBTHR105","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"P05",,,"3.4.21.5","D-phenylalanyl-N-(pyridin-4-ylmethyl)-L-prolinamide",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"SODIUM ION",
"5AF9","SJR","5AF9","Thrombin in complex with 4-Methoxy-N-(2-pyridinyl)benzamide","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"SJR",,,,"SODIUM ION",
,"SJR",,,"3.4.21.5","DIMETHYL SULFOXIDE",
,"SJR",,,,"4-methoxy-N-(pyridin-2-yl)benzamide",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"1,2-ETHANEDIOL",
"5JDU",,"5JDU","Crystal structure for human thrombin mutant D189A","3.4.21.5","CHLORIDE ION",
,,,,"3.4.21.5","GLYCEROL",
"3BV9",,"3BV9","Structure of Thrombin Bound to the Inhibitor FM19","3.4.21.5","IODIDE ION",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"GLYCEROL",
"1G2M","R11","1G2M","FACTOR XA INHIBITOR COMPLEX","3.4.21.6","CALCIUM ION",
,"R11",,,"3.4.21.6","4-{[1-METHYL-5-(2-METHYL-BENZOIMIDAZOL-1-YLMETHYL)-1H-BENZOIMIDAZOL-2-YLMETHYL]-AMINO}-BENZAMIDINE",
"1G2L","T87","1G2L","FACTOR XA INHIBITOR COMPLEX","3.4.21.6","CALCIUM ION",
,"T87",,,"3.4.21.6","[(1-{2[(4-CARBAMIMIDOYL-PHENYLAMINO)-METHYL]-1-METHYL-1H-BENZOIMIDAZOL-5-YL}-CYCLOPROPYL)-PYRIDIN-2-YL-METHYLENEAMINOOXY]-ACETIC ACID ETHYL ESTER",
,"T87",,,,,
"3SQH",,"3SQH","Crystal structure of prethrombin-2 mutant S195A in the the open form","3.4.21.5",
"2BVX","5CB","2BVX","Design and Discovery of Novel, Potent Thrombin Inhibitors with a Solubilizing Cationic P1-P2-Linker","3.4.21.5","N-(5-CHLORO-BENZO[B]THIOPHEN-3-YLMETHYL)-2-[6-CHLORO-OXO-3-(2-PYRIDIN-2-YL-ETHYLAMINO)-2H-PYRAZIN-1-YL]-ACETAMIDE",
,,,,,,
,,,,"3.4.21.5",,
"2BVS","2CE","2BVS","Human thrombin complexed with fragment-based small molecules occupying the S1 pocket","3.4.21.5","N-[2-(2-CARBAMOYLMETHOXY-ETHOXY)-ETHYL]-2-[2-(4-CHLORO-PHENYLSULFANYL)-ACETYLAMINO]-3-(4-GUANIDINO-PHENYL)-PROPIONAMIDE",
,,,,,,
,,,,"3.4.21.5",,
"2BVR","4CP","2BVR","Human thrombin complexed with fragment-based small molecules occupying the S1 pocket","3.4.21.5","2-[2-(4-CHLORO-PHENYLSULFANYL)-ACETYLAMINO]-3-(4-GUANIDINO-PHENYL)-PROPIONAMIDE",
,,,,,,
,,,,"3.4.21.5",,
"2BXU","C1D","2BXU","Design and Discovery of Novel, Potent Thrombin Inhibitors with a Solubilizing Cationic P1-P2-Linker","3.4.21.5","1-(2-{[(6-AMINO-2-METHYLPYRIDIN-3-YL)METHYL]AMINO}ETHYL)-6-CHLORO-3-[(2,2-DIFLUORO-2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL",
,,,,,,
,,,,"3.4.21.5",,
"2BXT","C2D","2BXT","Design and Discovery of Novel, Potent Thrombin Inhibitors with a Solubilizing Cationic P1-P2-Linker","3.4.21.5","6-CHLORO-1-(2-{[(5-CHLORO-1-BENZOTHIEN-3-YL)METHYL]AMINO}ETHYL)-3-[(2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL",
,,,,,,
,,,,"3.4.21.5",,
"6CYM",,"6CYM","Reversible Covalent Direct Thrombin Inhibitors","3.4.21.5","2-methoxybenzoic acid",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
"1T4V","14A","1T4V","Crystal Structure Analysis of a novel Oxyguanidine bound to Thrombin","3.4.21.5","N-ALLYL-5-AMIDINOAMINOOXY-PROPYLOXY-3-CHLORO-N-CYCLOPENTYLBENZAMIDE",
,"14A",,,"3.4.21.5",,
,"14A",,,,,
"1T4U","81A","1T4U","Crystal Structure Analysis of a novel Oxyguanidine bound to Thrombin","3.4.21.5","2-METHANESULFONYL-BENZENESULFONIC ACID 3-METHYL-5-((1-AMIDINOAMINOOXYMETHYL-CYCLOPROPYL)METHYLOXY)-PHENYLESTER",
,,,,"3.4.21.5",,
,,,,,,
"1Z71","L17","1Z71","thrombin and P2 pyridine N-oxide inhibitor complex structure","3.4.21.5","L17",
,"L17",,,,,
"1JWT","BLI","1JWT","CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH A NOVEL BICYCLIC LACTAM INHIBITOR","3.4.21.5","4-OXO-2-PHENYLMETHANESULFONYL-OCTAHYDRO-PYRROLO[1,2-A]PYRAZINE-6-CARBOXYLIC ACID [1-(N-HYDROXYCARBAMIMIDOYL)-PIPERIDIN-4-YLMETHYL]-AMIDE",
,"BLI",,,,,
"3E6P",,"3E6P","Crystal structure of human meizothrombin desF1","3.4.21.5","SULFATE ION",
,,,,"3.4.21.5","D-PHENYLALANYL-N-[(1S)-4-{[(Z)-AMINO(IMINO)METHYL]AMINO}-1-(CHLOROACETYL)BUTYL]-L-PROLINAMIDE",
,,,,,"SODIUM ION",
"4MLF",,"4MLF","Crystal structure for the complex of thrombin mutant D102N and hirudin","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"ACETATE ION",
"6EO9","2OJ","6EO9","Crystal structure of thrombin in complex with a novel glucose-conjugated potent inhibitor","3.4.21.5","DIMETHYL SULFOXIDE",
,,,,"3.4.21.5","N-(2-{[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]methoxy}-6-{3-[(2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl)oxy]propoxy}phenyl)-1-(propan-2-yl)piperidine-4-carboxamide",
,,,,,,
"6EO8","2FN","6EO8","Crystal structure of thrombin in complex with a novel glucose-conjugated potent inhibitor","3.4.21.5","DIMETHYL SULFOXIDE",
,,,,"3.4.21.5","N-(2-{[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]methoxy}-6-[3-(beta-D-glucopyranosyloxy)propoxy]phenyl)-1-(propan-2-yl)piperidine-4-carboxamide",
,,,,,,
"6ZUN",,"6ZUN","Crystal Structure of Thrombin in complex with compound20a","3.4.21.5","[2-[(3-chlorophenyl)methylamino]-7-methoxy-1,3-benzoxazol-5-yl]-[(3~{R},4~{R})-3-methyl-4-oxidanyl-piperidin-1-yl]methanone",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,,
"6ZUH",,"6ZUH","Crystal Structure of Thrombin in complex with compound17","3.4.21.5","[2-[(3-chlorophenyl)methylamino]-7-methoxy-1,3-benzoxazol-5-yl]-(2,2-dimethylmorpholin-4-yl)methanone",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"DIMETHYL SULFOXIDE",
"6ZUG",,"6ZUG","Crystal Structure of Thrombin in complex with compound10","3.4.21.5","2-[(3-chlorophenyl)methylamino]-7-methoxy-~{N}-[[(3~{S})-oxolan-3-yl]methyl]-~{N}-propyl-1,3-benzoxazole-5-carboxamide",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,,
"6ZV7",,"6ZV7","Crystal Structure of Thrombin in complex with compound42b","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","[2-[[(1~{R})-1-(3-chlorophenyl)ethyl]amino]-7-methoxy-1,3-benzoxazol-5-yl]-[(2~{R},5~{R})-5-(2-hydroxyethyl)-2-methyl-morpholin-4-yl]methanone",
,,,,,,
"6ZUU",,"6ZUU","Crystal structure of Thrombin in complex with compound30","3.4.21.5","[2-[(3-chlorophenyl)methylamino]-4-methoxy-1,3-benzoxazol-6-yl]-[(3~{R},4~{R})-3-methyl-4-oxidanyl-piperidin-1-yl]methanone",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,,
"6ZUX",,"6ZUX","Crystal Structure of Thrombin in complex with compound42a","3.4.21.5","[2-[[(1~{R})-1-(3-chlorophenyl)ethyl]amino]-7-methoxy-1,3-benzoxazol-5-yl]-[(2~{S},5~{S})-5-(2-hydroxyethyl)-2-methyl-morpholin-4-yl]methanone",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,,
"6ZUW",,"6ZUW","Crystal Structure of Thrombin in complex with compound40","3.4.21.5","[2-[[(1~{R})-1-(3-chlorophenyl)ethyl]amino]-7-methoxy-1,3-benzoxazol-5-yl]-[(2~{S},5~{R})-5-ethyl-2-(2-hydroxyethyl)-2-methyl-morpholin-4-yl]methanone",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,,
"6ZV8",,"6ZV8","Crystal Structure of Thrombin in complex with compound51","3.4.21.5","[2-[[(1~{S})-1-(3-chlorophenyl)-2-fluoranyl-ethyl]amino]-7-methoxy-1,3-benzoxazol-5-yl]-[(2~{S},5~{S})-5-(2-hydroxyethyl)-2-methyl-morpholin-4-yl]methanone",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,,
"5TO3",,"5TO3","Crystal structure of thrombin mutant W215A/E217A fused to EGF456 of thrombomodulin via a 31-residue linker and bound to PPACK","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","POTASSIUM ION",
,,,,,"SODIUM ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"3RML","M31","3RML","Human Thrombin in complex with MI331","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","N-(benzylsulfonyl)glycyl-N-[2-(aminomethyl)-5-chlorobenzyl]-L-prolinamide",
,,,,,"GLYCEROL",
,,,,,"PHOSPHATE ION",
,,,,,"SODIUM ION",
"3RMM","M32","3RMM","Human Thrombin in complex with MI332","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","N-(benzylsulfonyl)-D-alanyl-N-[2-(aminomethyl)-5-chlorobenzyl]-L-prolinamide",
,,,,,"GLYCEROL",
,,,,,"PHOSPHATE ION",
,,,,,"SODIUM ION",
"3RLW","S28","3RLW","Human Thrombin in complex with MI328","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","N-(benzylsulfonyl)glycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"SODIUM ION",
"3RLY","S29","3RLY","Human Thrombin in complex with MI329","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","N-(benzylsulfonyl)-D-alanyl-N-(4-carbamimidoylbenzyl)-L-prolinamide",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"SODIUM ION",
"3RM0","S54","3RM0","Human Thrombin in complex with MI354","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","N-(benzylsulfonyl)-D-valyl-N-(4-carbamimidoylbenzyl)-L-prolinamide",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"SODIUM ION",
"3RM2","S00","3RM2","Human Thrombin in complex with MI003","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"S00",,,"3.4.21.5","N-(benzylsulfonyl)-3-cyclohexyl-D-alanyl-N-(4-carbamimidoylbenzyl)-L-prolinamide",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"SODIUM ION",
"3RMN","M41","3RMN","Human Thrombin in complex with MI341","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","N-(benzylsulfonyl)-D-valyl-N-[2-(aminomethyl)-5-chlorobenzyl]-L-prolinamide",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"SODIUM ION",
"3RMO","S04","3RMO","Human Thrombin in complex with MI004","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"S04",,,"3.4.21.5","N-(benzylsulfonyl)-3-cyclohexyl-D-alanyl-N-[2-(aminomethyl)-5-chlorobenzyl]-L-prolinamide",
,,,,,"GLYCEROL",
,,,,,"PHOSPHATE ION",
,,,,,"SODIUM ION",
"4UE7","MRZ","4UE7","Thrombin in complex with 1-amidinopiperidine","3.4.21.5","piperidine-1-carboximidamide",
,"MRZ",,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,"MRZ",,,"3.4.21.5","IODIDE ION",
,"MRZ",,,,"GLYCEROL",
,"MRZ",,,,"SODIUM ION",
,,,,,"PHOSPHATE ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"1,2-ETHANEDIOL",
"3BEI",,"3BEI","Crystal structure of the slow form of thrombin in a self_inhibited conformation","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","GLYCEROL",
"3T5F","M34","3T5F","Human Thrombin In Complex With MI340","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","N-(benzylsulfonyl)-D-leucyl-N-[2-(aminomethyl)-5-chlorobenzyl]-L-prolinamide",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"SODIUM ION",
"6T3Q",,"6T3Q","Thrombin in Complex with a D-Phe-Pro-2-aminopyridine derivative","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"SODIUM ION",
,,,,,"(2~{S})-1-[(2~{R})-2-azanyl-3-phenyl-propanoyl]-~{N}-[(2-azanylpyridin-4-yl)methyl]pyrrolidine-2-carboxamide",
"6T4A",,"6T4A","Thrombin in Complex with a D-Phe-Pro-p-aminopyridine derivative","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","(2~{S})-1-[(2~{R})-2-azanyl-3-phenyl-propanoyl]-~{N}-[(6-azanylpyridin-3-yl)methyl]pyrrolidine-2-carboxamide",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"SODIUM ION",
"4RKO",,"4RKO","Crystal structure of thrombin mutant S195T bound with PPACK","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","2-(N-MORPHOLINO)-ETHANESULFONIC ACID",
,,,,,"GLYCEROL",
,,,,,"SODIUM ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"2UU8",,"2UU8","X-ray structure of Ni, Ca concanavalin A at Ultra-high resolution (0. 94A)",,"NICKEL (II) ION",
,,,,,"CALCIUM ION",
"2UWP","894","2UWP","Factor Xa inhibitor complex","3.4.21.6","2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHANESULFONAMIDE",
,"894",,,"3.4.21.6","CALCIUM ION",
,"894",,,,"MAGNESIUM ION",
"1ZAQ",,"1ZAQ","FOURTH EGF-LIKE DOMAIN OF THROMBOMODULIN, NMR, 12 STRUCTURES",
"1GI9","123","1GI9","A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE","3.4.21.73","2-(2-HYDROXY-5-METHOXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE",
,"123",,,"3.4.21.73","CITRIC ACID",
"1GI8","122","1GI8","A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE","3.4.21.73","CITRIC ACID",
,"122",,,"3.4.21.73","2-(2-HYDROXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE",
,"BMZ",,,,,
,"122",,,,,
,"122",,,,,
"1GI7","120","1GI7","A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE","3.4.21.73","2-(2-OXO-1,2-DIHYDRO-PYRIDIN-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE",
,"120",,,"3.4.21.73","CITRIC ACID",
"4H6T",,"4H6T","Crystal structure of prethrombin-2 mutant E14eA/D14lA/E18A/S195A","3.4.21.5","PHOSPHATE ION",
"2V3H",,"2V3H","Thrombin with 3-cycle no F","3.4.21.5","(2R)-({4-[AMINO(IMINO)METHYL]PHENYL}AMINO){3-[3-(DIMETHYLAMINO)-2,2-DIMETHYLPROPOXY]-5-ETHYLPHENYL}ACETIC ACID",
,,,,,"SODIUM ION",
,,,,"3.4.21.5","CALCIUM ION",
"1GJ5","130","1GJ5","SELECTIVITY AT S1, H2O DISPLACEMENT, UPA, TPA, SER190/ALA190 PROTEASE, STRUCTURE-BASED DRUG DESIGN","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","2-(2-HYDROXY-BIPHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE",
,,,,,,
"1GJ4","132","1GJ4","SELECTIVITY AT S1, H2O DISPLACEMENT, UPA, TPA, SER190/ALA190 PROTEASE, STRUCTURE-BASED DRUG DESIGN","3.4.21.5","SODIUM ION",
,"132",,,"3.4.21.5","6-CHLORO-2-(2-HYDROXY-BIPHENYL-3-YL)-1H-INDOLE-5-CARBOXAMIDINE",
,"132",,,,,
"6PX5",,"6PX5","CRYSTAL STRUCTURE OF HUMAN MEIZOTHROMBIN DESF1 MUTANT S195A bound with PPACK","3.4.21.5","ZINC ION",
,,,,"3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,,"SODIUM ION",
"1SR5",,"1SR5","ANTITHROMBIN-ANHYDROTHROMBIN-HEPARIN TERNARY COMPLEX STRUCTURE",,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","2,3,4,6-tetra-O-sulfonato-alpha-D-glucopyranose",
,,,,"3.4.21.5",,
"3S7H",,"3S7H","Structure of thrombin mutant Y225P in the E* form","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","GLYCEROL",
"5AFY",,"5AFY","Thrombin in complex with 3-chloro-benzamide","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
,,,,"3.4.21.5","3-CHLORO-BENZAMIDE",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"O-SULFO-L-TYROSINE",
"5AHG",,"5AHG","Thrombin in complex with ((4-chlorophenyl)sulfamoyl))diemethylamine","3.4.21.5","SODIUM ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,"3.4.21.5","PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"((4-Chlorophenyl)sulfamoyl))dimethylamine",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"6PXJ",,"6PXJ","Crystal structure of human thrombin mutant I16T","3.4.21.5","GLYCEROL",
,,,,"3.4.21.5","MAGNESIUM ION",
"2ADX",,"2ADX","FIFTH EGF-LIKE DOMAIN OF THROMBOMODULIN (TMEGF5), NMR, MINIMIZED AVERAGE STRUCTURE",
"1ADX",,"1ADX","FIFTH EGF-LIKE DOMAIN OF THROMBOMODULIN (TMEGF5), NMR, 14 STRUCTURES",
"1O2K","656","1O2K","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"656",,,,"CHLORIDE ION",
,,,,,"SULFATE ION",
,,,,,"2-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-6-ISOBUTOXYBENZENOLATE",
"1O2J","656","1O2J","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"656",,,,"CHLORIDE ION",
,,,,,"SULFATE ION",
,,,,,"2-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-6-ISOBUTOXYBENZENOLATE",
"1O2I","655","1O2I","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"2-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-6-(CYCLOPENTYLOXY)BENZENOLATE",
"1O2H","CR3","1O2H","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"CR3",,,,"2-{5-[AMINO(IMINIO)METHYL]-1H-INDOL-2-YL}-6-(CYCLOPENTYLOXY)BENZENOLATE",
,"CR3",,,,,
"1O2S","CR4","1O2S","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"122",,,,"CHLORIDE ION",
,"122",,,,"2-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}BENZENOLATE",
,"122",,,,,
,"122",,,,,
,"CR4",,,,,
"1O34","801","1O34","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"801",,,,"CHLORIDE ION",
,,,,,"2-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}PYRIDIN-3-OLATE",
"1O2R","CR9","1O2R","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,,,,,"CHLORIDE ION",
,,,,,"SULFATE ION",
,,,,,"2-{5-[AMINO(IMINIO)METHYL]-6-FLUORO-1H-BENZIMIDAZOL-2-YL}-6-[(2-METHYLCYCLOHEXYL)OXY]BENZENOLATE",
"1O33","801","1O33","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"801",,,,"CHLORIDE ION",
,,,,,"2-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}PYRIDIN-3-OLATE",
"1O2Q","991","1O2Q","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"991",,,,"SULFATE ION",
,"991",,,,"2-{5-[AMINO(IMINIO)METHYL]-6-CHLORO-1H-INDOL-2-YL}-6-(CYCLOPENTYLOXY)BENZENOLATE",
"1O32","801","1O32","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"801",,,,"2-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}PYRIDIN-3-OLATE",
"1O2P","972","1O2P","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,,,,,"CHLORIDE ION",
,,,,,"SULFATE ION",
,,,,,"2-{5-[AMINO(IMINIO)METHYL]-6-CHLORO-1H-BENZIMIDAZOL-2-YL}-6-ISOBUTOXYBENZENOLATE",
"1O31","801","1O31","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,,,,,"2-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}PYRIDIN-3-OLATE",
"1O2O","950","1O2O","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"950",,,,"SULFATE ION",
,,,,,"2-{5-[AMINO(IMINIO)METHYL]-6-FLUORO-1H-BENZIMIDAZOL-2-YL}-6-ISOBUTOXYBENZENOLATE",
"1O30","693","1O30","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"693",,,,"CHLORIDE ION",
,,,,,"2-(5-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-2'-FLUORO-6-OXIDO-1,1'-BIPHENYL-3-YL)SUCCINATE",
"1O2N","762","1O2N","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"762",,,,"SULFATE ION",
,,,,,"3-{5-[AMINO(IMINIO)METHYL]-6-CHLORO-1H-BENZIMIDAZOL-2-YL}-1,1'-BIPHENYL-2-OLATE",
"1O2M",,"1O2M","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,,,,,"CHLORIDE ION",
,,,,,"3-{5-[AMINO(IMINIO)METHYL]-6-CHLORO-1H-BENZIMIDAZOL-2-YL}-1,1'-BIPHENYL-2-OLATE",
"1O2L",,"1O2L","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,,,,,"3-{5-[AMINO(IMINIO)METHYL]-6-CHLORO-1H-BENZIMIDAZOL-2-YL}-1,1'-BIPHENYL-2-OLATE",
"1O3L","678","1O3L","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,,,,,"CHLORIDE ION",
,,,,,"(3-{5-[AMINO(IMINIO)METHYL]-1H-INDOL-2-YL}-5-BROMO-4-OXIDOPHENYL)ACETATE",
"1O3K","334","1O3K","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"334",,,,"CHLORIDE ION",
,,,,,"2-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-6-BROMO-4-METHYLBENZENOLATE",
"1O3J","334","1O3J","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"334",,,,"2-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-6-BROMO-4-METHYLBENZENOLATE",
"1O3I","907","1O3I","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"907",,,,"2-{5-[AMINO(IMINIO)METHYL]-1H-INDOL-2-YL}-6-BROMO-4-METHYLBENZENOLATE",
,"907",,,,,
"1O3H","907","1O3H","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"907",,,,"CHLORIDE ION",
,"907",,,,"2-{5-[AMINO(IMINIO)METHYL]-1H-INDOL-2-YL}-6-BROMO-4-METHYLBENZENOLATE",
"1O3G","696","1O3G","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"696",,,,"CHLORIDE ION",
,"696",,,,"3-{5-[AMINO(IMINIO)METHYL]-1H-INDOL-2-YL}-1,1'-BIPHENYL-2-OLATE",
,"696",,,,,
"1O3F","696","1O3F","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"696",,,,"CHLORIDE ION",
,"696",,,,"3-{5-[AMINO(IMINIO)METHYL]-1H-INDOL-2-YL}-1,1'-BIPHENYL-2-OLATE",
,"696",,,,,
"1O3E","696","1O3E","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"696",,,,"CHLORIDE ION",
,"696",,,,"3-{5-[AMINO(IMINIO)METHYL]-1H-INDOL-2-YL}-1,1'-BIPHENYL-2-OLATE",
,"696",,,,,
"1O3O",,"1O3O","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,,,,,"2-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-4-(TRIFLUOROMETHOXY)BENZENOLATE",
"1O3N",,"1O3N","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,,,,,"2-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-4-(TRIFLUOROMETHOXY)BENZENOLATE",
"1O3M",,"1O3M","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,,,,,"CHLORIDE ION",
,,,,,"2-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-4-(TRIFLUOROMETHOXY)BENZENOLATE",
"1O2Z","312","1O2Z","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"312",,,,"2-(5-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-2'-METHOXY-6-OXIDO-1,1'-BIPHENYL-3-YL)SUCCINATE",
"1O2Y","847","1O2Y","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"847",,,,"2-(3-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-5-BROMO-4-OXIDOPHENYL)SUCCINATE",
"1O2X","847","1O2X","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"847",,,,"CHLORIDE ION",
,,,,,"2-(3-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-5-BROMO-4-OXIDOPHENYL)SUCCINATE",
"1O39","780","1O39","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"780",,,,"3-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-1,1'-BIPHENYL-2-OLATE",
"1O2W","847","1O2W","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"847",,,,"CHLORIDE ION",
,,,,,"2-(3-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-5-BROMO-4-OXIDOPHENYL)SUCCINATE",
"1O38","653","1O38","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"653",,,,"SULFATE ION",
,,,,,"5-(2-AMINOETHYL)-3-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-1,1'-BIPHENYL-2-OLATE",
"1O2V","847","1O2V","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"847",,,,"CHLORIDE ION",
,,,,,"2-(3-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-5-BROMO-4-OXIDOPHENYL)SUCCINATE",
"1O37","653","1O37","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"653",,,,"5-(2-AMINOETHYL)-3-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-1,1'-BIPHENYL-2-OLATE",
"1O2U","847","1O2U","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"847",,,,"2-(3-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-5-BROMO-4-OXIDOPHENYL)SUCCINATE",
"1O36","607","1O36","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"607",,,,"CHLORIDE ION",
,,,,,"2-(2'-AMINO-5-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-6-OXIDO-1,1'-BIPHENYL-3-YL)SUCCINATE",
"1O2T","783","1O2T","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"783",,,,"CHLORIDE ION",
,,,,,"3-{5-[AMINO(IMINIO)METHYL]-1H-INDOL-2-YL}-5-METHOXY-1,1'-BIPHENYL-2-OLATE",
"1O35","802","1O35","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"2-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-4-FLUOROBENZENOLATE",
"1O3D","780","1O3D","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"780",,,,"CHLORIDE ION",
,,,,,"3-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-1,1'-BIPHENYL-2-OLATE",
"1O3C","780","1O3C","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,,,,,"CHLORIDE ION",
,,,,,"3-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-1,1'-BIPHENYL-2-OLATE",
"1O3B","780","1O3B","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,"780",,,,"CHLORIDE ION",
,,,,,"3-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-1,1'-BIPHENYL-2-OLATE",
"1O3A",,"1O3A","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.4","CALCIUM ION",
,,,,,"3-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-1,1'-BIPHENYL-2-OLATE",
"6GN7",,"6GN7","X-ray structure of the complex between human alpha thrombin and NU172, a duplex/quadruplex 26-mer DNA aptamer, in the presence of sodium ions.","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"GLYCEROL",
"6HSX",,"6HSX","Thrombin in Complex with a D-Phe-Pro-diaminopyridine derivative","3.4.21.5","DIMETHYL SULFOXIDE",
,,,,"3.4.21.5","GLYCEROL",
,,,,,"SODIUM ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"PHOSPHATE ION",
,,,,,"(2~{S})-1-[(2~{R})-2-azanyl-3-phenyl-propanoyl]-~{N}-[[2,6-bis(azanyl)pyridin-4-yl]methyl]pyrrolidine-2-carboxamide",
"6EVV",,"6EVV","X-ray structure of the complex between human alpha thrombin and NU172, a duplex/quadruplex 26-mer DNA aptamer, in the presence of potassium ions.","3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"POTASSIUM ION",
,,,,,"GLYCEROL",
"4UD9","FQI","4UD9","Thrombin in complex with 5-chlorothiophene-2-carboxamide","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"FQI",,,,"O-SULFO-L-TYROSINE",
,"FQI",,,"3.4.21.5","SODIUM ION",
,"FQI",,,,"PHOSPHATE ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"GLYCEROL",
,,,,,"1,2-ETHANEDIOL",
,,,,,"5-CHLORO-2-THIOPHENECARBOXAMIDE",
"6TKG",,"6TKG","Tsetse thrombin inhibitor in complex with human alpha-thrombin - orthorhombic form at 12keV","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","GLYCEROL",
,,,,,"SODIUM ION",
"6TKL",,"6TKL","Non-cleavable tsetse thrombin inhibitor in complex with human alpha-thrombin","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"GLYCEROL",
"1YPE","UIP","1YPE","Thrombin Inhibitor Complex","3.4.21.5","SODIUM ION",
,"UIP",,,"3.4.21.5","(1R,3AS,4R,8AS,8BR)-4-(2-BENZO[1,3]DIOXOL-5-YLMETHYL-1-ETHYL-3-OXO-DECAHYDRO-PYRROLO[3,4-A]PYRROLIZIN-4-YL)-BENZAMIDINE",
,,,,,"GLYCEROL",
"2V3O",,"2V3O","Thrombin with 3-cycle with F","3.4.21.5","(2R)-[(4-CARBAMIMIDOYLPHENYL)AMINO]{3-[3-(DIMETHYLAMINO)-2,2-DIMETHYLPROPOXY]-5-ETHYL-2-FLUOROPHENYL}ETHANOIC ACID",
,,,,,"SODIUM ION",
,,,,"3.4.21.5","CALCIUM ION",
"1XM1",,"1XM1","Nonbasic Thrombin Inhibitor Complex","3.4.21.5","N-{[(2S)-1-(N-{[4-({[AMINO(IMINO)METHYL]AMINO}METHYL)CYCLOHEXYL]CARBONYL}-3-CYCLOHEXYL-L-ALANYL)AZETIDIN-2-YL]CARBONYL}-L-TYROSYL-N~6~-[AMINO(IMINO)METHYL]-L-LYSINAMIDE",
,,,,,,
"3EGK","M18","3EGK","KNOBLE Inhibitor","3.4.21.5","{(2S)-1-[N-(tert-butoxycarbonyl)glycyl]pyrrolidin-2-yl}methyl (3-chlorophenyl)acetate",
,"M18",,,"3.4.21.5","SODIUM ION",
,,,,,,
"2YZ4",,"2YZ4","The neutron structure of concanavalin A at 2.2 Angstroms",,"MANGANESE (II) ION",
,,,,,"CALCIUM ION",
"2JEW","720","2JEW","Crystal structure of ((2S)-5-amino-2-((1-n-propyl-1H-imidazol-4-yl) methyl)pentanoic acid) UK396,082 a TAFIa inhibitor, Bound to Activated Porcine Pancreatic carboxypeptidaseB","3.4.17.2","ZINC ION",
,"720",,,,"(2S)-5-AMINO-2-[(1-PROPYL-1H-IMIDAZOL-4-YL)METHYL]PENTANOIC ACID",
,"720",,,,,
"5A2M",,"5A2M","Thrombin Inhibitor","3.4.21.5","GLYCEROL",
,,,,,"SODIUM ION",
,,,,"3.4.21.5","(2S)-1-[(2R)-5-carbamimidamido-2-[(phenylmethyl)sulfonylamino]pentanoyl]-N-[[5-chloranyl-2-(hydroxymethyl)phenyl]methyl]pyrrolidine-2-carboxamide",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"2CN0","F25","2CN0","Complex of Recombinant Human Thrombin with a Designed Inhibitor","3.4.21.5","4-(1R,3AS,4R,8AS,8BR)-[1-DIFLUOROMETHYL-2-(4-FLUOROBENZYL)-3-OXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZAMIDINE",
,"F25",,,,"SODIUM ION",
,,,,"3.4.21.5","CALCIUM ION",
"4YES","45S","4YES","Thrombin in complex with (S)-(4-chloro-2-((1-(5-methyl-1H-pyrrole-2-carbonyl)pyrrolidine-2-carboxamido)methyl)phenyl)methanaminium","3.4.21.5","MAGNESIUM ION",
,,,,"3.4.21.5","GLYCEROL",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"N-[2-(aminomethyl)-5-chlorobenzyl]-1-[(5-methyl-1H-pyrrol-2-yl)carbonyl]-L-prolinamide",
"6I51",,"6I51","Thrombin in complex with fragment J02","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","DIMETHYL SULFOXIDE",
,,,,,"PHOSPHATE ION",
,,,,,"SODIUM ION",
,,,,,"2H-isoindol-1-amine",
"1QB1","974","1QB1","Bovine Trypsin with 1-[2-[5-[amino(imino)methyl]-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]piperidine-3-carboxylic Acid (ZK-806974)","3.4.21.4","CALCIUM ION",
,"974",,,,"1-[2-[5-[AMINO(IMINO)METHYL]-2-HYDROXYPHENOXY]-6-[3-(4,5-DIHYDRO-1-METHYL-1H-IMIDAZOL-2-YL)PHENOXY] PYRIDIN-4-YL]PIPERIDINE-3-CARBOXYLIC ACID",
"2ZFQ",,"2ZFQ","Exploring thrombin S3 pocket","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide",
,,,,,"BENZAMIDINE",
,,,,,"GLYCEROL",
"2ZFR",,"2ZFR","Exploring thrombin S3 pocket","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide",
,,,,,"GLYCEROL",
"2ZHF","49U","2ZHF","Exploring thrombin S3 pocket","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide",
,,,,,"GLYCEROL",
"3U9A",,"3U9A","Human Thrombin In Complex With MI330","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","(2S)-N-[[2-(aminomethyl)-5-chloranyl-phenyl]methyl]-1-[(2S)-2-[(3-chloranyl-4-methoxy-phenyl)sulfonylamino]-4-[(4-cyanophenyl)methylamino]-4-oxidanylidene-butanoyl]pyrrolidine-2-carboxamide",
,,,,,"GLYCEROL",
,,,,,"PHOSPHATE ION",
,,,,,"SODIUM ION",
"5MLS",,"5MLS","Thrombin Mutant A190S in complex with (S)-1-(D-phenylalanyl)-N-(3-chlorobenzyl)pyrrolidine-2-carboxamide","3.4.21.5","D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide",
,,,,"3.4.21.5","DIMETHYL SULFOXIDE",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"SODIUM ION",
"5MM6",,"5MM6","Thrombin Mutant A190S in complex with (S)-1-(D-phenylalanyl)-N-(4-carbamimidoylbenzyl)pyrrolidine-2-carboxamide","3.4.21.5","GLYCEROL",
,,,,"3.4.21.5","DIMETHYL SULFOXIDE",
,,,,,"PHOSPHATE ION",
,,,,,"SODIUM ION",
,,,,,"D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide",
"6V5T",,"6V5T","Crystal structure of human prethrombin-2 with tryptophans replaced by 5-F-tryptophan","3.4.21.5","GLYCEROL",
,,,,,"SULFATE ION",
"4CBN",,"4CBN","Crystal structure of Complement Factor D mutant R202A after conventional refinement","3.4.21.46","GLYCEROL",
"4CBO",,"4CBO","Crystal structure of Complement Factor D mutant R202A after ensemble refinement","3.4.21.46","GLYCEROL",
"1ZOM","339","1ZOM","Crystal Structure of the Catalytic Domain of Coagulation Factor XI in complex with a peptidomimetic Inhibitor","3.4.21.27","SULFATE ION",
,,,,,"(S)-2-(3-((R)-1-(4-BROMOPHENYL)ETHYL)UREIDO)-N-((S)-1-((S)-5-GUANIDINO-1-OXO-1-(THIAZOL-2-YL)PENTAN-2-YLAMINO)-3-METHYL-1-OXOBUTAN-2-YL)-5-UREIDOPENTANAMIDE",
"1I34",,"1I34","SOLUTION DNA QUADRUPLEX WITH DOUBLE CHAIN REVERSAL LOOP AND TWO DIAGONAL LOOPS CONNECTING GGGG TETRADS FLANKED BY G-(T-T) TRIAD AND T-T-T TRIPLE",
"5MJT",,"5MJT","Thrombin Mutant A190S in complex with (S) -1 - ((R) -2-amino-3,3-diphenylpropanoyl) -N- (3-chlorobenzyl) pyrrolidine-2-carboxamide","3.4.21.5","beta-phenyl-D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide",
,,,,"3.4.21.5","DIMETHYL SULFOXIDE",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"SODIUM ION",
"4DY0",,"4DY0","Crystal structure of native protease nexin-1 with heparin",,"SULFATE ION",
,,,,,"GLYCEROL",
"6GWE","ODB","6GWE","Crystal structure of Thrombin bound to P2 macrocycle","3.4.21.5","(10~{S},14~{S},17~{R})-14-(3-carbamimidamidopropyl)-3-[[2-(hydroxymethyl)phenyl]methyl]-5,12,15-tris(oxidanylidene)-19-thia-3,6,13,16-tetrazatricyclo[19.4.0.0^{6,10}]pentacosa-1(21),22,24-triene-17-carboxamide",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","1,2-ETHANEDIOL",
,,,,"3.4.21.5","SODIUM ION",
"4LK4",,"4LK4","Structure of Vibrio cholerae VesB protease","3",
"1C5U",,"1C5U","STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR","3.4.21.4","CALCIUM ION",
,,,,,"MAGNESIUM ION",
,,,,,"SULFATE ION",
,,,,,"THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDINE",
"1C5T","ESP","1C5T","STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR","3.4.21.4","CALCIUM ION",
,"ESP",,,,"THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDINE",
"1C5S","ESX","1C5S","STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR","3.4.21.4","CALCIUM ION",
,"ESX",,,,"SULFATE ION",
,,,,,"BENZO[B]THIOPHENE-2-CARBOXAMIDINE",
"1C5Q","ESI","1C5Q","STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR","3.4.21.4","CALCIUM ION",
,"ESI",,,,"CHLORIDE ION",
,,,,,"4-IODOBENZO[B]THIOPHENE-2-CARBOXAMIDINE",
"1C5P","BAM","1C5P","STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR","3.4.21.4","CALCIUM ION",
,"BAM",,,,"MAGNESIUM ION",
,,,,,"SULFATE ION",
,,,,,"BENZAMIDINE",
"3VW7","VPX","3VW7","Crystal structure of human protease-activated receptor 1 (PAR1) bound with antagonist vorapaxar at 2.2 angstrom","3.2.1.17","ethyl
[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl}-1-methyl-3-oxododecahydronaphtho[2,3-c]fur
an-6-yl]carbamate",
,,,,,"(2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate",
,,,,,"CHLORIDE ION",
,,,,,"SODIUM ION",
"1O3P","655","1O3P","Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors","3.4.21.73","CITRIC ACID",
,"655",,,"3.4.21.73","2-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-6-(CYCLOPENTYLOXY)BENZENOLATE",
"4E7R","ONW","4E7R","Thrombin in complex with 3-amidinophenylalanine inhibitor","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-{[(2',4'-dichlorobiphenyl-3-yl)sulfonyl]amino}-3-oxopropyl]benzenecarboximidamide",
,,,,,"SODIUM ION",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
"3OSL",,"3OSL","Structure of bovine thrombin-activatable fibrinolysis inhibitor in complex with tick carboxypeptidase inhibitor","3.4.17.20","ZINC ION",
,,,,,,
"4C41",,"4C41","Corticosteroid-binding globulin with engineered disulphide bridge between residues 100 and 236",
"1C5V",,"1C5V","STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR","3.4.21.4","CALCIUM ION",
,,,,,"MAGNESIUM ION",
"1C5R",,"1C5R","STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR","3.4.21.4","CITRATE ANION",
,,,,,"CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"4-IODOBENZO[B]THIOPHENE-2-CARBOXAMIDINE",
"1BJV","GP8","1BJV","BETA-TRYPSIN COMPLEXED WITH APPU","3.4.21.4","CALCIUM ION",
,"GP8",,,,"SULFATE ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"1-(2-AMIDINOPHENYL)-3-(PHENOXYPHENYL)UREA",
"1BJU","GP6","1BJU","BETA-TRYPSIN COMPLEXED WITH ACPU","3.4.21.4","CALCIUM ION",
,"GP6",,,,"SULFATE ION",
,,,,,"1-(4-AMIDINOPHENYL)-3-(4-CHLOROPHENYL)UREA",
,,,,,"DIMETHYL SULFOXIDE",
"1C1S",,"1C1S","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.4","CALCIUM ION",
,,,,,"SODIUM ION",
,,,,,"PHOSPHATE ION",
,,,,,"BIS(5-AMIDINO-BENZIMIDAZOLYL)METHANE",
"1OPH",,"1OPH","NON-COVALENT COMPLEX BETWEEN ALPHA-1-PI-PITTSBURGH AND S195A TRYPSIN",
,,,,3.4.21.4,
"6NOX",,"6NOX","Solution structure of SFTI-KLK5 inhibitor",
"6T3M",,"6T3M","Thrombin in Complex with a D-Phe-Pro-p-phenol derivative","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","(2~{S})-1-[(2~{R})-2-azanyl-3-phenyl-propanoyl]-~{N}-[(4-hydroxyphenyl)methyl]pyrrolidine-2-carboxamide",
,,,,,"PHOSPHATE ION",
,,,,,"SODIUM ION",
"6T52",,"6T52","Thrombin in Complex with a D-Phe-Pro-imidazole derivative","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","PHOSPHATE ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"(2~{S})-1-[(2~{R})-2-azanyl-3-phenyl-propanoyl]-~{N}-[2-(1~{H}-imidazol-4-yl)ethyl]pyrrolidine-2-carboxamide",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"6T57",,"6T57","Thrombin in Complex with a D-Phe-Pro-N-amidinopiperidine Derivative","3.4.21.5","DIMETHYL SULFOXIDE",
,,,,"3.4.21.5","PHOSPHATE ION",
,,,,,"SODIUM ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"(2~{S})-1-[(2~{R})-2-azanyl-3-phenyl-propanoyl]-~{N}-[(1-carbamimidoylpiperidin-4-yl)methyl]pyrrolidine-2-carboxamide",
,,,,,"trifluoroacetic acid",
"6T89",,"6T89","Thrombin in complex with (S)-N-(tert-butyl)-4-(3-(3-carbamimidoylphenyl)-2-((2',4'-dimethoxy-[1,1'-biphenyl])-3-sulfonamido)propanoyl)piperazine-1-carboxamide (MI-498)","3.4.21.5","4-[(2~{S})-3-(3-carbamimidoylphenyl)-2-[[3-(4-methoxy-2-oxidanyl-phenyl)phenyl]sulfonylamino]propanoyl]-~{N}-methyl-piperazine-1-carboxamide",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
,,,,,"DIMETHYL SULFOXIDE",
"6T8A",,"6T8A","Thrombin in complex with diphenyl ((4-carbamimidoylphenyl)((S)-1-((R)-3-cyclohexyl 2-((phenylmethyl)sulfonamido)propanoyl)pyrrolidine-2-carboxamido)methyl)phosphonate (MI-492)","3.4.21.5","[(~{R})-(4-carbamimidoylphenyl)-[[(2~{S})-1-[(2~{R})-3-cyclohexyl-2-[(phenylmethyl)sulfonylamino]propanoyl]pyrrolidin-2-yl]carbonylamino]methyl]-phenoxy-phosphinous acid",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
,,,,,"PHOSPHATE ION",
,,,,,"DIMETHYL SULFOXIDE",
"4HZH",,"4HZH","Structure of recombinant Gla-domainless prothrombin mutant S525A","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
"4DVY",,"4DVY","Crystal structure of the Helicobacter pylori CagA oncoprotein",
"4DVZ",,"4DVZ","Crystal structure of the Helicobacter pylori CagA oncoprotein",
"5DAE",,"5DAE","Kazal type inhibitor from salivary glands of Aedes aegypti mosquito",
"3SQE",,"3SQE","Crystal structure of prethrombin-2 mutant S195A in the alternative form","3.4.21.5","GLYCEROL",
"5LPD",,"5LPD","Thrombin in complex with (S)-1-((R)-2-amino-3-cyclohexylpropanoyl)-N-(2-(aminomethyl)-5-chlorobenzyl) pyrrolidine-2-carboxamide","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"(2~{S})-~{N}-[[2-(aminomethyl)-5-chloranyl-phenyl]methyl]-1-[(2~{R})-2-azanyl-3-cyclohexyl-propanoyl]pyrrolidine-2-carboxamide",
"3D4U",,"3D4U","Bovine thrombin-activatable fibrinolysis inhibitor (TAFIa) in complex with tick-derived carboxypeptidase inhibitor.","3.4.17.20","ZINC ION",
,,,,,"ACETATE ION",
,,,,,"SULFATE ION",
"2V24",,"2V24","Structure of the human SPRY domain-containing SOCS box protein SSB-4",,"NICKEL (II) ION",
"6HHC",,"6HHC","Allosteric Inhibition as a new mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated form of Coagulation Factor XI",,"SULFATE ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,"3.4.21.27",,
"1OO8",,"1OO8","CRYSTAL STRUCTURE OF A1PI-PITTSBURGH IN THE NATIVE CONFORMATION",
"1C5M",,"1C5M","STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR","3.4.21.6",
,,,,"3.4.21.6",
"1WQV","PSM","1WQV","Human Factor Viia-Tissue Factor Complexed with propylsulfonamide-D-Thr-Met-p-aminobenzamidine","3.4.21.21","beta-D-glucopyranose",
,"PSM",,,"3.4.21.21","alpha-L-fucopyranose",
,,,,,"CALCIUM ION",
,,,,,"N-[DIHYDROXY(PROPYL)-LAMBDA~4~-SULFANYL]THREONYL-N~1~-{4-[AMINO(IMINO)METHYL]BENZYL}METHIONINAMIDE",
"5DO4",,"5DO4","Thrombin-RNA aptamer complex","3.4.21.5","MAGNESIUM ION",
,,,,"3.4.21.5","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"1,2-ETHANEDIOL",
,,,,,"GLYCEROL",
,,,,,"CALCIUM ION",
,,,,,"(4R)-2-METHYLPENTANE-2,4-DIOL",
"6GBW","EU5","6GBW","Thrombin in complex with MI2100 ((S)-N-(2-(aminomethyl)-5-chlorobenzyl)-1-((benzylsulfonyl)-L-arginyl)pyrrolidine-2-carboxamide)","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","SODIUM ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"(2~{S})-~{N}-[[2-(aminomethyl)-5-chloranyl-phenyl]methyl]-1-[(2~{S})-5-carbamimidamido-2-[(phenylmethyl)sulfonylamino]pentanoyl]pyrrolidine-2-carboxamide",
"6BJR",,"6BJR","Crystal structure of prothrombin mutant S101C/A470C","3.4.21.5","MAGNESIUM ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"6C2W",,"6C2W","Crystal structure of human prothrombin mutant S101C/A470C","3.4.21.5","MAGNESIUM ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"5JZY",,"5JZY","Thrombin in complex with (S)-1-((R)-2-amino-3-cyclohexylpropanoyl)-N-(4-carbamimidoylbenzyl)pyrrolidine-2-carboxamide","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","DIMETHYL SULFOXIDE",
,,,,,"PHOSPHATE ION",
,,,,,"SODIUM ION",
,,,,,"3-cyclohexyl-D-alanyl-N-[(4-carbamimidoylphenyl)methyl]-L-prolinamide",
"1O5G","CR9","1O5G","Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA)","3.4.21.5","SODIUM ION",
,"CR9",,,"3.4.21.5","CALCIUM ION",
,"CR9",,,,"2-{5-[AMINO(IMINIO)METHYL]-6-FLUORO-1H-BENZIMIDAZOL-2-YL}-6-[(2-METHYLCYCLOHEXYL)OXY]BENZENOLATE",
"6ROT","KDQ","6ROT","Thrombin in complex with MI2105","3.4.21.5","(2~{S})-~{N}-[[5-chloranyl-2-(hydroxymethyl)phenyl]methyl]-1-[2-[(phenylmethyl)sulfonylamino]ethanoyl]pyrrolidine-2-carboxamide",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"PHOSPHATE ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"SODIUM ION",
"3EMW",,"3EMW","Crystal Structure of human splA/ryanodine receptor domain and SOCS box containing 2 (SPSB2) in complex with a 20-residue VASA peptide",,"1,2-ETHANEDIOL",
,,,,,,
"3F6U",,"3F6U","Crystal structure of human Activated Protein C (APC) complexed with PPACK","3.4.21.69","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.69","SODIUM ION",
,,,,,"CALCIUM ION",
"3F2O",,"3F2O","Crystal Structure of human splA/ryanodine receptor domain and SOCS box containing 1 (SPSB1) in complex with a 20-residue VASA peptide",
,,,,3.6.1,
"1C5X","ESI","1C5X","STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR","3.4.21.73","CITRATE ANION",
,"ESI",,,"3.4.21.73","4-IODOBENZO[B]THIOPHENE-2-CARBOXAMIDINE",
"1C5W",,"1C5W","STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR","3.4.21.73","CITRATE ANION",
,,,,"3.4.21.73","4-IODOBENZO[B]THIOPHENE-2-CARBOXAMIDINE",
"1Y3Y","UIR","1Y3Y","TRYPSIN INHIBITOR COMPLEX","3.4.21.4","CALCIUM ION",
,"UIR",,,,"(1R,3AS,4R,8AS,8BR)-4-(2-BENZO[1,3]DIOXOL-5-YL-1-CYCLOPROPYL-3-OXO-DECAHYDRO-PYRROLO[3,4-A]PYRROLIZIN-4-YL)-BENZAMIDINE",
"1Y3X","UIB","1Y3X","TRYPSIN INHIBITOR COMPLEX","3.4.21.4","CALCIUM ION",
,"UIB",,,,"(1R,3AS,4R,8AS,8BR)-4-{5-(PHENYL[1,3]DIOXOL-5-YLMETHYL)-4-ETHYL-2,3,3-TRIMETHYL-6-OXO-OCTAHYDRO-PYRROLO[3,4-C]PYRROL-1-YL}-BENZAMIDINE",
"1Y3W","UIP","1Y3W","TRYPSIN INHIBITOR COMPLEX","3.4.21.4","CALCIUM ION",
,"UIP",,,,"(1R,3AS,4R,8AS,8BR)-4-(2-BENZO[1,3]DIOXOL-5-YLMETHYL-1-ETHYL-3-OXO-DECAHYDRO-PYRROLO[3,4-A]PYRROLIZIN-4-YL)-BENZAMIDINE",
"1Y3V","UIR","1Y3V","Trypsin Inhibitor Complex","3.4.21.4","CALCIUM ION",
,"UIR",,,,"(1R,3AS,4R,8AS,8BR)-4-(2-BENZO[1,3]DIOXOL-5-YL-1-CYCLOPROPYL-3-OXO-DECAHYDRO-PYRROLO[3,4-A]PYRROLIZIN-4-YL)-BENZAMIDINE",
"2FRG",,"2FRG","Structure of the immunoglobulin-like domain of human TLT-1",
"5XRF",,"5XRF","Crystal structure of Da-36, a thrombin-like enzyme from Deinagkistrodon acutus",,"DI(HYDROXYETHYL)ETHER",
"1DLK",,"1DLK","CRYSTAL STRUCTURE ANALYSIS OF DELTA-CHYMOTRYPSIN BOUND TO A PEPTIDYL CHLOROMETHYL KETONE INHIBITOR","3.4.21.1","CHLORIDE ION",
,,,,"3.4.21.1",,
,,,,,,
"1WBU",,"1WBU","Fragment based lead discovery using crystallography","3.1.27.5","5-AMINO-1H-PYRIMIDINE-2,4-DIONE",
,,,,"4.6.1.18",,
"1QCP","RWJ","1QCP","CRYSTAL STRUCTURE OF THE RWJ-51084 BOVINE PANCREATIC BETA-TRYPSIN AT 1.8 A","3.4.21.4","CALCIUM ION",
,,,,,"CYCLOPENTANECARBOXYLIC ACID [1-(BENZOTHIAZOLE-2-CARBONYL)-4-GUANIDINO-BUTYL]-AMIDE",
"3DY0",,"3DY0","Crystal Structure of Cleaved PCI Bound to Heparin",,"NITRATE ION",
,,,,,"GLYCEROL",
"1C34",,"1C34","SOLUTION STRUCTURE OF A QUADRUPLEX FORMING DNA AND ITS INTERMIDIATE",
"1C32",,"1C32","SOLUTION STRUCTURE OF A QUADRUPLEX FORMING DNA AND ITS INTERMIDIATE",
"1WSS","3CB","1WSS","Human Factor Viia-Tissue Factor in Complex with peptide-mimetic inhibitor that has two charged groups in P2 and P4","3.4.21.21","beta-D-glucopyranose",
,,,,"3.4.21.21","alpha-L-fucopyranose",
,,,,,"CALCIUM ION",
,,,,,"N-[(3-CARBOXYBENZYL)SULFONYL]ISOLEUCYL-N~1~-{4-[AMINO(IMINO)METHYL]BENZYL}-5-IMINOORNITHINAMIDE",
"1C5Z","BAM","1C5Z","STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR","3.4.21.73","CITRATE ANION",
,"BAM",,,"3.4.21.73","BENZAMIDINE",
"1C5Y","ESP","1C5Y","STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR","3.4.21.73","CITRATE ANION",
,"ESP",,,"3.4.21.73","THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDINE",
"1C38",,"1C38","SOLUTION STRUCTURE OF A QUADRUPLEX FORMING DNA AND ITS INTERMEDIATE",,"POTASSIUM ION",
"1C35",,"1C35","SOLUTION STRUCTURE OF A QUADRUPLEX FORMING DNA AND ITS INTERMIDIATE",,"POTASSIUM ION",
"1I71",,"1I71","HIGH RESOLUTION CRYSTAL STRUCTURE OF APOLIPOPROTEIN(A) KRINGLE IV TYPE 7: INSIGHTS INTO LIGAND BINDING","3.4.21","SULFATE ION",
"6FJT",,"6FJT","4-chloro-benzamidine in complex with thrombin","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","4-chloranylbenzenecarboximidamide",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"5LCE",,"5LCE","Thrombin in complex with (S)-1-((R)-2-amino-3-cyclohexylpropanoyl)-N-(5-chloro-2-(hydroxymethyl)benzy l)pyrrolidine-2-carboxamide","3.4.21.5","GLYCEROL",
,,,,"3.4.21.5","(2~{S})-1-[(2~{R})-2-azanyl-3-cyclohexyl-propanoyl]-~{N}-[[5-chloranyl-2-(hydroxymethyl)phenyl]methyl]pyrrolidine-2-carboxamide",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"PHOSPHATE ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"SODIUM ION",
,,,,,"1,2-ETHANEDIOL",
"4B3Z",,"4B3Z","Structure of the human collapsin response mediator protein-1, a lung cancer suppressor",
"4IW4",,"4IW4","Crystal structure of the serine protease domain of MASP-3 in complex with ecotin",
,,,,3.4.21,
"2BMG","I1H","2BMG","Crystal structure of factor Xa in complex with 50","3.4.21.6","CALCIUM ION",
,"I1H",,,"3.4.21.6","3-[2-(2,4-DICHLOROPHENYL)ETHOXY]-4-METHOXY-N-[(1-PYRIDIN-4-YLPIPERIDIN-4-YL)METHYL]BENZAMIDE",
"2BOK","784","2BOK","Factor Xa - cation","3.4.21.6","[AMINO (4-{(3AS,4R,8AS,8BR)-1,3-DIOXO-2- [3-(TRIMETHYLAMMONIO) PROPYL]DECAHYDROPYRROLO[3,4-A] PYRROLIZIN-4-YL}PHENYL) METHYLENE]AMMONIUM",
,"784",,,"3.4.21.6","SODIUM ION",
"2CJI","GSK","2CJI","Crystal structure of a Human Factor Xa inhibitor complex","3.4.21.6","CALCIUM ION",
,"GSK",,,"3.4.21.6","6-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-(4-MORPHOLINYL)-2-OXO ETHYL]-2-OXO-3-PYRROLIDINYL}-2-NAPHTHALENESULFONAMIDE",
,"GSK",,,,,
"1ANT",,"1ANT","BIOLOGICAL IMPLICATIONS OF A 3 ANGSTROMS STRUCTURE OF DIMERIC ANTITHROMBIN",
"1ATH",,"1ATH","THE INTACT AND CLEAVED HUMAN ANTITHROMBIN III COMPLEX AS A MODEL FOR SERPIN-PROTEINASE INTERACTIONS",
"1NL2",,"1NL2","BOVINE PROTHROMBIN FRAGMENT 1 IN COMPLEX WITH CALCIUM AND LYSOPHOSPHOTIDYLSERINE","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"CALCIUM ION",
,,,,,"CHLORIDE ION",
,,,,,"O-{HYDROXY[((2R)-2-HYDROXY-3-{[(1S)-1-HYDROXYPENTADECYL]OXY}PROPYL)OXY]PHOSPHORYL}-L-SERINE",
"1NL1",,"1NL1","BOVINE PROTHROMBIN FRAGMENT 1 IN COMPLEX WITH CALCIUM ION","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"CALCIUM ION",
"2B5T",,"2B5T","2.1 Angstrom structure of a nonproductive complex between antithrombin, synthetic heparin mimetic SR123781 and two S195A thrombin molecules","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","GLYCEROL",
,,,,,"SULFATE ION",
"2JK9",,"2JK9","The structure of splA-ryanodine receptor domain and SOCS box containing 1 in complex with a PAR-4 peptide",
,,,,
"2JOO",,"2JOO","The NMR Solution Structure of Recombinant RGD-hirudin",
"1R17",,"1R17","Crystal Structure Analysis of S.epidermidis adhesin SdrG binding to Fibrinogen (adhesin-ligand complex)",,"CALCIUM ION",
,,,,,,
"1R19",,"1R19","Crystal Structure Analysis of S.epidermidis adhesin SdrG binding to Fibrinogen (Apo structure)",
"1WTG","3BP","1WTG","Human Factor Viia-Tissue Factor Complexed with ethylsulfonamide-D-biphenylalanine-Gln-p-aminobenzamidine","3.4.21.21","beta-D-glucopyranose",
,"3BP",,,"3.4.21.21","alpha-L-fucopyranose",
,,,,,"CALCIUM ION",
,,,,,"2-(3-BIPHENYL-4-YL-2-ETHANESULFONYLAMINO-PROPIONYLAMINO)-PENTANEDIOIC ACID 5-AMIDE 1-(4-CARBAMIMIDOYL-BENZYLAMIDE)",
"1T7C",,"1T7C","CRYSTAL STRUCTURE OF THE P1 GLU BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX","3.4.21.1","SULFATE ION",
,,,,,,
"1T8L",,"1T8L","CRYSTAL STRUCTURE OF THE P1 MET BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX","3.4.21.1","SULFATE ION",
,,,,,,
"1T8O",,"1T8O","CRYSTAL STRUCTURE OF THE P1 TRP BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX","3.4.21.1","SULFATE ION",
,,,,,,
"1T8N",,"1T8N","CRYSTAL STRUCTURE OF THE P1 THR BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX","3.4.21.1","SULFATE ION",
,,,,,,
"1T8M",,"1T8M","CRYSTAL STRUCTURE OF THE P1 HIS BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX","3.4.21.1","SULFATE ION",
,,,,,,
"1LMW",,"1LMW","LMW U-PA Structure complexed with EGRCMK (GLU-GLY-ARG Chloromethyl Ketone)","3.4.21.73","L-alpha-glutamyl-N-{(1S)-4-{[amino(iminio)methyl]amino}-1-[(1S)-2-chloro-1-hydroxyethyl]butyl}glycinamide",
,,,,"3.4.21.73",,
"1M1J",,"1M1J","Crystal structure of native chicken fibrinogen with two different bound ligands",,"2-acetamido-2-deoxy-alpha-D-glucopyranose",
,,,,,"CALCIUM ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,,
,,,,,,
"5JFD",,"5JFD","Thrombin in complex with (S)-N-(2-(aminomethyl)-5-chlorobenzyl)-1-((benzylsulfonyl)-D-arginyl)pyrrolidine-2-carboxamide","3.4.21.5","(2S)-N-[[2-(aminomethyl)-5-chloro-phenyl]methyl]-1-[(2R)-5-carbamimidamido-2-(phenylmethylsulfonylamino)pentanoyl]pyrrolidine-2-carboxamide",
,,,,"3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SODIUM ION",
,,,,,"GLYCEROL",
,,,,,"DIMETHYL SULFOXIDE",
"3ZUI",,"3ZUI","OMCI in complex with palmitoleic acid",,"PALMITOLEIC ACID",
"3ZUO",,"3ZUO","OMCI in complex with leukotriene B4",,"LEUKOTRIENE B4",
"4JD9",,"4JD9","Contact pathway inhibitor from a sand fly",,"SULFATE ION",
"4YHL",,"4YHL","Reversal Agent for Dabigatran",
,,,,
"4YHM","4CC","4YHM","Reversal Agent for Dabigatran",,"N-[(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-beta-alanine",
,,,,,,
"4YHN",,"4YHN","Dabigatran Reversal Agent",
,,,,
"4YHO","4CC","4YHO","Reversal Agent for Dabigatran",,"N-[(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-beta-alanine",
,,,,,,
"4YHI","4CC","4YHI","Reversal Agent for Dabigatran",,"N-[(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-beta-alanine",
,,,,,,
"1TMR",,"1TMR","THE STRUCTURE OF A 19 RESIDUE FRAGMENT FROM THE C-LOOP OF THE FOURTH EPIDERMAL GROWTH FACTOR-LIKE DOMAIN OF THROMBOMODULIN",
"2WZJ",,"2WZJ","Catalytic and UBA domain of kinase MARK2/(Par-1) K82R, T208E double mutant","2.7.11.1",
,,,,"2.7.11.26",
"4E7N",,"4E7N","Crystal Structure of AhV_TL-I, a Glycosylated Snake-venom Thrombin-like Enzyme from Agkistrodon halys","3.4.21","GLYCEROL",
"4O03",,"4O03","Crystal structure of Ca2+ bound prothrombin deletion mutant residues 146-167","3.4.21.5","CALCIUM ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"4NZQ",,"4NZQ","Crystal structure of Ca2+-free prothrombin deletion mutant residues 146-167","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
"2PF1",,"2PF1","STRUCTURE OF BOVINE PROTHROMBIN FRAGMENT 1 REFINED AT 2.25 ANGSTROMS RESOLUTION","3.4.21.5",
"1XEP",,"1XEP","Catechol in complex with T4 lysozyme L99A/M102Q","3.2.1.17","PHOSPHATE ION",
,,,,,"CATECHOL",
,,,,,"BETA-MERCAPTOETHANOL",
"1QB9","806","1QB9","BOVINE TRYPSIN 7-[[2-[[1-(1-IMINOETHYL)PIPERIDIN-4-YL]OXY]-9H-CARBOZOL-9-YL] METHYL]NAPHTHALENE-2-CARBOXIMIDAMIDE (ZK-806450) COMPLEX","3.4.21.4","CALCIUM ION",
,"806",,,,"POTASSIUM ION",
,"806",,,,"7-[[2-[[1-(1-IMINOETHYL)PIPERIDIN-4-YL]OXY]-9H-CARBOZOL-9-YL]METHYL]NAPHTHALENE-2-CARBOXIMIDAMID",
"1QB6","623","1QB6","BOVINE TRYPSIN 3,3'-[3,5-DIFLUORO-4-METHYL-2, 6-PYRIDINEDIYLBIS(OXY)]BIS(BENZENECARBOXIMIDAMIDE) (ZK-805623) COMPLEX","3.4.21.4","CALCIUM ION",
,"623",,,,"POTASSIUM ION",
,,,,,"3,3'-[3,5-DIFLUORO-4-METHYL-2,6-PYRIDYLENEBIS(OXY)]-BIS(BENZENECARBOXIMIDAMIDE)",
"1QBO","711","1QBO","BOVINE TRYPSIN 7-[[6-[[1-(1-IMINOETHYL)PIPERIDIN-4-YL]OXY]-2-METHYL-BENZIMIDAZOL-1-YL]METHYL]NAPHTHALENE-2-CARBOXIMIDAMID ZK-806711 INHIBITOR COMPLEX","3.4.21.4","CALCIUM ION",
,"711",,,,"7-[[6-[[1-(1-IMINOETHYL)PIPERIDIN-4-YL]OXY]-2-METHYL-BENZIMIDAZOL-1-YL]METHYL]NAPHTHALENE-2-CARBOXIMIDAMID",
"1QBN","688","1QBN","Bovine Trypsin 2-[amino(imino)methyl]-2-hydroxyphenoxy]-6-[3-(4,5-dihydro-1H-imidazol-2-yl)phenoxy]pyridine-4-carboxylic Acid (ZK-806688) Complex","3.4.21.4","CALCIUM ION",
,"688",,,,"2-[AMINO(IMINO)METHYL]-2-HYDROXYPHENOXY]-6-[3-(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)PHENOXY]PYRIDINE-4-CARBOXYLIC ACID",
"6T54",,"6T54","Thrombin in Complex with a D-Phe-Pro-2-bromothiophene Derivative","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","DIMETHYL SULFOXIDE",
,,,,,"GLYCEROL",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"(2~{S})-1-[(2~{R})-2-azanyl-3-phenyl-propanoyl]-~{N}-[(5-bromanylthiophen-2-yl)methyl]pyrrolidine-2-carboxamide",
"6T53",,"6T53","Thrombin in Complex with a D-Phe-Pro-p-benzylamine derivative","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","DIMETHYL SULFOXIDE",
,,,,,"(2~{S})-~{N}-[[4-(aminomethyl)phenyl]methyl]-1-[(2~{R})-2-azanyl-3-phenyl-propanoyl]pyrrolidine-2-carboxamide",
,,,,,"GLYCEROL",
,,,,,"PHOSPHATE ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"6T7H",,"6T7H","Crystal structure of Thrombin in complex with macrocycle N14-PR4-A","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21.5","1,2-ETHANEDIOL",
,,,,,"macrocycle N14-PR4-A",
,,,,,"SODIUM ION",
"2PF2",,"2PF2","THE CA+2 ION AND MEMBRANE BINDING STRUCTURE OF THE GLA DOMAIN OF CA-PROTHROMBIN FRAGMENT 1","3.4.21.5","CALCIUM ION",
"2PTC",,"2PTC","THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS","3.4.21.4","CALCIUM ION",
,,,,,,
"2TPI",,"2TPI","ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY","3.4.21.4","ISOLEUCINE",
,,,,,"VALINE",
,,,,,"MERCURY (II) ION",
"2SPT",,"2SPT","DIFFERENCES IN THE METAL ION STRUCTURE BETWEEN SR-AND CA-PROTHROMBIN FRAGMENT 1","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"STRONTIUM ION",
"2TGP",,"2TGP","THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"3FP7",,"3FP7","Anionic trypsin variant S195A in complex with bovine pancreatic trypsin inhibitor (BPTI) cleaved at the scissile bond (LYS15-ALA16) determined to the 1.46 A resolution limit","3.4.21.4","1,2-ETHANEDIOL",
,,,,,"TETRAETHYLENE GLYCOL",
,,,,,"CALCIUM ION",
,,,,,"SULFATE ION",
"3TPI",,"3TPI","THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS","3.4.21.4","ISOLEUCINE",
,,,,,"VALINE",
,,,,,"CALCIUM ION",
,,,,,"SULFATE ION",
"3BTK",,"3BTK","THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"1TPA",,"1TPA","THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS","3.4.21.4","CALCIUM ION",
,,,,,,
"1MTN",,"1MTN","BOVINE ALPHA-CHYMOTRYPSIN:BPTI CRYSTALLIZATION","3.4.21.1","SULFATE ION",
,,,,"3.4.21.1",,
,,,,"3.4.21.1",,
,,,,,,
"1KOT",,"1KOT","Solution Structure of Human GABA Receptor Associated Protein GABARAP",
"1KWM",,"1KWM","Human procarboxypeptidase B: Three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI)","3.4.17.2","ZINC ION",
,,,,,"CITRIC ACID",
"1BRB",,"1BRB","CRYSTAL STRUCTURES OF RAT ANIONIC TRYPSIN COMPLEXED WITH THE PROTEIN INHIBITORS APPI AND BPTI","3.4.21.4",
,,,,,
"1BZX",,"1BZX","THE CRYSTAL STRUCTURE OF ANIONIC SALMON TRYPSIN IN COMPLEX WITH BOVINE PANCREATIC TRYPSIN INHIBITOR","3.4.21.4","CALCIUM ION",
,,,,,,
"1CO7",,"1CO7","R117H mutant rat anionic trypsin complexed with bovine pancreatic trypsin inhibitor (BPTI)","3.4.21.4","CALCIUM ION",
,,,,,,
"2DWL",,"2DWL","Crystal structure of the PriA protein complexed with oligonucleotides",
,,,,3.6.1,
,,,,3.6.4,
"2DWN",,"2DWN","Crystal structure of the PriA protein complexed with oligonucleotides","3.6.4",
,,,,,
"2DWM",,"2DWM","Crystal structure of the PriA protein complexed with oligonucleotides",
,,,,3.6.1,
,,,,3.6.4,
"2KAI",,"2KAI","REFINED 2.5 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF THE COMPLEX FORMED BY PORCINE KALLIKREIN A AND THE BOVINE PANCREATIC TRYPSIN INHIBITOR. CRYSTALLIZATION, PATTERSON SEARCH, STRUCTURE DETERMINATION, REFINEMENT, STRUCTURE AND COMPARISON WITH ITS COMPONENTS AND WITH THE BOVINE TRYPSIN-PANCREATIC TRYPSIN INHIBITOR COMPLEX","3.4.21.8",
,,,,"3.4.21.35",
,,,,"3.4.21.8",
,,,,"3.4.21.35",
,,,,,
"2RA3",,"2RA3","Human cationic trypsin complexed with bovine pancreatic trypsin inhibitor (BPTI)","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"2FI4",,"2FI4","Crystal structure of a BPTI variant (Cys14->Ser) in complex with trypsin","3.4.21.4","SODIUM ION",
,,,,,"CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"2FI3",,"2FI3","Crystal structure of a BPTI variant (Cys14->Ser, Cys38->Ser) in complex with trypsin","3.4.21.4","SODIUM ION",
,,,,,"CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"2FI5",,"2FI5","Crystal structure of a BPTI variant (Cys38->Ser) in complex with trypsin","3.4.21.4","SODIUM ION",
,,,,,"CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"3OTJ",,"3OTJ","A Crystal Structure of Trypsin Complexed with BPTI (Bovine Pancreatic Trypsin Inhibitor) by X-ray/Neutron Joint Refinement","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"3GYM",,"3GYM","Structure of Prostasin in Complex with Aprotinin","3.4.21",
,,,,,
"3FP6",,"3FP6","Anionic trypsin in complex with bovine pancreatic trypsin inhibitor (BPTI) determined to the 1.49 A resolution limit","3.4.21.4","1,2-ETHANEDIOL",
,,,,,"TETRAETHYLENE GLYCOL",
,,,,,"CALCIUM ION",
,,,,,"SULFATE ION",
"3FP8",,"3FP8","Anionic trypsin variant S195A in complex with bovine pancreatic trypsin inhibitor (BPTI) determined to the 1.46 A resolution limit","3.4.21.4","1,2-ETHANEDIOL",
,,,,,"TETRAETHYLENE GLYCOL",
,,,,,"CALCIUM ION",
,,,,,"SULFATE ION",
"3TGI",,"3TGI","WILD-TYPE RAT ANIONIC TRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"3TGJ",,"3TGJ","S195A TRYPSINOGEN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"3TGK",,"3TGK","TRYPSINOGEN MUTANT D194N AND DELETION OF ILE 16-VAL 17 COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"4TPI",,"4TPI","THE REFINED 2.2-ANGSTROMS (0.22-NM) X-RAY CRYSTAL STRUCTURE OF THE TERNARY COMPLEX FORMED BY BOVINE TRYPSINOGEN, VALINE-VALINE AND THE ARG15 ANALOGUE OF BOVINE PANCREATIC TRYPSIN INHIBITOR","3.4.21.4","VALINE",
,,,,,"CALCIUM ION",
,,,,,"SULFATE ION",
"1FY8",,"1FY8","CRYSTAL STRUCTURE OF THE DELTAILE16VAL17 RAT ANIONIC TRYPSINOGEN-BPTI COMPLEX","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"2FTM",,"2FTM","Crystal structure of trypsin complexed with the BPTI variant (Tyr35->Gly)","3.4.21.4","SODIUM ION",
,,,,,"SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"1,2-ETHANEDIOL",
"2FTL",,"2FTL","Crystal structure of trypsin complexed with BPTI at 100K","3.4.21.4","SODIUM ION",
,,,,,"CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"2D7H",,"2D7H","Crystal structure of the ccc complex of the N-terminal domain of PriA","3.6.4",
,,,,,
"2D7G",,"2D7G","Crystal structure of the aa complex of the N-terminal domain of PriA","3.6.4",
,,,,,
"2D7E",,"2D7E","Crystal structure of N-terminal domain of PriA from E.coli","3.6.1",
,,,,"3.6.4",
"4BNR",,"4BNR","Extremely stable complex of crayfish trypsin with bovine trypsin inhibitor","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"4BXS",,"4BXS","Crystal Structure of the Prothrombinase Complex from the Venom of Pseudonaja Textilis","3.4.21.6","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"CALCIUM ION",
,,,,,"COPPER (II) ION",
"3BTD",,"3BTD","The Crystal Structures of the Complexes Between the Bovine Beta-Trypsin and Ten P1 Variants of BPTI.","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"3BTW",,"3BTW","THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"3BTM",,"3BTM","THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"3BTQ",,"3BTQ","THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"3BTT",,"3BTT","THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"3BTE",,"3BTE","The Crystal Structures of the Complexes Between Bovine Beta-Trypsin and Ten P1 Variants of BPTI.","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"3BTF",,"3BTF","THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI.","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"3BTG",,"3BTG","THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"3BTH",,"3BTH","THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"1EJM",,"1EJM","CRYSTAL STRUCTURE OF THE BPTI ALA16LEU MUTANT IN COMPLEX WITH BOVINE TRYPSIN","3.4.21.4","SULFATE ION",
,,,,,,
"1F5R",,"1F5R","RAT TRYPSINOGEN MUTANT COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR","3.4.21.4","CALCIUM ION",
,,,,,,
"1F7Z",,"1F7Z","RAT TRYPSINOGEN K15A COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"1YKT",,"1YKT","Trypsin/Bpti complex mutant","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"1YLC",,"1YLC","Trypsin/BPTI complex mutant","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"1YLD",,"1YLD","Trypsin/BPTI complex mutant","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"1P2J",,"1P2J","Structural consequences of accommodation of four non-cognate amino-acid residues in the S1 pocket of bovine trypsin and chymotrypsin","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"1P2I",,"1P2I","Structural consequences of accommodation of four non-cognate amino-acid residues in the S1 pocket of bovine trypsin and chymotrypsin","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"1P2Q",,"1P2Q","Structural consequences of accommodation of four non-cognate amino-acid residues in the S1 pocket of bovine trypsin and chymotrypsin","3.4.21.1","SULFATE ION",
,,,,,"2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL",
"1P2O",,"1P2O","Structural consequences of accommodation of four non-cognate amino-acid residues in the S1 pocket of bovine trypsin and chymotrypsin","3.4.21.1","SULFATE ION",
,,,,,,
"1P2N",,"1P2N","Structural consequences of accommodation of four non-cognate amino-acid residues in the S1 pocket of bovine trypsin and chymotrypsin","3.4.21.1","SULFATE ION",
,,,,,,
"1P2M",,"1P2M","Structural consequences of accommodation of four non-cognate amino-acid residues in the S1 pocket of bovine trypsin and chymotrypsin","3.4.21.1","SULFATE ION",
,,,,,,
"1P2K",,"1P2K","Structural consequences of accommodation of four non-cognate amino-acid residues in the S1 pocket of bovine trypsin and chymotrypsin","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"1CBW",,"1CBW","BOVINE CHYMOTRYPSIN COMPLEXED TO BPTI","3.4.21.1","SULFATE ION",
,,,,"3.4.21.1",,
,,,,"3.4.21.1",,
,,,,,,
"4EB1",,"4EB1","Hyperstable in-frame insertion variant of antithrombin",,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,,
"6TFI",,"6TFI","PXR IN COMPLEX WITH THROMBIN INHIBITOR COMPOUND 17","2.3.1.48","GLYCEROL",
,,,,,"(4S)-2-METHYL-2,4-PENTANEDIOL",
,,,,,"PHOSPHATE ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"[2-[(3-chlorophenyl)methylamino]-7-methoxy-1,3-benzoxazol-5-yl]-(2,2-dimethylmorpholin-4-yl)methanone",
"3NXP",,"3NXP","Crystal structure of human prethrombin-1","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL",
,,,,,"GLYCEROL",
"6T56",,"6T56","Thrombin in Complex with Benzylamine","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","BENZYLAMINE",
,,,,,"GLYCEROL",
,,,,,"PHOSPHATE ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"6T55",,"6T55","Thrombin in Complex with Methylbenzylamine","3.4.21.5","SODIUM ION",
,,,,"3.4.21.5","1-(4-methylphenyl)methanamine",
,,,,,"PHOSPHATE ION",
,,,,,"GLYCEROL",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"1Y3U",,"1Y3U","TRYPSIN INHIBITOR COMPLEX","3.4.21.4","CALCIUM ION",
,,,,,"(1R,3AS,4R,8AS,8BR)-4-(2-BENZO[1,3]DIOXOL-5-YLMETHYL-1-ISOPROPYL-3-OXO-DECAHYDRO-PYRROLO[3,4-A]PYRROLIZIN-4-YL)-BENZAMIDINE",
"2R9P",,"2R9P","Human mesotrypsin complexed with bovine pancreatic trypsin inhibitor(BPTI)","3.4.21.4","SULFATE ION",
,,,,,,
"4DG4",,"4DG4","Human mesotrypsin-S39Y complexed with bovine pancreatic trypsin inhibitor (BPTI)","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
"3P95",,"3P95","Human mesotrypsin complexed with bovine pancreatic trypsin inhibitor variant (BPTI-K15R/R17D)","3.4.21.4","CALCIUM ION",
,,,,,,
"3P92",,"3P92","Human mesotrypsin complexed with bovine pancreatic trypsin inhibitor variant (BPTI-K15R/R17G)","3.4.21.4","CALCIUM ION",
,,,,,,
"3D66",,"3D66","Crystal structure of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI)","3.4.17.20","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"ZINC ION",
"3D67","GEM","3D67","Crystal structure of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) in complex with 2-guanidino-ethyl-mercaptosuccinic acid (GEMSA)","3.4.17.20","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"ZINC ION",
,,,,,"(2-GUANIDINOETHYLMERCAPTO)SUCCINIC ACID",
"3D68",,"3D68","Crystal structure of a T325I/T329I/H333Y/H335Q mutant of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI-IIYQ)","3.4.17.20","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"ZINC ION",
,,,,,"ARGININE",
"4WWY",,"4WWY","human cationic trypsin G193R mutant in complex with bovine pancreatic trypsin inhibitor","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
"4WXV",,"4WXV","Human cationic trypsin K97D mutant in complex with bovine pancreatic trypsin inhibitor (BPTI)","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"1EAW",,"1EAW","Crystal structure of the MTSP1 (matriptase)-BPTI (aprotinin) complex","3.4.21",
,,,,"3.4.21.109",
,,,,,
"3U1J",,"3U1J","Aprotinin bound to Dengue virus protease","3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"2.1.1.56",
,,,,"2.1.1.57",
,,,,"2.7.7.48",
,,,,"3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"2.1.1.56",
,,,,"2.1.1.57",
,,,,"2.7.7.48",
,,,,,
"1WCC","CIG","1WCC","screening for fragment binding by X-ray crystallography","2.7.1.37","2-AMINO-6-CHLOROPYRAZINE",
,"CIG",,,"2.7.11.22",,
,"CIG",,,,,
"3EVJ",,"3EVJ","Intermediate structure of antithrombin bound to the natural pentasaccharide",,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"2PIY","528","2PIY","CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B (S)-2-(3-Aminomethyl-phenyl)-3-{hydroxy-[(R)-2-methyl-1-(3-phenyl-propane-1-sulfonylamino)-propyl]-phosphinoyl}-propionic acid {ZK 528} COMPLEX","3.4.17.2","ZINC ION",
,"528",,,,"(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-{(R)-HYDROXY[(1R)-2-METHYL-1-{[(3-PHENYLPROPYL)SULFONYL]AMINO}PROPYL]PHOSPHORYL}PROPANOIC ACID",
"3WNY",,"3WNY","A simplified BPTI variant with poly Lys amino acid tag (C3K) at the C-terminus",,"SULFATE ION",
"3A1M",,"3A1M","A fusion protein of a beta helix region of gene product 5 and the foldon region of bacteriophage T4","3.2.1.17","POTASSIUM ION",
"4PTI",,"4PTI","THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS",
"4TYD",,"4TYD","Structure-based design of a novel series of azetidine inhibitors of the hepatitis C virus NS3/4A serine protease",,"ZINC ION",
,,,,,"(4R,6S,7Z,15S,17S)-17-[({7-methoxy-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl}oxy)methyl]-13-methyl-N-[(1-methylcyclopropyl)sulfonyl]-2,14-dioxo-1,3,13-triazatricyclo[13.2.0.0~4,6~]heptadec-7-ene-4-carboxamide",
,,,,,"CHLORIDE ION",
"1UUB",,"1UUB","Solution structure of a truncated bovine pancreatic trypsin inhibitor mutant, 3-58 BPTI (K15R, R17A, R42S)",
"1UUA",,"1UUA","Solution structure of a truncated bovine pancreatic trypsin inhibitor, 3-58 BPTI.",
"5ZEQ",,"5ZEQ","Carboxypeptidase B in complex with DD28","3.4.17.2","ZINC ION",
,,,,,"(2~{S})-2-[(6-azanyl-5-chloranyl-pyridin-3-yl)methyl]-3-selanyl-propanoic acid",
,,,,,"CACODYLATE ION",
"5JB6",,"5JB6","A simplified BPTI variant containing 23 alanines out of 58 residues",,"SULFATE ION",
"5JB5",,"5JB5","A simplified BPTI variant containing 22 alanines out of 58 residues",,"SULFATE ION",
"5JB7",,"5JB7","A simplified BPTI variant containing 24 alanines out of 58 residues",,"SULFATE ION",
"5JB4",,"5JB4","A simplified BPTI variant containing 21 alanines out 58 of residues",,"SULFATE ION",
"6QL0",,"6QL0","Cationic Trypsin in Complex with a D-Phe-Pro-p-aminopyridine derivative","3.4.21.4","CALCIUM ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"(2~{S})-1-[(2~{R})-2-azanyl-3-phenyl-propanoyl]-~{N}-[(6-azanylpyridin-3-yl)methyl]pyrrolidine-2-carboxamide",
,,,,,"SULFATE ION",
"9PTI",,"9PTI","BASIC PANCREATIC TRYPSIN INHIBITOR (MET 52 OXIDIZED)",,"PHOSPHATE ION",
"1K6U",,"1K6U","Crystal Structure of Cyclic Bovine Pancreatic Trypsin Inhibitor",,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"1LD6",,"1LD6","STRUCTURE OF BPTI_8A MUTANT",
"1QA0","AX7","1QA0","BOVINE TRYPSIN 2-AMINOBENZIMIDAZOLE COMPLEX","3.4.21.4","CALCIUM ION",
,,,,,"2H-BENZOIMIDAZOL-2-YLAMINE",
"2HEX",,"2HEX","DECAMERS OBSERVED IN THE CRYSTALS OF BOVINE PANCREATIC TRYPSIN INHIBITOR",,"SULFATE ION",
"3LDJ",,"3LDJ","Crystal structure of aprotinin in complex with sucrose octasulfate: unusual interactions and implication for heparin binding",,"ACETATE ION",
"3LDM",,"3LDM","Crystal structure of aprotinin in complex with sucrose octasulfate: unusual interactions and implication for heparin binding",
"2ZJX",,"2ZJX","Bovine pancreatic trypsin inhibitor (BPTI) containing only the [5,55] disulfide bond",,"SULFATE ION",
"2ZVX",,"2ZVX","Structure of a BPTI-[5,55] variant containing Gly/Val at the 14/38th positions",,"SULFATE ION",
"1FAN",,"1FAN","CREVICE-FORMING MUTANTS IN THE RIGID CORE OF BOVINE PANCREATIC TRYPSIN INHIBITOR: CRYSTAL STRUCTURES OF F22A, Y23A, N43G, AND F45A",
"1G6X",,"1G6X","ULTRA HIGH RESOLUTION STRUCTURE OF BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI) MUTANT WITH ALTERED BINDING LOOP SEQUENCE",,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"5PTI",,"5PTI","STRUCTURE OF BOVINE PANCREATIC TRYPSIN INHIBITOR. RESULTS OF JOINT NEUTRON AND X-RAY REFINEMENT OF CRYSTAL FORM II",,"PHOSPHATE ION",
,,,,,"UNKNOWN ATOM OR ION",
"5LRK",,"5LRK","Crystal structure of the porcine carboxypeptidase B - Anabaenopeptin F complex","3.4.17.2","ZINC ION",
,,,,,,
"5LRG",,"5LRG","Crystal structure of the porcine carboxypeptidase B - Anabaenopeptin B complex","3.4.17.2","ZINC ION",
,,,,,,
"5LRJ",,"5LRJ","Crystal structure of the porcine carboxypeptidase B - Anabaenopeptin C complex","3.4.17.2","ZINC ION",
,,,,,,
"6PTI",,"6PTI","STRUCTURE OF FORM III CRYSTALS OF BOVINE PANCREATIC TRYPSIN INHIBITOR",,"PHOSPHATE ION",
"5XX2",,"5XX2","A BPTI-[5,55] variant with C14GA38L mutations",,"SULFATE ION",
"5XX4",,"5XX4","A BPTI-[5,55] variant with C14GA38K mutations",,"SULFATE ION",
"5XX3",,"5XX3","A BPTI-[5,55] variant with C14GA38G mutations",,"SULFATE ION",
"5XX6",,"5XX6","Hetero-micro-seeding: Crystal structure of BPTI-[5,55]C14GA38I variant using micro-seeds from -C14GA38G variant",,"SULFATE ION",
"5XX5",,"5XX5","A BPTI-[5,55] variant with C14GA38I mutations",,"SULFATE ION",
"5XX8",,"5XX8","Hetero-micro-seeding: Crystal structure of BPTI-[555]C14GA38I variant using micro-seeds from -C14GA38L variant",,"SULFATE ION",
"5XX7",,"5XX7","Hetero-micro-seeding: Crystal structure of BPTI-[5,55]C14GA38I variant using micro-seeds from -C14GA38I variant",,"SULFATE ION",
"8PTI",,"8PTI","CRYSTAL STRUCTURE OF A Y35G MUTANT OF BOVINE PANCREATIC TRYPSIN INHIBITOR",
"7PTI",,"7PTI","STRUCTURAL EFFECTS INDUCED BY REMOVAL OF A DISULFIDE BRIDGE. THE X-RAY STRUCTURE OF THE C30A(SLASH)C51A MUTANT OF BASIC PANCREATIC TRYPSIN INHIBITOR AT 1.6 ANGSTROMS",,"PHOSPHATE ION",
"1AAL",,"1AAL","STRUCTURAL EFFECTS INDUCED BY MUTAGENESIS AFFECTED BY CRYSTAL PACKING FACTORS: THE STRUCTURE OF A 30-51 DISULFIDE MUTANT OF BASIC PANCREATIC TRYPSIN INHIBITOR",,"PHOSPHATE ION",
"1B0C",,"1B0C","EVIDENCE OF A COMMON DECAMER IN THREE CRYSTAL STRUCTURES OF BPTI, CRYSTALLIZED FROM THIOCYANATE, CHLORIDE OR SULFATE",
"1OA6",,"1OA6","The solution structure of bovine pancreatic trypsin inhibitor at high pressure",
"1OA5",,"1OA5","The solution structure of bovine pancreatic trypsin inhibitor at high pressure",
"1PIT",,"1PIT","DETERMINATION OF A HIGH-QUALITY NUCLEAR MAGNETIC RESONANCE SOLUTION STRUCTURE OF THE BOVINE PANCREATIC TRYPSIN INHIBITOR AND COMPARISON WITH THREE CRYSTAL STRUCTURES",
"1JV9",,"1JV9","NMR Structure of BPTI Mutant G37A",
"1JV8",,"1JV8","NMR Structure of BPTI Mutant G37A",
"1LD5",,"1LD5","STRUCTURE OF BPTI MUTANT A16V",
"1BTI",,"1BTI","CREVICE-FORMING MUTANTS IN THE RIGID CORE OF BOVINE PANCREATIC TRYPSIN INHIBITOR: CRYSTAL STRUCTURES OF F22A, Y23A, N43G, AND F45A",
"1BPI",,"1BPI","THE STRUCTURE OF BOVINE PANCREATIC TRYPSIN INHIBITOR AT 125K: DEFINITION OF CARBOXYL-TERMINAL RESIDUES GLYCINE-57 AND ALANINE-58",,"PHOSPHATE ION",
"1NAG",,"1NAG","CREVICE-FORMING MUTANTS IN THE RIGID CORE OF BOVINE PANCREATIC TRYPSIN INHIBITOR: CRYSTAL STRUCTURES OF F22A, Y23A, N43G, AND F45A",,"PHOSPHATE ION",
"1K09",,"1K09","Solution structure of BetaCore, A Designed Water Soluble Four-Stranded Antiparallel b-sheet Protein",
,,,,
"1BHC",,"1BHC","BOVINE PANCREATIC TRYPSIN INHIBITOR CRYSTALLIZED FROM THIOCYANATE",,"THIOCYANATE ION",
"1BPT",,"1BPT","CREVICE-FORMING MUTANTS OF BPTI: CRYSTAL STRUCTURES OF F22A, Y23A, N43G, AND F45A",,"PHOSPHATE ION",
"2IJO",,"2IJO","Crystal Structure of the West Nile virus NS2B-NS3 protease complexed with bovine pancreatic trypsin inhibitor","3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"2.1.1.56",
,,,,"2.1.1.57",
,,,,"2.7.7.48",
,,,,"3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"2.1.1.56",
,,,,"2.1.1.57",
,,,,"2.7.7.48",
,,,,,
"3E1I",,"3E1I","Crystal Structure of BbetaD432A Variant Fibrinogen Fragment D with the Peptide Ligand Gly-His-Arg-Pro-amide",,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"CALCIUM ION",
,,,,,,
,,,,,,
"1YP9","UIZ","1YP9","Trypsin Inhibitor Complex","3.4.21.4","CALCIUM ION",
,"UIZ",,,,"(1R,3AS,4R,8AS,8BR)-4-(2-BENZO[1,3]DIOXOL-5-YLMETHYL)-1-BENZYL-3-OXO-DECAHYDRO-PYRROLO[3,4-A]PYRROZILIN-4-YL-BENZAMIDINE",
,,,,,"GLYCEROL",
"1WAX","LO1","1WAX","Protein tyrosine phosphatase 1B with active site inhibitor","3.1.3.48","MAGNESIUM ION",
,"LO1",,,,"[[4-(AMINOMETHYL)PHENYL]AMINO]OXO-ACETIC ACID,",
"1RE4",,"1RE4","Crystal Structure of Fragment D of BbetaD398A Fibrinogen",,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"CALCIUM ION",
,,,,,,
"1RE3",,"1RE3","Crystal Structure of Fragment D of BbetaD398A Fibrinogen with the Peptide Ligand Gly-His-Arg-Pro-Amide",,"CALCIUM ION",
,,,,,,
,,,,,,
,,,,,,
"1XKB","4PP","1XKB","FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S)-(3'-AMIDINO-3-BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID","3.4.21.6","CALCIUM ION",
,"4PP",,,"3.4.21.6","(2S)-(3'-AMIDINO-3-BIPHENYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID",
,"4PP",,,,,
"1XKA","4PP","1XKA","FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S)-(3'-AMIDINO-3-BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID","3.4.21.6","CALCIUM ION",
,"4PP",,,"3.4.21.6","(2S)-(3'-AMIDINO-3-BIPHENYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID",
,"4PP",,,,,
,"4PP",,,,,
"1QLQ",,"1QLQ","Bovine Pancreatic Trypsin Inhibitor (BPTI) Mutant with Altered Binding Loop Sequence",,"SULFATE ION",
"1FAX","DX9","1FAX","COAGULATION FACTOR XA INHIBITOR COMPLEX","3.4.21.6","CALCIUM ION",
,"DX9",,,"3.4.21.6","(2S)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-({(3R)-1-[(1Z)-ethanimidoyl]pyrrolidin-3-yl}oxy)phenyl]propanoic acid",
,"DX9",,,,,
,"DX9",,,,,
,"DX9",,,,,
,"DX9",,,,,
,"DX9",,,,,
,"DX9",,,,,
"1BZ5",,"1BZ5","EVIDENCE OF A COMMON DECAMER IN THREE CRYSTAL STRUCTURES OF BPTI, CRYSTALLIZE FROM THIOCYANATE, CHLORIDE OR SULFATE",,"SULFATE ION",
"1D0D",,"1D0D","CRYSTAL STRUCTURE OF TICK ANTICOAGULANT PROTEIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR",,"SULFATE ION",
,,,,,,
"2AIQ",,"2AIQ","Crystal structure of benzamidine-inhibited protein C activator from the venom of copperhead snake Agkistrodon contortrix contortrix","3.4.21.74","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21","SULFATE ION",
,,,,,"ACETATE ION",
,,,,,"CHLORIDE ION",
,,,,,"BENZAMIDINE",
,,,,,"GLYCEROL",
"2AIP",,"2AIP","Crystal structure of native protein C activator from the venom of copperhead snake Agkistrodon contortrix contortrix","3.4.21.74","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"3.4.21","SULFATE ION",
,,,,,"ACETATE ION",
,,,,,"GLYCEROL",
"6MV4",,"6MV4","CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR IXa","3.4.21.22","SULFATE ION",
,,,,"3.4.21.22","1,2-ETHANEDIOL",
,,,,,"FORMIC ACID",
,,,,,"P-AMINO BENZAMIDINE",
,,,,,"CALCIUM ION",
,,,,,"SODIUM ION",
,,,,,"CHLORIDE ION",
"1AUT",,"1AUT","Human activated protein C","3.4.21.69","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.69",,
"1TFX",,"1TFX","COMPLEX OF THE SECOND KUNITZ DOMAIN OF TISSUE FACTOR PATHWAY INHIBITOR WITH PORCINE TRYPSIN","3.4.21.4","CALCIUM ION",
,,,,,,
"3LMS",,"3LMS","Structure of human activated thrombin-activatable fibrinolysis inhibitor, TAFIa, in complex with tick-derived funnelin inhibitor, TCI.","3.4.17.20","ZINC ION",
,,,,,"GLYCINE",
,,,,,"GLYCEROL",
,,,,,"CHLORIDE ION",
,,,,,"CALCIUM ION",
,,,,,"POTASSIUM ION",
"2MKM",,"2MKM","G-triplex structure and formation propensity",
"1FAK",,"1FAK","HUMAN TISSUE FACTOR COMPLEXED WITH COAGULATION FACTOR VIIA INHIBITED WITH A BPTI-MUTANT","3.4.21.21","alpha-D-glucopyranose",
,,,,"3.4.21.21","alpha-L-fucopyranose",
,,,,,"CALCIUM ION",
,,,,,,
"4P10","2B8","4P10","pro-carboxypeptidase U In Complex With 5-(3-aminopropyl)-1-propyl-6,7-dihydro-4H-benzimidazole-5-carboxylic acid","3.4.17.20","(5R)-5-(3-aminopropyl)-1-propyl-4,5,6,7-tetrahydro-1H-benzimidazole-5-carboxylic acid",
,"2B8",,,,"ZINC ION",
,"2B8",,,,"DIMETHYL SULFOXIDE",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"2LYG",,"2LYG","Fuc_TBA",,"2-hydroxyethyl 6-deoxy-beta-L-galactopyranoside",
"2MKO",,"2MKO","G-triplex structure and formation propensity",,"POTASSIUM ION",
"3PIS",,"3PIS","Crystal Structure of Carcinoscorpius rotundicauda Serine Protease Inhibitor Domain 1",
"1W7H","3IP","1W7H","p38 Kinase crystal structure in complex with small molecule inhibitor","2.7.1.37","3-(BENZYLOXY)PYRIDIN-2-AMINE",
,"3IP",,,"2.7.11.24",,
,"3IP",,,,,
,"3IP",,,,,
"1WBO","2CH","1WBO","fragment based p38 inhibitors","2.7.1.37","2-CHLOROPHENOL",
,"2CH",,,"2.7.11.24",,
"4JN1",,"4JN1","An Antidote for Dabigatran",,"GLYCEROL",
,,,,,,
"4JN2",,"4JN2","An Antidote for Dabigatran",,"N-[(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-beta-alanine",
,,,,,"GLYCEROL",
"5EDK",,"5EDK","Crystal structure of prothrombin deletion mutant residues 146-167 ( Form II ).","3.4.21.5","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"MAGNESIUM ION",
"4YGV",,"4YGV","Reversal Agent for Dabigatran",,"GLYCEROL",
,,,,,,
"4YHK","4CC","4YHK","Reversal Agent for Dabigatran",,"N-[(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-beta-alanine",
,,,,,"GLYCEROL",
"1RF1",,"1RF1","Crystal Structure of Fragment D of gammaE132A Fibrinogen with the Peptide Ligand Gly-His-Arg-Pro-amide",,"CALCIUM ION",
,,,,,,
,,,,,,
,,,,,,
"1RF0",,"1RF0","Crystal Structure of Fragment D of gammaE132A Fibrinogen",,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"CALCIUM ION",
,,,,,,
"4MXC","DWF","4MXC","Crystal structure of CMET in complex with novel inhibitor","2.7.10.1","N-(3-fluoro-4-{[2-({3-[(methylsulfonyl)methyl]phenyl}amino)pyrimidin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide",
"5T3Q","75H","5T3Q","Crystal structure of the c-Met kinase domain in complex with a pyrazolone inhibitor","2.7.10.1","N-{3-fluoro-4-[(7-methoxyquinolin-4-yl)oxy]phenyl}-1-(2-hydroxy-2-methylpropyl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide",
,"75H",,,,,
,"75H",,,,,
"5YW1",,"5YW1","Crystal structure of full length NS3 protein (eD4NS2BNS3) in complex with Bovine Pancreatic Trypsin Inhibitor","3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,,
"5HTI",,"5HTI","Crystal structure of c-Met kinase domain in complex with LXM108","2.7.10.1","N-[3-fluoro-4-({7-[2-(morpholin-4-yl)ethoxy]-1,6-naphthyridin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide",
"6SDC",,"6SDC","Crystal structure of D1228V cMET bound by foretinib","2.7.10.1","N-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide",
"6SDE",,"6SDE","Crystal structure of wild-type cMET bound by savolitinib","2.7.10.1","volitinib",
"6SD9",,"6SD9","Crystal structure of wild-type cMET bound by foretinib","2.7.10.1","CHLORIDE ION",
,,,,,"N-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide",
"1SSL",,"1SSL","Solution structure of the PSI domain from the Met receptor","2.7.10.1",
"7B3Z",,"7B3Z","Crystal structure of c-MET bound by compound 5","2.7.10.1","DIMETHYL SULFOXIDE",
,,,,,"3-[3-(phenylmethyl)-1~{H}-pyrrolo[2,3-b]pyridin-5-yl]-4,5-dihydro-1~{H}-pyrrolo[3,4-b]pyrrol-6-one",
"7B3Q",,"7B3Q","Crystal structure of c-MET bound by compound 1","2.7.10.1","1-(phenylmethyl)-5~{H}-pyrrolo[3,2-c]pyridin-4-one",
,,,,,"SULFATE ION",
"7B42",,"7B42","Crystal structure of c-MET bound by compound 8","2.7.10.1","3-[(3-fluorophenyl)methyl]-5-(1-piperidin-4-ylpyrazol-4-yl)-1~{H}-pyrrolo[2,3-b]pyridine",
"7B41",,"7B41","Crystal structure of c-MET bound by compound 7","2.7.10.1","3-[(2-fluorophenyl)methyl]-5-(1-piperidin-4-ylpyrazol-4-yl)-1~{H}-pyrrolo[2,3-b]pyridine",
"7B44",,"7B44","Crystal structure of c-MET bound by compound S1","2.7.10.1","5-methoxy-1~{H}-indazole",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"SULFATE ION",
"7B43",,"7B43","Crystal structure of c-MET bound by compound 9","2.7.10.1","3-[(4-fluorophenyl)methyl]-5-(1-piperidin-4-ylpyrazol-4-yl)-1~{H}-pyrrolo[2,3-b]pyridine",
"7B3T",,"7B3T","Crystal structure of c-MET bound by compound 2","2.7.10.1","3-(phenylmethyl)-1~{H}-pyrrolo[2,3-b]pyridine",
,,,,,"CHLORIDE ION",
,,,,,"SULFATE ION",
"7B3W",,"7B3W","Crystal structure of c-MET bound by compound 4","2.7.10.1","1,2-ETHANEDIOL",
,,,,,"3-(6-fluoranyl-1~{H}-indazol-4-yl)-4,5-dihydro-1~{H}-pyrrolo[3,4-b]pyrrol-6-one",
"7B3V",,"7B3V","Crystal structure of c-MET bound by compound 3","2.7.10.1","3-(3-methyl-1~{H}-pyrrolo[2,3-b]pyridin-5-yl)-1~{H}-pyrrolo[3,4-b]pyrrol-6-one",
"7B40",,"7B40","Crystal structure of c-MET bound by compound 6","2.7.10.1","3-(phenylmethyl)-5-(1-piperidin-4-ylpyrazol-4-yl)-1~{H}-pyrrolo[2,3-b]pyridine",
"2J5U",,"2J5U","MreC Lysteria monocytogenes",
"2QF5",,"2QF5","High resolution structure of the major periplasmic domain from the cell shape-determining filament MreC (monoclinic form)",
"2QF4",,"2QF4","High resolution structure of the major periplasmic domain from the cell shape-determining filament MreC (orthorhombic form)",,"1,2-ETHANEDIOL",
,,,,,"SULFATE ION",
"3NDA",,"3NDA","Crystal structure of serpin from tick Ixodes ricinus",,"PENTAETHYLENE GLYCOL",
"2W7Z",,"2W7Z","Structure of the pentapeptide repeat protein EfsQnr, a DNA gyrase inhibitor. Free amines modified by cyclic pentylation with glutaraldehyde.",,"CHLORIDE ION",
"2WV1",,"2WV1","CRYSTAL STRUCTURE OF THE HLYIIR MUTANT PROTEIN WITH RESIDUES 169-186 SUBSTITUTED BY A LINKER CONTAINING TWO THROMBIN SITES",,"NITRATE ION",
"1AZ8",,"1AZ8","BOVINE TRYPSIN COMPLEXED TO BIS-PHENYLAMIDINE INHIBITOR","3.4.21.4","+/-METHYL 4-(AMINOIMINOMETHYL)-BETA-[3- INH (AMINOIMINO)PHENYL]BENZENE PENTANOATE",
"2V5E",,"2V5E","The structure of the GDNF:Coreceptor complex: Insights into RET signalling and heparin binding.",,"1,2-ETHANEDIOL",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"4Y0Y",,"4Y0Y","Trypsin in complex with with BPTI","3.4.21.4","SULFATE ION",
,,,,,"GLYCEROL",
,,,,,"CALCIUM ION",
"4Y10",,"4Y10","Trypsin in complex with with BPTI mutant (2S)-2-amino-4,4-difluorobutanoic acid","3.4.21.4","SULFATE ION",
,,,,,"GLYCEROL",
,,,,,"CALCIUM ION",
"4Y11",,"4Y11","Trypsin in complex with with BPTI mutant (2S)-2-amino-4,4,4-trifluorobutanoic acid","3.4.21.4","SULFATE ION",
,,,,,"GLYCEROL",
,,,,,"CALCIUM ION",
"4BXW",,"4BXW","Crystal Structure of the Prothrombinase Complex from the Venom of Pseudonaja Textilis","3.4.21.6","L-alpha-glutamyl-N-{(1S)-4-{[amino(iminio)methyl]amino}-1-[(1S)-2-chloro-1-hydroxyethyl]butyl}glycinamide",
,,,,,"SODIUM ION",
,,,,,"GLYCEROL",
"4UIA","FH9","4UIA","Crystal structure of 3a in complex with tafCPB","3.4.17.2","ZINC ION",
,,,,"3.4.17.20","(2S)-6-azanyl-2-[[(2R)-3-cyclohexyl-1-(3-methylbutylamino)-1-oxidanylidene-propan-2-yl]carbamoylamino]hexanoic acid",
"2PJC","343","2PJC","CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B ({(R)-1-[(S)-2-Benzyloxycarbonylamino-3-(4-hydroxy-phenyl)-propionylamino]-2-methyl-propyl}-hydroxy-phosphinoyloxy)-(3-guanidino-phenyl)-acetic acid COMPLEX","3.4.17.2","ZINC ION",
,"343",,,,"(2S)-(3-{[AMINO(IMINO)METHYL]AMINO}PHENYL){[(S)-[(1R)-1-({N-[(BENZYLOXY)CARBONYL]-L-TYROSYL}AMINO)-2-METHYLPROPYL](HYDROXY)PHOSPHORYL]OXY}ACETIC ACID",
"2PJB","983","2PJB","CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B 2-(3-Aminomethyl-phenyl)-3-{[1-((S)-2-benzyloxycarbonylamino-3-phenyl-propane-1-sulfonylamino)-2-methyl-propyl]-hydroxy-phosphinoyl}-propionic acid COMPLEX","3.4.17.2","ZINC ION",
,"983",,,,"(5S,9R,10R,12S)-12-[3-(AMINOMETHYL)PHENYL]-5-BENZYL-10-HYDROXY-9-ISOPROPYL-3-OXO-1-PHENYL-2-OXA-7-THIA-4,8-DIAZA-10-PHOSPHATRIDECAN-13-OIC ACID 7,7,10-TRIOXIDE",
"2PJA","33Z","2PJA","CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B 3-{[(R)-1-((S)-2-Benzyloxycarbonylamino-3-phenyl-propionylamino)-2-methyl-propyl]-hydroxy-phosphinoyl}-2-(3-guanidino-phenyl)-propionic acid COMPLEX","3.4.17.2","ZINC ION",
,"33Z",,,,"(2S)-2-(3-{[AMINO(IMINO)METHYL]AMINO}PHENYL)-3-[(R)-[(1R)-1-({N-[(BENZYLOXY)CARBONYL]-L-PHENYLALANYL}AMINO)-2-METHYLPROPYL](HYDROXY)PHOSPHORYL]PROPANOIC ACID",
"2PJ3","86A","2PJ3","CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B (3-Guanidino-phenyl)-{hydroxy-[(R)-2-methyl-1-(3-phenyl-propionylamino)-propyl]-phosphinoyloxy}-acetic acid COMPLEX","3.4.17.2","ZINC ION",
,"86A",,,,"(2S)-(3-{[AMINO(IMINO)METHYL]AMINO}PHENYL){[(S)-HYDROXY{(1R)-2-METHYL-1-[(3-PHENYLPROPANOYL)AMINO]PROPYL}PHOSPHORYL]OXY}ACETIC ACID",
"2PJ2","864","2PJ2","CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B 2-(3-Aminomethyl-phenyl)-3-[((R)-1-benzyloxycarbonylamino-2-methyl-propyl)-hydroxy-phosphinoyl]-propionic acid COMPLEX","3.4.17.2","ZINC ION",
,"864",,,,"(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-[(R)-[(1R)-1-{[(BENZYLOXY)CARBONYL]AMINO}-2-METHYLPROPYL](HYDROXY)PHOSPHORYL]PROPANOIC ACID",
"2PJ1","578","2PJ1","CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B (3-Aminomethyl-phenyl)-[((R)-1-benzyloxycarbonylamino-2-methyl-propyl)-hydroxy-phosphinoyloxy]-acetic acid COMPLEX","3.4.17.2","ZINC ION",
,"578",,,,"(5R,6S,8S)-8-[3-(AMINOMETHYL)PHENYL]-6-HYDROXY-5-ISOPROPYL-3-OXO-1-PHENYL-2,7-DIOXA-4-AZA-6-PHOSPHANONAN-9-OIC ACID 6-OXIDE",
"2PJ0","922","2PJ0","CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B [((R)-1-Benzyloxycarbonylamino-2-methyl-propyl)-hydroxy-phosphinoyloxy]-(3-guanidino-phenyl)-acetic acid COMPLEX","3.4.17.2","ZINC ION",
,"922",,,,"(5R,6S,8S)-8-(3-{[AMINO(IMINO)METHYL]AMINO}PHENYL)-6-HYDROXY-5-ISOPROPYL-3-OXO-1-PHENYL-2,7-DIOXA-4-AZA-6-PHOSPHANONAN-9-OIC ACID 6-OXIDE",
"2PIZ","606","2PIZ","CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B 2-(3-Guanidino-phenyl)-3-[hydroxy-(3-phenyl-propyl)-phosphinoyl]-propionic acid COMPLEX","3.4.17.2","ZINC ION",
,"606",,,,"(2S)-2-(3-{[AMINO(IMINO)METHYL]AMINO}PHENYL)-3-[(S)-HYDROXY(3-PHENYLPROPYL)PHOSPHORYL]PROPANOIC ACID",
"2PJ9","281","2PJ9","CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B 2-(3-Aminomethyl-phenyl)-3-{[(R)-1-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-2-methyl-propyl]-hydroxy-phosphinoyl}-propionic acid COMPLEX","3.4.17.2","ZINC ION",
,"281",,,,"(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-[(S)-{(1R)-1-[(2,1,3-BENZOTHIADIAZOL-4-YLSULFONYL)AMINO]-2-METHYLPROPYL}(HYDROXY)PHOSPHORYL]PROPANOIC ACID",
"2PJ8","17A","2PJ8","CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B 2-(3-Aminomethyl-phenyl)-3-{[(R)-1-(biphenyl-4-sulfonylamino)-2-methyl-propyl]-hydroxy-phosphinoyl}-propionic acid COMPLEX","3.4.17.2","ZINC ION",
,"17A",,,,"(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-[(R)-{(1R)-1-[(BIPHENYL-4-YLSULFONYL)AMINO]-2-METHYLPROPYL}(HYDROXY)PHOSPHORYL]PROPANOIC ACID",
"2PJ7","235","2PJ7","CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B 2-(3-Aminomethyl-phenyl)-3-[((R)-1-benzenesulfonylamino-2-methyl-propyl)-hydroxy-phosphinoyl]-propionic acid COMPLEX","3.4.17.2","ZINC ION",
,"235",,,,"(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-[(R)-HYDROXY{(1R)-2-METHYL-1-[(PHENYLSULFONYL)AMINO]PROPYL}PHOSPHORYL]PROPANOIC ACID",
"2PJ6","059","2PJ6","CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B 2-(3-Aminomethyl-phenyl)-3-{hydroxy-[(R)-2-methyl-1-(2-phenyl-ethanesulfonylamino)-propyl]-phosphinoyl}-propionic acid COMPLEX","3.4.17.2","ZINC ION",
,"59",,,,"(2S)-2-[3-(AMINOMETHYL)PHENYL]-3-{(S)-HYDROXY[(1R)-2-METHYL-1-{[(2-PHENYLETHYL)SULFONYL]AMINO}PROPYL]PHOSPHORYL}PROPANOIC ACID",
"2PJ5","11B","2PJ5","CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B [((R)-1-Benzyloxycarbonylamino-hexyl)-hydroxy-phosphinoyloxy]-(3-guanidino-phenyl)-acetic acid COMPLEX","3.4.17.2","ZINC ION",
,"11B",,,,"(5R,6S,8S)-8-(3-{[AMINO(IMINO)METHYL]AMINO}PHENYL)-6-HYDROXY-3-OXO-5-PENTYL-1-PHENYL-2,7-DIOXA-4-AZA-6-PHOSPHANONAN-9-OIC ACID 6-OXIDE",
"2PJ4","414","2PJ4","CRYSTAL STRUCTURE OF ACTIVATED PORCINE PANCREATIC CARBOXYPEPTIDASE B [((R)-Benzyloxycarbonylamino-cyclohexyl-methyl)-hydroxy-phosphinoyloxy]-(3-guanidino-phenyl)-acetic acid COMPLEX","3.4.17.2","ZINC ION",
,"414",,,,"(5R,6R,8S)-8-(3-{[AMINO(IMINO)METHYL]AMINO}PHENYL)-5-CYCLOHEXYL-6-HYDROXY-3-OXO-1-PHENYL-2,7-DIOXA-4-AZA-6-PHOSPHANONAN-9-OIC ACID 6-OXIDE",
"2OQ5",,"2OQ5","Crystal structure of DESC1, a new member of the type II transmembrane serine proteinases family","3.4.21","BENZAMIDINE",
"4WF8",,"4WF8","Crystal structure of NS3/4A protease in complex with Asunaprevir",,"ZINC ION",
,,,,,"CHLORIDE ION",
,,,,,"N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-chloro-4-methoxyisoquinolin-1-yl)oxy]-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-L-prolinamide",
"4TPY",,"4TPY","High throughput screening using acoustic droplet ejection to combine protein crystals and chemical libraries on crystallization plates at high density","3.4.21.4","CALCIUM ION",
,,,,,"SODIUM ION",
,,,,,"BROMIDE ION",
,,,,,"BENZAMIDINE",
,,,,,"2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL",
,,,,,"1,2-ETHANEDIOL",
"3S9A",,"3S9A","Russell's viper venom serine proteinase, RVV-V (closed-form)","3.4.21.95","2-acetamido-2-deoxy-beta-D-glucopyranose",
"3S9B",,"3S9B","Russell's viper venom serine proteinase, RVV-V (open-form)","3.4.21.95","2-acetamido-2-deoxy-beta-D-glucopyranose",
"1QL8",,"1QL8","FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"[4-(6-CHLORO-NAPHTHALENE-2-SULFONYL)-PIPERAZIN-1-YL]- (3,4,5,6-TETRAHYDRO-2H-[1,4']BIPYRIDINYL-4-YL)- METHANONE",
"1QL7","ZEN","1QL7","FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN","3.4.21.4","CALCIUM ION",
,"ZEN",,,,"SULFATE ION",
,,,,,"[4-(6-CHLORO-NAPHTHALENE-2-SULFONYL)-PIPERAZIN-1-YL]- (3,4,5,6-TETRAHYDRO-2H-[1,4']BIPYRIDINYL-4-YL)- METHANONE",
"6CVW","FH1","6CVW","Crystal structure of HCV NS3/4A WT protease in complex with AJ-52 (MK-5172 linear analogue)",,"ZINC ION",
,,,,,"SULFATE ION",
,,,,,"N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-N-[(1R,2S)-2-ethenyl-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-4-[(7-methoxy-3-methylquinoxalin-2-yl)oxy]-L-prolinamide",
"6C2M",,"6C2M","Crystal structure of HCV NS3/4A protease variant Y56H in complex with MK-5172",,"ZINC ION",
,,,,,"(1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-di
oxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadec
ino[11,12-b]quinoxaline-8-carboxamide",
,,,,,"SULFATE ION",
"6FE6",,"6FE6","Solution structure of a last generation P2-P4 macrocyclic inhibitor",,"(3aR,7S,10S,12R,24aR)-7-cyclopentyl-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-5,8-dioxo-1,2,3,3a,5,6,7,8,11,12,20,21,22,23,24,24a-hexadecahydro-10H-9,12-methanocyclopenta[18,19][1,10,3,6]dioxadiazacyclononadecino[12,11-b]quinoline-10-carboxamide",
,,,,,"ZINC ION",
"5EPY",,"5EPY","Crystal structure of HCV NS3/4A protease A156T variant in complex with 5172-mcP1P3 (MK-5172 P1-P3 macrocyclic analogue)",,"ZINC ION",
,,,,,"SULFATE ION",
,,,,,"2-Methyl-2-propanyl {(2R,6S,12Z,13aS,14aR,16aS)-14a-[(cyclopropylsulfonyl)carbamoyl]-2-[(3-ethyl-7-methoxy-2-quinoxalinyl)oxy]-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclop ropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl}carbamate",
"5EPN","5R2","5EPN","Crystal structure of HCV NS3/4A protease in complex with 5172-mcP1P3 (MK-5172 P1-P3 macrocyclic analogue)",,"ZINC ION",
,,,,,"SULFATE ION",
,,,,,"2-Methyl-2-propanyl {(2R,6S,12Z,13aS,14aR,16aS)-14a-[(cyclopropylsulfonyl)carbamoyl]-2-[(3-ethyl-7-methoxy-2-quinoxalinyl)oxy]-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclop ropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl}carbamate",
"5EQQ","5RS","5EQQ","Crystal structure of HCV NS3/4A WT protease in complex with 5172-Linear (MK-5172 linear analogue)",,"SULFATE ION",
,,,,,"ZINC ION",
,,,,,"~{tert}-butyl ~{N}-[(2~{S})-1-[(2~{S},4~{R})-2-[[(1~{R},2~{R})-1-(cyclopropylsulfonylcarbamoyl)-2-ethyl-cyclopropyl]carbamoyl]-4-(3-ethyl-7-methoxy-quinoxalin-2-yl)oxy-pyrrolidin-1-yl]-3,3-dimethyl-1-oxidanylidene-butan-2-yl]carbamate",
"5LYL",,"5LYL","Crystal structure of 1 in complex with tafCPB","3.4.17.2","ZINC ION",
,,,,,"(2~{S})-2-[[(2~{S})-1-(1-adamantylamino)-3-cyclohexyl-1-oxidanylidene-propan-2-yl]sulfamoylamino]-6-azanyl-hexanoic acid",
"5LYD",,"5LYD","Crystal structure of 1 in complex with tafCPB","3.4.17.2","ZINC ION",
,,,,,"(2~{S})-6-azanyl-2-(sulfamoylamino)hexanoic acid",
"5LYF",,"5LYF","Crystal structure of 1 in complex with tafCPB","3.4.17.2","ZINC ION",
,,,,,"(2~{S})-6-azanyl-2-[[(2~{R})-1-[[(1~{R},2~{S},4~{S})-2-bicyclo[2.2.1]heptanyl]amino]-3-cyclohexyl-1-oxidanylidene-propan-2-yl]carbamoylamino]hexanoic acid",
"5LYI",,"5LYI","Crystal structure of 1 in complex with tafCPB","3.4.17.2","ZINC ION",
,,,,,"(2~{S})-6-azanyl-2-[[(2~{S})-3-cyclohexyl-1-oxidanylidene-1-[[(1~{R},2~{S},4~{R})-1,7,7-trimethyl-2-bicyclo[2.2.1]hepta
nyl]amino]propan-2-yl]sulfamoylamino]hexanoic acid",
"1F0U","RPR","1F0U","BOVINE TRYPSIN COMPLEXED WITH RPR128515","3.4.21.4","CALCIUM ION",
,"RPR",,,,"SULFATE ION",
,"RPR",,,,"3-[(3'-AMINOMETHYL-BIPHENYL-4-CARBONYL)-AMINO]-2-(3-CARBAMIMIDOYL-BENZYL)-BUTYRIC ACID METHYL ESTER",
"1F0T","PR1","1F0T","BOVINE TRYPSIN COMPLEXED WITH RPR131247","3.4.21.4","CALCIUM ION",
,"PR1",,,,"SULFATE ION",
,"PR1",,,,"4-HYDROXY-3-[2-OXO-3-(THIENO[3,2-B]PYRIDINE-2-SULFONYLAMINO)-PYRROLIDIN-1-YLMETHYL]-BENZAMIDINE",
"6DIT",,"6DIT","Crystal structure of HCV NS3/4A protease in complex with P4-2 (JZ01-19)",,"pentyl
[(2R,6S,12Z,13aS,14aR,16aS)-2-[(7-methoxy-3-methylquinoxalin-2-yl)oxy]-14a-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}-5,
16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl]carbamate",
,,,,,"ZINC ION",
"6DIR",,"6DIR","Crystal structure of HCV NS3/4A protease in complex with P4-P5-2 (AJ-67)",,"(2R,6S,12Z,13aS,14aR,16aS)-6-[(N-acetyl-3-methyl-L-valyl)amino]-2-[(7-methoxy-3-methylquinoxalin-2-yl)oxy]-N-[(1-methyl
cyclopropyl)sulfonyl]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diaz
acyclopentadecine-14a(5H)-carboxamide",
,,,,,"SULFATE ION",
,,,,,"ZINC ION",
"1AQ7","AEB","1AQ7","TRYPSIN WITH INHIBITOR AERUGINOSIN 98-B","3.4.21.4",
,,,,,
"2G15",,"2G15","Structural Characterization of autoinhibited c-Met kinase","2.7.10.1",
"2RFS",,"2RFS","X-ray structure of SU11274 bound to c-Met","2.7.10.1","N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide",
"2RFN","AM7","2RFN","x-ray structure of c-Met with inhibitor.","2.7.10.1","2-benzyl-5-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-3-methylpyrimidin-4(3H)-one",
,"AM7",,,,,
,"AM7",,,,,
,"AM7",,,,,
,"AM7",,,,,
"3DKC",,"3DKC","Structure of MET receptor tyrosine kinase in complex with ATP","2.7.10.1","MAGNESIUM ION",
,,,,,"CHLORIDE ION",
,,,,,"ADENOSINE-5'-TRIPHOSPHATE",
"3DKF","SX8","3DKF","Structure of MET receptor tyrosine kinase in complex with inhibitor SGX-523","2.7.10.1","CHLORIDE ION",
,"SX8",,,,"6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}quinoline",
,"SX8",,,,,
,"SX8",,,,,
,"SX8",,,,,
,"SX8",,,,,
,"SX8",,,,,
,"SX8",,,,,
"3DKG","SX8","3DKG","Structure of Mutant(Y1248L) MET receptor tyrosine kinase in complex with inhibitor SGX-523","2.7.10.1","CHLORIDE ION",
,"SX8",,,,"6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}quinoline",
,"SX8",,,,,
,"SX8",,,,,
,"SX8",,,,,
,"SX8",,,,,
,"SX8",,,,,
"3EFJ","MT3","3EFJ","Structure of c-Met with pyrimidone inhibitor 7","2.7.10.1","2-benzyl-5-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]-3-fluorophenyl}-3-methylpyrimidin-4(3H)-one",
,"MT3",,,,,
,"MT3",,,,,
"3EFK","MT4","3EFK","Structure of c-Met with pyrimidone inhibitor 50","2.7.10.1","5-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]-3-fluorophenyl}-2-[(4-fluorophenyl)amino]-3-methylpyrimidin-4(3H)-one",
,"MT4",,,,,
,"MT4",,,,,
,"MT4",,,,,
"3Q6U",,"3Q6U","Structure of the apo MET receptor kinase in the dually-phosphorylated, activated state","2.7.10.1",
"3Q6W","Q6W","3Q6W","Structure of dually-phosphorylated MET receptor kinase in complex with an MK-2461 analog with specificity for the activated receptor","2.7.10.1","3-{5-oxo-3-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl}-N-(pyridin-2-ylmethyl)propanamide",
,"Q6W",,,,,
,"Q6W",,,,,
,"Q6W",,,,,
"4AP7","F47","4AP7","Crystal structure of C-MET kinase domain in complex with 4-((6-(4- fluorophenyl)-(1,2,4)triazolo(4,3-b)(1,2,4)triazin-3-yl)methyl)phenol","2.7.10.1","4-[[6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl]methyl]phenol",
,"F47",,,,,
,"F47",,,,,
,"F47",,,,,
"4AOI","4K0","4AOI","Crystal structure of C-MET kinase domain in complex with 4-(3-((1H- pyrrolo(2,3-b)pyridin-3-yl)methyl)-(1,2,4)triazolo(4,3-b)(1,2,4) triazin-6-yl)benzonitrile","2.7.10.1","4-[3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzenecarbonitrile",
,"4K0",,,,,
,"4K0",,,,,
,"4K0",,,,,
"3ZXZ","KRW","3ZXZ","X-ray Structure of PF-04217903 bound to the kinase domain of c-Met","2.7.10.1","2-{4-[1-(QUINOLIN-6-YLMETHYL)-1H-[1,2,3]TRIAZOLO[4,5-B]PYRAZIN-6-YL]-1H-PYRAZOL-1-YL}ETHANOL",
,"KRW",,,,,
,"KRW",,,,,
,"KRW",,,,,
,"KRW",,,,,
,"KRW",,,,,
"3ZZE","6XP","3ZZE","Crystal structure of C-MET kinase domain in complex with N'-((3Z)-4- chloro-7-methyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2-(4- hydroxyphenyl)propanohydrazide","2.7.10.1","(2S)-N'-[(3R)-4-chloro-7-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-2-(4-hydroxyphenyl)propanehydrazide",
,"6XP",,,,,
"3L8V","L8V","3L8V","Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in complex with a biarylamine based inhibitor","2.7.10.1","2-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}amino)-N-(2,4-difluorophenyl)pyridine-3-carboxamide",
,"L8V",,,,,
,"L8V",,,,,
"4DEG","0JJ","4DEG","Crystal structure of c-Met in complex with triazolopyridazine inhibitor 2","2.7.10.1","7-methoxy-N-{[6-(3-methyl-1,2-thiazol-5-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}-1,5-naphthyridin-4-amine",
,"0JJ",,,,,
,"0JJ",,,,,
,"0JJ",,,,,
,"0JJ",,,,,
,"0JJ",,,,,
"4DEH","0JK","4DEH","Crystal structure of c-Met in complex with triazolopyridinone inhibitor 3","2.7.10.1","5-phenyl-3-(quinolin-6-ylmethyl)-3,5,6,7-tetrahydro-4H-[1,2,3]triazolo[4,5-c]pyridin-4-one",
,"0JK",,,,,
,"0JK",,,,,
"4DEI","0JL","4DEI","Crystal structure of c-Met in complex with triazolopyridinone inhibitor 24","2.7.10.1","3-{(1S)-1-[3-(2-methoxyethoxy)quinolin-6-yl]ethyl}-5-(3-methyl-1,2-thiazol-5-yl)-3,5-dihydro-4H-[1,2,3]triazolo[4,5-c]pyridin-4-one",
,"0JL",,,,,
,"0JL",,,,,
,"0JL",,,,,
,"0JL",,,,,
"3VW8","DF6","3VW8","Crystal structure of human c-Met kinase domain with its inhibitor","2.7.10.1","N-({4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}carbamothioyl)-2-phenylacetamide",
,"DF6",,,,"CHLORIDE ION",
"3ZC5","W9Z","3ZC5","X-ray Structure of c-Met kinase in complex with inhibitor (S)-6-(1-(6- (1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)ethyl) quinoline.","2.7.10.1","6-{(1S)-1-[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]ethyl}quinoline",
,"W9Z",,,,,
,"W9Z",,,,,
,"W9Z",,,,,
"3ZBX","6XE","3ZBX","X-ray Structure of c-Met kinase in complex with inhibitor 6-((6-(4- fluorophenyl)-(1,2,4)triazolo(4,3-b)(1,2,4)triazin-3-yl)methyl) quinoline.","2.7.10.1","6-[[6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl]methyl]quinoline",
,"6XE",,,,,
,"6XE",,,,,
,"6XE",,,,,
"3ZCL","5TF","3ZCL","X-ray Structure of c-Met kinase in complex with inhibitor (S)-3-(1-(1H-pyrrolo(2,3-b)pyridin-3-yl)ethyl)-N-isopropyl-(1,2,4)triazolo(4,3- b)pyridazin-6-amine","2.7.10.1","(S)-3-(1-(1H-pyrrolo(2,3-b)pyridin-3-yl)ethyl)-N-isopropyl-(1,2,4)triazolo(4,3-b)pyridazin-6-amine",
,"5TF",,,,,
,"5TF",,,,,
,"5TF",,,,,
"2WD1","ZZY","2WD1","Human c-Met Kinase in complex with azaindole inhibitor","2.7.10.1","1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE",
,"ZZY",,,,"GAMMA-BUTYROLACTONE",
,"ZZY",,,,,
"2WGJ","VGH","2WGJ","X-ray Structure of PF-02341066 bound to the kinase domain of c-Met","2.7.10.1","3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine",
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
,"VGH",,,,,
"2WKM","PFY","2WKM","X-ray Structure of PHA-00665752 bound to the kinase domain of c-Met","2.7.10.1","(3Z)-5-[(2,6-DICHLOROBENZYL)SULFONYL]-3-[(3,5-DIMETHYL-4-{[(2S)-2-(PYRROLIDIN-1-YLMETHYL)PYRROLIDIN-1-YL]CARBONYL}-1H-PYRROL-2-YL)METHYLIDENE]-1,3-DIHYDRO-2H-INDOL-2-ONE",
"2ZP0","PI0","2ZP0","Human factor viia-tissue factor complexed with benzylsulfonamide-D-ile-gln-P-aminobenzamidine","3.4.21.21","beta-D-glucopyranose",
,,,,"3.4.21.21","alpha-L-fucopyranose",
,,,,,"CALCIUM ION",
,,,,,"(2S)-N-[(4-carbamimidoylphenyl)methyl]-2-[[(2R,3R)-3-methyl-2-(phenylmethylsulfonylamino)pentanoyl]amino]pentanediamide",
"3R7O","M61","3R7O","Structure of dually phosphorylated c-MET receptor kinase in complex with an MK-2461 analog","2.7.10.1","N-[(2R)-1,4-dioxan-2-ylmethyl]-N-methyl-N'-{5-oxo-3-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl}sulfuric diamide",
,"M61",,,,,
,"M61",,,,,
"3RHK","M97","3RHK","Crystal structure of the catalytic domain of c-Met kinase in complex with ARQ 197","2.7.10.1","1-[(3R,4R)-4-(1H-indol-3-yl)-2,5-dioxopyrrolidin-3-yl]pyrrolo[3,2,1-ij]quinolinium",
,"M97",,,,,
"3CCN","LKG","3CCN","X-ray structure of c-Met with triazolopyridazine inhibitor.","2.7.10.1","4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]phenol",
,"LKG",,,,,
,"LKG",,,,,
"3CE3","1FN","3CE3","Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in complex with a Pyrrolopyridinepyridone based inhibitor","2.7.10.1","1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide",
,"1FN",,,,,
,"1FN",,,,,
"3CD8","L5G","3CD8","X-ray Structure of c-Met with triazolopyridazine Inhibitor.","2.7.10.1","7-methoxy-4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]quinoline",
,"L5G",,,,,
,"L5G",,,,,
,"L5G",,,,,
,"L5G",,,,,
,"L5G",,,,,
,"L5G",,,,,
"3CTH","319","3CTH","Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in complex with a aminopyridine based inhibitor","2.7.10.1","N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide",
,"319",,,,,
,"319",,,,,
"3CTJ","320","3CTJ","Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in complex with a aminopyridine based inhibitor","2.7.10.1","2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide",
,"320",,,,,
,"320",,,,,
"3F66","IHX","3F66","Human c-Met Kinase in complex with quinoxaline inhibitor","2.7.10.1","3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol",
,"IHX",,,,"GAMMA-BUTYROLACTONE",
,"IHX",,,,"SODIUM ION",
"3F82","353","3F82","Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in complex with N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide","2.7.10.1","N-{4-[(2-amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl}-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide",
,"353",,,,,
,"353",,,,,
,"353",,,,,
,"353",,,,,
,"353",,,,,
"4GG5","0J3","4GG5","Crystal structure of CMET in complex with novel inhibitor","2.7.10.1","3-(4-methylpiperazin-1-yl)-N-(3-nitrobenzyl)-7-(trifluoromethyl)quinolin-5-amine",
,"0J3",,,,,
,"0J3",,,,,
"4GG7","0J8","4GG7","Crystal structure of cMET in complex with novel inhibitor","2.7.10.1","N-(3-nitrobenzyl)-6-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-2-(trifluoromethyl)pyrido[2,3-d]pyrimidin-4-amine",
,"0J8",,,,,
,"0J8",,,,,
"4KNB","1RU","4KNB","C-Met in complex with OSI ligand","2.7.10.1","7-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-3-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]furo[3,2-c]pyridin-6-amine",
,"1RU",,,,"GAMMA-BUTYROLACTONE",
,"1RU",,,,,
"3U6H","03X","3U6H","Crystal structure of c-Met in complex with pyrazolone inhibitor 26","2.7.10.1","N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]-3-fluorophenyl}-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide",
,"03X",,,,,
,"03X",,,,,
,"03X",,,,,
,"03X",,,,,
,"03X",,,,,
"3U6I","044","3U6I","Crystal structure of c-Met in complex with pyrazolone inhibitor 58a","2.7.10.1","N-{3-fluoro-4-[(7-methoxyquinolin-4-yl)oxy]phenyl}-1-[(2R)-2-hydroxypropyl]-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide",
,"044",,,,,
,"044",,,,,
,"044",,,,,
,"044",,,,,
,"44",,,,,
"4R1V","3E8","4R1V","Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors","2.7.10.1","3-[1-(3-{5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl}benzyl)-6-oxo-1,6-dihydropyridazin-3-yl]benzonitrile",
,"3E8",,,,"GAMMA-BUTYROLACTONE",
,"3E8",,,,,
,"3E8",,,,,
,"3E8",,,,,
"4R1Y","3EH","4R1Y","Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitor","2.7.10.1","3-(diethylamino)propyl (3-{[5-(3,4-dimethoxyphenyl)-2-oxo-2H-1,3,4-thiadiazin-3(6H)-yl]methyl}phenyl)carbamate",
,"3EH",,,,"2-(2-(2-(2-(2-(2-ETHOXYETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHANOL",
,"3EH",,,,,
"4IWD","1JC","4IWD","Structure of dually phosphorylated c-MET receptor kinase in complex with an MK-8033 analog","2.7.10.1","1-{5-oxo-3-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl}-N-(pyridin-2-ylmethyl)methanesulfonamide",
,"1JC",,,,,
,"1JC",,,,,
"2UZX",,"2UZX","Structure of the human receptor tyrosine kinase Met in complex with the Listeria monocytogenes invasion protein InlB: Crystal form I",
,,,,2.7.10.1,
"2UZY",,"2UZY","Structure of the human receptor tyrosine kinase Met in complex with the Listeria monocytogenes invasion protein inlb: low resolution, Crystal form II",
,,,,2.7.10.1,
"1R0P","KSA","1R0P","Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met in complex with the microbial alkaloid K-252a","2.7.1.112","K-252A",
,"KSA",,,"2.7.10.1",,
"1R1W",,"1R1W","CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET","2.7.1.112",
,,,,"2.7.10.1",
"3I5N","B2D","3I5N","Crystal structure of c-Met with triazolopyridazine inhibitor 13","2.7.10.1","7-methoxy-N-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]-1,5-naphthyridin-4-amine",
,"B2D",,,,,
,"B2D",,,,,
,"B2D",,,,,
"6GCU",,"6GCU","MET receptor in complex with InlB internalin domain and DARPin A3A","2.7.10.1",
,,,,,
,,,,,
"6I04",,"6I04","Crystal structure of Sema domain of the Met receptor in complex with FAB","2.7.10.1",
,,,,,
,,,,,
"5UAD",,"5UAD","MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody","2.7.10.1","N-(6-{[6-(1-methyl-1H-pyrazol-4-yl)-1H-benzotriazol-1-yl]methyl}imidazo[1,2-b]pyridazin-2-yl)cyclopropanecarboxamide",
,,,,,"CHLORIDE ION",
"5HLW","62E","5HLW","Crystal structure of c-Met mutant Y1230H in complex with compound 14","2.7.10.1","CHLORIDE ION",
,,,,,"1-[2-(1-ethylpiperidin-4-yl)ethyl]-3-(6-{[6-(thiophen-2-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)urea",
"5HO6","63K","5HO6","CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH CMPD.","2.7.10.1","1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-[2-(morpholin-4-yl)ethyl]urea",
"5HNI","63B","5HNI","CRYSTAL STRUCTURE OF CMET WT with compound 3","2.7.10.1","methyl (6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1H-benzimidazol-2-yl)carbamate",
"5HOR","63K","5HOR","Crystal structure of c-Met-M1250T in complex with SAR125844.","2.7.10.1","1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-[2-(morpholin-4-yl)ethyl]urea",
"5HOA","63K","5HOA","Crystal structure of c-Met L1195V in complex with SAR125844","2.7.10.1","1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-[2-(morpholin-4-yl)ethyl]urea",
"5EOB","5QQ","5EOB","Crystal structure of CMET in complex with novel inhibitor","2.7.10.1","6-[bis(fluoranyl)-[6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl]methyl]quinoline",
,"5QQ",,,,,
,"5QQ",,,,,
,"5QQ",,,,,
"5EYD","5T1","5EYD","Crystal structure of c-Met in complex with AMG 337","2.7.10.1","6-[(1~{R})-1-[8-fluoranyl-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl]-3-(2-methoxyethoxy)-1,6-naphthyridin-5-one",
,"5T1",,,,,
,"5T1",,,,,
"5EYC","5SZ","5EYC","Crystal structure of c-Met in complex with naphthyridinone inhibitor 5","2.7.10.1","6-[(1~{R})-1-[8-fluoranyl-6-(3-methyl-1,2-oxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl]-1,6-naphthyridin-5-one",
,"5SZ",,,,,
,"5SZ",,,,,
"5DG5",,"5DG5","CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP-4157","2.7.10.1","N-(2,5-difluoro-4-{[2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxam
ide",
"4XYF","44X","4XYF","Crystal structure of c-Met in complex with (S)-5-(8-fluoro-3-(1-(3-(2-methoxyethoxy)quinolin-6-yl)ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-3-methylisoxazole","2.7.10.1","6-{(1S)-1-[8-fluoro-6-(3-methyl-1,2-oxazol-5-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)quinoline",
,"44X",,,,,
"4XMO","46G","4XMO","Crystal structure of c-Met in complex with (R)-5-(8-fluoro-3-(1-fluoro-1-(3-methoxyquinolin-6-yl)ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-3-methylisoxazole","2.7.10.1","6-{(1R)-1-fluoro-1-[8-fluoro-6-(3-methyl-1,2-oxazol-5-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-methoxyquinoline",
,"46G",,,,,
,"46G",,,,,
"3C1X","CKK","3C1X","Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-MET in complex with a Pyrrolotriazine based inhibitor","2.7.10.1","N-{[4-({5-[(4-aminopiperidin-1-yl)methyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}oxy)-3-fluorophenyl]carbamoyl}-2-(4-fluorophenyl)acetamide",
,"CKK",,,,,
,"CKK",,,,,
"5YA5","6TD","5YA5","CRYSTAL STRUCTURE OF c-MET IN COMPLEX WITH NOVEL INHIBITOR","2.7.10.1","2-[3-(4-methoxybenzyl)[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl]-1H-indole",
"6UBW",,"6UBW","MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody","2.7.10.1","N-(6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]methyl}imidazo[1,2-b]pyridazin-2-yl)cyclopropanecarboxamide",
,,,,,"CHLORIDE ION",
"4EEV","L1X","4EEV","Crystal structure of c-Met in complex with LY2801653","2.7.10.1","N-(3-fluoro-4-{[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxy}phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide",
,"L1X",,,,,
"3LQ8","88Z","3LQ8","Structure of the kinase domain of c-Met bound to XL880 (GSK1363089)","2.7.10.1","N-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide",
,"88Z",,,,,
,"88Z",,,,,
,"88Z",,,,,
,"88Z",,,,,
,"88Z",,,,,
,"88Z",,,,,
,"88Z",,,,,
,"88Z",,,,,
,"88Z",,,,,
,"88Z",,,,,
,"88Z",,,,,
,"88Z",,,,,
,"88Z",,,,,
,"88Z",,,,,
,"88Z",,,,,
,"88Z",,,,,
,"88Z",,,,,
,"88Z",,,,,
"4Y0Z",,"4Y0Z","Trypsin in complex with with BPTI mutant AMINOBUTYRIC ACID","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"GLYCEROL",
"2R0K",,"2R0K","Protease domain of HGFA with inhibitor Fab58","3.4.21",
,,,,,
,,,,,
"2F83",,"2F83","Crystal structure at 2.9 Angstroms resolution of human plasma coagulation factor XI zymogen","3.4.21.27","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"PLATINUM (II) ION",
"2F9U","5NH","2F9U","HCV NS3 protease domain with NS4a peptide and a ketoamide inhibitor with a P2 norborane",,"ZINC ION",
,,,,,"1,1-DIMETHYLETHYL [1-CYCLOHEXYL-2-[3-[[[1-[2-[[2-[[2-(DIMETHYLAMINO)-2-OXO-1-PHENYLETHYL]AMINO]-2-OXOETHYL]AMINO]-1,2-DIOXOETHYL]PENTYL]AMINO]CARBONYL]-2-AZABICYCLO[2.2.1]HEPTAN-2-YL]-2-OXOETHYL]CARBAMATE",
"3LJJ","10U","3LJJ","Bovine trypsin in complex with UB-THR 10","3.4.21.4","(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide",
,"10U",,,,"CALCIUM ION",
,,,,,"SULFATE ION",
"3LJO","11U","3LJO","Bovine trypsin in complex with UB-THR 11","3.4.21.4","(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide",
,"11U",,,,"CALCIUM ION",
,,,,,"SULFATE ION",
"4RI0",,"4RI0","Serine Protease HtrA3, mutationally inactivated","3.4.21","PHOSPHATE ION",
"3SBK",,"3SBK","Russell's viper venom serine proteinase, RVV-V (PPACK-bound form)","3.4.21.95","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
"2XCN","C8D","2XCN","Crystal structure of HCV NS3 protease with a boronate inhibitor",,"N-[(CYCLOPENTYLOXY)CARBONYL]-3-METHYL-L-VALYL-(4R)-N-{(1R)-3-HYDROXY-1-[HYDROXY(OXIDO)BORANYL]PROPYL}-4-(ISOQUINOLIN-1-YLOXY)-L-PROLINAMIDE",
,,,,,"MAGNESIUM ION",
,,,,,"ZINC ION",
"2XCF",,"2XCF","Crystal structure of HCV NS3 protease with a boronate inhibitor",,"ZINC ION",
,,,,,"MAGNESIUM ION",
,,,,,"CYCLOPENTYL N-[(2S)-1-[(2S,4R)-2-[[(4R)-8-HYDROXY-1,6,10-TRIOXA-5$L^{4}-BORASPIRO[4.5]DECAN-4-YL]CARBAMOYL]-4-ISOQUINOLIN-1-YLOXY-PYRROLIDIN-1-YL]-3,3-DIMETHYL-1-OXO-BUTAN-2-YL]CARBAMATE",
"1J17","ZEN","1J17","FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH RAT TRYPSIN MUTANT X99/175/190RT","3.4.21.4","CALCIUM ION",
,"ZEN",,,,"SULFATE ION",
,,,,,"[4-(6-CHLORO-NAPHTHALENE-2-SULFONYL)-PIPERAZIN-1-YL]- (3,4,5,6-TETRAHYDRO-2H-[1,4']BIPYRIDINYL-4-YL)- METHANONE",
"1J16","BEN","1J16","BENZAMIDINE IN COMPLEX WITH RAT TRYPSIN MUTANT X99/175/190RT","3.4.21.4","CALCIUM ION",
,"BEN",,,,"SULFATE ION",
,,,,,"BENZAMIDINE",
"1J15","BEN","1J15","BENZAMIDINE IN COMPLEX WITH RAT TRYPSIN MUTANT X99/175/190RT","3.4.21.4","CALCIUM ION",
,"BEN",,,,"SULFATE ION",
,,,,,"BENZAMIDINE",
"1J14","BEN","1J14","BENZAMIDINE IN COMPLEX WITH RAT TRYPSIN MUTANT X99RT","3.4.21.4","CALCIUM ION",
,"BEN",,,,"SULFATE ION",
,,,,,"BENZAMIDINE",
"1QL9","ZEN","1QL9","FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH RAT TRYPSIN MUTANT X99RT","3.4.21.4","CALCIUM ION",
,"ZEN",,,,"SULFATE ION",
,,,,,"[4-(6-CHLORO-NAPHTHALENE-2-SULFONYL)-PIPERAZIN-1-YL]- (3,4,5,6-TETRAHYDRO-2H-[1,4']BIPYRIDINYL-4-YL)- METHANONE",
"2A4Q","FNH","2A4Q","HCV NS3 protease with NS4a peptide and a covalently bound macrocyclic ketoamide compound.",,"ZINC ION",
,,,,,"BETA-MERCAPTOETHANOL",
,,,,,"(2R)-({N-[(3S)-3-({[(3S,6S)-6-CYCLOHEXYL-5,8-DIOXO-4,7-DIAZABICYCLO[14.3.1]ICOSA-1(20),16,18-TRIEN-3-YL]CARBONYL}AMINO)-2-OXOHEXANOYL]GLYCYL}AMINO)(PHENYL)ACETIC ACID",
"5EQR",,"5EQR","Crystal structure of a genotype 1a/3a chimeric HCV NS3/4A protease in complex with danoprevir",,"(2R,6S,12Z,13aS,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-14a-[(cyclopropylsulfonyl)carbamoyl]-5,16-dioxo-1,2,3,5,6,7,8
,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoro-2H-isoindole-2-carboxylate",
,,,,,"ZINC ION",
,,,,,"SULFATE ION",
"5EQS",,"5EQS","Crystal structure of a genotype 1a/3a chimeric HCV NS3/4A protease in complex with Asunaprevir",,"N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-chloro-4-methoxyisoquinolin-1-yl)oxy]-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-L-prolinamide",
,,,,,"ZINC ION",
"5ESB",,"5ESB","Crystal structure of a genotype 1a/3a chimeric HCV NS3/4A protease in complex with Vaniprevir",,"ZINC ION",
,,,,,"SULFATE ION",
,,,,,"(5R,7S,10S)-10-tert-butyl-N-{(1R,2R)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethylcyclopropyl}-15,15-dimethyl-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide",
"5ETX",,"5ETX","Crystal structure of HCV NS3/4A protease A156T variant in complex with 5172-Linear (MK-5172 linear analogue)",,"ZINC ION",
,,,,,"~{tert}-butyl ~{N}-[(2~{S})-1-[(2~{S},4~{R})-2-[[(1~{R},2~{R})-1-(cyclopropylsulfonylcarbamoyl)-2-ethyl-cyclopropyl]carbamoyl]-4-(3-ethyl-7-methoxy-quinoxalin-2-yl)oxy-pyrrolidin-1-yl]-3,3-dimethyl-1-oxidanylidene-butan-2-yl]carbamate",
,,,,,"CHLORIDE ION",
"6PIX",,"6PIX","Crystal structure of HCV NS3/4A D168A protease in complex with P4-P5-5 (WK-25)",,"ZINC ION",
,,,,,"methyl (1-{[(2R,6S,12Z,13aS,14aR,16aS)-2-[(7-methoxy-3-methyl-5,8-dihydroquinoxalin-2-yl)oxy]-14a-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]carbamoyl}cyclopentyl)carbamate",
,,,,,"1,2-ETHANEDIOL",
,,,,,"SULFATE ION",
"6PIW",,"6PIW","Crystal structure of HCV NS3/4A D168A protease in complex with P4-6 (NR03-67)",,"ZINC ION",
,,,,,"cyclohexyl
[(2R,6S,12Z,13aS,14aR,16aS)-2-[(7-methoxy-3-methylquinoxalin-2-yl)oxy]-14a-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}-5,
16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl]carbamate",
,,,,,"1,2-ETHANEDIOL",
"6PIY",,"6PIY","Crystal structure of HCV NS3/4A D168A protease in complex with P4-2 (NR02-61)",,"1-methylcyclobutyl [(2R,6S,12Z,13aS,14aR,16aS)-2-[(7-methoxy-3-methylquinoxalin-2-yl)oxy]-14a-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]carbamate",
,,,,,"ZINC ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"SULFATE ION",
"6PJ1",,"6PJ1","Crystal structure of HCV NS3/4A D168A protease in complex with P4-4(AJ-74)",,"ZINC ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"1-methylcyclopentyl [(2R,6S,12Z,13aS,14aR,16aS)-2-[(7-methoxy-3-methylquinoxalin-2-yl)oxy]-14a-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]carbamate",
,,,,,"SULFATE ION",
"6PJ0",,"6PJ0","Crystal structure of HCV NS3/4A D168A protease in complex with P4-5 (NR01-97)",,"1-ethylcyclopentyl [(2R,6S,12Z,13aS,14aR,16aS)-2-[(7-methoxy-3-methylquinoxalin-2-yl)oxy]-14a-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]carbamate",
,,,,,"ZINC ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"SULFATE ION",
"6PJ2",,"6PJ2","Crystal structure of HCV NS3/4A D168A protease in complex with P4-P5-4 (AJ-65)",,"ZINC ION",
,,,,,"(2R,6S,12Z,13aS,14aR,16aS)-6-[(N-acetyl-L-isoleucyl)amino]-2-[(7-methoxy-3-methylquinoxalin-2-yl)oxy]-N-[(1-methylcyclo
propyl)sulfonyl]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacycl
opentadecine-14a(5H)-carboxamide",
,,,,,"1,2-ETHANEDIOL",
,,,,,"SULFATE ION",
"6PIV",,"6PIV","Crystal structure of HCV NS3/4A D168A protease in complex with P4-7 (NR03-77)",,"ZINC ION",
,,,,,"(1R,3r,5S)-bicyclo[3.1.0]hexan-3-yl [(2R,6S,12Z,13aS,14aR,16aS)-2-[(7-methoxy-3-methylquinoxalin-2-yl)oxy]-14a-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]carbamate",
,,,,,"1,2-ETHANEDIOL",
,,,,,"SULFATE ION",
"6PIU",,"6PIU","Crystal structure of HCV NS3/4A D168A protease in complex with P4-P5-6 (NR03-68)",,"ZINC ION",
,,,,,"methyl [(1S)-1-cyclohexyl-2-{[(2R,6S,12Z,13aS,14aR,16aS)-2-[(7-methoxy-3-methylquinoxalin-2-yl)oxy]-14a-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]amino}-2-oxoethyl]carbamate",
,,,,,"1,2-ETHANEDIOL",
"1DXW","2ZF","1DXW","structure of hetero complex of non structural protein (NS) of hepatitis C virus (HCV) and synthetic peptidic compound",,"N-(tert-butoxycarbonyl)-L-alpha-glutamyl-N-[(1R)-1-(carboxycarbonyl)-3,3-difluoropropyl]-L-leucinamide",
,,,,,"ZINC ION",
"1ADZ",,"1ADZ","THE SOLUTION STRUCTURE OF THE SECOND KUNITZ DOMAIN OF TISSUE FACTOR PATHWAY INHIBITOR, NMR, 30 STRUCTURES",
"1ZMJ",,"1ZMJ","Crystal Structure of the Catalytic Domain of Factor XI in complex with 4-(guanidinomethyl)-phenylboronic acid","3.4.21.27","SULFATE ION",
,,,,,"(R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)BENZYL)GUANIDINE",
,,,,,"2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL",
"1ZMN",,"1ZMN","Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with (R)-1-(4-(4-(hydroxymethyl)-1,3,2-dioxaborolan-2-yl)phenyl)guanidine","3.4.21.27","SULFATE ION",
,,,,,"(R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENYL)GUANIDINE",
"1ZML",,"1ZML","Crystal Structure of the Catalytic Domain of Factor XI in complex with (R)-1-(4-(4-(hydroxymethyl)-1,3,2-dioxaborolan-2-yl)phenethyl)guanidine","3.4.21.27","SULFATE ION",
,,,,,"BICARBONATE ION",
,,,,,"(R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENETHYL)GUANIDINE",
"1KIG",,"1KIG","BOVINE FACTOR XA","3.4.21.6",
,,,,"3.4.21.6",
,,,,,
"1NC6","ABB","1NC6","Potent, small molecule inhibitors of human mast cell tryptase. Anti-asthmatic action of a dipeptide-based transition state analogue containing benzothiazole ketone","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"(2S,4R)-1-ACETYL-N-[(1S)-4-[(AMINOIMINOMETHYL)AMINO]-1-(2-BENZOTHIAZOLYLCARBONYL)BUTYL]-4-HYDROXY-2-PYRROLIDINECARBOXAMIDE",
"2YOL","EBN","2YOL","West Nile Virus NS2B-NS3 protease in complex with 3,4- dichlorophenylacetyl-Lys-Lys-GCMA","3.4.21.91","CHLORIDE ION",
,"EBN",,,"3.6.1.15","(S)-6-amino-N-((S)-6-amino-1-(((1r,4S)-4-guanidinocyclohexyl)methylamino)-1-oxohexan-2-yl)-2-(2-(3,4-dichlorophenyl)acetamido)hexanamide",
,,,,"3.6.4.13","NICKEL (II) ION",
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
"5LSP",,"5LSP","107_A07 Fab in complex with fragment of the Met receptor","2.7.10.1","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,,
,,,,,,
,,,,"2.7.10.1",,
"3OTP",,"3OTP","Crystal structure of the DegP dodecamer with a model substrate","3.4.21",
,,,,"3.4.21.107",
,,,,"3.2.1.17",
"2WPH",,"2WPH","factor IXa superactive triple mutant","3.4.21.22","CALCIUM ION",
,,,,,"PENTAETHYLENE GLYCOL",
,,,,"3.4.21.22",,
"2WPI",,"2WPI","factor IXa superactive double mutant","3.4.21.22","CALCIUM ION",
,,,,,,
,,,,"3.4.21.22",,
"2WPJ",,"2WPJ","factor IXa superactive triple mutant, NaCl-soaked","3.4.21.22","CALCIUM ION",
,,,,,,
,,,,"3.4.21.22",,
"2WPK",,"2WPK","factor IXa superactive triple mutant, ethylene glycol-soaked","3.4.21.22","CALCIUM ION",
,,,,,"1,2-ETHANEDIOL",
,,,,"3.4.21.22",,
"2WPL",,"2WPL","factor IXa superactive triple mutant, EDTA-soaked","3.4.21.22",
,,,,,
,,,,"3.4.21.22",
"1EZQ","RPR","1EZQ","CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR128515","3.4.21.6","CALCIUM ION",
,"RPR",,,"3.4.21.6","3-[(3'-AMINOMETHYL-BIPHENYL-4-CARBONYL)-AMINO]-2-(3-CARBAMIMIDOYL-BENZYL)-BUTYRIC ACID METHYL ESTER",
,"RPR",,,,,
"5EGM","5NY","5EGM","Development of a novel tricyclic class of potent and selective FIXa inhibitors","3.4.21.22","SODIUM ION",
,,,,"3.4.21.22","2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID",
,,,,,"2-chloranyl-~{N}-[(7~{S})-2-methyl-7-phenyl-10-(1~{H}-1,2,3,4-tetrazol-5-yl)-8,9-dihydro-6~{H}-pyrido[1,2-a]indol-7-yl]-4-(1,2,4-triazol-4-yl)benzamide",
"4ZAE","4M1","4ZAE","Development of a novel class of potent and selective FIXa inhibitors","3.4.21.22","2,6-dichloro-N-[(2R)-2-(5,6-dimethyl-1H-benzimidazol-2-yl)-2-phenylethyl]-4-(4H-1,2,4-triazol-4-yl)benzamide",
,"4M1",,,"3.4.21.22","SODIUM ION",
,"4M1",,,,"2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID",
"1F0R","815","1F0R","CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208815","3.4.21.6","CALCIUM ION",
,"815",,,"3.4.21.6","THIENO[3,2-B]PYRIDINE-2-SULFONIC ACID [1-(1-AMINO-ISOQUINOLIN-7-YLMETHYL)-2-OXO-PYRROLDIN-3-YL]-AMIDE",
,"815",,,,,
"1F0S","PR2","1F0S","Crystal Structure of Human Coagulation Factor XA Complexed with RPR208707","3.4.21.6","CALCIUM ION",
,"PR2",,,"3.4.21.6","THIENO[3,2-B]PYRIDINE-2-SULFONIC ACID [2-OXO-1-(1H-PYRROLO[2,3-C]PYRIDIN-2-YLMETHYL)-PYRROLIDIN-3-YL]-AMIDE",
,"PR2",,,,,
"1HFD",,"1HFD","HUMAN COMPLEMENT FACTOR D IN A P21 CRYSTAL FORM","3.4.21.46",
"4O3T",,"4O3T","Zymogen HGF-beta/MET with Zymogen Activator Peptide ZAP.14",,"PENTAETHYLENE GLYCOL",
,,,,"2.7.10.1",,
,,,,,,
"4O3U",,"4O3U","Zymogen HGF-beta/MET with Zymogen Activator Peptide ZAP2.3",
,,,,2.7.10.1,
,,,,
"1SHY",,"1SHY","The Crystal Structure of HGF beta-chain in Complex with the Sema Domain of the Met Receptor.",
,,,,2.7.10.1,
"2R0L",,"2R0L","Short Form HGFA with Inhibitory Fab75",
,,,,
,,,,3.4.21,
,,,,3.4.21,
"1QYY",,"1QYY","Crystal Structure of N-Terminal Domain of Human Platelet Receptor Glycoprotein Ib-alpha at 2.8 Angstrom Resolution",,"PLATINUM (II) ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"5QCL","BUY","5QCL","FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(1~{S})-2-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]benzoic acid","3.4.21.27","4-[[(1~{S})-2-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]benzoic acid",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"5QCK",,"5QCK","FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(2~{S},3~{R})-1-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3-phenyl-pyrrolidin-2-yl]carbonylamino]benzoic acid","3.4.21.27","4-[[(2~{S},3~{R})-1-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3-phenyl-pyrrolidin-2-yl]carbonylamino]benzoic acid",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"5QCN","BVM","5QCN","FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(1~{S})-2-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-5-[(3~{S})-3-ethoxycarbonylpiperidin-1-yl]carbonyl-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]benzoic acid","3.4.21.27","4-[[(1~{S})-2-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-5-[(3~{S})-3-ethoxycarbonylpiperidin-1-yl]carbonyl-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]benzoic acid",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"5QCM","BVJ","5QCM","FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[[(1~{S})-2-[(~{E})-3-[3-chloranyl-2-fluoranyl-6-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]phenyl]carbamate","3.4.21.27","methyl ~{N}-[4-[[(1~{S})-2-[(~{E})-3-[3-chloranyl-2-fluoranyl-6-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]-3,4-dihydro-1~{H}-isoquinolin-1-yl]carbonylamino]phenyl]carbamate",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"1P0S",,"1P0S","Crystal Structure of Blood Coagulation Factor Xa in Complex with Ecotin M84R","3.4.21.6","MAGNESIUM ION",
,,,,"3.4.21.6","SODIUM ION",
,,,,,,
"4K3J",,"4K3J","Crystal structure of Onartuzumab Fab in complex with MET and HGF-beta",,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,"2.7.10.1",,
,,,,,,
,,,,,,
"5EDM",,"5EDM","Crystal structure of prothrombin deletion mutant residues 154-167 ( Form I )","3.4.21.5","MAGNESIUM ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SULFATE ION",
,,,,,"GLYCEROL",
"4R8T",,"4R8T","Structure of JEV protease","3.4.21.91","CHLORIDE ION",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
"3S9C",,"3S9C","Russell's viper venom serine proteinase, RVV-V in complex with the fragment (residues 1533-1546) of human factor V","3.4.21.95","beta-D-glucopyranose",
,,,,,"alpha-D-glucopyranose",
,,,,,"ACETATE ION",
,,,,,"ZINC ION",
"5H4I",,"5H4I","Unlinked NS2B-NS3 Protease from Zika Virus in complex with a compound fragment","3.4.21.91","benzimidazol-1-ylmethanol",
,,,,"3.6.1.15","ACETATE ION",
,,,,"3.6.4.13",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
"5H6V",,"5H6V","Structure of Zika virus protease in complex with a dipeptide inhibitor","3.4.21.91","(S)-2-acetamido-6-amino-N-((S)-5-guanidino-1-oxopentan-2-yl)hexanamide",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
"8EST",,"8EST","REACTION OF PORCINE PANCREATIC ELASTASE WITH 7-SUBSTITUTED 3-ALKOXY-4-CHLOROISOCOUMARINS: DESIGN OF POTENT INHIBITORS USING THE CRYSTAL STRUCTURE OF THE COMPLEX FORMED WITH 4-CHLORO-3-ETHOXY-7-GUANIDINO-ISOCOUMARIN","3.4.21.36","SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"ETHYL-(2-CARBOXY-4-GUANIDINIUM-PHENYL)-CHLOROACETATE",
"9EST",,"9EST","STRUCTURAL STUDY OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH 7-AMINO-3-(2-BROMOETHOXY)-4-CHLOROISOCOUMARIN AS A NONREACTIVATABLE DOUBLY COVALENT ENZYME-INHIBITOR COMPLEX","3.4.21.36","SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"(2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE",
"1OYH",,"1OYH","Crystal Structure of P13 Alanine Variant of Antithrombin",,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,,
"6URV",,"6URV","Crystal structure of Yellow Fever Virus NS2B-NS3 protease domain","3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
"3LDI",,"3LDI","Crystal structure of aprotinin in complex with sucrose octasulfate: unusual interactions and implication for heparin binding",,"SULFATE ION",
,,,,,"MERCURY (II) ION",
,,,,,"GLYCEROL",
"6F1F",,"6F1F","The methylene thioacetal BPTI (Bovine Pancreatic Trypsin Inhibitor) mutant structure",,"SULFATE ION",
,,,,,"GLYCEROL",
"2V95","PDN","2V95","Structure of Corticosteroid-Binding Globulin in complex with Cortisol",,"(11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione",
"1JBU",,"1JBU","Coagulation Factor VII Zymogen (EGF2/Protease) in Complex with Inhibitory Exosite Peptide A-183","3.4.21.21","SULFATE ION",
,,,,"3.4.21.21","BENZAMIDINE",
,,,,,,
"1SQ0",,"1SQ0","Crystal Structure of the Complex of the Wild-type Von Willebrand Factor A1 domain and Glycoprotein Ib alpha at 2.6 Angstrom Resolution",
,,,,
"1O5F","CR9","1O5F","Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA)","3.4.21","2-{5-[AMINO(IMINIO)METHYL]-6-FLUORO-1H-BENZIMIDAZOL-2-YL}-6-[(2-METHYLCYCLOHEXYL)OXY]BENZENOLATE",
,"CR9",,,"3.4.21.106",,
,,,,"3.4.21",,
,,,,"3.4.21.106",,
"1O5E","132","1O5E","Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA)","3.4.21","6-CHLORO-2-(2-HYDROXY-BIPHENYL-3-YL)-1H-INDOLE-5-CARBOXAMIDINE",
,"132",,,"3.4.21.106",,
,"132",,,"3.4.21",,
,,,,"3.4.21.106",,
"3BUX",,"3BUX","Crystal structure of c-Cbl-TKB domain complexed with its binding motif in c-Met",
,,,,6.3.2,
,,,,2.3.2.27,
"6JPW",,"6JPW","Crystal structure of Zika NS2B-NS3 protease with compound 1C","3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"2.1.1.56",
,,,,"2.1.1.57",
,,,,"2.7.7.48",
,,,,"3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"2.1.1.56",
,,,,"2.1.1.57",
,,,,"2.7.7.48",
,,,,,
"6KK3",,"6KK3","Crystal structure of Zika NS2B-NS3 protease with compound 4","3.4.21.91","1-[(10~{R},17~{S},20~{S})-17,20-bis(4-azanylbutyl)-4,9,16,19,22-pentakis(oxidanylidene)-3,8,15,18,21-pentazabicyclo[22.2.2]octacosa-1(26),24,27-trien-10-yl]guanidine",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
"6KK2",,"6KK2","Crystal structure of Zika NS2B-NS3 protease with compound 2","3.4.21.91","1-[(10~{S},17~{S},20~{S})-17,20-bis(4-azanylbutyl)-4,9,16,19,22-pentakis(oxidanylidene)-3,8,15,18,21-pentazabicyclo[22.2.2]octacosa-1(27),24(28),25-trien-10-yl]guanidine",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
"6KK5",,"6KK5","Crystal structure of Zika NS2B-NS3 protease with compound 15","3.4.21.91","1-[(5~{S},8~{R},15~{S},18~{S})-15,18-bis(4-azanylbutyl)-5-methyl-4,7,14,17,20-pentakis(oxidanylidene)-3,6,13,16,19-pentazabicyclo[20.3.1]hexacosa-1(25),22(26),23-trien-8-yl]guanidine",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
"6C2N",,"6C2N","Crystal structure of HCV NS3/4A double mutant variant Y56H/D168A in complex with danoprevir","2.7.7.48","ZINC ION",
,,,,"3.4.21.98","SULFATE ION",
,,,,"3.6.1.15","(2R,6S,12Z,13aS,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-14a-[(cyclopropylsulfonyl)carbamoyl]-5,16-dioxo-1,2,3,5,6,7,8
,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoro-2H-isoindole-2-carboxylate",
,,,,"3.6.4.13",,
"5GJ4",,"5GJ4","Structure of NS2B-NS3 Protease from Zika Virus caught after self-cleavage","3.4.21.91","CHLORIDE ION",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
"5GPI",,"5GPI","Crystal Structures of Unlinked NS2B-NS3 Protease from Zika Virus and Its Complex with a Reverse Peptide Inhibitor","3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"2.1.1.56",
,,,,"2.1.1.57",
,,,,"2.7.7.48",
,,,,"3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"2.1.1.56",
,,,,"2.1.1.57",
,,,,"2.7.7.48",
"6P6M",,"6P6M","HCV NS3/4A protease domain of genotype 1a C159 in complex with glecaprevir","3.4.21.98","(3aR,7S,10S,12R,21E,24aR)-7-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclop
ropyl]-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta[18,19][1,10,17,
3,6]trioxadiazacyclononadecino[11,12-b]quinoxaline-10-carboxamide",
,,,,"3.6.1.15","ZINC ION",
,,,,"3.6.4.13","SULFATE ION",
,,,,"3.4.22","CHLORIDE ION",
,,,,"2.7.7.48",,
"6KPQ",,"6KPQ","Crystal structure of Zika NS2B-NS3 protease with compound 8","3.4.21.91","1-[(10~{R},17~{S},20~{S})-17,20-bis(4-azanylbutyl)-4,9,16,19,22-pentakis(oxidanylidene)-3,8,15,18,21-pentazabicyclo[22.3.1]octacosa-1(27),24(28),25-trien-10-yl]guanidine",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
"6L50",,"6L50","Crystal structure of Zika NS2B-NS3 protease with compound 16","3.4.21.91","2-sulfanylidene-1,3-thiazolidin-4-one",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
"1NES",,"1NES","STRUCTURE OF THE PRODUCT COMPLEX OF ACETYL-ALA-PRO-ALA WITH PORCINE PANCREATIC ELASTASE AT 1.65 ANGSTROMS RESOLUTION","3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
"1O5C","CR9","1O5C","Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA)","3.4.21.73","2-{5-[AMINO(IMINIO)METHYL]-6-FLUORO-1H-BENZIMIDAZOL-2-YL}-6-[(2-METHYLCYCLOHEXYL)OXY]BENZENOLATE",
,"CR9",,,"3.4.21.73","CITRIC ACID",
,"CR9",,,,,
,"CR9",,,,,
,"CR9",,,,,
"1O5B","ESI","1O5B","Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA)","3.4.21.73","4-IODOBENZO[B]THIOPHENE-2-CARBOXAMIDINE",
,"ESI",,,"3.4.21.73","CITRIC ACID",
,"ESI",,,,,
,"ESI",,,,,
,"ESI",,,,,
"1O5A","696","1O5A","Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA)","3.4.21.73","3-{5-[AMINO(IMINIO)METHYL]-1H-INDOL-2-YL}-1,1'-BIPHENYL-2-OLATE",
,"696",,,"3.4.21.73","CITRIC ACID",
,"696",,,,,
,"696",,,,,
,"696",,,,,
,"696",,,,,
"1FYR",,"1FYR","DIMER FORMATION THROUGH DOMAIN SWAPPING IN THE CRYSTAL STRUCTURE OF THE GRB2-SH2 AC-PYVNV COMPLEX",
,,,,
"5YVU",,"5YVU","Crystal structures of unlinked full length NS3 from Dengue virus provide insights into dynamics of protease domain","3.4.21.91","GLYCEROL",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,,,
"2EC9","24X","2EC9","Crystal structure analysis of human Factor VIIa , Souluble tissue factor complexed with BCX-3607","3.4.21.21","1,5-anhydro-D-glucitol",
,,,,"3.4.21.21","alpha-L-fucopyranose",
,,,,,"CALCIUM ION",
,,,,,"2'-((5-CARBAMIMIDOYLPYRIDIN-2-YLAMINO)METHYL)-4-(ISOBUTYLCARBAMOYL)-4'-VINYLBIPHENYL-2-CARBOXYLIC ACID",
"2K1Q",,"2K1Q","NMR structure of hepatitis c virus ns3 serine protease complexed with the non-covalently bound phenethylamide inhibitor","2.7.7.48","ZINC ION",
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,,,
"2GVF","NHN","2GVF","HCV NS3-4A protease domain complexed with a macrocyclic ketoamide inhibitor, SCH419021","3.4.22","ZINC ION",
,,,,"3.4.21.98","(6R,8S,11S)-11-CYCLOHEXYL-N-(1-{[(2-{[(1S)-2-(DIMETHYLAMINO)-2-OXO-1-PHENYLETHYL]AMINO}-2-OXOETHYL)AMINO](OXO)ACETYL}BUTYL)-10,13-DIOXO-2,5-DIOXA-9,12-DIAZATRICYCLO[14.3.1.1~6,9~]HENICOSA-1(20),16,18-TRIENE-8-CARBOXAMIDE",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,,,
"2FM2","3BC","2FM2","HCV NS3-4A protease domain complexed with a ketoamide inhibitor, SCH446211","2.7.7.48","ZINC ION",
,"3BC",,,"3.4.21.98","BETA-MERCAPTOETHANOL",
,,,,"3.6.1.15","TERT-BUTYL
[(1S)-1-({(1R,2S,5S)-2-[(3S,10S)-3-(CYCLOPROPYLMETHYL)-12-METHYL-4,5,8,11-TETRAOXO-10-PHENYL-2,6,9,12-TETRAAZATRIDECAN-1
-OYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEX-3-YL}CARBONYL)-2,2-DIMETHYLPROPYL]CARBAMATE",
,,,,"3.6.4.13",,
,,,,,,
"3ELA",,"3ELA","Crystal structure of active site inhibited coagulation factor VIIA mutant in complex with soluble tissue factor","3.4.21.21","alpha-D-glucopyranose",
,,,,"3.4.21.21","alpha-L-fucopyranose",
,,,,,"CALCIUM ION",
,,,,,"D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-phenylalaninamide",
"4A92",,"4A92","Full-length HCV NS3-4A protease-helicase in complex with a macrocyclic protease inhibitor.","3.4.21.98","ZINC ION",
,,,,"3.6.1.15","(1'R,2R,2'S,6S,24AS)-17-FLUORO-6-(1-METHYL-2-OXOPIPERIDINE-3-CARBOXAMIDO)-19,19-DIOXIDO-5,21,24-TRIOXO-2'-VINYL-1,2,3,5,6,7,8,9,10,11,12,13,14,20,21,23,24,24A-OCTADECAHYDROSPIRO[BENZO[S]PYRROLO[2,1-G][1,2,5,8,18]THIATETRAAZACYCLOICOSINE-22,1'-CYCLOPRO-2-CARBOXYLATEPAN]-2-YL 4-FLUOROISOINDOLINE",
,,,,"3.6.4.13",,
,,,,"3.4.22",,
,,,,"2.7.7.48",,
"3KF2",,"3KF2","The HCV NS3/NS4A protease apo structure","3.4.21.98","ZINC ION",
,,,,"2.7.7.48",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
"3KN2",,"3KN2","HCV NS3 Protease Domain with ketoamide inhibitor","3.4.22","ZINC ION",
,,,,"3.4.21.98","(1R,2S,5S)-3-{(2S)-2-(2,3-dihydro-1H-inden-2-yl)-2-[({(1S)-2,2-dimethyl-1-[(2-oxopiperidin-1-yl)methyl]propyl}carbamoyl)amino]acetyl}-6,6-dimethyl-N-{(1S)-1-[oxo(prop-2-en-1-ylamino)acetyl]butyl}-3-azabicyclo[3.1.0]hexane-2-carboxamide",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,,,
"3KNX",,"3KNX","HCV NS3 protease domain with P1-P3 macrocyclic ketoamide inhibitor","2.7.7.48","ZINC ION",
,,,,"3.4.21.98","(2R)-2-{(3S,13S,16aS,17aR,17bS)-13-[({(1S)-1-[(4,4-dimethyl-2,6-dioxopiperidin-1-yl)methyl]-2,2-dimethylpropyl}carbamoyl)amino]-17,17-dimethyl-1,14-dioxooctadecahydro-2H-cyclopropa[3,4]pyrrolo[1,2-a][1,4]diazacyclohexadecin-3-yl}-2-hydroxy-N-prop-2-en-1-ylethanamide",
,,,,"3.6.1.15","BETA-MERCAPTOETHANOL",
,,,,"3.6.4.13",,
,,,,,,
"3L6P",,"3L6P","Crystal Structure of Dengue Virus 1 NS2B/NS3 protease","3.4.21.91","NICKEL (II) ION",
,,,,"3.6.1.15","CADMIUM ION",
,,,,"3.6.4.13","SULFATE ION",
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
"3LON",,"3LON","HCV NS3-4a protease domain with ketoamide inhibitor narlaprevir","2.7.7.48","ZINC ION",
,,,,"3.4.21.98","(1R,2S,5S)-3-[N-({1-[(tert-butylsulfonyl)methyl]cyclohexyl}carbamoyl)-3-methyl-L-valyl]-N-{(1S)-1-[(1R)-2-(cyclopropyla
mino)-1-hydroxy-2-oxoethyl]pentyl}-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide",
,,,,"3.6.1.15","BETA-MERCAPTOETHANOL",
,,,,"3.6.4.13",,
,,,,,,
"3O8R",,"3O8R","Visualizing ATP-dependent RNA Translocation by the NS3 Helicase from HCV","3.4.21.98","ZINC ION",
,,,,"3.6.1.15","MAGNESIUM ION",
,,,,"3.6.4.13","ADENOSINE-5'-DIPHOSPHATE",
,,,,"2.7.7.48","BERYLLIUM TRIFLUORIDE ION",
,,,,,"SULFATE ION",
"3O8D",,"3O8D","Visualizing ATP-dependent RNA Translocation by the NS3 Helicase from HCV","3.4.21.98","MAGNESIUM ION",
,,,,"3.6.1.15","ADENOSINE-5'-DIPHOSPHATE",
,,,,"3.6.4.13","BERYLLIUM TRIFLUORIDE ION",
,,,,"2.7.7.48","SULFATE ION",
"3O8B",,"3O8B","Visualizing ATP-dependent RNA Translocation by the NS3 Helicase from HCV","3.4.21.98","ZINC ION",
,,,,"3.6.1.15","SULFATE ION",
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
"3O8C",,"3O8C","Visualizing ATP-dependent RNA Translocation by the NS3 Helicase from HCV","3.4.21.98","ZINC ION",
,,,,"3.6.1.15","SULFATE ION",
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,,,
"3RC6",,"3RC6","Molecular mechanisms of viral and host-cell substrate recognition by HCV NS3/4A protease","2.7.7.48","ZINC ION",
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
"3EYD","BE8","3EYD","Structure of HCV NS3-4A Protease with an Inhibitor Derived from a Boronic Acid","3.4.22","ZINC ION",
,"BE8",,,"3.4.21.98","[(1R)-2-cyclobutyl-1-({[(1R,2S,5S)-3-(N-{[(1S)-2,2-dimethyl-1-{[methyl(methylsulfonyl)amino]methyl}propyl]carbamoyl}-3-methyl-L-valyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hex-2-yl]carbonyl}amino)ethyl]boronic acid",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,,,
"4K8B",,"4K8B","Crystal structure of HCV NS3/4A protease complexed with inhibitor","3.4.21.98","ZINC ION",
,,,,"3.4.22","N-(tert-butylcarbamoyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide",
,,,,"3.4.21.98","SULFATE ION",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
"3U1I",,"3U1I","Dengue virus protease covalently bound to a peptide","3.4.21.91","SULFATE ION",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,,,
"4WH6",,"4WH6","Crystal structure of HCV NS3/4A protease variant R155K in complex with Asunaprevir","2.7.7.48","SULFATE ION",
,,,,"3.4.21.98","ZINC ION",
,,,,"3.6.1.15","N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-chloro-4-methoxyisoquinolin-1-yl)oxy]-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-L-prolinamide",
,,,,"3.6.4.13",,
"4WH8",,"4WH8","Crystal Structure of HCV NS3/4A protease in complex with an Asunaprevir P1-P3 macrocyclic analog.","2.7.7.48","tert-butyl [(2R,6S,12Z,13aS,14aR,16aS)-2-[(7-chloro-4-methoxyisoquinolin-1-yl)oxy]-14a-{[cyclopropyl(dihydroxy)-lambda~4~-sulfanyl]carbamoyl}-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]carbamate",
,,,,"3.4.21.98","SULFATE ION",
,,,,"3.6.1.15","ZINC ION",
,,,,"3.6.4.13",,
"4U01",,"4U01","HCV NS3/4A serine protease in complex with 6570","3.4.22","(2S,3aS,10Z,11aS,12aR)-2-({8-fluoro-7-methoxy-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl}oxy)-5-methyl-N-[(1-methylcyclopropyl)sulfonyl]-4,14-dioxo-1,2,3,3a,4,5,6,7,8,9,11a,12,13,14-tetradecahydro-12aH-cyclopropa[m]pyrrolo[1,2-c][1,3,6]triazacyclotetradecine-12a-carboxamide",
,,,,"3.4.21.98","ZINC ION",
,,,,"3.6.1.15","CHLORIDE ION",
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,,,
"4JMY",,"4JMY","Crystal structure of HCV NS3/NS4A protease complexed with DDIVPC peptide","3.4.21.98","ZINC ION",
,,,,"2.7.7.48","SODIUM ION",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,,,
,,,,,,
"4B71","DJL","4B71","Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function","3.4.21.98","(1R)-1-(4-chloro-2-fluoro-3-phenoxyphenyl)propan-1-aminium",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"3.4.22",,
,,,,"2.7.7.48",,
"4B73","4VA","4B73","Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function","3.4.21.98","(2S)-4-amino-N-[(1R)-1-(4-chloro-2-fluoro-3-phenoxyphenyl)propyl]-4-oxobutan-2-aminium",
,"4VA",,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"3.4.22",,
,,,,"2.7.7.48",,
"4B74","1LH","4B74","Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function","3.4.21.98","(2S)-4-[(2-ammonioethyl)amino]-N-[(1R)-1-(4-chloro-2-fluoro-3-phenoxyphenyl)propyl]-4-oxobutan-2-aminium",
,"1LH",,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"3.4.22",,
,,,,"2.7.7.48",,
"4B75",,"4B75","Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function","3.4.21.98","(2S)-4-amino-N-[(1R)-1-(4-chloro-2-fluoro-3-phenoxyphenyl)propyl]-4-oxobutan-2-aminium",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"3.4.22",,
,,,,"2.7.7.48",,
"4B76","PW1","4B76","Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function","3.4.21.98","[2,4-bis(fluoranyl)-3-phenoxy-phenyl]methylazanium",
,"PW1",,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"3.4.22",,
,,,,"2.7.7.48",,
"3SU0","TSV","3SU0","Crystal structure of NS3/4A protease variant R155K in complex with danoprevir","2.7.7.48","(2R,6S,12Z,13aS,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-14a-[(cyclopropylsulfonyl)carbamoyl]-5,16-dioxo-1,2,3,5,6,7,8
,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoro-2H-isoindole-2-carboxylate",
,"TSV",,,"3.4.21.98","SULFATE ION",
,,,,"3.6.1.15","ZINC ION",
,,,,"3.6.4.13",,
"3SU1","TSV","3SU1","Crystal structure of NS3/4A protease variant D168A in complex with danoprevir","2.7.7.48","(2R,6S,12Z,13aS,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-14a-[(cyclopropylsulfonyl)carbamoyl]-5,16-dioxo-1,2,3,5,6,7,8
,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoro-2H-isoindole-2-carboxylate",
,"TSV",,,"3.4.21.98","SULFATE ION",
,,,,"3.6.1.15","ZINC ION",
,,,,"3.6.4.13",,
"3SU2","TSV","3SU2","Crystal structure of NS3/4A protease variant A156T in complex with danoprevir","2.7.7.48","(2R,6S,12Z,13aS,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-14a-[(cyclopropylsulfonyl)carbamoyl]-5,16-dioxo-1,2,3,5,6,7,8
,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoro-2H-isoindole-2-carboxylate",
,"TSV",,,"3.4.21.98","SULFATE ION",
,,,,"3.6.1.15","ZINC ION",
,,,,"3.6.4.13",,
"3SU3","SU3","3SU3","Crystal structure of NS3/4A protease in complex with vaniprevir","2.7.7.48","(5R,7S,10S)-10-tert-butyl-N-{(1R,2R)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethylcyclopropyl}-15,15-dimethyl-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide",
,"SU3",,,"3.4.21.98","SULFATE ION",
,,,,"3.6.1.15","ZINC ION",
,,,,"3.6.4.13",,
"3SU4","SU3","3SU4","Crystal structure of NS3/4A protease variant R155K in complex with vaniprevir","3.4.22","(5R,7S,10S)-10-tert-butyl-N-{(1R,2R)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethylcyclopropyl}-15,15-dimethyl-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide",
,"SU3",,,"3.4.21.98","SULFATE ION",
,,,,"3.6.1.15","ZINC ION",
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
"3SUE","SUE","3SUE","Crystal structure of NS3/4A protease variant R155K in complex with MK-5172","2.7.7.48","(1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-di
oxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadec
ino[11,12-b]quinoxaline-8-carboxamide",
,"SUE",,,"3.4.21.98","ZINC ION",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
"3SUF","SUE","3SUF","Crystal structure of NS3/4A protease variant D168A in complex with MK-5172","2.7.7.48","(1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-di
oxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadec
ino[11,12-b]quinoxaline-8-carboxamide",
,"SUE",,,"3.4.21.98","ZINC ION",
,,,,"3.6.1.15","SULFATE ION",
,,,,"3.6.4.13",,
"3SUG","SUE","3SUG","Crystal structure of NS3/4A protease variant A156T in complex with MK-5172","2.7.7.48","(1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-di
oxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadec
ino[11,12-b]quinoxaline-8-carboxamide",
,"SUE",,,"3.4.21.98","SULFATE ION",
,,,,"3.6.1.15","ZINC ION",
,,,,"3.6.4.13",,
"3SUD","SUE","3SUD","Crystal structure of NS3/4A protease in complex with MK-5172","2.7.7.48","(1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-di
oxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadec
ino[11,12-b]quinoxaline-8-carboxamide",
,"SUE",,,"3.4.21.98","SULFATE ION",
,,,,"3.6.1.15","ZINC ION",
,,,,"3.6.4.13",,
"3SU5","SU3","3SU5","Crystal structure of NS3/4A protease variant D168A in complex with vaniprevir","2.7.7.48","(5R,7S,10S)-10-tert-butyl-N-{(1R,2R)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethylcyclopropyl}-15,15-dimethyl-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1H,5H-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7(3H)-carboxamide",
,"SU3",,,"3.4.21.98","SULFATE ION",
,,,,"3.6.1.15","ZINC ION",
,,,,"3.6.4.13",,
"3SV7","SV6","3SV7","Crystal structure of NS3/4A protease variant R155K in complex with Telaprevir","2.7.7.48","(1S,3aR,6aS)-2-[(2S)-2-({(2S)-2-cyclohexyl-2-[(pyrazin-2-ylcarbonyl)amino]acetyl}amino)-3,3-dimethylbutanoyl]-N-[(2R,3S)-1-(cyclopropylamino)-2-hydroxy-1-oxohexan-3-yl]octahydrocyclopenta[c]pyrrole-1-carboxamide",
,,,,"3.4.21.98","SULFATE ION",
,,,,"3.6.1.15","ZINC ION",
,,,,"3.6.4.13",,
"2A4G","UNH","2A4G","Hepatitis C Protease NS3-4A serine protease with Ketoamide Inhibitor SCH225724 Bound","3.4.22","ZINC ION",
,,,,"3.4.21.98","({1-[1-CARBAMOYL-PHENYL-METHYL)-CARBAMOYL]-METHYL}-AMINOOXALYL)-BUTYLCARBAMOYL)-3-METHYL-BUTYLCARBAMOYL)-CYCLOHEXYL-METHYL)-CARBAMIC ACID ISOBUTYL ESTER",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,,,
"4NWL",,"4NWL","Crystal structure of hepatis c virus protease (ns3) complexed with bms-650032 aka n-(tert-butoxycarbonyl)-3-me thyl-l-valyl-(4r)-4-((7-chloro-4-methoxy-1-isoquinolinyl)o xy)-n-((1r,2s)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylc yclopropyl)-l-prolinamide","2.7.7.48","N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-chloro-4-methoxyisoquinolin-1-yl)oxy]-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}-L-prolinamide",
,,,,"3.4.21.98","ZINC ION",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
"6N4N",,"6N4N","Crystal structure of the designed protein DNCR2/danoprevir/NS3a complex","3.4.21","ZINC ION",
,,,,"3.4.22","(2R,6S,12Z,13aS,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-14a-[(cyclopropylsulfonyl)carbamoyl]-5,16-dioxo-1,2,3,5,6,7,8
,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoro-2H-isoindole-2-carboxylate",
,,,,"3.4.21.98","SULFATE ION",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,,,
"5ZMQ",,"5ZMQ","Crystal structure of Zika NS3 protease with phenylacetyl-Lys-Lys-Arg-COOH inhibitor","3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"2.1.1.56",
,,,,"2.1.1.57",
,,,,"2.7.7.48",
,,,,"3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"2.1.1.56",
,,,,"2.1.1.57",
,,,,"2.7.7.48",
,,,,,
"5ZMS",,"5ZMS","Crystal structure of Zika NS3 protease in complex with 4-guanidinomethyl-phenylacetyl-Lys-Lys-Arg-H","3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"2.1.1.56",
,,,,"2.1.1.57",
,,,,"2.7.7.48",
,,,,"3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"2.1.1.56",
,,,,"2.1.1.57",
,,,,"2.7.7.48",
,,,,,
"5ZOB",,"5ZOB","Crystal structure of Zika NS3 protease with 4-guanidinomethyl-phenylacetyl-Arg-Arg-Arg-4-amidinobenzylamide","3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"2.1.1.56",
,,,,"2.1.1.57",
,,,,"2.7.7.48",
,,,,"3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"2.1.1.56",
,,,,"2.1.1.57",
,,,,"2.7.7.48",
,,,,,
"5WDX",,"5WDX","Structure of NS3 from HCV strain JFH-1 that is an unusually robust helicase that is primed to bind and unwind viral RNA","2.7.7.48","ZINC ION",
,,,,"3.4.21.98","MAGNESIUM ION",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
"5VOJ","9H4","5VOJ","Crystal structure of HCV NS3/4A protease in complex with JZ01-15, an analogue of 5172-mcP1P3","3.4.22","tert-butyl [(2R,6S,12Z,13aS,14aR,16aS)-2-[(7-methoxy-3-methylquinoxalin-2-yl)oxy]-14a-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]carbamate",
,,,,"3.4.21.98","SULFATE ION",
,,,,"3.6.1.15","ZINC ION",
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
"5VP9","9H7","5VP9","Crystal structure of HCV NS3/4A protease in complex with AM-07, an analogue of 5172-mcP1P3","3.4.22","tert-butyl [(2R,6S,12Z,13aS,14aR,16aS)-14a-[(cyclopropylsulfonyl)carbamoyl]-5,16-dioxo-2-{[3-(thiophen-2-yl)quinoxalin-2-yl]oxy}-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]carbamate",
,,,,"3.4.21.98","SULFATE ION",
,,,,"3.6.1.15","ZINC ION",
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
"5FPY",,"5FPY","Structure of hepatitis C virus (HCV) full-length NS3 complex with small-molecule ligand 5-bromo-1-methyl-1H-indole-2-carboxylic acid (AT21457) in an alternate binding site.","3.4.21","5-bromo-1-methyl-1H-indole-2-carboxylic acid",
,,,,"3.4.22",,
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
"5FPT",,"5FPT","Structure of hepatitis C virus (HCV) full-length NS3 complex with small-molecule ligand 2-(1-methyl-1H-indol-3-yl)acetic acid (AT3437) in an alternate binding site.","3.4.21","(1-methyl-1H-indol-3-yl)acetic acid",
,,,,"3.4.22",,
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
"5FPS",,"5FPS","Structure of hepatitis C virus (HCV) full-length NS3 complex with small-molecule ligand 3-aminobenzene-1,2-dicarboxylic acid (AT1246) in an alternate binding site.","3.4.21","3-AMINOBENZENE-1,2-DICARBOXYLIC ACID",
,,,,"3.4.22",,
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
"6NZT",,"6NZT","Crystal structure of HCV NS3/4A protease in complex with voxilaprevir","2.7.7.48","Voxilaprevir",
,,,,"3.4.21.98","ZINC ION",
,,,,"3.6.1.15","SULFATE ION",
,,,,"3.6.4.13",,
"6NZV",,"6NZV","Crystal structure of HCV NS3/4A protease in complex with compound 12","2.7.7.48","(1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide",
,,,,"3.4.21.98","ZINC ION",
,,,,"3.6.1.15","SULFATE ION",
,,,,"3.6.4.13",,
"6L4Z",,"6L4Z","Crystal structure of Zika NS2B-NS3 protease with compound 6","3.4.21.91","4-(hydroxymethyl)benzoic acid",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
"5YOD",,"5YOD","Crystal structure of zika virus NS3 protease in complex with a small molecule inhibitor","3.4.21.91","BENZOIC ACID",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
"5YOF",,"5YOF","Crystal structure of zika virus NS3 protease in complex with a dipeptide inhibitor","3.4.21.91","(S)-2-acetamido-6-amino-N-((S)-5-guanidino-1-oxopentan-2-yl)hexanamide",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
"1NS3",,"1NS3","STRUCTURE OF HCV PROTEASE (BK STRAIN)","3.4.22","ZINC ION",
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,"3.4.22",,
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
"1O5D",,"1O5D","Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA)","3.4.21.21","2-{5-[AMINO(IMINIO)METHYL]-6-FLUORO-1H-BENZIMIDAZOL-2-YL}-6-[(2-METHYLCYCLOHEXYL)OXY]BENZENOLATE",
,,,,"3.4.21.21",,
,,,,,,
"1RTL","CPX","1RTL","CRYSTAL STRUCTURE OF HCV NS3 PROTEASE DOMAIN: NS4A PEPTIDE COMPLEX WITH COVALENTLY BOUND PYRROLIDINE-5,5-TRANSLACTAM INHIBITOR","3.4.22","ZINC ION",
,,,,"3.4.21.98","N-[(2R,3S)-1-((2S)-2-{[(CYCLOPENTYLAMINO)CARBONYL]AMINO}-3-METHYLBUTANOYL)-2-(1-FORMYL-1-CYCLOBUTYL)PYRROLIDINYL]CYCLOPROPANECARBOXAMIDE",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,,,
"1JXP",,"1JXP","BK STRAIN HEPATITIS C VIRUS (HCV) NS3-NS4A","3.4.22","ZINC ION",
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,"3.4.22",,
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
"1BT7",,"1BT7","THE SOLUTION NMR STRUCTURE OF THE N-TERMINAL PROTEASE DOMAIN OF THE HEPATITIS C VIRUS (HCV) NS3-PROTEIN, FROM BK STRAIN, 20 STRUCTURES","3.4.22","ZINC ION",
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
"1CU1",,"1CU1","CRYSTAL STRUCTURE OF AN ENZYME COMPLEX FROM HEPATITIS C VIRUS","3.4.21","ZINC ION",
,,,,"3.4.22","PHOSPHATE ION",
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
"3LOX","MCX","3LOX","HCV NS3-4a protease domain with a ketoamide inhibitor derivative of Boceprevir bound","2.7.7.48","ZINC ION",
,,,,"3.4.21.98","(1R,2S,5S)-N-[(2S,3R)-4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl]-6,6-dimethyl-3-{3-methyl-N-[(1-methylcyclohexyl)c
arbamoyl]-L-valyl}-3-azabicyclo[3.1.0]hexane-2-carboxamide",
,,,,"3.6.1.15","BETA-MERCAPTOETHANOL",
,,,,"3.6.4.13",,
,,,,,,
"3M5L",,"3M5L","Crystal structure of HCV NS3/4A protease in complex with ITMN-191","3.4.21.98","(2R,6S,12Z,13aS,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-14a-[(cyclopropylsulfonyl)carbamoyl]-5,16-dioxo-1,2,3,5,6,7,8
,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoro-2H-isoindole-2-carboxylate",
,,,,"2.7.7.48","SULFATE ION",
,,,,"3.6.1.15","ZINC ION",
,,,,"3.6.4.13",,
"3M5N",,"3M5N","Crystal structure of HCV NS3/4A protease in complex with N-terminal product 4B5A","3.4.21.98","SULFATE ION",
,,,,"2.7.7.48","ZINC ION",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
"3A4P","DFQ","3A4P","human c-MET kinase domain complexed with 6-benzyloxyquinoline inhibitor","2.7.10.1","CHLORIDE ION",
,"DFQ",,,,"ISOPROPYL ALCOHOL",
,,,,,"(2E)-3-{6-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]quinolin-3-yl}-N-methylprop-2-enamide",
"4RIK",,"4RIK","Amyloid forming segment, AVVTGVTAV, from the NAC domain of Parkinson's disease protein alpha-synuclein, residues 69-77",
"4RIL",,"4RIL","Structure of the amyloid forming segment, GAVVTGVTAVA, from the NAC domain of Parkinson's disease protein alpha-synuclein, residues 68-78, determined by electron diffraction",
"4R0U",,"4R0U","Tgvtava, an amyloid forming segment from alpha synuclein, residues 72-78",
"4R0W",,"4R0W","Vvtgvta, an amyloid forming segment from alpha synuclein, residues 70-76",
"4ZNN",,"4ZNN","MicroED structure of the segment, GVVHGVTTVA, from the A53T familial mutant of Parkinson's disease protein, alpha-synuclein residues 47-56",
"6SDD",,"6SDD","Crystal structure of D1228V cMET bound by BMS-777607","2.7.10.1","N-{4-[(2-amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl}-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide",
,,,,,"GLYCEROL",
"5F53",,"5F53","Nano-ring of cadmium ions coordinated by nvPizza2-S16S58",,"CADMIUM ION",
,,,,,"CHLORIDE ION",
"4ZCN",,"4ZCN","Crystal structure of nvPizza2-S16S58",,"IODIDE ION",
,,,,,"SULFATE ION",
"2N0A",,"2N0A","Atomic-resolution structure of alpha-synuclein fibrils",
"2JN5",,"2JN5","Solution Structure of a Dodecapeptide from Alpha-Synuclein Bound with Synphilin-1",
"2KKW",,"2KKW","SLAS-micelle bound alpha-synuclein",
"1XQ8",,"1XQ8","Human micelle-bound alpha-synuclein",
"3QTI","3QT","3QTI","c-Met Kinase in Complex with NVP-BVU972","2.7.10.1","6-{[6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-3-yl]methyl}quinoline",
,"3QT",,,,"CHLORIDE ION",
,"3QT",,,,"GLYCEROL",
"6OSJ",,"6OSJ","Cryo-EM structure of the N-terminally acetylated full length alpha-synuclein fibrils (Ac1-140)",
"6OSM",,"6OSM","Cryo-EM structure of the N-terminally acetylated C-terminal Alpha-synuclein truncation Ac1-103",
"6OSL",,"6OSL","Cryo-EM structure of the N-terminally acetylated C-terminal Alpha-synuclein truncation Ac1-122",
"6A6B",,"6A6B","cryo-em structure of alpha-synuclein fiber",
"6H6B",,"6H6B","Structure of alpha-synuclein fibrils",
"6FLT",,"6FLT","Structure of alpha-synuclein fibrils",
"5UAB",,"5UAB","MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody","2.7.10.1","N-{6-[([1,2,4]triazolo[4,3-a]pyridin-3-yl)sulfanyl]imidazo[1,2-b]pyridazin-2-yl}cyclopropanecarboxamide",
,,,,,"GLYCEROL",
,,,,,"CHLORIDE ION",
"6CU8",,"6CU8","Alpha Synuclein fibril formed by full length protein - Twister Polymorph",
"6CU7",,"6CU7","Alpha Synuclein fibril formed by full length protein - Rod Polymorph",
"4BXL",,"4BXL","Structure of alpha-synuclein in complex with an engineered binding protein",
,,,,
"6PES",,"6PES","Cryo-EM structure of alpha-synuclein H50Q Wide Fibril",
"6PEO",,"6PEO","Cryo-EM structure of alpha-synuclein H50Q Narrow Fibril",
"6SST",,"6SST","cryo-em structure of alpha-synuclein fibril polymorph 2B",
"6SSX",,"6SSX","cryo-em structure of alpha-synuclein fibril polymorph 2A",
"6LRQ",,"6LRQ","Cryo-EM structure of A53T alpha-synuclein amyloid fibril",
"6L1T",,"6L1T","Cryo-EM structure of phosphorylated Tyr39 a-synuclein amyloid fibril",
"6L1U",,"6L1U","Cryo-EM structure of phosphorylated Tyr39 alpha-synuclein amyloid fibril",
"6L4S",,"6L4S","cryo-em structure of alpha-synuclein fiber mutation type E46K",
"6RT0",,"6RT0","cryo-em structure of alpha-synuclein fibril polymorph 2A",
"6UFR",,"6UFR","Structure of recombinantly assembled E46K alpha-synuclein fibrils",
"6XYP",,"6XYP","Multiple system atrophy Type II-1 alpha-synuclein filament",
"6XYO",,"6XYO","Multiple system atrophy Type I alpha-synuclein filament",
"6XYQ",,"6XYQ","Multiple system atrophy Type II-2 alpha-synuclein filament",
"6RTB",,"6RTB","cryo-em structure of alpha-synuclein fibril polymorph 2B",
"2FP7",,"2FP7","West Nile Virus NS2B/NS3protease in complex with Bz-Nle-Lys-Arg-Arg-H","3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"2.1.1.56",
,,,,"2.1.1.57",
,,,,"2.7.7.48",
,,,,"3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"2.1.1.56",
,,,,"2.1.1.57",
,,,,"2.7.7.48",
,,,,,
"2OBO","HUD","2OBO","Structure of HEPATITIS C VIRAL NS3 protease domain complexed with NS4A peptide and ketoamide SCH476776",,"ZINC ION",
,,,,"2.7.7.48","BETA-MERCAPTOETHANOL",
,,,,"3.4.21.98","tert-butyl {(2S)-1-[(1R,2S,5S)-2-{[(2S,3R)-4-amino-1-cyclopropyl-3-hydroxy-4-oxobutan-2-yl]carbamoyl}-6,6-dimethyl-3-azabicyclo[3.1.0]hex-3-yl]-3,3-dimethyl-1-oxobutan-2-yl}carbamate",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
"3E90","NKK","3E90","West Nile vi rus NS2B-NS3protease in complexed with inhibitor Naph-KKR-H","3.4.21.91","N~2~-(naphthalen-2-ylcarbonyl)-L-lysyl-N-[(1S)-4-carbamimidamido-1-formylbutyl]-L-lysinamide",
,"NKK",,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
"4A1V",,"4A1V","Co-Complex structure of NS3-4A protease with the optimized inhibitory peptide CP5-46A-4D5E","3.4.21.98","CHLORIDE ION",
,,,,"3.6.1.15","POTASSIUM ION",
,,,,"3.6.4.13",,
,,,,"3.4.22",,
,,,,"2.7.7.48",,
,,,,,,
"4A1X",,"4A1X","Co-Complex structure of NS3-4A protease with the inhibitory peptide CP5-46-A (Synchrotron data)","3.4.21.98","ZINC ION",
,,,,"3.6.1.15","CHLORIDE ION",
,,,,"3.6.4.13",,
,,,,"3.4.22",,
,,,,"2.7.7.48",,
,,,,,,
"3P8N","L4T","3P8N","Crystal structure of HCV NS3/NS4A protease complexed with BI 201335","3.4.21.98","SODIUM ION",
,"L4T",,,"3.4.22","N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-7-methoxy-2-{2-[(2-methylpropanoyl)amino]-1,3-thiazol-4-yl}quinolin-4-yl)oxy]-N-[(1R,2S)-1-carboxy-2-ethenylcyclopropyl]-L-prolinamide",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,,,
"3P8O","L5T","3P8O","Crystal structure of HCV NS3/NS4A protease complexed with des-bromine analogue of BI 201335","3.4.21.98","SODIUM ION",
,"L5T",,,"3.4.22","N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-{2-[(2-methylpropanoyl)amino]-1,3-thiazol-4-yl}quinolin-4-yl)oxy]-L-prolinamide",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,,,
"3OYP","3OY","3OYP","HCV NS3/4A in complex with ligand 3","3.4.21.98","ZINC ION",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"3.4.22",,
,,,,"2.7.7.48",,
,,,,"3.4.22",,
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,,,
"4I31",,"4I31","Crystal structure of HCV NS3/NS4A protease complexed with compound 4","3.4.22","SODIUM ION",
,,,,"3.4.21.98","(2R,6S,7E,10E,13aR,14aR,16aS)-2-{[7-methoxy-8-methyl-2-(propan-2-yloxy)quinolin-4-yl]oxy}-N-[(1-methylcyclopropyl)sulfonyl]-6-{[(1-methyl-1H-pyrazol-3-yl)carbonyl]amino}-5,16-dioxo-1,2,3,6,9,12,13,13a,14,15,16,16a-dodecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,"3.4.22",,
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
"4I32",,"4I32","Crystal structure of HCV NS3/4A D168V protease complexed with compound 4","3.4.22","SODIUM ION",
,,,,"3.4.21.98","(2R,6S,7E,10E,13aR,14aR,16aS)-2-{[7-methoxy-8-methyl-2-(propan-2-yloxy)quinolin-4-yl]oxy}-N-[(1-methylcyclopropyl)sulfonyl]-6-{[(1-methyl-1H-pyrazol-3-yl)carbonyl]amino}-5,16-dioxo-1,2,3,6,9,12,13,13a,14,15,16,16a-dodecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,"3.4.22",,
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
"4I33",,"4I33","Crystal structure of HCV NS3/4A R155K protease complexed with compound 4","3.4.22","SODIUM ION",
,,,,"3.4.21.98","(2R,6S,7E,10E,13aR,14aR,16aS)-2-{[7-methoxy-8-methyl-2-(propan-2-yloxy)quinolin-4-yl]oxy}-N-[(1-methylcyclopropyl)sulfonyl]-6-{[(1-methyl-1H-pyrazol-3-yl)carbonyl]amino}-5,16-dioxo-1,2,3,6,9,12,13,13a,14,15,16,16a-dodecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,"3.4.22",,
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
"4KTC","1X3","4KTC","NS3/NS4A protease with inhibitor","3.4.21.98","ZINC ION",
,"1X3",,,"3.6.1.15","(2R,6S,13aR,14aR,16aS)-6-{[(cyclopentyloxy)carbonyl]amino}-14a-[(cyclopropylsulfonyl)carbamoyl]-5,16-dioxooctadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 3,4-dihydroisoquinoline-2(1H)-carboxylate",
,,,,"3.6.4.13",,
,,,,"3.4.22",,
,,,,"2.7.7.48",,
,,,,,,
"2GGV",,"2GGV","Crystal structure of the West Nile virus NS2B-NS3 protease, His51Ala mutant","3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"2.1.1.56",
,,,,"2.1.1.57",
,,,,"2.7.7.48",
,,,,"3.4.21.91",
,,,,"3.6.1.15",
,,,,"3.6.4.13",
,,,,"2.1.1.56",
,,,,"2.1.1.57",
,,,,"2.7.7.48",
"1DAN",,"1DAN","Complex of active site inhibited human blood coagulation factor VIIA with human recombinant soluble tissue factor","3.4.21.21","CHLORIDE ION",
,,,,"3.4.21.21","beta-D-glucopyranose",
,,,,,"alpha-L-fucopyranose",
,,,,,"CALCIUM ION",
,,,,,"D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-phenylalaninamide",
,,,,,"CACODYLATE ION",
"1DY9","2ZF","1DY9","Inhibition of the Hepatitis C Virus NS3/4A Protease. The Crystal Structures of Two Protease-Inhibitor Complexes (inhibitor I)","3.4.22","N-(tert-butoxycarbonyl)-L-alpha-glutamyl-N-[(1R)-1-(carboxycarbonyl)-3,3-difluoropropyl]-L-leucinamide",
,,,,"3.4.21.98","ZINC ION",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,"3.4.22",,
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
"1DY8","0F7","1DY8","Inhibition of the Hepatitis C Virus NS3/4A Protease. The Crystal Structures of Two Protease-Inhibitor Complexes (inhibitor II)","3.4.22","N-[(benzyloxy)carbonyl]-L-isoleucyl-N-[(1R)-1-(carboxycarbonyl)-3,3-difluoropropyl]-L-leucinamide",
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,"3.4.22",,
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
"1W3C",,"1W3C","Crystal structure of the Hepatitis C Virus NS3 Protease in complex with a peptidomimetic inhibitor","3.4.22","3-({(2S)-2-[({(1R)-1-[({(1R)-1-[(R)-CARBOXY(HYDROXY)METHYL]-3,3-DIFLUOROPROPYL}AMINO)CARBONYL]-3-METHYLBUTYL}AMINO)CARB
ONYL]-2,3-DIHYDRO-1H-INDOL-2-YL}METHYL)THIOPHENE-2-CARBOXYLIC ACID",
,,,,"3.4.21.98","3-({(2S)-2-[({(1S)-1-[({(1S)-1-[(R)-CARBOXY(HYDROXY)METHYL]-3,3-DIFLUOROPROPYL}AMINO)CARBONYL]-3-METHYLBUTYL}AMINO)CARBONYL]-2,3-DIHYDRO-1H-INDOL-2-YL}METHYL)THIOPHENE-2-CARBOXYLIC ACID",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,"3.4.22",,
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
"3M5M",,"3M5M","Avoiding drug resistance against HCV NS3/4A protease inhibitors","3.4.21.98","2-(N-MORPHOLINO)-ETHANESULFONIC ACID",
,,,,"2.7.7.48","SULFATE ION",
,,,,"3.6.1.15","ZINC ION",
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
"3M5O",,"3M5O","Crystal structure of HCV NS3/4A protease in complex with N-terminal product 5A5B","3.4.21.98","SULFATE ION",
,,,,"2.7.7.48","ZINC ION",
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.7.7.48",,
,,,,"3.4.21.98",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
"2LQK",,"2LQK","NMR solution structure of the N-terminal domain of the CdnL protein from Thermus thermophilus",
"2KCP",,"2KCP","SOLUTION STRUCTURE OF 30S RIBOSOMAL PROTEIN S8E; FROM Methanothermobacter thermautotrophicus, NORTHEASTSTRUCTURAL GENOMICS CONSORTIUM (NESG) TARGET Tr71d",
"2KCY",,"2KCY","SOLUTION STRUCTURE OF RIBOSOMAL PROTEIN S8E FROM Methanothermobacter thermautotrophicus, NORTHEASTSTRUCTURAL GENOMICS CONSORTIUM (NESG) TARGET TR71D",
"3NRL",,"3NRL","Crystal Structure of protein RUMGNA_01417 from Ruminococcus gnavus, Northeast Structural Genomics Consortium Target UgR76",,"SULFATE ION",
"3WWF",,"3WWF","Crystal structure of the computationally designed Pizza2-SR protein",
"3WWB",,"3WWB","Crystal structure of the computationally designed Pizza2-SR protein",
"5CHB",,"5CHB","Crystal structure of nvPizza2-S16H58 coordinating a CdCl2 nanocrystal",,"CADMIUM ION",
,,,,,"CHLORIDE ION",
,,,,,"SULFATE ION",
"5I1Z",,"5I1Z","Structure of nvPizza2-H16S58",,"SULFATE ION",
"5I1Y",,"5I1Y","NvPizza2-H16S58 with cobalt",,"SULFATE ION",
,,,,,"COBALT (II) ION",
"1DEC",,"1DEC","STRUCTURE OF THE RGD PROTEIN DECORSIN: CONSERVED MOTIF AND DISTINCT FUNCTION IN LEECH PROTEINS THAT AFFECT BLOOD CLOTTING",
"2M2A",,"2M2A","NMR solution structure of the two domain PPIase SlpA from Escherichia coli","5.2.1.8",
"2LT4",,"2LT4","CdnLNt from Myxoccoccus xanthus",
"2M3X",,"2M3X","Solution structure of Ph1500: a homohexameric protein centered on a 12-bladed beta-propeller",
"2KZ4",,"2KZ4","Solution structure of protein SF1141 from Shigella flexneri 2a, Northeast structural genomics consortium (NESG) target SFT2",
"2KCO",,"2KCO","Solution NMR structure of ribosomal protein sso0164 from Sulfolobus solfataricus. Northeast Structural Genomics Consortium (NESG) target SsT4.",
"2KR7",,"2KR7","solution structure of Helicobacter pylori SlyD","5.2.1.8",
"2KY9",,"2KY9","Solution NMR Structure of ydhK C-terminal Domain from B.subtilis, Northeast Structural Genomics Consortium Target Target SR518",
"2PP6",,"2PP6","Crystal structure of the ATP-binding sugar transporter-like protein from Salmonella typhimurium",
"1Y8T",,"1Y8T","Crystal Structure of RV0983 from Mycobacterium tuberculosis- Proteolytically active form","3.4.21.107",
"3DCL",,"3DCL","Crystal structure of TM1086",,"SULFATE ION",
,,,,,"CHLORIDE ION",
,,,,,"POTASSIUM ION",
"3PRB",,"3PRB","Structural analysis of protein folding by the Methanococcus jannaschii chaperone FKBP26","5.2.1.8",
"3PRD",,"3PRD","Structural analysis of protein folding by the Methanococcus jannaschii chaperone FKBP26","5.2.1.8",
"3N7D",,"3N7D","Crystal structure of CopK bound to Cu(I) and Cu(II)",,"COPPER (II) ION",
,,,,,"COPPER (I) ION",
"3N7E",,"3N7E","Crystal structure of CopK bound to Cu(II)",,"COPPER (II) ION",
"4FIB",,"4FIB","Crystal structure of the ydhK protein from Bacillus subtilis. Northeast Structural Genomics Consortium Target SR518A.",
"4L5G",,"4L5G","Crystal structure of Thermus thermophilus CarD",
"3F3B",,"3F3B","Structure of the phage-like element PBSX protein xkdH from Bacillus Subtilus. Northeast Structural Genomics Consortium target SR352.",,"PHOSPHATE ION",
"5JD8",,"5JD8","Crystal structure of the serine endoprotease from Yersinia pestis","3.4.21.107","3-CYCLOHEXYL-1-PROPYLSULFONIC ACID",
,,,,"3.4.21","DI(HYDROXYETHYL)ETHER",
,,,,,"SULFATE ION",
"6PYM",,"6PYM","Structure of active-site serine mutant of ESP, serine protease from Staphylococcus epidermidis","3.4.21.19",
"6E0U",,"6E0U","Staphylococcus pseudintermedius exfoliative toxin EXI","3.4.21",
"1WCZ",,"1WCZ","Crystal structure of an alkaline form of v8 protease from Staphylococcus aureus","3.4.21.19","ZINC ION",
"6CVY","FHD","6CVY","Crystal structure of HCV NS3/4A WT protease in complex with AJ-21 (MK-5172 linear analogue)",,"ZINC ION",
,,,,,"SULFATE ION",
,,,,,"3-methyl-N-[(pentyloxy)carbonyl]-L-valyl-(4R)-4-[(3-chloro-7-methoxyquinoxalin-2-yl)oxy]-N-[(1R,2S)-2-ethenyl-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-L-prolinamide",
,,,,,"GLYCEROL",
"6CVX","FH4","6CVX","Crystal structure of HCV NS3/4A WT protease in complex with AJ-50 (MK-5172 linear analogue)",,"N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-N-[(1R,2S)-2-ethenyl-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-4-{[7-methoxy-3-(propan-2-yl)quinoxalin-2-yl]oxy}-L-prolinamide",
,,,,,"SULFATE ION",
,,,,,"ZINC ION",
,,,,,"GLYCEROL",
"6C2O",,"6C2O","Crystal structure of HCV NS3/4A protease variant Y56H in complex with danoprevir",,"(2R,6S,12Z,13aS,14aR,16aS)-6-[(tert-butoxycarbonyl)amino]-14a-[(cyclopropylsulfonyl)carbamoyl]-5,16-dioxo-1,2,3,5,6,7,8
,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoro-2H-isoindole-2-carboxylate",
,,,,,"ZINC ION",
,,,,,"GLYCEROL",
"6DIS",,"6DIS","Crystal structure of HCV NS3/4A protease in complex with P4-1 (AJ-71)",,"1,1,1-trifluoro-2-methylpropan-2-yl
[(2R,6S,12Z,13aS,14aR,16aS)-2-[(7-methoxy-3-methylquinoxalin-2-yl)oxy]-14a-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}-5,
16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl]carbamate",
,,,,,"SULFATE ION",
,,,,,"ZINC ION",
,,,,,"GLYCEROL",
"6DIV",,"6DIV","Crystal structure of HCV NS3/4A D168A protease in complex with P4-P5-2 (AJ-67)",,"(2R,6S,12Z,13aS,14aR,16aS)-6-[(N-acetyl-3-methyl-L-valyl)amino]-2-[(7-methoxy-3-methylquinoxalin-2-yl)oxy]-N-[(1-methyl
cyclopropyl)sulfonyl]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diaz
acyclopentadecine-14a(5H)-carboxamide",
,,,,,"ZINC ION",
,,,,,"SULFATE ION",
,,,,,"GLYCEROL",
"6DIU",,"6DIU","Crystal structure of HCV NS3/4A protease in complex with P4-3(AJ-74)",,"ZINC ION",
,,,,,"SULFATE ION",
,,,,,"1-methylcyclopentyl [(2R,6S,12Z,13aS,14aR,16aS)-2-[(7-methoxy-3-methylquinoxalin-2-yl)oxy]-14a-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]carbamate",
,,,,,"GLYCEROL",
"6DIW",,"6DIW","Crystal structure of HCV NS3/4A D168A protease in complex with P4-1 (AJ-71)",,"1,1,1-trifluoro-2-methylpropan-2-yl
[(2R,6S,12Z,13aS,14aR,16aS)-2-[(7-methoxy-3-methylquinoxalin-2-yl)oxy]-14a-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}-5,
16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl]carbamate",
,,,,,"SULFATE ION",
,,,,,"ZINC ION",
,,,,,"GLYCEROL",
"6DIQ",,"6DIQ","Crystal structure of HCV NS3/4A protease in complex with P4-P5-1 (WK-23)",,"methyl [(2S)-1-{[(2R,6S,12Z,13aS,14aR,16aS)-2-[(7-methoxy-3-methylquinoxalin-2-yl)oxy]-14a-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]amino}-3,3-dimethyl-1-oxobutan-2-yl]carbamate",
,,,,,"SULFATE ION",
,,,,,"ZINC ION",
,,,,,"GLYCEROL",
"3Q28",,"3Q28","Cyrstal structure of human alpha-synuclein (58-79) fused to maltose binding protein (MBP)",,"SULFATE ION",
"2X6M",,"2X6M","Structure of a single domain camelid antibody fragment in complex with a C-terminal peptide of alpha-synuclein",
,,,,
"5CRW",,"5CRW","Crystal structure of the b'-a' domain of oxidized protein disulfide isomerase complexed with alpha-synuclein peptide (31-41)","5.3.4.1",
,,,,,
"2LEL",,"2LEL","Structure of Cu(I)Cu(II)-CopK from Cupriavidus metallidurans CH34",,"COPPER (I) ION",
,,,,,"COPPER (II) ION",
"2LP6",,"2LP6","Refined Solution NMR Structure of the 50S ribosomal protein L35Ae from Pyrococcus furiosus, Northeast Structural Genomics Consortium Target (NESG) PfR48",
"2LT1",,"2LT1","Solution NMR structure of the 72-residue N-terminal domain of Myxococcus xanthus CarD",
"2IPQ",,"2IPQ","Crystal structure of C-terminal domain of Salmonella Enterica protein STY4665, PFAM DUF1528",
"2EA3",,"2EA3","Crystal Structure Of Cellulomonas Bogoriensis Chymotrypsin","3.4.21","SULFATE ION",
"2EEK",,"2EEK","Crystal structure of Atlantic cod trypsin complexed with benzamidine","3.4.21.4","CALCIUM ION",
,,,,,"SODIUM ION",
,,,,,"BENZAMIDINE",
"2K0Q",,"2K0Q","Solution structure of CopK, a periplasmic protein involved in copper resistance in Cupriavidus metallidurans CH34",
"2KCA",,"2KCA","GP16",
"2KM0",,"2KM0","Cu(I)-bound CopK",,"COPPER (I) ION",
"2L6O",,"2L6O","NMR structure of the protein YP_926445.1 from Shewanella Amazonensis",
"2KX4",,"2KX4","Solution structure of Bacteriophage Lambda gpFII",
"2OXS",,"2OXS","Crystal Structure of the trypsin complex with benzamidine at high temperature (35 C)","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"BENZAMIDINE",
"2PTN",,"2PTN","ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY","3.4.21.4","CALCIUM ION",
"2HIR",,"2HIR","SOLUTION STRUCTURE OF RECOMBINANT HIRUDIN AND THE LYS-47 (RIGHT ARROW) GLU MUTANT. A NUCLEAR MAGNETIC RESONANCE AND HYBRID DISTANCE GEOMETRY-DYNAMICAL SIMULATED ANNEALING STUDY",
"2HLC",,"2HLC","HL COLLAGENASE STRUCTURE AT 1.7A RESOLUTION","3.4.21",
,,,,"3.4.21.49",
"2QF3",,"2QF3","Structure of the delta PDZ truncation of the DegS protease","3.4.21","PHOSPHATE ION",
,,,,"3.4.21.107",,
"2QF0",,"2QF0","Structure of the delta PDZ truncation of the DegS protease","3.4.21",
,,,,"3.4.21.107",
"2QGR",,"2QGR","Structure of the R178A mutant of delta PDZ DegS protease","3.4.21",
,,,,"3.4.21.107",
"2F4L",,"2F4L","Crystal structure of a putative acetamidase (tm0119) from thermotoga maritima msb8 at 2.50 A resolution",,"ZINC ION",
,,,,,"CHLORIDE ION",
"1XVM",,"1XVM","Trypsin from Fusarium oxysporum- room temperature to atomic resolution","3.4.21.4",
,,,,,
"1XVO",,"1XVO","Trypsin from Fusarium oxysporum at pH 6","3.4.21.4","SULFATE ION",
"2NU1",,"2NU1","Molecular structures of the complexes of SGPB with OMTKY3 aromatic P1 variants Trp18I, His18I, Phe18I and Tyr18I","3.4.21.81",
,,,,,
"2O8L",,"2O8L","Structure of V8 protease from staphylococcus aureus","3.4.21.19","POTASSIUM ION",
"2O9Q",,"2O9Q","The crystal structure of Bovine Trypsin complexed with a small inhibition peptide ORB2K","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"2TGD",,"2TGD","LACK OF THE TRANSITION STATE STABILIZATION SITE IS A FACTOR IN THE INACTIVITY OF TRYPSINOGEN, A SERINE PROTEASE ZYMOGEN. STRUCTURE OF DFP INHIBITED BOVINE TRYPSINOGEN AT 2.1 ANGSTROMS RESOLUTION","3.4.21.4","CALCIUM ION",
,,,,,"DIISOPROPYL PHOSPHONATE",
"2SFA",,"2SFA","SERINE PROTEINASE FROM STREPTOMYCES FRADIAE ATCC 14544","3.4.21",
"2RCE",,"2RCE","DFP modified DegS delta PDZ","3.4.21",
,,,,"3.4.21.107",
"3UFA","VPF","3UFA","Crystal structure of the staphylococcal serine protease SplA in complex with a specific phosphonate inhibitor","3.4.21","N-(3-carboxypropanoyl)-L-valyl-N-[(1S)-2-phenyl-1-phosphonoethyl]-L-prolinamide",
,,,,,"CHLORIDE ION",
"3DSO",,"3DSO","Crystal structure of Cu(I) bound copper resistance protein CopK",,"COPPER (I) ION",
,,,,,"THIOCYANATE ION",
"3DSP",,"3DSP","Crystal structure of apo copper resistance protein CopK",
"3DSG",,"3DSG","XC1028 from Xanthomonas campestris Adopts a PilZ Domain-like Structure Yet with Trivial c-di-GMP Binding Activity",
"3PTB",,"3PTB","THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
"3PV2",,"3PV2","Structure of Legionella fallonii DegQ (wt)","3.4.21.107",
"3PV3",,"3PV3","Structure of Legionella fallonii DegQ (S193A variant)","3.4.21.107",
,,,,,
"3PV4",,"3PV4","Structure of Legionella fallonii DegQ (Delta-PDZ2 variant)",,"CADMIUM ION",
"3PV5",,"3PV5","Structure of Legionella fallonii DegQ (N189G/P190G variant)","3.4.21.107",
"4DT4",,"4DT4","Crystal structure of the PPIase-chaperone SlpA with the chaperone binding site occupied by the linker of the purification tag","5.2.1.8",
"3N99",,"3N99","Crystal structure of TM1086",,"CHLORIDE ION",
"3WY8",,"3WY8","Crystal Structure of Protease Anisep from Arthrobacter Nicotinovorans","3.4.21.1",
"2YMS",,"2YMS","Structure and assembly of a b-propeller with nine blades and a new conserved repetitive sequence motif",,"SODIUM ION",
,,,,,,
,,,,,,
,,,,,,
"2Z9I",,"2Z9I","Crystal structure of RV0983 from Mycobacterium tuberculosis- Proteolytically active form","3.4.21",
,,,,"3.4.21.107",
,,,,,
,,,,,
"2W7S",,"2W7S","SplA serine protease of Staphylococcus aureus (1.8A)","3.4.21.19",
,,,,"3.4.21",
"2W7U",,"2W7U","SplA serine protease of Staphylococcus aureus (2.4A)","3.4.21.19",
,,,,"3.4.21",
"3A8C",,"3A8C","Crystal Structure of Trypsin complexed with (E)-2-(4-carbamimidoylbenzylideneaminooxy)acetic acid (soaking with mixture of [(E)-2-(4-carbamimidoylbenzylideneaminooxy)acetic acid] and [(E)-2-(4-carbamimidoylbenzylideneaminooxy)-2-methylpropanoic acid])","3.4.21.4","CALCIUM ION",
,,,,,"(E)-2-(4-carbamimidoylbenzylideneaminooxy)acetic acid",
"3A80",,"3A80","Crystal Structure of Trypsin complexed with (E)-2-(4-carbamimidoylbenzylideneaminooxy)-2-methylpropanoic acid (soaking 40seconds)","3.4.21.4","CALCIUM ION",
,,,,,"(E)-2-(4-carbamimidoylbenzylideneaminooxy)-2-methylpropanoic acid",
"3AK5",,"3AK5","Hemoglobin protease (Hbp) passenger missing domain-2","3.4.21","CALCIUM ION",
"3CNR",,"3CNR","Crystal Structure of PilZ (XAC1133) from Xanthomonas axonopodis pv citri",
"3CP7",,"3CP7","Crystal structure of a thermostable serine protease AL20 from extremophilic microoganism","3.4.21.1","FORMIC ACID",
"3GCN",,"3GCN","Crystal structure of DegS H198P/D320A mutant modified by DFP in complex with OMP peptide (YQF)","3.4.21",
,,,,"3.4.21.107",
,,,,,
"3GCO",,"3GCO","Crystal structure of DegS H198P/D320A mutant modified by DFP in complex with DNRDGNVYQF OMP peptide","3.4.21",
,,,,"3.4.21.107",
,,,,,
"3GDS",,"3GDS","Crystal structure of DegS H198P/D320A mutant modified by DFP in complex with DNRDGNVYYF peptide","3.4.21",
,,,,"3.4.21.107",
,,,,,
"3GDU",,"3GDU","Crystal structure of DegS H198P/D320A mutant modified by DFP and in complex with YRF peptide","3.4.21",
,,,,"3.4.21.107",
,,,,,
"3GDV",,"3GDV","Crystal structure of DegS H198P/D320A mutant modified by DFP and in complex with YQF peptide","3.4.21",
,,,,"3.4.21.107",
,,,,,
"3GS9",,"3GS9","Crystal structure of prophage tail protein gp18 (NP_465809.1) from Listeria monocytogenes EGD-e at 1.70 A resolution",
"3FO8",,"3FO8","Crystal structure of the bacteriophage T4 tail sheath protein, protease resistant fragment gp18PR",,"ACETATE ION",
"3M7U",,"3M7U","Crystal Structure of Alpha-Lytic Protease SB1+2 R64A/E182Q Mutant","3.4.21.12","SULFATE ION",
,,,,,,
"4HIR",,"4HIR","SOLUTION STRUCTURE OF RECOMBINANT HIRUDIN AND THE LYS-47 (RIGHT ARROW) GLU MUTANT. A NUCLEAR MAGNETIC RESONANCE AND HYBRID DISTANCE GEOMETRY-DYNAMICAL SIMULATED ANNEALING STUDY",
"4Q63",,"4Q63","Crystal Structure of Legionella Uncharacterized Protein Lpg0364",,"CADMIUM ION",
,,,,,"FORMIC ACID",
,,,,,"1,2-ETHANEDIOL",
,,,,,"CHLORIDE ION",
"4RR0",,"4RR0","re-refined 1vcw, CRYSTAL STRUCTURE OF DEGS AFTER BACKSOAKING THE ACTIVATING PEPTIDE","3.4.21.107",
"4RR1",,"4RR1","re-refinement of entry 1sot, Crystal Structure of the DegS stress sensor","3.4.21.107","PHOSPHATE ION",
,,,,,"NICKEL (II) ION",
"4RQY",,"4RQY","RE-REFINED STRUCTURE OF 1TE0 - STRUCTURAL ANALYSIS of DEGS, A STRESS SENSOR OF THE BACTERIAL PERIPLASM","3.4.21.107","PHOSPHATE ION",
"4RQZ",,"4RQZ","re-refinement of 1soz, Crystal Structure of DegS protease in complex with an activating peptide","3.4.21.107",
,,,,,
"4MVN",,"4MVN","Crystal structure of the staphylococcal serine protease SplA in complex with a specific phosphonate inhibitor","3.4.21","[(1S)-1-{[(benzyloxy)carbonyl]amino}-2-phenylethyl]phosphonic acid",
"4JCN",,"4JCN","Structure of ESP, serine protease from Staphylococcus epidermidis","3.4.21.19",
"4K1S",,"4K1S","Gly-Ser-SplB protease from Staphylococcus aureus at 1.96 A resolution","3.4.21",
"4K1T",,"4K1T","Gly-Ser-SplB protease from Staphylococcus aureus at 1.60 A resolution","3.4.21","ZINC ION",
,,,,,"SULFATE ION",
,,,,,"CHLORIDE ION",
"3B8J",,"3B8J","Q191A mutant of DegS-deltaPDZ","3.4.21",
,,,,"3.4.21.107",
"3STI",,"3STI","Crystal structure of the protease domain of DegQ from Escherichia coli","3.4.21",
,,,,"3.4.21.107",
"2VID",,"2VID","Serine protease SplB from Staphylococcus aureus at 1.8A resolution","3.4.21",
"4INK",,"4INK","Crystal structure of SplD protease from Staphylococcus aureus at 1.56 A resolution","3.4.21",
"4INL",,"4INL","Crystal structure of SplD protease from Staphylococcus aureus at 2.1 A resolution","3.4.21",
"5B6L",,"5B6L","Structure of Deg protease HhoA from Synechocystis sp. PCC 6803",,"ZINC ION",
,,,,,"SODIUM ION",
"2NU0",,"2NU0","Molecular structures of the complexes of SGPB with OMTKY3 aromatic P1 variants Trp18I, His18I, Phe18I, and Tyr18I","3.4.21.81",
,,,,,
"1HYL",,"1HYL","THE 1.8 A STRUCTURE OF COLLAGENASE FROM HYPODERMA LINEATUM","3.4.21",
,,,,"3.4.21.49",
"1QTF",,"1QTF","CRYSTAL STRUCTURE OF EXFOLIATIVE TOXIN B","3.4.21",
"1QY6",,"1QY6","Structue of V8 Protease from Staphylococcus aureus","3.4.21.19","POTASSIUM ION",
"2AEG",,"2AEG","X-Ray Crystal Structure of Protein Atu5096 from Agrobacterium tumefaciens. Northeast Structural Genomics Consortium Target AtR63.","3.4",
"2AS9",,"2AS9","Functional and structural characterization of Spl proteases from staphylococcus aureus","3.4.21","ZINC ION",
"2G52",,"2G52","Anomalous substructure of trypsin (P21)","3.4.21.4","SULFATE ION",
"2G51",,"2G51","anomalous substructure of trypsin (p1)","3.4.21.4","CHLORIDE ION",
"2G5V",,"2G5V","Indole-amidine Complexes with Bovine Trypsin","3.4.21.4","CALCIUM ION",
,,,,,"2-(2-METHYLPHENYL)-1H-INDOLE-6-CARBOXIMIDAMIDE",
"2G5N",,"2G5N","Indole-amidine Complexes with Bovine Trypsin","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"2-(3-METHYLPHENYL)-1H-INDOLE-5-CARBOXIMIDAMIDE",
"2GJG",,"2GJG","CRYSTAL STRUCTURE OF A PILZ-CONTAINING PROTEIN (PP4397) FROM PSEUDOMONAS PUTIDA KT2440 AT 2.25 A RESOLUTION",,"1,2-ETHANEDIOL",
"3I78",,"3I78","35/99/170/186/220-loops of FXa in SGT","3.4.21.4","SODIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"6HIR",,"6HIR","SOLUTION STRUCTURE OF RECOMBINANT HIRUDIN AND THE LYS-47 (RIGHT ARROW) GLU MUTANT. A NUCLEAR MAGNETIC RESONANCE AND HYBRID DISTANCE GEOMETRY-DYNAMICAL SIMULATED ANNEALING STUDY",
"6IEO",,"6IEO","Crystal structure of Mycobacterium tuberculosis HtrA1 (Rv1223) in regulated conformation","3.4.21.107","phenylmethanesulfonic acid",
"5C2Z",,"5C2Z","Molecular insights into the specificity of exfoliative toxins from Staphylococcus aureus","3.4.21",
"5T63",,"5T63","The HhoA protease from Synechocystis sp. PCC 6803",,"MAGNESIUM ION",
,,,,,,
"5T69",,"5T69","The HhoA protease from Synechocystis sp. PCC 6803, active site mutant",,"ACETATE ION",
,,,,,"MAGNESIUM ION",
"5WOT",,"5WOT","NMR solution structure of a-lytic protease using two 4D-spectra","3.4.21.12",
"6EW9",,"6EW9","CRYSTAL STRUCTURE OF DEGS STRESS SENSOR PROTEASE IN COMPLEX WITH ACTIVATING DNRLGLVYQF PEPTIDE","3.4.21.107","DI(HYDROXYETHYL)ETHER",
,,,,,"CALCIUM ION",
"6FEZ",,"6FEZ","Ryegrass mottle virus protease domain","2.7.7.48",
"5KWM",,"5KWM","S. erythraea trypsin long construct apoenzyme",
"5DK1",,"5DK1","S. erythraea trypsin mixed catalytic intermediate","3.4.21.4",
"5DKM",,"5DKM","S. erythraea trypsin Michaelis-Menten complex","3.4.21.4",
"5HIR",,"5HIR","SOLUTION STRUCTURE OF RECOMBINANT HIRUDIN AND THE LYS-47 (RIGHT ARROW) GLU MUTANT. A NUCLEAR MAGNETIC RESONANCE AND HYBRID DISTANCE GEOMETRY-DYNAMICAL SIMULATED ANNEALING STUDY",
"5HM9",,"5HM9","Crystal structure of MamO protease domain from Magnetospirillum magneticum (apo form)",
,,,,
"5HMA",,"5HMA","Crystal structure of MamO protease domain from Magnetospirillum magneticum (Ni bound form)",,"NICKEL (II) ION",
,,,,,"CHLORIDE ION",
"5G4B",,"5G4B","Crystal structure of Aura virus capsid protein in complex with piperazine.","3.4.21.90","piperazine",
"5GND",,"5GND","Structure of Deg protease HhoA from Synechocystis sp. PCC 6803",,"ZINC ION",
,,,,,"SODIUM ION",
"5EJL","C2E","5EJL","MrkH, A novel c-di-GMP dependence transcription regulatory factor.",,"9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one)",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"5DJ7",,"5DJ7","S. erythraea trypsin acyl-enzyme",
"4YNN",,"4YNN","Structure of Legionella pneumophila DegQ (S190A variant)","3.4.21",
,,,,"3.4.21.107",
,,,,,
,,,,,
,,,,,
,,,,,
"4YO1",,"4YO1","Structure of Legionella pneumophila DegQ (delta PDZ2 variant)","3.4.21","CADMIUM ION",
,,,,"3.4.21.107",,
"4XRN",,"4XRN","Pilz domain with c-di-gmp of a protein from Pseudomonas aeruginosa","2.4.1.33","9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one)",
,,,,,"ZINC ION",
"5KED",,"5KED","Structure of the 2.65 Angstrom P2(1) crystal of K. pneumonia MrkH",
"5KEC",,"5KEC","Structure of K. pneumonia MrkH in its apo state.",
"5KGO",,"5KGO","Structure of K. pneumonia MrkH-c-di-GMP complex",,"9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one)",
"5JQN",,"5JQN","NitN Amidase from Neterenkonia sp. AN1 after thrombin His-tag removal.","3.5.1.4",
"5MM8",,"5MM8","Atomic resolution structure of SplE protease from Staphylococcus aureus","3.4.21","ACETATE ION",
"5MNP",,"5MNP","Cationic trypsin in complex with N-amidinopiperidine (at 295 K)","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"piperidine-1-carboximidamide",
"5MO1",,"5MO1","Neutron structure of cationic trypsin in complex with benzylamine","3.4.21.4","CALCIUM ION",
,,,,,"(phenylmethyl)azanium",
"5MNK",,"5MNK","Cationic trypsin in complex with benzylamine (deuterated sample at 100 K)","3.4.21.4","CALCIUM ION",
,,,,,"BENZYLAMINE",
,,,,,"SULFATE ION",
"5MNM",,"5MNM","Cationic trypsin in complex with benzylamine (at 295 K)","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"BENZYLAMINE",
"5MNL",,"5MNL","Cationic trypsin in complex with benzylamine (deuterated sample at 295 K)","3.4.21.4","CALCIUM ION",
,,,,,"BENZYLAMINE",
,,,,,"SULFATE ION",
"5MOR",,"5MOR","Joint X-ray/neutron structure of cationic trypsin in complex with benzylamine","3.4.21.4","CALCIUM ION",
,,,,,"(phenylmethyl)azanium",
,,,,,"SULFATE ION",
"6Q12",,"6Q12","Structure of pro-Esp mutant- S66V","3.4.21.19",
"6Q24",,"6Q24","Structure of pro-Esp mutant- S235A","3.4.21.19",
"6U1B",,"6U1B","Structure of N-terminus locked Esp with eight pro-peptide residues - V67C, D255C","3.4.21.19",
"5Y28",,"5Y28","Crystal structure of H. pylori HtrA with PDZ2 deletion","3.4.21.107","1,2-ETHANEDIOL",
,,,,,,
"1DUE",,"1DUE","CRYSTAL STRUCTURE OF EXFOLIATIVE TOXIN A S195A MUTANT","3.4.21",
"1DT2",,"1DT2","CRYSTAL STRUCTURE OF EXFOLIATIVE TOXIN B","3.4.21",
"1DUA",,"1DUA","CRYSTAL STRUCTURE OF EXFOLIATIVE TOXIN A","3.4.21",
"1ELT",,"1ELT","STRUCTURE OF NATIVE PANCREATIC ELASTASE FROM NORTH ATLANTIC SALMON AT 1.61 ANGSTROMS RESOLUTION","3.4.21.36","CALCIUM ION",
"1EQ9",,"1EQ9","CRYSTAL STRUCTURE OF FIRE ANT CHYMOTRYPSIN COMPLEXED TO PMSF","3.4.21.1","phenylmethanesulfonic acid",
"1EPT",,"1EPT","REFINED 1.8 ANGSTROMS RESOLUTION CRYSTAL STRUCTURE OF PORCINE EPSILON-TRYPSIN","3.4.21.4","CALCIUM ION",
,,,,"3.4.21.4",,
,,,,"3.4.21.4",,
"1EXF",,"1EXF","EXFOLIATIVE TOXIN A","3.4.21","GLYCINE",
"6DI8",,"6DI8","Crystal structure of bovine alpha-chymotrypsin in space group P65","3.4.21.1","SULFATE ION",
,,,,"3.4.21.1",,
,,,,"3.4.21.1",,
"1AGJ",,"1AGJ","EPIDERMOLYTIC TOXIN A FROM STAPHYLOCOCCUS AUREUS","3.4.21",
"1AKS",,"1AKS","CRYSTAL STRUCTURE OF THE FIRST ACTIVE AUTOLYSATE FORM OF THE PORCINE ALPHA TRYPSIN","3.4.21.4","CALCIUM ION",
,,,,"3.4.21.4",,
"1ARC",,"1ARC","THE PRIMARY STRUCTURE AND STRUCTURAL CHARACTERISTICS OF ACHROMOBACTER LYTICUS PROTEASE I, A LYSINE-SPECIFIC SERINE PROTEASE","3.4.21.50","N-[(1S)-5-amino-1-(chloroacetyl)pentyl]-4-methylbenzenesulfonamide",
"1ARB",,"1ARB","THE PRIMARY STRUCTURE AND STRUCTURAL CHARACTERISTICS OF ACHROMOBACTER LYTICUS PROTEASE I, A LYSINE-SPECIFIC SERINE PROTEASE","3.4.21.50",
"1SOT",,"1SOT","Crystal Structure of the DegS stress sensor","3.4.21",
,,,,"3.4.21.107",
"1SQR",,"1SQR","Solution Structure of the 50S Ribosomal Protein L35AE from Pyrococcus furiosus. Northeast Structural Genomics Consortium Target PfR48.",
"1TE0",,"1TE0","Structural analysis of DegS, a stress sensor of the bacterial periplasm","3.4.21",
,,,,"3.4.21.107",
"1TPO",,"1TPO","THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS","3.4.21.4","CALCIUM ION",
"1YPH",,"1YPH","High resolution structure of bovine alpha-chymotrypsin","3.4.21.1","SULFATE ION",
,,,,"3.4.21.1",,
,,,,"3.4.21.1",,
"1YWU",,"1YWU","Solution NMR structure of Pseudomonas Aeruginosa protein PA4608. Northeast Structural Genomics target PaT7",
"1P09",,"1P09","STRUCTURAL PLASTICITY AS A DETERMINANT OF ENZYME SPECIFICITY. CREATING BROADLY SPECIFIC PROTEASES","3.4.21.12","SULFATE ION",
"1OX1",,"1OX1","crystal structure of the bovine trypsin complex with a synthetic 11 peptide inhibitor","3.4.21.4","CALCIUM ION",
,,,,,,
"1PQ7",,"1PQ7","Trypsin at 0.8 A, pH5 / borax","3.4.21.4","SULFATE ION",
,,,,,"ARGININE",
"1PQ5",,"1PQ5","Trypsin at pH 5, 0.85 A","3.4.21.4","SULFATE ION",
,,,,,"ARGININE",
"1S0R",,"1S0R","Bovine Pancreatic Trypsin inhibited with Benzamidine at Atomic resolution","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
"1S0Q",,"1S0Q","Native Bovine Pancreatic Trypsin","3.4.21.4","CALCIUM ION",
"1SGC",,"1SGC","THE 1.8 ANGSTROMS STRUCTURE OF THE COMPLEX BETWEEN CHYMOSTATIN AND STREPTOMYCES GRISEUS PROTEASE A. A MODEL FOR SERINE PROTEASE CATALYTIC TETRAHEDRAL INTERMEDIATES","3.4.21.80",
,,,,,
"6TYA",,"6TYA","Structure of N-terminus locked Esp with one pro-peptide residue - V67C, D255C","3.4.21.19",
"1JIR",,"1JIR","Crystal Structure of Trypsin Complex with Amylamine in Cyclohexane","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"AMYLAMINE",
"1K0H",,"1K0H","Solution structure of bacteriophage lambda gpFII",
"1TYN","CTA","1TYN","ATOMIC STRUCTURE OF THE TRYPSIN-CYCLOTHEONAMIDE A COMPLEX: LESSONS FOR THE DESIGN OF SERINE PROTEASE INHIBITORS","3.4.21.4","CYCLOTHEONAMIDE A",
"4UIB","GWX","4UIB","Crystal structure of 3p in complex with tafCPB","3.4.17.2","ZINC ION",
,,,,,"ACETATE ION",
,,,,,"GLYCEROL",
,,,,,"(2S)-6-AMINO-2-[[(1R)-1-(CYCLOHEXYLMETHYL)-2-OXO-2-[[(2S)-1,7,7-TRIMETHYLNORBORNAN-2-YL]AMINO]ETHYL]ARBAMOYLAMINO]HEXANOIC ACID",
"2ZDL","45U","2ZDL","Exploring trypsin S3 pocket","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide",
,,,,,"GLYCEROL",
"2ZDM","46U","2ZDM","Exploring trypsin S3 pocket","3.4.21.4","CALCIUM ION",
,,,,,"(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide",
,,,,,"GLYCEROL",
"2ZDN","49U","2ZDN","Exploring trypsin S3 pocket","3.4.21.4","CALCIUM ION",
,,,,,"(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide",
,,,,,"GLYCEROL",
"2ZDK","50U","2ZDK","Exploring Trypsin S3 Pocket","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"GLYCEROL",
"2ZFS","12U","2ZFS","Exploring trypsin S3 pocket","3.4.21.4","CALCIUM ION",
,,,,,"N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"GLYCEROL",
"2ZFT","10U","2ZFT","Exploring trypsin S3 pocket","3.4.21.4","CALCIUM ION",
,,,,,"(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"GLYCEROL",
"2ZHD","12U","2ZHD","Exploring trypsin S3 pocket","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide",
,,,,,"GLYCEROL",
"2ZQ1","11U","2ZQ1","Exploring trypsin S3 pocket","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide",
,,,,,"GLYCEROL",
"2ZQ2","13U","2ZQ2","Exploring trypsin S3 pocket","3.4.21.4","CALCIUM ION",
,"13U",,,,"N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide",
,,,,,"GLYCEROL",
"6PIZ",,"6PIZ","Crystal structure of HCV NS3/4A D168A protease in complex with P4-1 (NR02-24)",,"SULFATE ION",
,,,,,"1-methylcyclopropyl [(2R,6S,12Z,13aS,14aR,16aS)-2-[(7-methoxy-3-methylquinoxalin-2-yl)oxy]-14a-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]carbamate",
,,,,,"GLYCEROL",
,,,,,"1,2-ETHANEDIOL",
,,,,,"ZINC ION",
"1ZLR",,"1ZLR","Factor XI catalytic domain complexed with 2-guanidino-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl nicotinate","3.4.21.27","SULFATE ION",
,,,,,"(1R)-2-{[AMINO(IMINO)METHYL]AMINO}-1-{4-[(4R)-4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL]PHENYL}ETHYL NICOTINATE",
,,,,,"GLYCEROL",
"6UE3",,"6UE3","Crystal structure of HCV NS3/4A D168A protease in complex with PC (JZ01-15)",,"tert-butyl [(2R,6S,12Z,13aS,14aR,16aS)-2-[(7-methoxy-3-methylquinoxalin-2-yl)oxy]-14a-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl]carbamate",
,,,,,"ZINC ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"GLYCEROL",
,,,,,"SULFATE ION",
"1D7P",,"1D7P","Crystal structure of the c2 domain of human factor viii at 1.5 a resolution at 1.5 A",,"SULFATE ION",
,,,,,"CYSTEINE",
,,,,,"GLYCEROL",
"1BIO","SOA","1BIO","HUMAN COMPLEMENT FACTOR D IN COMPLEX WITH ISATOIC ANHYDRIDE INHIBITOR","3.4.21.46","ISATOIC ANHYDRIDE",
,,,,,"GLYCEROL",
"4V07",,"4V07","Dimeric pseudorabies virus protease pUL26N at 2.1 A resolution","3.4.21.97","CHLORIDE ION",
,,,,,"MAGNESIUM ION",
"4V08",,"4V08","Inhibited dimeric pseudorabies virus protease pUL26N at 2 A resolution","3.4.21.97","DIISOPROPYL PHOSPHONATE",
,,,,,"CHLORIDE ION",
,,,,,"MAGNESIUM ION",
"2LPR",,"2LPR","STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS","3.4.21.12","SULFATE ION",
,,,,,,
"2LWJ",,"2LWJ","NMR solution structure Myxoccoccus xanthus CdnL",
"2K8I",,"2K8I","Solution structure of E.Coli SlyD","5.2.1.8",
"2KFW",,"2KFW","Solution structure of full-length SlyD from E.coli","5.2.1.8",
"2L74",,"2L74","Solution structure of the PilZ domain protein PA4608 complex with c-di-GMP identifies charge clustering as molecular readout",,"9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one)",
"2PKA",,"2PKA","REFINED 2 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF PORCINE PANCREATIC KALLIKREIN A, A SPECIFIC TRYPSIN-LIKE SERINE PROTEINASE. CRYSTALLIZATION, STRUCTURE DETERMINATION, CRYSTALLOGRAPHIC REFINEMENT, STRUCTURE AND ITS COMPARISON WITH BOVINE TRYPSIN","3.4.21.35","BENZAMIDINE",
,,,,"3.4.21.35",,
"2P8O","BVA","2P8O","Crystal Structure of a Benzohydroxamic Acid/Vanadate complex bound to chymotrypsin A","3.4.21.1","SULFATE ION",
,"BVA",,,"3.4.21.1","TRIHYDROXY[(N-HYDROXYBENZAMIDATO)OXO]VANADATE",
,,,,"3.4.21.1",,
"2QN5",,"2QN5","Crystal Structure and Functional Study of the Bowman-Birk Inhibitor from Rice Bran in Complex with Bovine Trypsin",
,,,,3.4.21.4,
"2R3Y",,"2R3Y","Crystal structure of the DegS protease in complex with the YWF activating peptide","3.4.21",
,,,,"3.4.21.107",
,,,,,
"2R3U",,"2R3U","Crystal structure of the PDZ deletion mutant of DegS","3.4.21",
,,,,"3.4.21.107",
"2QYI",,"2QYI","Crystal structure of a binary complex between an engineered trypsin inhibitor and Bovine trypsin","3.4.21.4","CALCIUM ION",
,,,,,"NICKEL (II) ION",
"2F91",,"2F91","1.2A resolution structure of a crayfish trypsin complexed with a peptide inhibitor, SGTI","3.4.21.4","CADMIUM ION",
,,,,,"CHLORIDE ION",
"2FMJ",,"2FMJ","220-loop mutant of streptomyces griseus trypsin","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"2FPZ","270","2FPZ","Human tryptase with 2-amino benzimidazole","3.4.21.59","2H-BENZOIMIDAZOL-2-YLAMINE",
,"AX7",,,,,
,"270",,,,,
"2FS9","C4A","2FS9","Human beta tryptase II with inhibitor CRA-28427","3.4.21.59","ETHYL {(1S)-5-AMINO-1-[(5-{4-[(2,3-DIHYDRO-1H-INDEN-2-YLAMINO)CARBONYL]BENZYL}-1,2,4-OXADIAZOL-3-YL)CARBONYL]PENTYL}CARBAMATE",
,"C4A",,,,,
,"C4A",,,,,
"2FS8","C3A","2FS8","Human beta-tryptase II with inhibitor CRA-29382","3.4.21.59","ALLYL {(1S)-1-[(5-{4-[(2,3-DIHYDRO-1H-INDEN-2-YLAMINO)CARBONYL]BENZYL}-1,2,4-OXADIAZOL-3-YL)CARBONYL]-3-PYRROLIDIN-3-YLPROPYL}CARBAMATE",
"1XUK","BAB","1XUK","TRYPSIN-BABIM-SULFATE, PH 5.9","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"BIS(5-AMIDINO-BENZIMIDAZOLYL)METHANE",
"1XUJ","BOZ","1XUJ","TRYPSIN-KETO-BABIM-ZN+2, PH 8.2","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"BIS(5-AMIDINO-BENZIMIDAZOLYL)METHANONE ZINC",
"1XUI",,"1XUI","TRYPSIN-KETO-BABIM, ZN+2-FREE, PH 8.2","3.4.21.4","CALCIUM ION",
,,,,,"SODIUM ION",
,,,,,"BIS(5-AMIDINO-2-BENZIMIDAZOLYL)METHANONE",
"1XUH",,"1XUH","TRYPSIN-KETO-BABIM-CO+2, PH 8.2","3.4.21.4","COBALT (II) ION",
,,,,,"CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"BIS(5-AMIDINO-2-BENZIMIDAZOLYL)METHANONE",
"1XUG","BAB","1XUG","TRYPSIN-BABIM-ZN+2, PH 8.2","3.4.21.4","CALCIUM ION",
,"BAB",,,,"ZINC ION",
,,,,,"BIS(5-AMIDINO-BENZIMIDAZOLYL)METHANE",
"1XUF","BAZ","1XUF","TRYPSIN-BABIM-ZN+2, PH 8.2","3.4.21.4","CALCIUM ION",
,,,,,"BIS(5-AMIDINO-BENZIMIDAZOLYL)METHANE ZINC",
"2NU4",,"2NU4","Accommodation of positively-charged residues in a hydrophobic specificity pocket: Crystal structures of SGPB in complex with OMTKY3 variants Lys18I and Arg18I","3.4.21.81",
,,,,,
"2NU3",,"2NU3","Accommodation of positively-charged residues in a hydrophobic specificity pocket: Crystal structures of SGPB in complex with OMTKY3 variants Lys18I and Arg18I","3.4.21.81",
,,,,,
"2NU2",,"2NU2","Accommodation of positively-charged residues in a hydrophobic specificity pocket: Crystal structures of SGPB in complex with OMTKY3 variants Lys18I and Arg18I","3.4.21.81",
,,,,,
"2OML",,"2OML","crystal structure of E. coli pseudouridine synthase RluE","5.4.99","SULFATE ION",
,,,,"5.4.99.20",,
"2SNV",,"2SNV","THE REFINED STRUCTURE OF SINDBIS VIRUS CORE PROTEIN IN COMPARISON WITH OTHER CHYMOTRYPSIN-LIKE SERINE PROTEINASE STRUCTURES","3.4.21.90",
"2STB",,"2STB","ANIONIC SALMON TRYPSIN IN COMPLEX WITH SQUASH SEED INHIBITOR (CUCURBITA PEPO TRYPSIN INHIBITOR II)","3.4.21.4","CALCIUM ION",
,,,,,,
"2STA",,"2STA","ANIONIC SALMON TRYPSIN IN COMPLEX WITH SQUASH SEED INHIBITOR (CUCURBITA MAXIMA TRYPSIN INHIBITOR I)","3.4.21.4","CALCIUM ION",
,,,,,,
"2TBS",,"2TBS","COLD-ADAPTION OF ENZYMES: STRUCTURAL COMPARISON BETWEEN SALMON AND BOVINE TRYPSINS","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
"2TGA",,"2TGA","ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY","3.4.21.4","CALCIUM ION",
"2TGT",,"2TGT","ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY","3.4.21.4","CALCIUM ION",
,,,,,"METHANOL",
"2SGD",,"2SGD","ASP 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 10.7","3.4.21.81","PHOSPHATE ION",
,,,,,"POTASSIUM ION",
"2SGA",,"2SGA","ELECTRON DENSITY CALCULATIONS AS AN EXTENSION OF PROTEIN STRUCTURE REFINEMENT. STREPTOMYCES GRISEUS PROTEASE AT 1.5 ANGSTROMS RESOLUTION","3.4.21.80",
"2RDL",,"2RDL","Hamster Chymase 2",,"SULFATE ION",
,,,,,,
"2SGF",,"2SGF","PHE 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B","3.4.21.81","PHOSPHATE ION",
,,,,,,
"2SGQ",,"2SGQ","GLN 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5","3.4.21.81","PHOSPHATE ION",
,,,,,,
"2TIO",,"2TIO","LOW PACKING DENSITY FORM OF BOVINE BETA-TRYPSIN IN CYCLOHEXANE","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"BENZAMIDINE",
,,,,,"HEXANE",
"3URE",,"3URE","Repack mutant (T181I, W199L, Q210I) of alpha-Lytic Protease","3.4.21.12","SULFATE ION",
"3UQO","3YH","3UQO","Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor","3.4.21.4","CALCIUM ION",
,,,,,"3-(3-carbamimidoylphenyl)-N-(2'-sulfamoylbiphenyl-4-yl)-1,2-oxazole-4-carboxamide",
"3UQV","3YH","3UQV","Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor","3.4.21.4","CALCIUM ION",
,,,,,"3-(3-carbamimidoylphenyl)-N-(2'-sulfamoylbiphenyl-4-yl)-1,2-oxazole-4-carboxamide",
,,,,,"SULFATE ION",
"3UOP",,"3UOP","Bovine trypsin variant X(triplePhe227) in complex with small molecule inhibitor","3.4.21.4","CALCIUM ION",
,,,,,"N~2~-(benzylsulfonyl)-D-arginyl-N-(4-carbamimidoylbenzyl)glycinamide",
,,,,,"CHLORIDE ION",
,,,,,"SULFATE ION",
,,,,,"DI(HYDROXYETHYL)ETHER",
"3V7T","0GX","3V7T","Crystal Structure of Human Beta-Tryptase Complexed with a Synthetic Inhibitor with a Tropanylamide Scaffold","3.4.21.59","{(3-exo)-3-[5-(aminomethyl)-2-fluorophenyl]-8-azabicyclo[3.2.1]oct-8-yl}(4-bromo-3-methyl-5-propoxythiophen-2-yl)methanone",
,"0GX",,,,"CARBONATE ION",
"3UY9",,"3UY9","Bovine trypsin variant X(tripleGlu217Phe227) in complex with small molecule inhibitor","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"CHLORIDE ION",
"3VGC","SRB","3VGC","GAMMA-CHYMOTRYPSIN L-NAPHTHYL-1-ACETAMIDO BORONIC ACID ACID INHIBITOR COMPLEX","3.4.21.1","SULFATE ION",
,,,,"3.4.21.1","L-1-NAPHTHYL-2-ACETAMIDO-ETHANE BORONIC ACID",
,,,,"3.4.21.1",,
"3W1E",,"3W1E","Structure of FlgT, a flagellar basal body component protein",
"3VPK",,"3VPK","Crystal Structure of 6-Guanidinohexanoyl Trypsin","3.4.21.4","6-carbamimidamidohexanoic acid",
,,,,,"CALCIUM ION",
,,,,,"ethyl 4-hydroxybenzoate",
"3PRO",,"3PRO","ALPHA-LYTIC PROTEASE COMPLEXED WITH C-TERMINAL TRUNCATED PRO REGION","3.4.21.12","4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE",
,,,,"3.4.21.12",,
"3PTN",,"3PTN","ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY","3.4.21.4","CALCIUM ION",
"3R0F",,"3R0F","Human enterovirus 71 3C protease mutant H133G in complex with rupintrivir",,"4-{2-(4-FLUORO-BENZYL)-6-METHYL-5-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-4-OXO-HEPTANOYLAMINO}-5-(2-OXO-PYRROLIDIN-3-YL)-PENTANOIC ACID ETHYL ESTER",
,,,,,"1,2-ETHANEDIOL",
"3PYH","3YH","3PYH","Bovine trypsin variant X(tripleGlu217Ile227) in complex with small molecule inhibitor","3.4.21.4","CALCIUM ION",
,,,,,"3-(3-carbamimidoylphenyl)-N-(2'-sulfamoylbiphenyl-4-yl)-1,2-oxazole-4-carboxamide",
,,,,,"SULFATE ION",
,,,,,"CHLORIDE ION",
"4AGJ",,"4AGJ","Crystal structure of the capsid protein (110-267) from Aura virus in complex with dioxane","3.4.21.90","1,4-DIETHYLENE DIOXIDE",
"4AGK",,"4AGK","Crystal structure of capsid protein (110-267) from Aura virus","3.4.21.90",
"4AN7",,"4AN7","Kunitz type trypsin inhibitor complex with porcine trypsin","3.4.21.4","CALCIUM ION",
,,,,,,
"4AOQ",,"4AOQ","Cationic trypsin in complex with mutated Spinacia oleracea trypsin inhibitor III (SOTI-III) (F14A)","3.4.21.4","CALCIUM ION",
,,,,,"PENTAETHYLENE GLYCOL",
"4A6L","P43","4A6L","beta-tryptase inhibitor","3.4.21.59","1-{3-[1-({5-[(2-fluorophenyl)ethynyl]furan-2-yl}carbonyl)piperidin-4-yl]phenyl}methanamine",
,"P43",,,,,
"4ABG","91B","4ABG","Fragments bound to bovine trypsin for the SAMPL challenge","3.4.21.4","CALCIUM ION",
,,,,,"CHLORIDE ION",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"1-[3-(4-METHYLPIPERAZIN-1-YL)PHENYL]METHANAMINE",
"4AB8","VXU","4AB8","Fragments bound to bovine trypsin for the SAMPL challenge","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"3,4-dihydro-2H-1,5-benzodioxepin-6-ylmethanamine",
"3KYG","5GP","3KYG","Crystal structure of VCA0042 (L135R) complexed with c-di-GMP",,"GUANOSINE-5'-MONOPHOSPHATE",
"3LGI",,"3LGI","Structure of the protease domain of DegS (DegS-deltaPDZ) at 1.65 A","3.4.21","PHOSPHATE ION",
,,,,"3.4.21.107",,
"3LGV",,"3LGV","H198P mutant of the DegS-deltaPDZ protease","3.4.21",
,,,,"3.4.21.107",
"3LGW",,"3LGW","H198P/T167V double mutant of DegS-deltaPDZ protease","3.4.21",
,,,,"3.4.21.107",
"3LGY",,"3LGY","R178A mutant of the DegS-deltaPDZ protease","3.4.21","CHLORIDE ION",
,,,,"3.4.21.107","MAGNESIUM ION",
"3LH1",,"3LH1","Q191A mutant of the DegS-deltaPDZ","3.4.21",
,,,,"3.4.21.107",
"3LH3",,"3LH3","DFP modified DegS delta PDZ","3.4.21",
,,,,"3.4.21.107",
"3LGT",,"3LGT","Y162A/H198P double mutant of DegS-deltaPDZ protease","3.4.21",
,,,,"3.4.21.107",
"3LGU",,"3LGU","Y162A mutant of the DegS-deltaPDZ protease","3.4.21",
,,,,"3.4.21.107",
"4DGJ",,"4DGJ","Structure of a human enteropeptidase light chain variant","3.4.21.9",
"3NKK","JLZ","3NKK","Trypsin in complex with fluorine containing fragment","3.4.21.4","DIMETHYL SULFOXIDE",
,"JLZ",,,,"CALCIUM ION",
,,,,,"3-fluoro-4-methylbenzenecarboximidamide",
"3NK8","JKZ","3NK8","Trypsin in complex with fluorine-containing fragment","3.4.21.4","DIMETHYL SULFOXIDE",
,,,,,"CALCIUM ION",
,,,,,"4-(trifluoromethyl)-1,5,6,7-tetrahydro-2H-cyclopenta[b]pyridin-2-one",
"3OU0",,"3OU0","re-refined 3CS0","3.4.21",
,,,,"3.4.21.107",
,,,,,
,,,,,
"3OSY",,"3OSY","Human enterovirus 71 3C protease",
"3W94",,"3W94","Structure of Oryzias latipes enteropeptidase light chain",
"3WAB","DDW","3WAB","Carboxypeptidase B in complex with DD2","3.4.17.2","ZINC ION",
,"DDW",,,,"(2R)-7-amino-2-(sulfanylmethyl)heptanoic acid",
,,,,,"CACODYLATE ION",
"3WC7","EF1","3WC7","Carboxypeptidase B in complex with EF6265","3.4.17.2","ZINC ION",
,"EF1",,,,"(2S)-7-amino-2-{[(R)-hydroxy{(1R)-2-methyl-1-[(3-phenylpropanoyl)amino]propyl}phosphoryl]methyl}heptanoic acid",
"3WC5",,"3WC5","Carboxypeptidase B in complex with DD9","3.4.17.2","ZINC ION",
,,,,,"(2R)-7-amino-2-(selanylmethyl)heptanoic acid",
,,,,,"CACODYLATE ION",
"3WC6",,"3WC6","Carboxypeptidase B in complex with 2nd zinc","3.4.17.2","ACETATE ION",
,,,,,"ZINC ION",
"4CQC",,"4CQC","The reaction mechanism of the N-isopropylammelide isopropylaminohydrolase AtzC: insights from structural and mutagenesis studies","3.5.99.4","ZINC ION",
,,,,"3.5.4.42","CHLORIDE ION",
,,,,,"4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID",
"4CHA",,"4CHA","STRUCTURE OF ALPHA-*CHYMOTRYPSIN REFINED AT 1.68 ANGSTROMS RESOLUTION","3.4.21.1",
,,,,"3.4.21.1",
,,,,"3.4.21.1",
"2ZA5","2FF","2ZA5","Crystal Structure of human tryptase with potent non-peptide inhibitor","3.4.21.59","(5-(aminomethyl)-2H-spiro[benzofuran-3,4'-piperidine]-1'-yl)(5-(phenylethynyl)furan-2-yl)methanone",
,"2FF",,,,,
"2ZEB",,"2ZEB","Potent, Nonpeptide Inhibitors of Human Mast Cell Tryptase","3.4.21","1-(1'-{[3-(methylsulfanyl)-2-benzothiophen-1-yl]carbonyl}spiro[1-benzofuran-3,4'-piperidin]-5-yl)methanamine",
,,,,"3.4.21.59",,
"2ZEC",,"2ZEC","Potent, Nonpeptide Inhibitors of Human Mast Cell Tryptase","3.4.21","1-[1'-(3-phenylacryloyl)spiro[1-benzofuran-3,4'-piperidin]-5-yl]methanamine",
,,,,"3.4.21.59",,
"2W5E",,"2W5E","Structural and biochemical analysis of human pathogenic astrovirus serine protease at 2.0 Angstrom resolution",,"CADMIUM ION",
,,,,,"CHLORIDE ION",
"2VU8",,"2VU8","Crystal structure of an insect inhibitor with a fungal trypsin","3.4.21.4",
,,,,,
"2ZPQ",,"2ZPQ","Crystal structure of anionic trypsin isoform 1 from chum salmon",,"SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"BENZAMIDINE",
"2ZPR",,"2ZPR","Crystal structure of anionic trypsin isoform 2 from chum salmon",,"CALCIUM ION",
,,,,,"BENZAMIDINE",
"2ZPS",,"2ZPS","Crystal structure of anionic trypsin isoform 3 from chum salmon",,"CALCIUM ION",
,,,,,"BENZAMIDINE",
"3AAS","GUS","3AAS","Bovine beta-trypsin bound to meta-guanidino schiff base copper (II) chelate","3.4.21.4","(E)-N-[(5-carbamimidamido-2-hydroxyphenyl)methylidene]-L-alanine",
,"GUS",,,,"CALCIUM ION",
,,,,,"COPPER (II) ION",
"3AAU","GZC","3AAU","Bovine beta-trypsin bound to meta-diguanidino schiff base copper (II) chelate","3.4.21.4","N,N'''-{ethane-1,2-diylbis[nitrilo(E)methylylidene(4-hydroxybenzene-3,1-diyl)]}diguanidine",
,,,,,"CALCIUM ION",
,,,,,"COPPER (II) ION",
"3AAV","A2C","3AAV","Bovine beta-trypsin bound to meta-diamidino schiff base copper (II) chelate","3.4.21.4","3,3'-[ethane-1,2-diylbis(nitrilomethylylidene)]bis(4-hydroxybenzenecarboximidamide)",
,,,,,"CALCIUM ION",
,,,,,"COPPER (II) ION",
"3QZQ","AG7","3QZQ","Human enterovirus 71 3C protease mutant E71D in complex with rupintrivir",,"4-{2-(4-FLUORO-BENZYL)-6-METHYL-5-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-4-OXO-HEPTANOYLAMINO}-5-(2-OXO-PYRROLIDIN-3-YL)-PENTANOIC ACID ETHYL ESTER",
"3QZR",,"3QZR","Human enterovirus 71 3C protease mutant E71A in complex with rupintrivir",,"4-{2-(4-FLUORO-BENZYL)-6-METHYL-5-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-4-OXO-HEPTANOYLAMINO}-5-(2-OXO-PYRROLIDIN-3-YL)-PENTANOIC ACID ETHYL ESTER",
,,,,,"1,2-ETHANEDIOL",
"3RP2",,"3RP2","THE STRUCTURE OF RAT MAST CELL PROTEASE II AT 1.9-ANGSTROMS RESOLUTION","3.4.21",
"3CS0",,"3CS0","Crystal structure of DegP24","3.4.21.107",
,,,,,
"3D65",,"3D65","Crystal structure of Textilinin-1, a Kunitz-type serine protease inhibitor from the Australian Common Brown snake venom, in complex with trypsin",,"CALCIUM ION",
,,,,"3.4.21.4",,
"3FZZ",,"3FZZ","Structure of GrC","3.4.21","SULFATE ION",
"3GCH",,"3GCH","CHEMISTRY OF CAGED ENZYMES. BINDING OF PHOTOREVERSIBLE CINNAMATES TO CHYMOTRYPSIN","3.4.21.1","TRANS-O-HYDROXY-ALPHA-METHYL CINNAMATE",
,,,,"3.4.21.1",,
,,,,"3.4.21.1",,
"3GCT",,"3GCT","STRUCTURE OF GAMMA-*CHYMOTRYPSIN IN THE RANGE $P*H 2.0 TO $P*H 10.5 SUGGESTS THAT GAMMA-CHYMOTRYPSIN IS A COVALENT ACYL-ENZYME ADDUCT AT LOW $P*H","3.4.21.1","SULFATE ION",
,,,,"3.4.21.1",,
,,,,"3.4.21.1",,
,,,,,,
"3H09",,"3H09","The structure of Haemophilus influenzae IgA1 protease","3.4.21.72","ACETATE ION",
,,,,,"MALONIC ACID",
,,,,,"SODIUM ION",
"3H7T",,"3H7T","Crystal structure of scabies mite inactivated protease paralogue S-D1 (SMIPP-S-D1)",,"ZINC ION",
"3GY5","BRN","3GY5","A comparative study on the inhibition of bovine beta-trypsin by bis-benzamidines diminazene and pentamidine by X-ray crystallography and ITC","3.4.21.4","CALCIUM ION",
,,,,,"BERENIL",
,,,,,"1,2-ETHANEDIOL",
,,,,,"SULFATE ION",
"3GY6","BRN","3GY6","A comparative study on the inhibition of bovine beta-trypsin by the bis-benzamidines diminazene and pentamidine","3.4.21.4","CALCIUM ION",
,,,,,"BERENIL",
,,,,,"1,2-ETHANEDIOL",
,,,,,"SULFATE ION",
"3GY7","BEN","3GY7","A comparative study on the inhibition of bovine beta-trypsin by bis-benzamidines diminazene and pentamidine by X-ray crystallography and ITC","3.4.21.4","CALCIUM ION",
,"BEN",,,,"BENZAMIDINE",
,,,,,"1,2-ETHANEDIOL",
,,,,,"SULFATE ION",
"3GY8","BRN","3GY8","A comparative study on the inhibition of bovine beta-trypsin by bis-benzamidines diminazene and pentamidine by X-ray crystallography and ITC","3.4.21.4","CALCIUM ION",
,,,,,"BERENIL",
,,,,,"1,2-ETHANEDIOL",
"3GY2","BRN","3GY2","A comparative study on the inhibition of bovine beta-trypsin by bis-benzamidines diminazene and pentamidine by X-ray crystallography and ITC","3.4.21.4","CALCIUM ION",
,"BRN",,,,"BERENIL",
,,,,,"1,2-ETHANEDIOL",
,,,,,"SULFATE ION",
"3GY3","PNT","3GY3","A comparative study on the inhibition of bovine beta-trypsin by bis-benzamidines diminazene and pentamidine by X-ray crystallography and ITC","3.4.21.4","CALCIUM ION",
,"PNT",,,,"1,5-BIS(4-AMIDINOPHENOXY)PENTANE",
,,,,,"1,2-ETHANEDIOL",
"3GY4","PBZ","3GY4","A comparative study on the inhibition of bovine beta-trypsin by bis-benzamidines diminazene and pentamidine by X-ray crystallography and ITC","3.4.21.4","CALCIUM ION",
,"PBZ",,,,"P-AMINO BENZAMIDINE",
,,,,,"1,2-ETHANEDIOL",
,,,,,"SULFATE ION",
"3G01",,"3G01","Structure of GrC mutant E192R/E193G","3.4.21",
"3FOA",,"3FOA","Crystal structure of the bacteriophage T4 tail sheath protein, deletion mutant gp18M",
"3ITI","BRV","3ITI","Structure of bovine trypsin with the MAD triangle B3C","3.4.21.4","5-amino-2,4,6-tribromobenzene-1,3-dicarboxylic acid",
,,,,,"BENZAMIDINE",
,,,,,"CALCIUM ION",
,,,,,"CHLORIDE ION",
"3MH6",,"3MH6","HtrA proteases are activated by a conserved mechanism that can be triggered by distinct molecular cues","3.4.21","DIISOPROPYL PHOSPHONATE",
,,,,"3.4.21.107",,
"3MH7",,"3MH7","HtrA proteases are activated by a conserved mechanism that can be triggered by distinct molecular cues","3.4.21",
,,,,"3.4.21.107",
,,,,,
"3MH4",,"3MH4","HtrA proteases are activated by a conserved mechanism that can be triggered by distinct molecular cues","3.4.21",
,,,,"3.4.21.107",
"3MH5",,"3MH5","HtrA proteases are activated by a conserved mechanism that can be triggered by distinct molecular cues","3.4.21","DIISOPROPYL PHOSPHONATE",
,,,,"3.4.21.107",,
"4GPG",,"4GPG","X/N joint refinement of Achromobacter Lyticus Protease I free form at pD8.0","3.4.21.50",
"4GCH",,"4GCH","STRUCTURE AND ACTIVITY OF TWO PHOTOREVERSIBLE CINNAMATES BOUND TO CHYMOTRYPSIN","3.4.21.1","3-(4-DIETHYLAMINO-2-HYDROXY-PHENYL)-2-METHYL-PROPIONIC ACID",
,,,,"3.4.21.1",,
,,,,"3.4.21.1",,
"4V0T",,"4V0T","Monomeric pseudorabies virus protease pUL26N at 2.1 A resolution","3.4.21.97",
"4VGC","SRD","4VGC","GAMMA-CHYMOTRYPSIN D-NAPHTHYL-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX","3.4.21.1","SULFATE ION",
,,,,"3.4.21.1","D-1-NAPHTHYL-2-ACETAMIDO-ETHANE BORONIC ACID",
,,,,"3.4.21.1",,
"4Q4L",,"4Q4L","Crystal structure of an ATP synthase subunit beta 1 (F1-B1) from Burkholderia thailandensis","3.6.3.14","SODIUM ION",
,,,,"7.1.2.2",,
"3TJV",,"3TJV","Crystal structure of human granzyme H with a peptidyl substrate","3.4.21","SULFATE ION",
,,,,,,
"3TK9",,"3TK9","Crystal structure of human granzyme H","3.4.21","SULFATE ION",
"4SGB",,"4SGB","STRUCTURE OF THE COMPLEX OF STREPTOMYCES GRISEUS PROTEINASE B AND POLYPEPTIDE CHYMOTRYPSIN INHIBITOR-1 FROM RUSSET BURBANK POTATO TUBERS AT 2.1 ANGSTROMS RESOLUTION","3.4.21.81","SULFATE ION",
,,,,,"CALCIUM ION",
"4U2W",,"4U2W","Atomic resolution crystal structure of HV-BBI protease inhibitor from amphibian skin in complex with bovine trypsin",,"CALCIUM ION",
,,,,"3.4.21.4","SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"4RT0","C2E","4RT0","Structure of the Alg44 PilZ domain from Pseudomonas aeruginosa PAO1 in complex with c-di-GMP","2.4.1.33","9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one)",
,,,,,"1,2-ETHANEDIOL",
"4RT1","C2E","4RT1","Structure of the Alg44 PilZ domain (R95A mutant) from Pseudomonas aeruginosa PAO1 in complex with c-di-GMP","2.4.1.33","9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one)",
,,,,,"CHLORIDE ION",
,,,,,"SODIUM ION",
"4MQA",,"4MQA","Human beta-tryptase co-crystal structure with {(1,1,3,3-tetramethyldisiloxane-1,3-diyl)bis[5-(methylsulfanyl)benzene-3,1-diyl]}bis({4-[3-(aminomethyl)phenyl]piperidin-1-yl}methanone)","3.4.21.59","SULFATE ION",
,,,,,"TETRAETHYLENE GLYCOL",
,,,,,"{(1,1,3,3-tetramethyldisiloxane-1,3-diyl)bis[5-(methylsulfanyl)benzene-3,1-diyl]}bis({4-[3-(aminomethyl)phenyl]piperidin-1-yl}methanone)",
"4MPX",,"4MPX","Human beta-tryptase co-crystal structure with [(1,1,3,3-tetramethyldisiloxane-1,3-diyl)di-1-benzothiene-4,2-diyl]bis({4-[3-(aminomethyl)phenyl]piperidin-1-yl}methanone)","3.4.21.59","SULFATE ION",
,,,,,"CHLORIDE ION",
,,,,,"TRIETHYLENE GLYCOL",
,,,,,"[(1,1,3,3-tetramethyldisiloxane-1,3-diyl)di-1-benzothiene-4,2-diyl]bis({4-[3-(aminomethyl)phenyl]piperidin-1-yl}methanone)",
,,,,,"2-(N-MORPHOLINO)-ETHANESULFONIC ACID",
"4MTB",,"4MTB","Bovine trypsin in complex with small molecule inhibitor","3.4.21.4","CALCIUM ION",
,,,,,"(2R)-2-amino-N-{(2S)-1-[(4-carbamimidoylbenzyl)amino]-1-oxopropan-2-yl}-4-(4-hydroxyphenyl)butanamide",
,,,,,"IMIDAZOLE",
"3K6Y",,"3K6Y","Crystal structure of Rv3671c protease from M. tuberculosis, active form","3.4.21",
"3K6Z",,"3K6Z","Crystal structure of Rv3671c protease, inactive form","3.4.21",
"3RXQ",,"3RXQ","Crystal structure of Trypsin complexed with benzamide (F01 and F05, cocktail experiment)","3.4.21.4","CALCIUM ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"BENZAMIDINE",
"3RXR",,"3RXR","Crystal structure of Trypsin complexed with cycloheptanamine (F01 and F03, cocktail experiment)","3.4.21.4","CALCIUM ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"cycloheptanamine",
"3RXS",,"3RXS","Crystal structure of Trypsin complexed with (3-methoxyphenyl)methanamine (F04 and A06, cocktail experiment)","3.4.21.4","CALCIUM ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"1-(3-methoxyphenyl)methanamine",
"3RXT",,"3RXT","Crystal structure of Trypsin complexed with (3-methoxyphenyl)methanamin (F04 and F03, cocktail experiment)","3.4.21.4","CALCIUM ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"1-(3-methoxyphenyl)methanamine",
"3RXU",,"3RXU","Crystal structure of Trypsin complexed with benzamide (F05 and A06, cocktail experiment)","3.4.21.4","CALCIUM ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"BENZAMIDINE",
"3RXV",,"3RXV","Crystal structure of Trypsin complexed with benzamide (F05 and F03, cocktail experiment)","3.4.21.4","CALCIUM ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"BENZAMIDINE",
"3SGB",,"3SGB","STRUCTURE OF THE COMPLEX OF STREPTOMYCES GRISEUS PROTEASE B AND THE THIRD DOMAIN OF THE TURKEY OVOMUCOID INHIBITOR AT 1.8 ANGSTROMS RESOLUTION","3.4.21.81",
,,,,,
"3SGQ",,"3SGQ","GLN 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 10.7","3.4.21.81","PHOSPHATE ION",
,,,,,,
"3ATI","SZ4","3ATI","Crystal structure of trypsin complexed with (3-methoxyphenyl)methanamine","3.4.21.4","CALCIUM ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"1-(3-methoxyphenyl)methanamine",
"3ATK","SZ1","3ATK","Crystal structure of trypsin complexed with cycloheptanamine","3.4.21.4","CALCIUM ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"cycloheptanamine",
"3ATL","BEN","3ATL","Crystal structure of trypsin complexed with benzamidine","3.4.21.4","CALCIUM ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"BENZAMIDINE",
"3ATM","TSS","3ATM","Crystal structure of trypsin complexed with 2-(1H-indol-3-yl)ethanamine","3.4.21.4","CALCIUM ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"2-(1H-INDOL-3-YL)ETHANAMINE",
"3BEU",,"3BEU","Na+-Dependent Allostery Mediates Coagulation Factor Protease Active Site Selectivity","3.4.21.4","SULFATE ION",
,,,,,"BENZAMIDINE",
,,,,,"SODIUM ION",
,,,,,"CALCIUM ION",
"3T29",,"3T29","TMAO-grown trigonal trypsin (bovine)","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"trimethylamine oxide",
"3T25",,"3T25","TMAO-grown orthorhombic trypsin (bovine)","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"BENZAMIDINE",
,,,,,"trimethylamine oxide",
"3T26",,"3T26","Orthorhombic trypsin (bovine) in the presence of sarcosine","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SARCOSINE",
"3T27",,"3T27","Orthorhombic trypsin (bovine) in the presence of betaine","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"BENZAMIDINE",
,,,,,"TRIMETHYL GLYCINE",
"3T28",,"3T28","TMAO-grown trypsin (bovine)-previously unreported tetragonal crystal form","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"trimethylamine oxide",
"3T62",,"3T62","Crystal structure of recombinant Kunitz Type serine protease Inhibitor-1 from the Caribbean Sea anemone Stichodactyla helianthus in complex with bovine chymotrypsin","3.4.21.1","SULFATE ION",
,,,,,,
"3STJ",,"3STJ","Crystal structure of the protease + PDZ1 domain of DegQ from Escherichia coli","3.4.21",
,,,,"3.4.21.107",
,,,,,
"3SYJ",,"3SYJ","Crystal structure of the Haemophilus influenzae Hap adhesin","3.4.21",
"3SZE",,"3SZE","Crystal structure of the passenger domain of the E. coli autotransporter EspP","3.4.21",
"2TRM",,"2TRM","THE THREE-DIMENSIONAL STRUCTURE OF ASN102 MUTANT OF TRYPSIN. ROLE OF ASP102 IN SERINE PROTEASE CATALYSIS","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
"2ULL",,"2ULL","MULTIPLE CONFORMATION STRUCTURE OF ALPHA-LYTIC PROTEASE AT 120 K","3.4.21.12","SULFATE ION",
,,,,,"TRIS(HYDROXYETHYL)AMINOMETHANE",
"2V3M",,"2V3M","Structure of the Gar1 domain of NAf1",,"SULFATE ION",
"2VGC","V35","2VGC","GAMMA-CHYMOTRYPSIN D-PARA-CHLORO-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX","3.4.21.1","SULFATE ION",
,,,,"3.4.21.1","D-1-(4-CHLOROPHENYL)-2-(ACETAMIDO)ETHANE BORONIC ACID",
,,,,"3.4.21.1",,
"4IC5",,"4IC5","Crystal structure of Deg5","3.4.21","CALCIUM ION",
"2X9C",,"2X9C","Crystal structure of a soluble PrgI mutant from Salmonella Typhimurium",
"4M7G",,"4M7G","Streptomyces Erythraeus Trypsin","3.4.21.4",
"5CHA",,"5CHA","THE REFINEMENT AND THE STRUCTURE OF THE DIMER OF ALPHA-*CHYMOTRYPSIN AT 1.67-*ANGSTROMS RESOLUTION","3.4.21.1",
,,,,"3.4.21.1",
,,,,"3.4.21.1",
"4OM9",,"4OM9","X-Ray Crystal Structure of the passenger domain of Plasmid encoded toxin, an Autrotansporter Enterotoxin from enteroaggregative Escherichia coli (EAEC)","3.4.21",
"4Q2K",,"4Q2K","Bovine alpha chymotrypsin bound to a cyclic peptide inhibitor, 5b","3.4.21.1","(11S)-4,9-dioxo-N-[(2S)-1-oxo-3-phenylpropan-2-yl]-17,22-dioxa-10,30-diazatetracyclo[21.2.2.2~13,16~.1~5,8~]triaconta-1(25),5,7,13,15,23,26,28-octaene-11-carboxamide",
"4PRO",,"4PRO","ALPHA-LYTIC PROTEASE COMPLEXED WITH PRO REGION","3.4.21.12",
,,,,"3.4.21.12",
"6FID",,"6FID","Bovine trypsin solved by S-SAD on ID30B","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"2BZA","ABN","2BZA","BOVINE PANCREAS BETA-TRYPSIN IN COMPLEX WITH BENZYLAMINE","3.4.21.4","CALCIUM ION",
,"ABN",,,,"CHLORIDE ION",
,,,,,"SULFATE ION",
,,,,,"BENZYLAMINE",
"1QQU",,"1QQU","CRYSTAL STRUCTURE OF PORCINE BETA TRYPSIN WITH BOUND ACETATE ION","3.4.21.4","CALCIUM ION",
,,,,,"ACETATE ION",
"2ALP",,"2ALP","REFINED STRUCTURE OF ALPHA-LYTIC PROTEASE AT 1.7 ANGSTROMS RESOLUTION. ANALYSIS OF HYDROGEN BONDING AND SOLVENT STRUCTURE","3.4.21.12","SULFATE ION",
"2A31","BO4","2A31","Trypsin in complex with borate","3.4.21.4","CALCIUM ION",
,,,,,"MAGNESIUM ION",
,,,,,"SODIUM ION",
,,,,,"SULFATE ION",
,,,,,"BORATE ION",
,,,,,"GUANIDINE-3-PROPANOL",
"2A7H",,"2A7H","On the Routine Use of Soft X-Rays in Macromolecular Crystallography, Part III- The Optimal Data Collection Wavelength","3.4.21.4","CALCIUM ION",
,,,,,"CHLORIDE ION",
"2AH4",,"2AH4","guanidinobenzoyl-trypsin acyl-enzyme at 1.13 A resolution","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"4-GUANIDINOBENZOIC ACID",
"2AGG",,"2AGG","succinyl-AAPK-trypsin acyl-enzyme at 1.28 A resolution","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
"2AGE",,"2AGE","Succinyl-AAPR-trypsin acyl-enzyme at 1.15 A resolution","3.4.21.4","CALCIUM ION",
,,,,,,
"1VCW",,"1VCW","Crystal structure of DegS after backsoaking the activating peptide","3.4.21",
,,,,"3.4.21.107",
"1UTM","PEA","1UTM","Trypsin specificity as elucidated by LIE calculations, X-ray structures and association constant measurements","3.4.21.4","2-PHENYLETHYLAMINE",
,"PEA",,,,"CALCIUM ION",
"1UTL","PRA","1UTL","Trypsin specificity as elucidated by LIE calculations, X-ray structures and association constant measurements","3.4.21.4","3-PHENYLPROPYLAMINE",
,"PRA",,,,"CALCIUM ION",
,,,,,"(4S)-2-METHYL-2,4-PENTANEDIOL",
"1UTK",,"1UTK","Trypsin specificity as elucidated by LIE calculations, X-ray structures and association constant measurements","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
"1UTJ","ABN","1UTJ","Trypsin specificity as elucidated by LIE calculations, X-ray structures and association constant measurements","3.4.21.4","BENZYLAMINE",
,"ABN",,,,"CALCIUM ION",
"1V6D",,"1V6D","The crystal structure of the trypsin complex with synthetic heterochiral peptide","3.4.21.4","CALCIUM ION",
,,,,,"ACETATE ION",
,,,,,"TERT-BUTYL FORMATE",
,,,,,"METHYLAMINE",
"1VGC","V36","1VGC","GAMMA-CHYMOTRYPSIN L-PARA-CHLORO-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX","3.4.21.1","SULFATE ION",
,,,,"3.4.21.1","L-1-(4-CHLOROPHENYL)-2-(ACETAMIDO)ETHANE BORONIC ACID",
,,,,"3.4.21.1",,
"1GBC",,"1GBC","ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-LEUCINE BORONIC ACID","3.4.21.12","SULFATE ION",
,,,,,,
"1GBB",,"1GBB","Alpha-lytic protease with met 190 replaced by ALA AND GLY 216 replaced by ALA complex with METHOXYSUCCINYL-ALA-ALA-PRO-ALANINE BORONIC ACID","3.4.21.12","SULFATE ION",
,,,,,,
"1GBA",,"1GBA","ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY ALA","3.4.21.12","SULFATE ION",
"1GBK",,"1GBK","ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-ALANINE BORONIC ACID","3.4.21.12","SULFATE ION",
,,,,,,
"1GBJ",,"1GBJ","ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA","3.4.21.12","SULFATE ION",
"1GBI",,"1GBI","ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-PHENYLALANINE BORONIC ACID","3.4.21.12","SULFATE ION",
,,,,,,
"1GBH",,"1GBH","ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-LEUCINE BORONIC ACID","3.4.21.12","SULFATE ION",
,,,,,,
"1GBF",,"1GBF","ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-ALANINE BORONIC ACID","3.4.21.12","SULFATE ION",
,,,,,,
"1GBE",,"1GBE","ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU","3.4.21.12","SULFATE ION",
"1GBD",,"1GBD","ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-PHENYLALANINE BORONIC ACID","3.4.21.12","SULFATE ION",
,,,,,,
"1GCD",,"1GCD","REFINED CRYSTAL STRUCTURE OF ""AGED"" AND ""NON-AGED"" ORGANOPHOSPHORYL CONJUGATES OF GAMMA-CHYMOTRYPSIN","3.4.21.1","SULFATE ION",
,,,,,"DIETHYL PHOSPHONATE",
"1GBM",,"1GBM","ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-PHENYLALANINE BORONIC ACID","3.4.21.12","SULFATE ION",
,,,,,,
"1GBL",,"1GBL","ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-LEUCINE BORONIC ACID","3.4.21.12","SULFATE ION",
,,,,,,
"1GBT","GBS","1GBT","STRUCTURE OF AN ACYL-ENZYME INTERMEDIATE DURING CATALYSIS: (GUANIDINOBENZOYL) TRYPSIN","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"4-GUANIDINOBENZOIC ACID",
"1GCT",,"1GCT","IS GAMMA-CHYMOTRYPSIN A TETRAPEPTIDE ACYL-ENZYME ADDUCT OF GAMMA-CHYMOTRYPSIN?","3.4.21.1","SULFATE ION",
,,,,"3.4.21.1",,
,,,,"3.4.21.1",,
,,,,,,
"1GDU",,"1GDU","FUSARIUM OXYSPORUM TRYPSIN AT ATOMIC RESOLUTION","3.4.21.4","SULFATE ION",
,,,,,,
"1GJ6","132","1GJ6","ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS","3.4.21.4","CALCIUM ION",
,"132",,,,"6-CHLORO-2-(2-HYDROXY-BIPHENYL-3-YL)-1H-INDOLE-5-CARBOXAMIDINE",
,"132",,,,,
,"132",,,,,
"1GL0",,"1GL0","structure of the complex between bovine alpha-chymotrypsin and PMP-D2v, an inhibitor from the insect Locusta migratoria","3.4.21.1","CADMIUM ION",
,,,,,,
"1GMH",,"1GMH","REFINED CRYSTAL STRUCTURE OF ""AGED"" AND ""NON-AGED"" ORGANOPHOSPHORYL CONJUGATES OF GAMMA-CHYMOTRYPSIN","3.4.21.1","SULFATE ION",
,,,,"3.4.21.1","PHOSPHORYLISOPROPANE",
,,,,"3.4.21.1",,
"1GMD",,"1GMD","X-ray crystal structure of gamma-chymotrypsin in hexane","3.4.21.1","HEXANE",
,,,,"3.4.21.1",,
,,,,"3.4.21.1",,
,,,,,,
"1GMC",,"1GMC","THE X-RAY CRYSTAL STRUCTURE OF THE TETRAHEDRAL INTERMEDIATE OF GAMMA-CHYMOTRYPSIN IN HEXANE","3.4.21.1",
,,,,"3.4.21.1",
,,,,"3.4.21.1",
,,,,,
"1G9I",,"1G9I","CRYSTAL STRUCTURE OF BETA-TRYSIN COMPLEX IN CYCLOHEXANE","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"1FN6",,"1FN6","CRYSTAL STRUCTURE OF PORCINE BETA TRYPSIN WITH 0.1% POLYDOCANOL","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"METHANOL",
"1FMG",,"1FMG","CRYSTAL STRUCTURE OF PORCINE BETA TRYPSIN WITH 0.04% POLYDOCANOL","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"1FNI",,"1FNI","CRYSTAL STRUCTURE OF PORCINE BETA TRYPSIN WITH 0.01% POLYDOCANOL","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"1,2-ETHANEDIOL",
"1FON",,"1FON","CRYSTAL STRUCTURE OF BOVINE PROCARBOXYPEPTIDASE A-S6 SUBUNIT III, A HIGHLY STRUCTURED TRUNCATED ZYMOGEN E",
"1G3B","108","1G3B","BOVINE BETA-TRYPSIN BOUND TO META-AMIDINO SCHIFF BASE MAGNESIUM(II) CHELATE","3.4.21.4","MAGNESIUM ION",
,"108",,,,"CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"2-(5-CARBAMIMIDOYL-2-HYDROXY-BENZYLAMINO)-PROPIONIC ACID",
"2G55",,"2G55","Anomalous substructure of trypsin (P3121)","3.4.21.4","CALCIUM ION",
,,,,,"CHLORIDE ION",
"2FWW",,"2FWW","human beta-tryptase II complexed with 4-piperidinebutyrate to make acylenzyme","3.4.21.59","4-PIPERIDINEBUTYRATE",
"2FX6","270","2FX6","bovine trypsin complexed with 2-aminobenzamidazole","3.4.21.4","CALCIUM ION",
,"270",,,,"2H-BENZOIMIDAZOL-2-YLAMINE",
,"AX7",,,,,
"2G8T",,"2G8T","Indole-amidine Complexes with Bovine Trypsin","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"2-(2-METHYLPHENYL)-1H-INDOLE-5-CARBOXIMIDAMIDE",
"2FX4",,"2FX4","Bovine trypsin bound by 4-piperidinebutyrate to make acylenzyme complex","3.4.21.4","CALCIUM ION",
,,,,,"4-PIPERIDINEBUTYRATE",
"2FXR","C3A","2FXR","human beta tryptase II complexed with activated ketone inhibitor CRA-29382","3.4.21.59","ALLYL {(1S)-1-[(5-{4-[(2,3-DIHYDRO-1H-INDEN-2-YLAMINO)CARBONYL]BENZYL}-1,2,4-OXADIAZOL-3-YL)CARBONYL]-3-PYRROLIDIN-3-YLPROPYL}CARBAMATE",
"2GCH",,"2GCH","REFINED CRYSTAL STRUCTURE OF GAMMA-CHYMOTRYPSIN AT 1.9 ANGSTROMS RESOLUTION","3.4.21.1",
,,,,"3.4.21.1",
,,,,"3.4.21.1",
"2GDD",,"2GDD","Human beta II tryptase with inhibitor CRA-27592","3.4.21.59","BENZYL {(1S)-5-AMINO-1-[(S)-HYDROXY(5-{[4-(4-PHENYLBUTANOYL)PIPERAZIN-1-YL]METHYL}-1,2,4-OXADIAZOL-3-YL)METHYL]PENTYL}CARBAMATE",
"2GCT",,"2GCT","STRUCTURE OF GAMMA-CHYMOTRYPSIN IN THE RANGE PH 2.0 TO PH 10.5 SUGGESTS THAT GAMMA-CHYMOTRYPSIN IS A COVALENT ACYL-ENZYME ADDUCT AT LOW PH","3.4.21.1","SULFATE ION",
,,,,"3.4.21.1",,
,,,,"3.4.21.1",,
,,,,,,
"2GMT",,"2GMT","THREE-DIMENSIONAL STRUCTURE OF CHYMOTRYPSIN INACTIVATED WITH (2S) N-ACETYL-L-ALANYL-L-PHENYLALANYL-CHLOROETHYL KETONE: IMPLICATIONS FOR THE MECHANISM OF INACTIVATION OF SERINE PROTEASES BY CHLOROKETONES","3.4.21.1","(2S) N-ACETYL-L-ALANYL-ALPHAL-PHENYLALANYL-CHLOROETHYLKETONE",
,,,,"3.4.21.1",,
,,,,"3.4.21.1",,
"2D8W",,"2D8W","Structure of HYPER-VIL-trypsin","3.4.21.4","CALCIUM ION",
,,,,,"IODIDE ION",
"2CGA",,"2CGA","BOVINE CHYMOTRYPSINOGEN A. X-RAY CRYSTAL STRUCTURE ANALYSIS AND REFINEMENT OF A NEW CRYSTAL FORM AT 1.8 ANGSTROMS RESOLUTION","3.4.21.1",
"2CHA",,"2CHA","THE STRUCTURE OF CRYSTALLINE ALPHA-CHYMOTRYPSIN, $V.THE ATOMIC STRUCTURE OF TOSYL-ALPHA-CHYMOTRYPSIN AT 2 ANGSTROMS RESOLUTION","3.4.21.1","PARA-TOLUENE SULFONATE",
,,,,"3.4.21.1",,
,,,,"3.4.21.1",,
"3I77",,"3I77","35/99/170-loops of FXa in SGT","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"ACETATE ION",
"5ZVJ",,"5ZVJ","Crystal structure of HtrA1 from Mycobacterium tuberculosis","3.4.21","2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL",
,,,,"3.4.21.107",,
"6B6R",,"6B6R","Orthorhombic trypsin cryocooled to 100 K with 50% mpd as cryoprotectant","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
,,,,,"(4R)-2-METHYLPENTANE-2,4-DIOL",
"6B6T",,"6B6T","Orthorhombic trypsin cryocooled to 100 K with 50% methanol as cryoprotectant","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
,,,,,"METHANOL",
"6B6N",,"6B6N","Orthorhombic trypsin (295 K) in the presence of 50% mpd","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
,,,,,"(4R)-2-METHYLPENTANE-2,4-DIOL",
"6GCO",,"6GCO","Truncated FtsH from A. aeolicus in P312","3.4.24","ADENOSINE-5'-DIPHOSPHATE",
,,,,,"ZINC ION",
"6GCH","APF","6GCH","STRUCTURE OF CHYMOTRYPSIN-*TRIFLUOROMETHYL KETONE INHIBITOR COMPLEXES. COMPARISON OF SLOWLY AND RAPIDLY EQUILIBRATING INHIBITORS","3.4.21.1","1,1,1-TRIFLUORO-3-ACETAMIDO-4-PHENYL BUTAN-2-ONE(N-ACETYL-L-PHENYLALANYL TRIFLUOROMETHYL KETONE)",
,,,,"3.4.21.1",,
,,,,"3.4.21.1",,
"4NSV",,"4NSV","Lysobacter enzymogenes lysc endoproteinase K30R mutant covalently inhibited by TLCK","3.4.21.50","N-[(2S,3S)-7-amino-1-chloro-2-hydroxyheptan-3-yl]-4-methylbenzenesulfonamide (Bound Form)",
,,,,,"SULFATE ION",
,,,,,"CHLORIDE ION",
"4NSY",,"4NSY","Wild-type lysobacter enzymogenes lysc endoproteinase covalently inhibited by TLCK","3.4.21.50","N-[(2S,3S)-7-amino-1-chloro-2-hydroxyheptan-3-yl]-4-methylbenzenesulfonamide (Bound Form)",
,,,,,"CHLORIDE ION",
,,,,,"CALCIUM ION",
"6NIR",,"6NIR","Crystal structure of a GII.4 norovirus HOV protease",
,,,,
"5BPE",,"5BPE","Crystal structure of EV71 3Cpro in complex with a potent and selective Inhibitor",,"(2~{S})-~{N}-[(1~{R},2~{S})-1-cyano-1-oxidanyl-3-[(3~{S})-2-oxidanylidenepiperidin-3-yl]propan-2-yl]-3-phenyl-2-[[(~{E})-3-phenylprop-2-enoyl]amino]propanamide",
"6CHA","PBA","6CHA","STRUCTURE OF A TETRAHEDRAL TRANSITION STATE COMPLEX OF ALPHA-*CHYMOTRYPSIN AT 1.8-*ANGSTROMS RESOLUTION","3.4.21.1","PHENYLETHANE BORONIC ACID",
,"PBA",,,"3.4.21.1",,
,"PBA",,,"3.4.21.1",,
"5WQ2",,"5WQ2","Crystal structure of 3C protease from a mild Human enterovirus 71 in complex with rupintrivir",,"4-{2-(4-FLUORO-BENZYL)-6-METHYL-5-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-4-OXO-HEPTANOYLAMINO}-5-(2-OXO-PYRROLIDIN-3-YL)-PENTANOIC ACID ETHYL ESTER",
,,,,,"SULFATE ION",
"6BFP",,"6BFP","Bovine trypsin bound to potent inhibitor","3.4.21.4","CALCIUM ION",
,,,,,"3-{2-[(4-carbamimidoylphenyl)carbamoyl]-4-ethenyl-5-methoxyphenyl}-6-[(cyclopropylmethyl)carbamoyl]pyridine-2-carboxylic acid",
"5HM2",,"5HM2","Crystal structure of the 3C protease from South African Territories type 2 foot-and-mouth disease virus",
"5FXL",,"5FXL","Structure of trypsin solved by MR from data collected by Direct Data Collection (DDC) using the ESRF RoboDiff goniometer","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"5GCH",,"5GCH","CHEMISTRY OF CAGED ENZYMES /II$. PHOTOACTIVATION OF INHIBITED CHYMOTRYPSIN","3.4.21.1",
,,,,"3.4.21.1",
,,,,"3.4.21.1",
"5GIB",,"5GIB","Succinic acid bound trypsin crystallized as dimer","3.4.21.4","SUCCINIC ACID",
,,,,,"CALCIUM ION",
"5GSW",,"5GSW","Crystal structure of EV71 3C in complex with N69S 1.8k",,"~{N}-[(2~{S})-3-(4-fluorophenyl)-1-oxidanylidene-1-[[(2~{S})-1-oxidanylidene-3-[(3~{S})-2-oxidanylidenepiperidin-3-yl]propan-2-yl]amino]propan-2-yl]-5-methyl-1,2-oxazole-3-carboxamide",
"5GSO",,"5GSO","Crystal Structures of EV71 3C Protease in complex with NK-1.8k",,"~{N}-[(2~{S})-3-(4-fluorophenyl)-1-oxidanylidene-1-[[(2~{S})-1-oxidanylidene-3-[(3~{S})-2-oxidanylidenepiperidin-3-yl]propan-2-yl]amino]propan-2-yl]-5-methyl-1,2-oxazole-3-carboxamide",
"5GVT",,"5GVT","Crystal structures of the serine protease domain of murine plasma kallikrein","3.4.21.34","beta-D-mannopyranose",
,,,,,"alpha-D-mannopyranose",
"5EG4","5N7","5EG4","BOVINE TRYPSIN IN COMPLEX WITH CYCLIC INHIBITOR","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"ACETATE ION",
,,,,,"(13S,16R)-N-(4-carbamimidoylbenzyl)-16-((N-cyclohexylsulfamoyl)amino)-3,9,15-trioxo-2,10,14-triaza-6(1,4)-piperazina-1,
11(1,4)-dibenzenacycloheptadecaphane-13-carboxamide",
"5F03",,"5F03","TRYPTASE B2 IN COMPLEX WITH 5-(3-Aminomethyl-phenoxymethyl)-3-[3-(2-chloro-pyridin-3-ylethynyl)-phenyl]-oxazolidin-2-one; compound with trifluoro-acetic acid","3.4.21.59","(5~{S})-5-[[3-(aminomethyl)phenoxy]methyl]-3-[3-[2-(2-chloranylpyridin-3-yl)ethynyl]phenyl]-1,3-oxazolidin-2-one",
"5F6M",,"5F6M","Isotropic Trypsin Model for Comparison of Diffuse Scattering","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"5HXF",,"5HXF","Crystal structure of 3C protease from a mild Human enterovirus 71 in complex with rupintrivir",,"4-{2-(4-FLUORO-BENZYL)-6-METHYL-5-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-4-OXO-HEPTANOYLAMINO}-5-(2-OXO-PYRROLIDIN-3-YL)-PENTANOIC ACID ETHYL ESTER",
,,,,,"SULFATE ION",
"4XAX",,"4XAX","Crystal structure of Thermus thermophilus CarD in complex with the Thermus aquaticus RNA polymerase beta1 domain","2.7.7.6","1,2-ETHANEDIOL",
,,,,,,
"5K7R",,"5K7R","MicroED structure of trypsin at 1.7 A resolution","3.4.21.4","CALCIUM ION",
"5JYI",,"5JYI","Trypsin bound with succinic acid at 1.9A","3.4.21.4","CALCIUM ION",
,,,,,"SUCCINIC ACID",
,,,,,"SODIUM ION",
"5MN1","2AP","5MN1","Cationic trypsin in complex with 2-aminopyridine (deuterated sample at 100 K)","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"2-AMINOPYRIDINE",
"5MNO","MRZ","5MNO","Cationic trypsin in complex with N-amidinopiperidine (deuterated sample at 295 K)","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"piperidine-1-carboximidamide",
"5MO0",,"5MO0","Neutron structure of cationic trypsin in complex with benzamidine","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
"5MNN",,"5MNN","Cationic trypsin in complex with N-amidinopiperidine (deuterated sample at 100 K)","3.4.21.4","CALCIUM ION",
,,,,,"piperidine-1-carboximidamide",
,,,,,"SULFATE ION",
"5MNQ","J3I","5MNQ","Cationic trypsin in complex with a derivative of N-amidinopiperidine","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"(2~{S})-1-[(2~{R})-2-azanyl-3-phenyl-propanoyl]-~{N}-[(1-carbamimidoylpiperidin-4-yl)methyl]pyrrolidine-2-carboxamide",
,,,,,"DIMETHYL SULFOXIDE",
"5MO2",,"5MO2","Neutron structure of cationic trypsin in complex with N-amidinopiperidine","3.4.21.4","CALCIUM ION",
,,,,,"[azanyl(piperidin-1-yl)methylidene]azanium",
,,,,,"SULFATE ION",
"5MNG",,"5MNG","Cationic trypsin in complex with benzamidine (deuterated sample at 100 K)","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"BENZAMIDINE",
"5MNF",,"5MNF","Cationic trypsin in its apo form (deuterated sample at 295 K)","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"5MNH","BAM","5MNH","Cationic trypsin in complex with benzamidine (deuterated sample at 295 K)","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"BENZAMIDINE",
"5MNA",,"5MNA","Cationic trypsin in complex with aniline (deuterated sample at 295 K)","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"ANILINE",
"5MNC",,"5MNC","Cationic trypsin in complex with aniline (deuterated sample at 100 K)","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"ANILINE",
"5MNB","2AP","5MNB","Cationic trypsin in complex with 2-aminopyridine (deuterated sample at 295 K)","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"2-AMINOPYRIDINE",
"5MNE",,"5MNE","Cationic trypsin in its apo form (deuterated sample at 100 K)","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"5MOP",,"5MOP","Joint X-ray/neutron structure of cationic trypsin in its apo form","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"5MOO","WOT","5MOO","Joint X-ray/neutron structure of cationic trypsin in complex with aniline","3.4.21.4","CALCIUM ION",
,,,,,"phenylazanium",
,,,,,"SULFATE ION",
"5MOQ",,"5MOQ","Joint X-ray/neutron structure of cationic trypsin in complex with benzamidine","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"5MOS",,"5MOS","Joint X-ray/neutron structure of cationic trypsin in complex with N-amidinopiperidine","3.4.21.4","CALCIUM ION",
,,,,,"[azanyl(piperidin-1-yl)methylidene]azanium",
,,,,,"SULFATE ION",
"5MON","2AP","5MON","Joint X-ray/neutron structure of cationic trypsin in complex with 2-aminopyridine","3.4.21.4","CALCIUM ION",
,,,,,"2-AMINOPYRIDINE",
,,,,,"SULFATE ION",
"5MNY",,"5MNY","Neutron structure of cationic trypsin in complex with aniline","3.4.21.4","CALCIUM ION",
,,,,,"phenylazanium",
"5MNX",,"5MNX","Neutron structure of cationic trypsin in complex with 2-aminopyridine","3.4.21.4","CALCIUM ION",
,,,,,"2-AMINOPYRIDINE",
"5MNZ",,"5MNZ","Neutron structure of cationic trypsin in its apo form","3.4.21.4","CALCIUM ION",
"5LGO",,"5LGO","Trypsin inhibitors for the treatment of pancreatitis - cpd 15","3.4.21.4","DIMETHYL SULFOXIDE",
,,,,,"CALCIUM ION",
,,,,,"(2~{S},4~{S})-1-[4-(aminomethyl)-3-methoxy-phenyl]carbonyl-4-[4-(2-cyclopropylethoxy)-6,8-dihydro-5~{H}-pyrido[3,4-d]pyrimidin-7-yl]-~{N}-methyl-pyrrolidine-2-carboxamide",
"5LH4",,"5LH4","Trypsin inhibitors for the treatment of pancreatitis - cpd 1","3.4.21.4","DIMETHYL SULFOXIDE",
,,,,,"SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"(2~{S},4~{S})-1-[4-(aminomethyl)phenyl]carbonyl-4-(4-cyclopropyl-1,2,3-triazol-1-yl)-~{N}-(2,2-diphenylethyl)pyrrolidine-2-carboxamide",
"5LH8",,"5LH8","Trypsin inhibitors for the treatment of pancreatitis - cpd 8","3.4.21.4","DIMETHYL SULFOXIDE",
,,,,,"CALCIUM ION",
,,,,,"(2~{S},4~{S})-1-[4-(aminomethyl)-3-methoxy-phenyl]carbonyl-4-(4-cyclopropyl-1,2,3-triazol-1-yl)-~{N}-[(1~{S},2~{R})-2-phenylcyclohexyl]pyrrolidine-2-carboxamide",
"5LPR",,"5LPR","STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS","3.4.21.12","SULFATE ION",
,,,,,,
"5LPF",,"5LPF","Kallikrein-related peptidase 10","3.4.21","SULFATE ION",
"5LPE",,"5LPE","Kallikrein-related peptidase 10 complex with Zn2+","3.4.21","SULFATE ION",
,,,,,"ZINC ION",
"5J4Q",,"5J4Q","alpha-chymotrypsin from bovine pancreas in complex with Bowman-Birk inhibitor from soybean","3.4.21.1",
,,,,,
"5J4S",,"5J4S","alpha-chymotrypsin from bovine pancreas in complex with a modified Bowman-Birk inhibitor from soybean","3.4.21.1",
,,,,,
"6SV6",,"6SV6","Non-terahertz irradiated structure of bovine trypsin (even frames of crystal x38)","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"6SV8",,"6SV8","Terahertz irradiated structure of bovine trypsin (odd frames of crystal x38)","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"6SV0",,"6SV0","Non-terahertz irradiated structure of bovine trypsin (odd frames of crystal x37)","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"6SVR",,"6SVR","Reference structure of bovine trypsin (odd frames of crystal x28)","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"6SVV",,"6SVV","Reference structure of bovine trypsin (odd frames of crystal x30)","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"6SVU",,"6SVU","Reference structure of bovine trypsin (even frames of crystal x30)","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"6SVX",,"6SVX","Reference structure of bovine trypsin (odd frames of crystal x33)","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"6SVW",,"6SVW","Reference structure of bovine trypsin (even frames of crystal x33)","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"6SVJ",,"6SVJ","Terahertz irradiated structure of bovine trypsin (odd frames of crystal x42)","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"6SVI",,"6SVI","Non-terahertz irradiated structure of bovine trypsin (even frames of crystal x42)","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"6SVN",,"6SVN","Reference structure of bovine trypsin (even frames of crystal x28)","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"6SW0",,"6SW0","Reference structure of bovine trypsin (odd frames of crystal x34)","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"6SVB",,"6SVB","Terahertz irradiated structure of bovine trypsin (odd frames of crystal x40)","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"6SVD",,"6SVD","Non-terahertz irradiated structure of bovine trypsin (even frames of crystal x41)","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"6SVG",,"6SVG","Terahertz irradiated structure of bovine trypsin (odd frames of crystal x41)","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"6SUX",,"6SUX","Terahertz irradiated structure of bovine trypsin (even frames of crystal x37)","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"6SV9",,"6SV9","Non-terahertz irradiated structure of bovine trypsin (even frames of crystal x40)","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"6SVZ",,"6SVZ","Reference structure of bovine trypsin (even frames of crystal x34)","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"6TDY",,"6TDY","Cryo-EM structure of Euglena gracilis mitochondrial ATP synthase, OSCP/F1/c-ring in rotational state 1",,"ADENOSINE-5'-TRIPHOSPHATE",
,,,,,"MAGNESIUM ION",
,,,,,"ADENOSINE-5'-DIPHOSPHATE",
,,,,,"FRAGMENT OF TRITON X-100",
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
"6TDZ",,"6TDZ","Cryo-EM structure of Euglena gracilis mitochondrial ATP synthase, OSCP/F1/c-ring, rotational state 2",,"ADENOSINE-5'-TRIPHOSPHATE",
,,,,,"MAGNESIUM ION",
,,,,,"ADENOSINE-5'-DIPHOSPHATE",
,,,,,"FRAGMENT OF TRITON X-100",
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
"6TE0",,"6TE0","Cryo-EM structure of Euglena gracilis mitochondrial ATP synthase, OSCP/F1/c-ring, rotational state 3",,"MAGNESIUM ION",
,,,,,"ADENOSINE-5'-DIPHOSPHATE",
,,,,,"FRAGMENT OF TRITON X-100",
,,,,,"ADENOSINE-5'-TRIPHOSPHATE",
,,,,,,
,,,,,,
,,,,,,
,,,,,,
"6LPR",,"6LPR","STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS","3.4.21.12","SULFATE ION",
,,,,,,
"5Y2D",,"5Y2D","Crystal structure of H. pylori HtrA","3.4.21.107",
,,,,,
,,,,,
,,,,,
,,,,,
,,,,,
"5Y4L",,"5Y4L","PRRSV nsp4",
"1EB2","BPO","1EB2","Trypsin inhibitor complex (BPO)","3.4.21.4","SULFATE ION",
,"BPO",,,,"CALCIUM ION",
,"BPO",,,,"3-[(Z)-AMINO(IMINO)METHYL]-N-[2-(4-BENZOYL-1-PIPERIDINYL)-2-OXO-1-PHENYLETHYL]BENZAMIDE",
"1DPO",,"1DPO","STRUCTURE OF RAT TRYPSIN","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"BENZAMIDINE",
"1EP6",,"1EP6","CRYSTAL STRUCTURE OF THE CONSERVED CORE DOMAIN OF VENEZUALAN EQUINE ENCEPHALITIS CAPSID PROTEIN","3.4.21",
,,,,"3.4.21.90",
"1F2S",,"1F2S","CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN BOVINE BETA-TRYPSIN AND MCTI-A, A TRYPSIN INHIBITOR OF SQUASH FAMILY AT 1.8 A RESOLUTION","3.4.21.4","CALCIUM ION",
,,,,,,
"1EX3",,"1EX3","CRYSTAL STRUCTURE OF BOVINE CHYMOTRYPSINOGEN A (TETRAGONAL)","3.4.21.1",
"6DWR",,"6DWR","Trypsin serine protease modified with the protease inhibitor cyanobenzylsulfonylfluoride","3.4.21.4","1,2-ETHANEDIOL",
,,,,,"CALCIUM ION",
,,,,,"SULFATE ION",
"6DZF",,"6DZF","Orthorhombic trypsin cryocooled to 100 K with 20% xylose as cryoprotectant","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
,,,,,"alpha-D-xylopyranose",
"6EAU",,"6EAU","Crystallographic structure of the octapeptide derived from the BTCI inhibitor bound to beta-trypsin in space group P 21 21 21.","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
"6EAW",,"6EAW","Crystallographic structure of the cyclic heptapeptide derived from the BTCI inhibitor bound to beta-trypsin in space group P 21 21 21","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
"6EAV",,"6EAV","Crystallographic structure of the cyclic heptapeptide derived from the BTCI inhibitor bound to beta-trypsin in space group P 4(1) 2(1) 2","3.4.21.4","CALCIUM ION",
,,,,,,
"6EAX",,"6EAX","Crystallographic structure of the cyclic hexapeptide derived from the BTCI inhibitor bound to beta-trypsin in space group P 21 21 21","3.4.21.4","CALCIUM ION",
,,,,,"N-carboxy-L-cysteine",
"8LPR",,"8LPR","STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS","3.4.21.12","SULFATE ION",
,,,,,,
"8GCH",,"8GCH","GAMMA-CHYMOTRYPSIN IS A COMPLEX OF ALPHA-CHYMOTRYPSIN WITH ITS OWN AUTOLYSIS PRODUCTS","3.4.21.1","SULFATE ION",
,,,,"3.4.21.1",,
,,,,"3.4.21.1",,
,,,,,,
"1ACB",,"1ACB","CRYSTAL AND MOLECULAR STRUCTURE OF THE BOVINE ALPHA-CHYMOTRYPSIN-EGLIN C COMPLEX AT 2.0 ANGSTROMS RESOLUTION","3.4.21.1",
,,,,,
"1AMH",,"1AMH","UNCOMPLEXED RAT TRYPSIN MUTANT WITH ASP 189 REPLACED WITH SER (D189S)","3.4.21.4","CALCIUM ION",
"1ANE",,"1ANE","ANIONIC TRYPSIN WILD TYPE","3.4.21.4","BENZAMIDINE",
"1AND",,"1AND","ANIONIC TRYPSIN MUTANT WITH ARG 96 REPLACED BY HIS","3.4.21.4","COPPER (II) ION",
,,,,,"BENZAMIDINE",
"1ANC",,"1ANC","ANIONIC TRYPSIN MUTANT WITH SER 214 REPLACED BY LYS","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
"1ANB",,"1ANB","ANIONIC TRYPSIN MUTANT WITH SER 214 REPLACED BY GLU","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
"1ATL","0QI","1ATL","Structural interaction of natural and synthetic inhibitors with the VENOM METALLOPROTEINASE, ATROLYSIN C (FORM-D)","3.4.24.42","ZINC ION",
,,,,,"CALCIUM ION",
,,,,,"O-methyl-N-[(2S)-4-methyl-2-(sulfanylmethyl)pentanoyl]-L-tyrosine",
"1AZZ",,"1AZZ","FIDDLER CRAB COLLAGENASE COMPLEXED TO ECOTIN","3.4.21.32",
,,,,,
"1SMF",,"1SMF","Studies on an artificial trypsin inhibitor peptide derived from the mung bean inhibitor","3.4.21.4","CALCIUM ION",
,,,,,,
"1SOZ",,"1SOZ","Crystal Structure of DegS protease in complex with an activating peptide","3.4.21",
,,,,"3.4.21.107",
,,,,,
"1SVP",,"1SVP","SINDBIS VIRUS CAPSID PROTEIN","3.4.21",
,,,,"3.4.21.90",
"1TAB",,"1TAB","STRUCTURE OF THE TRYPSIN-BINDING DOMAIN OF BOWMAN-BIRK TYPE PROTEASE INHIBITOR AND ITS INTERACTION WITH TRYPSIN","3.4.21.4",
,,,,,
"1TAL",,"1TAL","ALPHA-LYTIC PROTEASE AT 120 K (SINGLE STRUCTURE MODEL)","3.4.21.12","SULFATE ION",
,,,,,"TRIS(HYDROXYETHYL)AMINOMETHANE",
"1TGC",,"1TGC","ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY","3.4.21.4","CALCIUM ION",
"1TGB",,"1TGB","CRYSTAL STRUCTURE OF BOVINE TRYPSINOGEN AT 1.8 ANGSTROMS RESOLUTION. II. CRYSTALLOGRAPHIC REFINEMENT, REFINED CRYSTAL STRUCTURE AND COMPARISON WITH BOVINE TRYPSIN","3.4.21.4","CALCIUM ION",
"1TGT",,"1TGT","ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY","3.4.21.4","CALCIUM ION",
,,,,,"METHANOL",
"1TGS",,"1TGS","THREE-DIMENSIONAL STRUCTURE OF THE COMPLEX BETWEEN PANCREATIC SECRETORY INHIBITOR (KAZAL TYPE) AND TRYPSINOGEN AT 1.8 ANGSTROMS RESOLUTION. STRUCTURE SOLUTION, CRYSTALLOGRAPHIC REFINEMENT AND PRELIMINARY STRUCTURAL INTERPRETATION","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
"1TGN",,"1TGN","STRUCTURE OF BOVINE TRYPSINOGEN AT 1.9 ANGSTROMS RESOLUTION","3.4.21.4",
"1TI1",,"1TI1","crystal structure of a mutant DsbA",,"DODECANE",
"1TIO","BAM","1TIO","HIGH PACKING DENSITY FORM OF BOVINE BETA-TRYPSIN IN CYCLOHEXANE","3.4.21.4","CALCIUM ION",
,"BAM",,,,"SULFATE ION",
,"BAM",,,,"BENZAMIDINE",
,"BAM",,,,"CYCLOHEXANE",
,"BAM",,,,,
,"BAM",,,,,
,"BAM",,,,,
,"BAM",,,,,
,"BAM",,,,,
,"BAM",,,,,
,"BAM",,,,,
,"BAM",,,,,
,"BAM",,,,,
,"BAM",,,,,
"1TNJ","PEA","1TNJ","PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS","3.4.21.4","CALCIUM ION",
,"PEA",,,,"2-PHENYLETHYLAMINE",
"1TNI","PBN","1TNI","PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS","3.4.21.4","CALCIUM ION",
,"PBN",,,,"4-PHENYLBUTYLAMINE",
"1TNH","FBA","1TNH","PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS","3.4.21.4","CALCIUM ION",
,"FBA",,,,"4-FLUOROBENZYLAMINE",
"1TNG","AMC","1TNG","PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS","3.4.21.4","CALCIUM ION",
,"AMC",,,,"AMINOMETHYLCYCLOHEXANE",
"1TNL","TPA","1TNL","PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS","3.4.21.4","CALCIUM ION",
,"TPA",,,,"TRANS-2-PHENYLCYCLOPROPYLAMINE",
"1TNK","PRA","1TNK","PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS","3.4.21.4","CALCIUM ION",
,"PRA",,,,"3-PHENYLPROPYLAMINE",
"1TON",,"1TON","RAT SUBMAXILLARY GLAND SERINE PROTEASE, TONIN. STRUCTURE SOLUTION AND REFINEMENT AT 1.8 ANGSTROMS RESOLUTION","3.4.21.35","ZINC ION",
"1TPS","A9A","1TPS","ATOMIC STRUCTURE OF THE TRYPSIN-A90720A COMPLEX: A UNIFIED APPROACH TO STRUCTURE AND FUNCTION","3.4.21.4","CALCIUM ION",
,,,,,,
"1TPP",,"1TPP","THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"(2S)-3-(4-carbamimidoylphenyl)-2-hydroxypropanoic acid",
"1U3A",,"1U3A","mutant DsbA",,"3,6,9,12,15,18,21,24-OCTAOXAHEXACOSAN-1-OL",
"1TRM",,"1TRM","THE THREE-DIMENSIONAL STRUCTURE OF ASN102 MUTANT OF TRYPSIN. ROLE OF ASP102 IN SERINE PROTEASE CATALYSIS","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
"1NTP",,"1NTP","USE OF THE NEUTRON DIFFRACTION H/D EXCHANGE TECHNIQUE TO DETERMINE THE CONFORMATIONAL DYNAMICS OF TRYPSIN","3.4.21.4","PHOSPHORYLISOPROPANE",
"1YLN",,"1YLN","The Crystal Structure of the Protein of Unknown Function VCA0042 from Vibrio cholerae O1",
"1ZG9",,"1ZG9","Crystal Structure of 5-{[amino(imino)methyl]amino}-2-(sulfanylmethyl)pentanoic acid Bound to Activated Porcine Pancreatic Carboxypeptidase B","3.4.17.2","ZINC ION",
,,,,,"5-{[AMINO(IMINO)METHYL]AMINO}-2-(SULFANYLMETHYL)PENTANOIC ACID",
"1ZG8",,"1ZG8","Crystal Structure of (R)-2-(3-{[amino(imino)methyl]amino}phenyl)-3-sulfanylpropanoic acid Bound to Activated Porcine Pancreatic Carboxypeptidase B","3.4.17.2","ZINC ION",
,,,,,"(2R)-2-(3-{[AMINO(IMINO)METHYL]AMINO}PHENYL)-3-SULFANYLPROPANOIC ACID",
"1ZG7",,"1ZG7","Crystal Structure of 2-(5-{[amino(imino)methyl]amino}-2-chlorophenyl)-3-sulfanylpropanoic acid Bound to Activated Porcine Pancreatic Carboxypeptidase B","3.4.17.2","ZINC ION",
,,,,,"2-(5-{[AMINO(IMINO)METHYL]AMINO}-2-CHLOROPHENYL)-3-SULFANYLPROPANOIC ACID",
"1ZSL",,"1ZSL","Factor XI complexed with a pyrimidinone inhibitor","3.4.21.27","2-(2-(3,4-DICHLOROPHENYL)-5-(ISOPROPYLAMINO)-6-OXOPYRIMIDIN-1(6H)-YL)-N-((S)-1-OXO-1-(THIAZOL-2-YL)-5-GUANIDINOPENTAN-2-YL)ACETAMIDE",
"1Z5R",,"1Z5R","Crystal Structure of Activated Porcine Pancreatic Carboxypeptidase B","3.4.17.2","ZINC ION",
"1YY3",,"1YY3","Structure of S-Adenosylmethionine:tRNA Ribosyltransferase-Isomerase (QueA)","5",
,,,,"2.4.99.17",
"1P10",,"1P10","STRUCTURAL PLASTICITY AS A DETERMINANT OF ENZYME SPECIFICITY. CREATING BROADLY SPECIFIC PROTEASES","3.4.21.12","SULFATE ION",
,,,,,,
"1P06",,"1P06","STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES","3.4.21.12","SULFATE ION",
,,,,,,
"1P05",,"1P05","STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES","3.4.21.12","SULFATE ION",
,,,,,,
"1P04",,"1P04","STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES","3.4.21.12","SULFATE ION",
,,,,,,
"1P03",,"1P03","STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES","3.4.21.12","SULFATE ION",
,,,,,,
"1P02",,"1P02","STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES","3.4.21.12","SULFATE ION",
,,,,,,
"1P01",,"1P01","Serine protease mechanism. structure of an inhibitory complex oF ALPHA-LYTIC Protease and a tightly bound peptide boronic acid","3.4.21.12","N-(tert-butoxycarbonyl)-L-alanyl-N-[(1R)-1-(dihydroxyboranyl)-2-methylpropyl]-L-prolinamide",
,,,,,"SULFATE ION",
"1P3E",,"1P3E","Structure of Glu endopeptidase in complex with MPD","3.4.21","(4S)-2-METHYL-2,4-PENTANEDIOL",
"1P3C",,"1P3C","Glutamyl endopeptidase from Bacillus intermedius","3.4.21",
"1OSS","BEN","1OSS","T190P STREPTOMYCES GRISEUS TRYPSIN IN COMPLEX WITH BENZAMIDINE","3.4.21.4","SULFATE ION",
,"BEN",,,,"CALCIUM ION",
,,,,,"BENZAMIDINE",
"1OS8",,"1OS8","RECOMBINANT STREPTOMYCES GRISEUS TRYPSIN","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
"1PPE",,"1PPE","THE REFINED 2.0 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN BOVINE BETA-TRYPSIN AND CMTI-I, A TRYPSIN INHIBITOR FROM SQUASH SEEDS (CUCURBITA MAXIMA): TOPOLOGICAL SIMILARITY OF THE SQUASH SEED INHIBITORS WITH THE CARBOXYPEPTIDASE A INHIBITOR FROM POTATOES","3.4.21.4",
,,,,,
"1PQA",,"1PQA","Trypsin with PMSF at atomic resolution","3.4.21.4","SULFATE ION",
"1PPZ",,"1PPZ","Trypsin complexes at atomic and ultra-high resolution","3.4.21.4","SULFATE ION",
"1VKY",,"1VKY","Crystal structure of S-adenosylmethionine tRNA ribosyltransferase (TM0574) from Thermotoga maritima at 2.00 A resolution","5","Unknown ligand",
,,,,"2.4.99.17",,
"1S6H",,"1S6H","PORCINE TRYPSIN COMPLEXED WITH GUANIDINE-3-PROPANOL INHIBITOR","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"MAGNESIUM ION",
,,,,,"4-(HYDROXYMETHYL)BENZAMIDINE",
"1S6F",,"1S6F","PORCINE TRYPSIN COVALENT COMPLEX WITH BORATE AND GUANIDINE-3 INHIBITOR","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"[3-(1,3,2-DIOXABOROLAN-2-YLOXY)PROPYL]GUANIDINE",
,,,,,"1,2-ETHANEDIOL",
"1S85",,"1S85","PORCINE TRYPSIN COMPLEXED WITH P-HYDROXYMETHYL BENZAMIDINE AND BORATE","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"[4-(1,3,2-DIOXABOROLAN-2-YLOXY)METHYL]BENZAMIDINE",
"1S84",,"1S84","PORCINE TRYPSIN COVALENT COMPLEX WITH 4-AMINO BUTANOL, BORATE AND ETHYLENE GLYCOL","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"4-(1,3,2-DIOXABOROLAN-2-YLOXY)BUTAN-1-AMINIUM",
"1S83",,"1S83","PORCINE TRYPSIN COMPLEXED WITH 4-AMINO PROPANOL","3.4.21.4","CALCIUM ION",
,,,,,"MAGNESIUM ION",
,,,,,"SULFATE ION",
,,,,,"4-HYDROXYBUTAN-1-AMINIUM",
"1S82",,"1S82","PORCINE TRYPSIN COMPLEXED WITH BORATE AND ETHYLENE GLYCOL","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"SODIUM ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"1,3,2-DIOXABOROLAN-2-OL",
"1S81",,"1S81","PORCINE TRYPSIN WITH NO INHIBITOR BOUND","3.4.21.4","CALCIUM ION",
,,,,,"SODIUM ION",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"1RXP","169","1RXP","STRUCTURE OF TRYPSIN (ORTHORHOMBIC) WITH 1-(4-TERT-BUTYLCARBAMOYL- PIPERAZINE-1-CARBONYL)-3-(3-GUANIDINO-PROPYL)-4-OXO-AZETIDINE-2-CARBOXYLIC ACID","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"1-(4-TERT-BUTYLCARBAMOYL-PIPERAZINE-1-CARBONYL)-3-(3-GUANIDINO-PROPYL)-4-OXO-AZETIDINE-2-CARBOXYLIC ACID",
"1SBW",,"1SBW","CRYSTAL STRUCTURE OF MUNG BEAN INHIBITOR LYSINE ACTIVE FRAGMENT COMPLEX WITH BOVINE BETA-TRYPSIN AT 1.8A RESOLUTION","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"1SGD",,"1SGD","ASP 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5","3.4.21.81","PHOSPHATE ION",
,,,,,,
"1SGY",,"1SGY","TYR 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5","3.4.21.81","PHOSPHATE ION",
,,,,,,
"1SGE",,"1SGE","GLU 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5","3.4.21.81","PHOSPHATE ION",
,,,,,,
"1SGT",,"1SGT","REFINED CRYSTAL STRUCTURE OF STREPTOMYCES GRISEUS TRYPSIN AT 1.7 ANGSTROMS RESOLUTION","3.4.21.4","CALCIUM ION",
"1SGN",,"1SGN","ASN 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B","3.4.21.81","PHOSPHATE ION",
,,,,,,
"1WYK",,"1WYK","SINDBIS VIRUS CAPSID PROTEIN (114-264)","3.4.21","FORMYL GROUP",
,,,,"3.4.21.90","1,4-DIETHYLENE DIOXIDE",
"1WXR",,"1WXR","Crystal structure of Heme Binding protein, an autotransporter hemoglobine protease from pathogenic Escherichia coli","3.4.21",
"1H9I",,"1H9I","COMPLEX OF EETI-II MUTANT WITH PORCINE TRYPSIN","3.4.21.4","CALCIUM ION",
,,,,,,
"1H9H",,"1H9H","COMPLEX OF EETI-II WITH PORCINE TRYPSIN","3.4.21.4","CALCIUM ION",
,,,,,,
"1HJ8",,"1HJ8","1.00 AA Trypsin from Atlantic Salmon","3.4.21.4","BENZAMIDINE",
,,,,,"SULFATE ION",
,,,,,"CALCIUM ION",
"1HJA",,"1HJA","LYS 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH ALPHA-CHYMOTRYPSIN","3.4.21.1",
,,,,"3.4.21.1",
,,,,"3.4.21.1",
,,,,,
"1HPG",,"1HPG","A glutamic acid specific serine protease utilizes a novel histidine triad in substrate binding","3.4.21.82",
,,,,,
"1LTO",,"1LTO","Human alpha1-tryptase","3.4.21.59",
"1M9U",,"1M9U","Crystal Structure of Earthworm Fibrinolytic Enzyme Component A from Eisenia fetida","3.4.21",
"1MBQ",,"1MBQ","Anionic Trypsin from Pacific Chum Salmon","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
"1MCT",,"1MCT","THE REFINED 1.6 ANGSTROMS RESOLUTION CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN PORCINE BETA-TRYPSIN AND MCTI-A, A TRYPSIN INHIBITOR OF SQUASH FAMILY","3.4.21.4","CALCIUM ION",
,,,,,,
"1L1J",,"1L1J","Crystal structure of the protease domain of an ATP-independent heat shock protease HtrA","3.4.21",
"1KY9",,"1KY9","Crystal Structure of DegP (HtrA)","3.4.21",
,,,,"3.4.21.107",
"1BQY",,"1BQY","Plasminogen activator (TSV-PA) from snake venom","3.4.21","L-alpha-glutamyl-N-{(1S)-4-{[amino(iminio)methyl]amino}-1-[(1S)-2-chloro-1-hydroxyethyl]butyl}glycinamide",
"1C2E",,"1C2E","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.4","CALCIUM ION",
,,,,,"MAGNESIUM ION",
,,,,,"ZINC ION",
,,,,,"BIS(5-AMIDINO-2-BENZIMIDAZOLYL)METHANE KETONE",
"1C2D","BAK","1C2D","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.4","CALCIUM ION",
,,,,,"MAGNESIUM ION",
,,,,,"ZINC ION",
,,,,,"BIS(5-AMIDINO-2-BENZIMIDAZOLYL)METHANE KETONE",
"1C2M",,"1C2M","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.4","CALCIUM ION",
,,,,,"ZINC ION",
,,,,,"MAGNESIUM ION",
,,,,,"SULFATE ION",
"1C2L",,"1C2L","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.4","CALCIUM ION",
,,,,,"CHLORIDE ION",
,,,,,"ZINC ION",
"1C2K",,"1C2K","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.4","CALCIUM ION",
,,,,,"CHLORIDE ION",
,,,,,"ZINC ION",
,,,,,"5-AMIDINO-BENZIMIDAZOLE",
"1C2J",,"1C2J","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.4","CALCIUM ION",
,,,,,"MAGNESIUM ION",
,,,,,"SULFATE ION",
,,,,,"ZINC ION",
,,,,,"BIS(5-AMIDINO-2-BENZIMIDAZOLYL)METHANE KETONE",
"1C2H",,"1C2H","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.4","CALCIUM ION",
,,,,,"MAGNESIUM ION",
,,,,,"ZINC ION",
,,,,,"BIS(5-AMIDINO-2-BENZIMIDAZOLYL)METHANE KETONE",
"1BRU",,"1BRU","STRUCTURE OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH THE ELASTASE INHIBITOR GR143783","3.4.21.71","2-(2-HYDROXY-CYCLOPENTYL)-PENT-4-ENAL",
"1BRA","BEN","1BRA","RELOCATING A NEGATIVE CHARGE IN THE BINDING POCKET OF TRYPSIN","3.4.21.4","CALCIUM ION",
,"BEN",,,,"BENZAMIDINE",
"1BTZ",,"1BTZ","Episelection: novel KI ~nanomolar inhibitors of serine proteases selected by binding or chemistry on an enzyme surface","3.4.21.4","N-(tert-butoxycarbonyl)-L-alanyl-N-{(1R)-5-ammonio-1-[hydroxy(methoxy)boranyl]pentyl}-L-valinamide",
,,,,,"CALCIUM ION",
"1BTY","BEN","1BTY","Crystal structure of beta-trypsin in complex with benzamidine","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
"1BTX",,"1BTX","Episelection: Novel Ki ~Nanomolar Inhibitors of Serine Proteases Selected by Binding or Chemistry on an Enzyme Surface","3.4.21.4","N-(tert-butoxycarbonyl)-L-alanyl-N-[(1S)-5-amino-1-(diethoxyboranyl)pentyl]-L-valinamide",
,,,,,"CALCIUM ION",
"1BTW",,"1BTW","Episelection: novel KI ~nanomolar inhibitors of serine proteases selected by binding or chemistry on an enzyme surface","3.4.21.4","N-(tert-butoxycarbonyl)-L-alanyl-N-{(1S)-5-ammonio-1-[hydroxy(3-hydroxypropoxy)boranyl]pentyl}-L-valinamide",
,,,,,"CALCIUM ION",
"1BTP",,"1BTP","UNIQUE BINDING OF A NOVEL SYNTHETIC INHIBITOR, N-[3-[4-[4-(AMIDINOPHENOXY)-CARBONYL]PHENYL]-2-METHYL-2-PROPENOYL]-N-ALLYLGLYCINE METHANESULFONATE TO BOVINE TRYPSIN, REVEALED BY THE CRYSTAL STRUCTURE OF THE COMPLEX","3.4.21.4","CALCIUM ION",
"1CE5","BEN","1CE5","BOVINE PANCREAS BETA-TRYPSIN IN COMPLEX WITH BENZAMIDINE","3.4.21.4","CALCIUM ION",
,"BEN",,,,"CHLORIDE ION",
,,,,,"SULFATE ION",
,,,,,"BENZAMIDINE",
"1CHG",,"1CHG","CHYMOTRYPSINOGEN,2.5 ANGSTROMS CRYSTAL STRUCTURE, COMPARISON WITH ALPHA-CHYMOTRYPSIN,AND IMPLICATIONS FOR ZYMOGEN ACTIVATION","3.4.21.1",
"1CT4",,"1CT4","CRYSTAL STRUCTURE OF THE OMTKY3 P1 VARIANT OMTKY3-VAL18I IN COMPLEX WITH SGPB","3.4.21.81",
,,,,,
"1CT2",,"1CT2","CRYSTAL STRUCTURE OF THE OMTKY3 P1 VARIANT OMTKY3-THR18I IN COMPLEX WITH SGPB","3.4.21.81",
,,,,,
"1CSO",,"1CSO","CRYSTAL STRUCTURE OF THE OMTKY3 P1 VARIANT OMTKY3-ILE18I IN COMPLEX WITH SGPB","3.4.21.81",
,,,,,
"1CT0",,"1CT0","CRYSTAL STRUCTURE OF THE OMTKY3 P1 VARIANT OMTKY3-SER18I IN COMPLEX WITH SGPB","3.4.21.81",
,,,,,
"7GCH","LPF","7GCH","STRUCTURE OF CHYMOTRYPSIN-*TRIFLUOROMETHYL KETONE INHIBITOR COMPLEXES. COMPARISON OF SLOWLY AND RAPIDLY EQUILIBRATING INHIBITORS","3.4.21.1","1,1,1-TRIFLUORO-3-((N-ACETYL)-L-LEUCYLAMIDO)-4-PHENYL-BUTAN-2-ONE(N-ACETYL-L-LEUCYL-L-PHENYLALANYL TRIFLUOROMETHYL KETONE)",
,,,,"3.4.21.1",,
,,,,"3.4.21.1",,
"1A0L",,"1A0L","HUMAN BETA-TRYPTASE: A RING-LIKE TETRAMER WITH ACTIVE SITES FACING A CENTRAL PORE","3.4.21.59","(2S)-3-(4-carbamimidoylphenyl)-2-hydroxypropanoic acid",
"1A0J",,"1A0J","CRYSTAL STRUCTURE OF A NON-PSYCHROPHILIC TRYPSIN FROM A COLD-ADAPTED FISH SPECIES.","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"BENZAMIDINE",
"1N8O",,"1N8O","Crystal structure of a complex between bovine chymotrypsin and ecotin","3.4.21.1",
,,,,"3.4.21.1",
,,,,"3.4.21.1",
,,,,,
"1MZD",,"1MZD","crystal structure of human pro-granzyme K","3.4.21",
"1MZA",,"1MZA","crystal structure of human pro-granzyme K","3.4.21",
"4I86",,"4I86","Crystal structure of PilZ domain of CeSA from cellulose synthesizing bacterium","2.4.1.12",
"1K2I","SN1","1K2I","Crystal Structure of Gamma-Chymotrypsin in Complex with 7-Hydroxycoumarin","3.4.21.1","SULFATE ION",
,,,,,"2,4-DIHYDROXY-TRANS CINNAMIC ACID",
"1TX8","AM4","1TX8","Bovine Trypsin complexed with AMSO","3.4.21.4","CALCIUM ION",
,,,,,"4-(METHYLSULFONYL)BENZENECARBOXIMIDAMIDE",
"1TX7","4CM","1TX7","Bovine Trypsin complexed with p-amidinophenylmethylphosphinic acid (AMPA)","3.4.21.4","CALCIUM ION",
,"4CM",,,,"(4-CARBAMIMIDOYLPHENYL)-METHYL-PHOSPHINIC ACID",
"1UHB",,"1UHB","Crystal structure of porcine alpha trypsin bound with auto catalyticaly produced native peptide at 2.15 A resolution","3.4.21.4","CALCIUM ION",
,,,,"3.4.21.4","ACETATE ION",
,,,,"3.4.21.4",,
"1BIT",,"1BIT","THE CRYSTAL STRUCTURE OF ANIONIC SALMON TRYPSIN IN A SECOND CRYSTAL FORM","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"BENZAMIDINE",
"1BOQ",,"1BOQ","PRO REGION C-TERMINUS: PROTEASE ACTIVE SITE INTERACTIONS ARE CRITICAL IN CATALYZING THE FOLDING OF ALPHA-LYTIC PROTEASE","3.4.21.12","SULFATE ION",
"1C1T",,"1C1T","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.4","CALCIUM ION",
,,,,,"MAGNESIUM ION",
,,,,,"SULFATE ION",
,,,,,"BIS(5-AMIDINO-BENZIMIDAZOLYL)METHANE",
"1C1Q",,"1C1Q","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.4","CALCIUM ION",
,,,,,"MAGNESIUM ION",
,,,,,"SULFATE ION",
,,,,,"(5-AMIDINO-2-BENZIMIDAZOLYL)(2-BENZIMIDAZOLYL)METHANE",
"1C1O",,"1C1O","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.4","CALCIUM ION",
,,,,,"MAGNESIUM ION",
,,,,,"SULFATE ION",
"1C1N",,"1C1N","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.4","CALCIUM ION",
,,,,,"ZINC ION",
,,,,,"SULFATE ION",
,,,,,"BENZAMIDINE",
"3LPR",,"3LPR","STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS","3.4.21.12","SULFATE ION",
,,,,,,
"3M35","M35","3M35","Trypsin in complex with the inhibitor 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423)","3.4.21.4","1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide",
,"M35",,,,"CALCIUM ION",
"3LT3",,"3LT3","Crystal structure of Rv3671c from M. tuberculosis H37Rv, Ser343Ala mutant, inactive form","3.4.21",
"2FOM",,"2FOM","Dengue Virus NS2B/NS3 Protease","3.4.21.91","CHLORIDE ION",
,,,,"3.6.1.15","GLYCEROL",
,,,,"3.6.4.13",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
"2ZPK",,"2ZPK","Crystal structure of P20.1 Fab fragment in complex with its antigen peptide",,"GLYCEROL",
,,,,,,
,,,,,,
"1FJS","Z34","1FJS","CRYSTAL STRUCTURE OF THE INHIBITOR ZK-807834 (CI-1031) COMPLEXED WITH FACTOR XA","3.4.21.6","CALCIUM ION",
,"Z34",,,"3.4.21.6","CHLORIDE ION",
,"Z34",,,,"N-[2-[5-[AMINO(IMINO)METHYL]-2-HYDROXYPHENOXY]-3,5-DIFLUORO-6-[3-(4,5-DIHYDRO-1-METHYL-1H-IMIDAZOL-2-YL)PHENOXY]PYRIDIN-4-YL]-N-METHYLGLYCINE",
,,,,,"GLYCEROL",
"5NJ6",,"5NJ6","Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in ternary complex with Fab3949 and AZ7188 at 4.0 angstrom resolution",
,,,,
,,,,
"2LNC",,"2LNC","Solution NMR structure of Norwalk virus protease","3.4.22.66",
,,,,"3.6.1.15",
,,,,"2.7.7.48",
"2ILN",,"2ILN","Crystal structure of the Bowman-Birk inhibitor from snail medic seeds in complex with bovine trypsin","3.4.21.4",
,,,,,
"2JET",,"2JET","Crystal structure of a trypsin-like mutant (S189D , A226G) chymotrypsin.","3.4.21.1",
,,,,"3.4.21.1",
,,,,"3.4.21.1",
"2IPH",,"2IPH","X-ray Structure at 1.75 A Resolution of a Norovirus Protease Linked to an Active Site Directed Peptide Inhibitor","3.4.22","N-ACETYL-L-ALPHA-GLUTAMYL-L-PHENYLALANYL-L-GLUTAMINYL-N-[(1S)-4-AMINO-1-(2-CARBOXYETHYL)-4-OXOBUTYL]-L-LEUCINAMIDE",
,,,,"3.6.1.15",,
,,,,"3.4.22.66",,
,,,,"2.7.7.48",,
"2J2U","GSQ","2J2U","CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX","3.4.21.6","5-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-5-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-SULFONAMIDE",
,"GSQ",,,"3.4.21.6",,
,"GSQ",,,,,
"2J9N","BEN","2J9N","Robotically harvested Trypsin complexed with Benzamidine containing polypeptide mediated crystal contacts","3.4.21.4","CALCIUM ION",
,,,,,"SODIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"PHENOL",
"2EI8","DT8","2EI8","FACTOR XA IN COMPLEX WITH THE INHIBITOR (1S,2R,4S)-N1-[(5-chloroindol-2-yl)carbonyl]-4-(N,N-dimethylcarbamoyl)-N2-[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine","3.4.21.6","CALCIUM ION",
,"DT8",,,"3.4.21.6","N-((1R,2S,5S)-2-(5-CHLORO-1H-INDOLE-2-CARBOXAMIDO)-5-(DIMETHYLCARBAMOYL)CYCLOHEXYL)-5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXAMIDE",
,"DT8",,,,,
,"DT8",,,,,
,"DT8",,,,,
,"DT8",,,,,
"2EI7","D93","2EI7","FACTOR XA IN COMPLEX WITH THE INHIBITOR trans-N1-[(5-Chloroindol-2-yl)carbonyl]-N2-[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine","3.4.21.6","CALCIUM ION",
,"D93",,,"3.4.21.6","N-((1R,2R)-2-(5-CHLORO-1H-INDOLE-2-CARBOXAMIDO)CYCLOHEXYL)-5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXAMIDE",
,"D93",,,,,
"2P94","ME4","2P94","Factor xa in complex with the inhibitor 3-chloro-N-((1R,2S)-2-(4-(2-oxopyridin-1(2H)-yl)benzamido)cyclohexyl)-1H-indole-6-carboxamide","3.4.21.6","3-CHLORO-N-((1R,2S) -2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)CYCLOHEXYL)-1H-INDOLE-6-CARBOXAMIDE",
,"ME4",,,"3.4.21.6",,
,"ME4",,,,,
"2FDA","682","2FDA","Crystal Structure of the Catalytic Domain of Human Coagulation Factor XIa in Complex with alpha-Ketothiazole Arginine Derived Ligand","3.4.21.27","BICARBONATE ION",
,,,,,"SULFATE ION",
,,,,,"N~2~-(AMINOCARBONYL)-N~1~-{4-{[AMINO(IMINO)METHYL]AMINO}-1-[HYDROXY(1,3-THIAZOL-2-YL)METHYL]BUTYL}VALINAMIDE",
"2G00","4QC","2G00","Factor Xa in complex with the inhibitor 3-(6-(2'-((dimethylamino)methyl)-4-biphenylyl)-7-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-1-yl)benzamide","3.4.21.6","3-[6-{2'-[(DIMETHYLAMINO)METHYL]BIPHENYL-4-YL}-7-OXO-3-(TRIFLUOROMETHYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-1-YL]BENZAMIDE",
,"4QC",,,"3.4.21.6",,
,"4QC",,,,,
"1Y5B","TL3","1Y5B","Dianhydrosugar-based benzamidine, factor Xa specific inhibitor in complex with bovine trypsin mutant","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"2,5-BIS-O-{4-[AMINO(IMINO)METHYL]PHENYL}-1,4:3,6-DIANHYDRO-D-GLUCITOL",
,,,,,"IMIDAZOLE",
"2OLG",,"2OLG","Crystal structure of the serine protease domain of prophenoloxidase activating factor-I in a zymogen form","3.4.21","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SULFATE ION",
,,,,,"CALCIUM ION",
"2SNW",,"2SNW","SINDBIS VIRUS CAPSID PROTEIN, TYPE3 CRYSTAL FORM","3.4.21",
,,,,"3.4.21.90",
"2SGE",,"2SGE","GLU 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 10.7","3.4.21.81","PHOSPHATE ION",
,,,,,"POTASSIUM ION",
"2RDE","C2E","2RDE","Crystal structure of VCA0042 complexed with c-di-GMP",,"9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one)",
"2SGP",,"2SGP","PRO 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5","3.4.21.81","PHOSPHATE ION",
,,,,,,
"3UR9","K36","3UR9","1.65A resolution structure of Norwalk Virus Protease Containing a covalently bound dipeptidyl inhibitor","3.4.22.66","CHLORIDE ION",
,,,,"3.6.1.15","(1S,2S)-2-({N-[(benzyloxy)carbonyl]-L-leucyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid",
,,,,"2.7.7.48",,
"3UR6",,"3UR6","1.5A resolution structure of apo Norwalk Virus Protease","3.4.22.66",
,,,,"3.6.1.15",
,,,,"2.7.7.48",
"3VEQ",,"3VEQ","A binary complex betwwen bovine pancreatic trypsin and a engineered mutant trypsin inhibitor","3.4.21.4","CALCIUM ION",
,,,,,,
"3DFJ",,"3DFJ","Crystal structure of human Prostasin","3.4.21","CHLORIDE ION",
"3DFL",,"3DFL","Crystal structure of human Prostasin complexed to 4-guanidinobenzoic acid","3.4.21","4-GUANIDINOBENZOIC ACID",
"3Q00",,"3Q00","Bovine trypsin variant X(tripleGlu217Ile227) in complex with small molecule inhibitor","3.4.21.4","CALCIUM ION",
,,,,,"N~2~-(benzylsulfonyl)-D-arginyl-N-(4-carbamimidoylbenzyl)glycinamide",
,,,,,"SULFATE ION",
,,,,,"2,5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,59,62,65,68,71,74,77,80-HEPTACOSAOXADOOCTACONTAN-82-OL",
"3Q3K","D90","3Q3K","Factor Xa in complex with a phenylenediamine derivative","3.4.21.6","CALCIUM ION",
,"D90",,,"3.4.21.6","N-(2-{[(5-chloro-1H-indol-2-yl)carbonyl]amino}phenyl)-5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-carboxamide",
,"D90",,,,,
"3QO6",,"3QO6","Crystal structure analysis of the plant protease Deg1","3.4.21",
,,,,,
,,,,,
,,,,,
,,,,,
"4A7I","A7I","4A7I","Factor Xa in complex with a potent 2-amino-ethane sulfonamide inhibitor","3.4.21.6","CALCIUM ION",
,"A7I",,,"3.4.21.6","5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID [2-(1--ISOPROPYL-PIPERIDIN-4-YLSULFAMOYL)-ETHYL]-AMIDE",
"4ABE","913","4ABE","Fragments bound to bovine trypsin for the SAMPL challenge","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"(3-PYRAZOL-1-YLPHENYL)METHANAMINE",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"CHLORIDE ION",
"4ABF","513","4ABF","Fragments bound to bovine trypsin for the SAMPL challenge","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"1-(5-BROMO-1-BENZOTHIOPHEN-3-YL)METHANAMINE",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"CHLORIDE ION",
"4ABH","7Z3","4ABH","Fragments bound to bovine trypsin for the SAMPL challenge","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"1-(3-PYRROLIDIN-1-YLPHENYL)METHANAMINE",
"4ABA","SW1","4ABA","Fragments bound to bovine trypsin for the SAMPL challenge","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"1-[2-(thiophen-2-yl)-1,3-thiazol-4-yl]methanamine",
"4ABB","K9S","4ABB","Fragments bound to bovine trypsin for the SAMPL challenge","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"1-(1-BENZOTHIOPHEN-3-YL)METHANAMINE",
"4ABD","SW2","4ABD","Fragments bound to bovine trypsin for the SAMPL challenge","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"1-[3-(1H-pyrrol-1-yl)phenyl]methanamine",
,,,,,"DIMETHYL SULFOXIDE",
"4AB9","VXQ","4AB9","Fragments bound to bovine trypsin for the SAMPL challenge","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"1-(2,3-dihydro-1-benzofuran-5-yl)methanamine",
,,,,,"DIMETHYL SULFOXIDE",
"3KQB","LGJ","3KQB","Factor xa in complex with the inhibitor n-(3-fluoro-2'- (methylsulfonyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro-1h- 1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-1h- pyrazole-5-carboxamide","3.4.21.6","N-(3-FLUORO-2'-(METHYLSULFONYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE",
,"LGJ",,,"3.4.21.6","SODIUM ION",
,"LGJ",,,,,
"3KQC","LGK","3KQC","Factor xa in complex with the inhibitor 6-(2'- (methylsulfonyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro-1h- 1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-5,6- dihydro-1h-pyrazolo[3,4-c]pyridin-7(4h)-one","3.4.21.6","6-(2'-(METHYLSULFONYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE",
,"LGK",,,"3.4.21.6","SODIUM ION",
,"LGK",,,,,
"3KQD","LGL","3KQD","Factor xa in complex with the inhibitor 1-(3-(5-oxo-4,5- dihydro-1h-1,2,4-triazol-3-yl)phenyl)-6-(2'-(pyrrolidin-1- ylmethyl)biphenyl-4-yl)-3-(trifluoromethyl)-5,6-dihydro- 1h-pyrazolo[3,4-c]pyridin-7(4h)-one","3.4.21.6","1-(3-(5-OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-6-(2'-(PYRROLIDIN-1-YLMETHYL)BIPHENYL-4-YL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE",
,"LGL",,,"3.4.21.6","SODIUM ION",
"3KQE","LGM","3KQE","Factor xa in complex with the inhibitor 3-methyl-1-(3-(5- oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl)phenyl)-6-(2'- (pyrrolidin-1-ylmethyl)biphenyl-4-yl)-5,6-dihydro-1h- pyrazolo[3,4-c]pyridin-7(4h)-one","3.4.21.6","3-METHYL-1-(3-(5-OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-6-(2'-(PYRROLIDIN-1-YLMETHYL)BIPHENYL-4-YL)-5,6-DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE",
,"LGM",,,"3.4.21.6","SODIUM ION",
,"LGM",,,,,
"3KYF","5GP","3KYF","Crystal structure of P4397 complexed with c-di-GMP",,"GUANOSINE-5'-MONOPHOSPHATE",
"4F48",,"4F48","The X-ray structural of FimXEAL-c-di-GMP-PilZ complexes from Xanthomonas campestris",,"9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one)",
,,,,,,
"3MYW",,"3MYW","The Bowman-Birk type inhibitor from mung bean in ternary complex with porcine trypsin","3.4.21.4","CALCIUM ION",
,,,,,,
"3NUM",,"3NUM","Substrate induced remodeling of the active site regulates HtrA1 activity","3.4.21",
"3NWU",,"3NWU","Substrate induced remodeling of the active site regulates HtrA1 activity","3.4.21","SULFATE ION",
"2Z6B",,"2Z6B","Crystal Structure Analysis of (gp27-gp5)3 conjugated with Fe(III) protoporphyrin","3.2.1.17","1-ETHYL-PYRROLIDINE-2,5-DIONE",
,,,,,,
"2ZGH",,"2ZGH","Crystal Structure of active granzyme M bound to its product","3.4.21","SULFATE ION",
,,,,,,
"2ZGJ",,"2ZGJ","Crystal Structure of D86N-GzmM Complexed with Its Optimal Synthesized Substrate","3.4.21","SULFATE ION",
,,,,,,
"2ZGC",,"2ZGC","Crystal Structure of Active Human Granzyme M","3.4.21","SULFATE ION",
"3RDZ",,"3RDZ","Crystal Structure of rBTI-trypsin complex at 2.26 angstrom resolution","3.4.21.4","CALCIUM ION",
,,,,,,
"3I29",,"3I29","Crystal structure of a binary complex between an mutant trypsin inhibitor with bovine trypsin","3.4.21.4","CALCIUM ION",
,,,,,,
"3FAN",,"3FAN","Crystal structure of chymotrypsin-like protease/proteinase (3CLSP/Nsp4) of porcine reproductive and respiratory syndrome virus (PRRSV)","3.4.21.114","PHOSPHATE ION",
"3FAO",,"3FAO","Crystal structure of S118A mutant 3CLSP of PRRSV","3.4.21.114","PHOSPHATE ION",
"3IEZ",,"3IEZ","Crystal structure of the RasGAP C-terminal (RGC) domain of IQGAP2",,"UNKNOWN ATOM OR ION",
"3MLQ",,"3MLQ","Crystal structure of the Thermus thermophilus transcription-repair coupling factor RNA polymerase interacting domain with the Thermus aquaticus RNA polymerase beta1 domain","2.7.7.6","PHOSPHATE ION",
,,,,"3.6.4",,
"3M7Q",,"3M7Q","Crystal structure of recombinant Kunitz Type serine protease Inhibitor-1 from the Caribbean sea anemone stichodactyla helianthus in complex with bovine pancreatic trypsin","3.4.21.4","PHOSPHATE ION",
,,,,,,
"4GUX",,"4GUX","Crystal structure of trypsin:MCoTi-II complex","3.4.21.4","CALCIUM ION",
,,,,,"ACETATE ION",
"4GAW",,"4GAW","Crystal structure of active human granzyme H","3.4.21","SULFATE ION",
,,,,,"CHLORIDE ION",
"4H4F",,"4H4F","Crystal structure of human chymotrypsin C (CTRC) bound to inhibitor eglin c from Hirudo medicinalis","3.4.21.2","PHOSPHATE ION",
,,,,,,
,,,,"3.4.21.2",,
"4JYT","N4A","4JYT","Crystal Structure of Matriptase in complex with Inhibitor","3.4.21.109","4,4'-[{3-[(naphthalen-2-ylsulfonyl)amino]pyridine-2,6-diyl}bis(oxy)]dibenzenecarboximidamide",
"4JZ1","F4D","4JZ1","Crystal Structure of Matriptase in complex with Inhibitor","3.4.21.109","4,4'-[(3-{[(4-fluorophenyl)sulfonyl]amino}pyridine-2,6-diyl)bis(oxy)]dibenzenecarboximidamide",
"4JZI","N4C","4JZI","Crystal Structure of Matriptase in complex with Inhibitor"".","3.4.21.109","N-(trans-4-aminocyclohexyl)-2,6-bis(4-carbamimidoylphenoxy)pyridine-4-carboxamide",
"4KBM",,"4KBM","Structure of the Mtb CarD/RNAP Beta subunit B1-B2 domains complex","2.7.7.6",
,,,,,
"4KGA",,"4KGA","Crystal structure of kallikrein-related peptidase 4","3.4.21","NICKEL (II) ION",
,,,,,"1,2-ETHANEDIOL",
"4Q7Y",,"4Q7Y","Neutrophil serine protease 4 (PRSS57) apo form 2","3.4.21","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"CHLORIDE ION",
"4Q80",,"4Q80","Neutrophil serine protease 4 (PRSS57) with val-leu-lys-chloromethylketone (VLK-cmk)","3.4.21","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"D-valyl-N-[(2S,3S)-7-amino-1-chloro-2-hydroxyheptan-3-yl]-L-leucinamide",
"3TK5","D1Q","3TK5","Factor Xa in complex with D102-4380","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","4-{3-[(4-chlorophenyl)amino]-3-oxopropyl}-3-({[5-(propan-2-yl)-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridin-2-yl]carbonyl}amino)benzoic acid",
"3TK6","D46","3TK6","factor Xa in complex with D46-5241","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","N-[2-({[(5-chlorothiophen-2-yl)carbonyl]amino}methyl)phenyl]-5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-carboxamide",
"4X2V",,"4X2V","Crystal structure of the Murine Norovirus NS6 protease (inactive C139A mutant) with a C-terminal extension to include residue P1 prime of NS7","2.7.7.48","IMIDAZOLE",
,,,,"3.4.22.66",,
,,,,"3.6.1.15",,
,,,,"2.7.7.48",,
,,,,"3.4.22.66",,
,,,,"3.6.1.15",,
,,,,,,
"4X2W",,"4X2W","Crystal structure of the Murine Norovirus NS6 protease (inactive C139A mutant) with a C-terminal extension to include residues P1 prime - P2 prime of NS7","2.7.7.48",
,,,,"3.4.22.66",
,,,,"3.6.1.15",
"4X2X",,"4X2X","Crystal structure of the Murine Norovirus NS6 protease (inactive C139A mutant) with a C-terminal extension to include residues P1 prime - P4 prime of NS7","2.7.7.48",
,,,,"3.4.22.66",
,,,,"3.6.1.15",
"4X2Y",,"4X2Y","Crystal structure of a chimeric Murine Norovirus NS6 protease (inactive C139A mutant) in which the P4-P4 prime residues of the cleavage junction in the extended C-terminus have been replaced by the corresponding residues from the NS2-3 junction.","2.7.7.48",
,,,,"3.4.22.66",
,,,,"3.6.1.15",
"4NA7","1T5","4NA7","Factor XIA in complex with the inhibitor 3'-[(2S,4R)-6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydroquinolin-2-yl]-4-carbamoyl-5'-[(3-methylbutanoyl)amino]biphenyl-2-carboxylic acid","3.4.21.27","3'-[(2S,4R)-6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetrahydroquinolin-2-yl]-4-carbamoyl-5'-[(3-methylbutanoyl)amino]biphenyl-2-carboxylic acid",
,"1T5",,,,"SULFATE ION",
,"1T5",,,,,
"4NA8","1T6","4NA8","Factor XIa in complex with the inhibitor 5-aminocarbonyl-2-[3-[(2s,4r)-6-carbamimidoyl-4-methyl-4-phenyl-2,3-dihydro-1h-quinolin-2-yl]phenyl]benzoic acid","3.4.21.27","5-aminocarbonyl-2-[3-[(2S,4R)-6-carbamimidoyl-4-methyl-4-phenyl-2,3-dihydro-1H-quinolin-2-yl]phenyl]benzoic acid",
,"1T6",,,,"SULFATE ION",
,"1T6",,,,"1,2-ETHANEDIOL",
,"1T6",,,,,
"4MPU",,"4MPU","Human beta-tryptase co-crystal structure with (6S,8R)-N,N'-bis[3-({4-[3-(aminomethyl)phenyl]piperidin-1-yl}carbonyl)phenyl]-8-hydroxy-6-(1-hydroxycyclobutyl)-5,7-dioxaspiro[3.4]octane-6,8-dicarboxamide","3.4.21.59","2-(N-MORPHOLINO)-ETHANESULFONIC ACID",
,,,,,"SULFATE ION",
,,,,,"TETRAETHYLENE GLYCOL",
,,,,,"(6S,8R)-N,N'-bis[3-({4-[3-(aminomethyl)phenyl]piperidin-1-yl}carbonyl)phenyl]-8-hydroxy-6-(1-hydroxycyclobutyl)-5,7-dioxaspiro[3.4]octane-6,8-dicarboxamide",
"4MPV",,"4MPV","Human beta-tryptase co-crystal structure with (2R,4S)-N,N'-bis[3-({4-[3-(aminomethyl)phenyl]piperidin-1-yl}carbonyl)phenyl]-4-hydroxy-2-(2-hydroxypropan-2-yl)-5,5-dimethyl-1,3-dioxolane-2,4-dicarboxamide","3.4.21.59","(2R,4S)-N,N'-bis[3-({4-[3-(aminomethyl)phenyl]piperidin-1-yl}carbonyl)phenyl]-4-hydroxy-2-(2-hydroxypropan-2-yl)-5,5-dimethyl-1,3-dioxolane-2,4-dicarboxamide",
,,,,,"SULFATE ION",
,,,,,"2-(N-MORPHOLINO)-ETHANESULFONIC ACID",
,,,,,"CHLORIDE ION",
"4MPW",,"4MPW","Human beta-tryptase co-crystal structure with [(1,1,3,3-tetramethyldisiloxane-1,3-diyl)di-1-benzofuran-3,5-diyl]bis({4-[3-(aminomethyl)phenyl]piperidin-1-yl}methanone)","3.4.21.59","CHLORIDE ION",
,,,,,"TRIETHYLENE GLYCOL",
,,,,,"ACETATE ION",
,,,,,"[(1,1,3,3-tetramethyldisiloxane-1,3-diyl)di-1-benzofuran-3,5-diyl]bis({4-[3-(aminomethyl)phenyl]piperidin-1-yl}methanone)",
"4ASH",,"4ASH","Crystal structure of the NS6 protease from murine norovirus 1","3.4.22.66",
,,,,"2.7.7.48",
,,,,"3.6.1.15",
"4BGA",,"4BGA","Nucleotide-bound open form of a putative sugar kinase MK0840 from Methanopyrus kandleri",,"POTASSIUM ION",
,,,,,"beta-D-glucopyranose",
,,,,,"ADENOSINE-5'-DIPHOSPHATE",
,,,,,"MAGNESIUM ION",
"3SJI","AG7","3SJI","crystal structure of CVA16 3C in complex with Rupintrivir (AG7088)","3.4.22.28","4-{2-(4-FLUORO-BENZYL)-6-METHYL-5-[(5-METHYL-ISOXAZOLE-3-CARBONYL)-AMINO]-4-OXO-HEPTANOYLAMINO}-5-(2-OXO-PYRROLIDIN-3-YL)-PENTANOIC ACID ETHYL ESTER",
,,,,,"SODIUM ION",
"3SJ8",,"3SJ8","Crystal structure of the 3C protease from coxsackievirus A16","3.4.22.28",
"3SJ9",,"3SJ9","crystal structure of the C147A mutant 3C of CVA16 in complex with FAGLRQAVTQ peptide","3.4.22.28",
,,,,,
"3BG4",,"3BG4","The crystal structure of guamerin in complex with chymotrypsin and the development of an elastase-specific inhibitor","3.4.21.1",
,,,,"3.4.21.1",
,,,,"3.4.21.1",
,,,,,
"3BG8","INH","3BG8","Crystal structure of Factor XIa in complex with Clavatadine A","3.4.21.27","N-(R-CARBOXY-ETHYL)-ALPHA-(S)-(2-PHENYLETHYL)GLYCYL-L-ARGININE-N-PHENYLAMIDE",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
"2UUY",,"2UUY","Structure of a tick tryptase inhibitor in complex with bovine trypsin","3.4.21.4","CALCIUM ION",
,,,,,"CHLORIDE ION",
"4IC6",,"4IC6","Crystal structure of Deg8","3.4.21",
"4IN1",,"4IN1","Structural Basis of Substrate Specificity and Protease Inhibition in Norwalk Virus","3.4.22.66","SULFATE ION",
,,,,"3.6.1.15",,
,,,,"2.7.7.48",,
"4IMQ",,"4IMQ","Structural Basis of Substrate Specificity and Protease Inhibition in Norwalk Virus","3.4.22.66","THIOCYANATE ION",
,,,,"3.6.1.15","SODIUM ION",
,,,,"2.7.7.48",,
,,,,,,
"4IN2",,"4IN2","Structural Basis of Substrate Specificity and Protease Inhibition in Norwalk Virus","3.4.22.66",
,,,,"3.6.1.15",
,,,,"2.7.7.48",
"4INH",,"4INH","Structural Basis of Substrate Specificity and Protease Inhibition in Norwalk Virus","3.6.1.15","DIMETHYL SULFOXIDE",
,,,,"3.4.22.66",,
,,,,"2.7.7.48",,
,,,,,,
"4IMZ",,"4IMZ","Structural Basis of Substrate Specificity and Protease Inhibition in Norwalk Virus","3.6.1.15","THIOCYANATE ION",
,,,,"3.4.22.66","SODIUM ION",
,,,,"2.7.7.48",,
,,,,,,
"4J1Y",,"4J1Y","The X-ray crystal structure of human complement protease C1s zymogen","3.4.21.42",
"4J2Y",,"4J2Y","Crystal structure of a plant trypsin inhibitor EcTI in complex with bovine trypsin.",,"SULFATE ION",
,,,,"3.4.21.4",,
"2XBW","455","2XBW","Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor","3.4.21.6","(3R,4R)-1-SULFAMOYL-PYRROLIDINE-3,4-DICARBOXYLIC ACID 3-[(4-CHLORO-PHENYL)-AMIDE] 4-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYL]-AMIDE}",
,"455",,,"3.4.21.6","CALCIUM ION",
,"455",,,,"SODIUM ION",
"2XBX","RR8","2XBX","Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor","3.4.21.6","(3R,4R)-1-METHANESULFONYL-PYRROLIDINE-3,4-DICARBOXYLIC ACID 3-[(4-CHLORO-PHENYL)-AMIDE] 4-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYL]-AMIDE}",
,"RR8",,,"3.4.21.6","CALCIUM ION",
,"RR8",,,,"SODIUM ION",
"2XC4","IVK","2XC4","Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor","3.4.21.6","CALCIUM ION",
,"IVK",,,"3.4.21.6","SODIUM ION",
,"IVK",,,,"(3R,4R)-N-(4-CHLOROPHENYL)-N'-[2-FLUORO-4-(2-OXOPYRIDIN-1(2H)-YL)PHENYL]-1-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-3,4-DICARBOXAMIDE",
"2XTT",,"2XTT","Bovine trypsin in complex with evolutionary enhanced Schistocerca gregaria protease inhibitor 1 (SGPI-1-P02)",,"CALCIUM ION",
,,,,"3.4.21.4","ACETATE ION",
"2Y6T",,"2Y6T","Molecular Recognition of Chymotrypsin by the Serine Protease Inhibitor Ecotin from Yersinia pestis","3.4.21.1","SULFATE ION",
,,,,,,
"2BM2","PM2","2BM2","human beta-II tryptase in complex with 4-(3-Aminomethyl-phenyl)- piperidin-1-yl-(5-phenethyl- pyridin-3-yl)-methanone","3.4.21.59","1-[3-(1-{[5-(2-PHENYLETHYL)PYRIDIN-3-YL]CARBONYL}PIPERIDIN-4-YL)PHENYL]METHANAMINE",
"2BTC",,"2BTC","BOVINE TRYPSIN IN COMPLEX WITH SQUASH SEED INHIBITOR (CUCURBITA PEPO TRYPSIN INHIBITOR II)","3.4.21.4","CALCIUM ION",
,,,,,,
"1IOE",,"1IOE","Human coagulation factor Xa in complex with M55532","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","(-)-7-[(6-CHLORO-2-NAPHTHALENYL)SULFONYL]TETRAHYDRO-8A-(METHOXYMETHYL)-1'-(4-PYRIDINYL)-SPIRO[5H-OXAZOLO[3,2-A]PYRAZINE-2(3H),4'-PIPERIDIN]-5-ONE",
"1IQN",,"1IQN","Human coagulation factor Xa in complex with M55192","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","4-[[4-[(6-CHLORO-2-NAPHTHALENYL)SULFONYL]-6-OXO-1-[[1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]-2-PIPERAZINYL]CARBONYL]MORPHOLINE",
"1IQM",,"1IQM","Human coagulation factor Xa in complex with M54471","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","1-[[(1E)-2-(4-CHLOROPHENYL)ETHENYL]SULFONYL]-4-[[1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]PIPERAZINE",
"1IQL",,"1IQL","Human coagulation factor Xa in complex with M54476","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","4-[[(1E)-2-(4-CHLOROPHENYL)ETHENYL]SULFONYL]-1-[[1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]PIPERAZINONE",
"1IQK",,"1IQK","Human coagulation factor Xa in complex with M55113","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","4-[(6-CHLORO-2-NAPHTHALENYL)SULFONYL]-1-[[1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]PIPERAZINONE",
"1IQJ",,"1IQJ","Human coagulation factor Xa in complex with M55124","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","4-[(6-CHLORO-2-NAPHTHALENYL)SULFONYL]-1-[[1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]-2-PIPERAZINECARBOXYLIC ACID ETHYL ESTER",
"1IQI",,"1IQI","Human coagulation factor Xa in complex with M55125","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","4-[(6-CHLORO-2-NAPHTHALENYL)SULFONYL]-1-[[1-(4-PYRIDINYL)-4-PIPERIDINYL] METHYL]-2-PIPERAZINECARBOXYLIC ACID",
"1IQH",,"1IQH","Human coagulation factor Xa in complex with M55143","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","4-[(6-CHLORO-2-NAPHTHALENYL)SULFONYL]-1-[[4-HYDROXYMETHYL-1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]PIPERAZINONE",
"1IQG",,"1IQG","Human coagulation factor Xa in complex with M55159","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","4-[(6-CHLORO-2-NAPHTHALENYL)SULFONYL]-1-[[4-HYDROXYIMINOMETHYL-1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]PIPERAZINONE",
"1IQF",,"1IQF","Human coagulation factor Xa in complex with M55165","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","(2R)-4-[(6-CHLORO-2-NAPHTHALENYL)SULFONYL]-6-OXO-1-[[1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]-2-PIPERAZINECARBOXYLIC ACID ETHYL ESTER",
"1IQE",,"1IQE","Human coagulation factor Xa in complex with M55590","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","4-[(2R)-3-[[(6-CHLORO-2-NAPHTHALENYL)SULFONYL]AMINO]-1-OXO-2-[[[1-(4-PYRIDINYL)-4-PIPERIDINYL]METHYL]AMINO]PROPYL]-THIOMORPHOLINE-1,1-DIOXIDE",
"1ITZ",,"1ITZ","Maize Transketolase in complex with TPP","2.2.1.1","MAGNESIUM ION",
,,,,,"THIAMINE DIPHOSPHATE",
"1ZTL",,"1ZTL","Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with N-[4-Guanidino-1-(thiazole-2-carbonyl)-butyl]-2-{6-oxo-5-[(quinolin-8-ylmethyl)-amino]-2-m-tolyl-6H-pyrimidin-1-yl}-acetamide","3.4.21.27","SULFATE ION",
,,,,,"N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]-2-{6-OXO-5-[(QUINOLIN-8-YLMETHYL)-AMINO]-2-M-TOLYL-6H-PYRIMIDIN-1-YL}-ACETAMIDE",
"1ZTK",,"1ZTK","Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 2-(5-Amino-6-oxo-2-m-tolyl-6H-pyrimidin-1-yl)-N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-acetamide","3.4.21.27","SULFATE ION",
,,,,,"2-(5-AMINO-6-OXO-2-M-TOLYL-6H-PYRIMIDIN-1-YL)-N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]-ACETAMIDE",
"2A32",,"2A32","Trypsin in complex with benzene boronic acid","3.4.21.4","CALCIUM ION",
,,,,,"SODIUM ION",
,,,,,"GUANIDINE-3-PROPANOL",
,,,,,"PHENYL BORONIC ACID",
,,,,,"BORATE ION",
,,,,,"3-CYCLOHEXYL-1-PROPYLSULFONIC ACID",
"1VCQ",,"1VCQ","SEMLIKI FOREST VIRUS CAPSID PROTEIN (CRYSTAL FORM II)","3.4.21.90",
"1V2L","BEN","1V2L","Benzamidine in complex with bovine trypsin variant X(triple.Glu)bT.D1","3.4.21.4","SULFATE ION",
,"BEN",,,,"CALCIUM ION",
,,,,,"BENZAMIDINE",
"1V2K","ZEN","1V2K","Factor XA specific Inhibitor in complex with bovine trypsin variant X(triple.Glu)bT.D2","3.4.21.4","SULFATE ION",
,"ZEN",,,,"CALCIUM ION",
,,,,,"[4-(6-CHLORO-NAPHTHALENE-2-SULFONYL)-PIPERAZIN-1-YL]- (3,4,5,6-TETRAHYDRO-2H-[1,4']BIPYRIDINYL-4-YL)- METHANONE",
"1V2J","BEN","1V2J","BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSRI)bT.C1","3.4.21.4","SULFATE ION",
,"BEN",,,,"CALCIUM ION",
,,,,,"BENZAMIDINE",
"1V2T","ANH","1V2T","Trypsin inhibitor in complex with bovine trypsin variant X(SSFI.Glu)bT.B4","3.4.21.4","SULFATE ION",
,"ANH",,,,"CALCIUM ION",
,,,,,"METHYL N-[(4-METHYLPHENYL)SULFONYL]GLYCYL-3-[AMINO(IMINO)METHYL]-D-PHENYLALANINATE",
"1V2S","BEN","1V2S","Benzamidine in complex with bovine trypsin variant X(SSFI.Glu)bT.D1","3.4.21.4","SULFATE ION",
,"BEN",,,,"CALCIUM ION",
,,,,,"BENZAMIDINE",
"1V2R","ANH","1V2R","Trypsin inhibitor in complex with bovine trypsin variant X(SSRI)bT.B4","3.4.21.4","SULFATE ION",
,"ANH",,,,"CALCIUM ION",
,,,,,"METHYL N-[(4-METHYLPHENYL)SULFONYL]GLYCYL-3-[AMINO(IMINO)METHYL]-D-PHENYLALANINATE",
"1V2Q","ANH","1V2Q","Trypsin inhibitor in complex with bovine trypsin variant X(SSWI)bT.B4","3.4.21.4","SULFATE ION",
,"ANH",,,,"CALCIUM ION",
,,,,,"METHYL N-[(4-METHYLPHENYL)SULFONYL]GLYCYL-3-[AMINO(IMINO)METHYL]-D-PHENYLALANINATE",
"1V2P","ANH","1V2P","Trypsin inhibitor in complex with bovine trypsin variant X(SSYI)bT.A4","3.4.21.4","SULFATE ION",
,"ANH",,,,"CALCIUM ION",
,,,,,"METHYL N-[(4-METHYLPHENYL)SULFONYL]GLYCYL-3-[AMINO(IMINO)METHYL]-D-PHENYLALANINATE",
"1V2O","ANH","1V2O","Trypsin inhibitor in complex with bovine trypsin variant X(SSYI)bT.B4","3.4.21.4","SULFATE ION",
,"ANH",,,,"CALCIUM ION",
,,,,,"METHYL N-[(4-METHYLPHENYL)SULFONYL]GLYCYL-3-[AMINO(IMINO)METHYL]-D-PHENYLALANINATE",
"1V2N","BBA","1V2N","Potent factor XA inhibitor in complex with bovine trypsin variant X(99/175/190)bT","3.4.21.4","CALCIUM ION",
,"BBA",,,,"2,7-BIS-(4-AMIDINOBENZYLIDENE)-CYCLOHEPTAN-1-ONE",
"1V2M","BEN","1V2M","Benzamidine in complex with bovine trypsin variant X(triple.Glu)bT.A1","3.4.21.4","SULFATE ION",
,"BEN",,,,"BENZAMIDINE",
"1V2W","ANH","1V2W","Trypsin inhibitor in complex with bovine trypsin variant X(SSAI)bT.B4","3.4.21.4","SULFATE ION",
,"ANH",,,,"CALCIUM ION",
,,,,,"METHYL N-[(4-METHYLPHENYL)SULFONYL]GLYCYL-3-[AMINO(IMINO)METHYL]-D-PHENYLALANINATE",
"1V2V","BEN","1V2V","Benzamidine in complex with bovine trypsin variant X(SSAI)bT.C1","3.4.21.4","SULFATE ION",
,"BEN",,,,"CALCIUM ION",
,,,,,"BENZAMIDINE",
"1V2U","BEN","1V2U","Benzamidine in complex with bovine trypsin varinat X(SSAI)bT.D1","3.4.21.4","SULFATE ION",
,"BEN",,,,"CALCIUM ION",
,,,,,"BENZAMIDINE",
"1GGD","FAF","1GGD","CRYSTAL STRUCTURE OF GAMMA CHYMOTRYPSIN WITH N-ACETYL-LEUCIL-PHENYLALANINE ALDEHYDE BOUND AT THE ACTIVE SITE","3.4.21.1","SULFATE ION",
,,,,"3.4.21.1","2-ACETYLAMINO-4-METHYL-PENTANOIC ACID (1-FORMYL-2-PHENYL-ETHYL)-AMIDE",
,,,,"3.4.21.1",,
"1GG6",,"1GG6","CRYSTAL STRUCTURE OF GAMMA CHYMOTRYPSIN WITH N-ACETYL-PHENYLALANINE TRIFLUOROMETHYL KETONE BOUND AT THE ACTIVE SITE","3.4.21.1","SULFATE ION",
,,,,"3.4.21.1","N-(1-BENZYL-3,3,3-TRIFLUORO-2,2-DIHYDROXY-PROPYL)-ACETAMIDE",
,,,,"3.4.21.1","1,2-ETHANEDIOL",
,,,,,"1,1,1-TRIFLUORO-3-ACETAMIDO-4-PHENYL BUTAN-2-ONE(N-ACETYL-L-PHENYLALANYL TRIFLUOROMETHYL KETONE)",
"1GGT",,"1GGT","THREE-DIMENSIONAL STRUCTURE OF A TRANSGLUTAMINASE: HUMAN BLOOD COAGULATION FACTOR XIII","2.3.2.13",
"1GL1",,"1GL1","structure of the complex between bovine alpha-chymotrypsin and PMP-C, an inhibitor from the insect Locusta migratoria","3.4.21.1","CADMIUM ION",
,,,,,,
"1FXY",,"1FXY","COAGULATION FACTOR XA-TRYPSIN CHIMERA INHIBITED WITH D-PHE-PRO-ARG-CHLOROMETHYLKETONE","3.4.21.4","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
"2B9L",,"2B9L","Crystal structure of prophenoloxidase activating factor-II from the beetle Holotrichia diomphalia",,"SULFATE ION",
,,,,,"CALCIUM ION",
"2BDH",,"2BDH","Human Kallikrein 4 complex with zinc and p-aminobenzamidine","3.4.21","ZINC ION",
,,,,,"P-AMINO BENZAMIDINE",
"2BDG",,"2BDG","Human Kallikrein 4 complex with nickel and p-aminobenzamidine","3.4.21","SODIUM ION",
,,,,,"CHLORIDE ION",
,,,,,"NICKEL (II) ION",
,,,,,"P-AMINO BENZAMIDINE",
"1EZU",,"1EZU","ECOTIN Y69F, D70P BOUND TO D102N TRYPSIN",,"CALCIUM ION",
,,,,"3.4.21.4",,
"1EZS",,"1EZS","CRYSTAL STRUCTURE OF ECOTIN MUTANT M84R, W67A, G68A, Y69A, D70A BOUND TO RAT ANIONIC TRYPSIN II",,"CALCIUM ION",
,,,,"3.4.21.4",,
"1G3D","108","1G3D","BOVINE BETA-TRYPSIN BOUND TO META-AMIDINO SCHIFF BASE COPPER (II) CHELATE","3.4.21.4","COPPER (II) ION",
,"108",,,,"CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"2-(5-CARBAMIMIDOYL-2-HYDROXY-BENZYLAMINO)-PROPIONIC ACID",
"1G3C","109","1G3C","BOVINE BETA-TRYPSIN BOUND TO PARA-AMIDINO SCHIFF BASE IRON(III) CHELATE","3.4.21.4","FE (III) ION",
,,,,,"CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"2-(4-CARBAMIMIDOYL-2-HYDROXY-BENZYLAMINO)-PROPIONIC ACID",
"1G3E","109","1G3E","BOVINE BETA-TRYPSIN BOUND TO PARA-AMIDINO SCHIFF-BASE COPPER (II) CHELATE","3.4.21.4","COPPER (II) ION",
,"109",,,,"CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"2-(4-CARBAMIMIDOYL-2-HYDROXY-BENZYLAMINO)-PROPIONIC ACID",
"2FYR",,"2FYR","Crystal Structure of Norwalk Virus Protease grown in the presence of AEBSF","3.6.1.15","CHLORIDE ION",
,,,,"3.4.22.66","MAGNESIUM ION",
,,,,"2.7.7.48",,
"2FYQ",,"2FYQ","Crystal Structure of the Norwalk Virus Protease","3.6.1.15","CHLORIDE ION",
,,,,"3.4.22.66","PHOSPHATE ION",
,,,,"2.7.7.48",,
"2GKV",,"2GKV","Crystal structure of the SGPB:P14'-Ala32 OMTKY3-del(1-5) complex","3.4.21.81",
,,,,,
"6A8O",,"6A8O","Crystal structures of the serine protease domain of murine plasma kallikrein with peptide inhibitor mupain-1-16","3.4.21.34","alpha-D-mannopyranose",
,,,,,"piperidine-1-carboximidamide",
"6B6I",,"6B6I","2.4A resolution structure of human Norovirus GII.4 protease","2.7.7.48",
,,,,"3.4.22.66",
,,,,"3.6.1.15",
"6B6O",,"6B6O","Orthorhombic trypsin cryocooled to 100 K with 20% xylose as cryoprotectant","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
,,,,,"beta-D-xylopyranose",
,,,,,"alpha-D-xylopyranose",
"6B6Q",,"6B6Q","Orthorhombic trypsin cryocooled to 100 K with 50% xylose as cryoprotectant","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
,,,,,"beta-D-xylopyranose",
,,,,,"alpha-D-xylopyranose",
"6B6P",,"6B6P","Orthorhombic trypsin cryocooled to 100 K with 30% xylose as cryoprotectant","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
,,,,,"beta-D-xylopyranose",
,,,,,"alpha-D-xylopyranose",
"6AVL",,"6AVL","Orthorhombic Trypsin (295 K) in the presence of 50% xylose","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"SULFATE ION",
,,,,,"beta-D-xylopyranose",
,,,,,"alpha-D-xylopyranose",
"6HAR",,"6HAR","Crystal structure of Mesotrypsin in complex with APPI-M17C/I18F/F34C",,"1,2-ETHANEDIOL",
,,,,,"CALCIUM ION",
"6FTZ","E7E","6FTZ","COMPLEMENT FACTOR D COMPLEXED WITH COMPOUND 6","3.4.21.46","~{N}4-[3-(aminomethyl)phenyl]-1~{H}-indole-2,4-dicarboxamide",
"6FUT","E82","6FUT","Complement factor D in complex with the inhibitor (S)-3'-(aminomethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-[1,1'-biphenyl]-3-carboxamide","3.4.21.46","3-[3-(aminomethyl)phenyl]-~{N}-[(1~{S})-1,2,3,4-tetrahydronaphthalen-1-yl]benzamide",
,,,,,"SUCCINIC ACID",
"6FUH","E88","6FUH","Complement factor D in complex with the inhibitor (4-((3-(aminomethyl)phenyl)amino)quinazolin-2-yl)-L-valine","3.4.21.46","(2~{S})-2-[[4-[[3-(aminomethyl)phenyl]amino]quinazolin-2-yl]amino]-3-methyl-butanoic acid",
"6FUG","E85","6FUG","Complement factor D in complex with the inhibitor 3-((3-((3-(aminomethyl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenol","3.4.21.46","3-[[3-[[3-(aminomethyl)phenyl]amino]-1~{H}-pyrazolo[3,4-d]pyrimidin-4-yl]amino]phenol",
"6FUJ","E8B","6FUJ","Complement factor D in complex with the inhibitor N-(3'-(aminomethyl)-[1,1'-biphenyl]-3-yl)-3-methylbutanamide","3.4.21.46","~{N}-[3-[3-(aminomethyl)phenyl]phenyl]-3-methyl-butanamide",
"6FUI","E7W","6FUI","Complement factor D in complex with the inhibitor 3-((3-((3-(aminomethyl)phenyl)amino)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino)phenol","3.4.21.46","(1~{R},2~{S})-2-[[4-[[3-(aminomethyl)phenyl]amino]quinazolin-2-yl]amino]cyclohexane-1-carboxylic acid",
"4NCY",,"4NCY","In situ trypsin crystallized on a MiTeGen micromesh with imidazole ligand","3.4.21.4","CALCIUM ION",
,,,,,"BENZAMIDINE",
,,,,,"1,2-ETHANEDIOL",
,,,,,"SULFATE ION",
,,,,,"IMIDAZOLE",
"4NFE",,"4NFE","Human kallikrein-related peptidase 2 in complex with benzamidine","3.4.21.35","BENZAMIDINE",
,,,,,"SULFATE ION",
"4NFF",,"4NFF","Human kallikrein-related peptidase 2 in complex with PPACK","3.4.21.35","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
"4NIY",,"4NIY","Crystal structure of trypsiligase (K60E/N143H/Y151H/D189K trypsin) complexed to YRH-ecotin (M84Y/M85R/A86H ecotin)","3.4.21.4","CALCIUM ION",
,,,,,"ZINC ION",
"6KD5",,"6KD5","Crystal structure of the extracellular domain of MSPL/TMPRSS13 in complex with dec-RVKR-cmk inhibitor","3.4.21","SULFATE ION",
,,,,"3.4.21","CALCIUM ION",
,,,,,,
"6O21",,"6O21","Crystal Structure of Human KLK4 in Complex With Cleaved SFTI-FCQR(Asn14)[1,14] Inhibitor","3.4.21","SULFATE ION",
,,,,,"(4S)-2-METHYL-2,4-PENTANEDIOL",
"5T6G",,"5T6G","2.45 A resolution structure of Norovirus 3CL protease in complex with the dipeptidyl inhibitor 7m (hexagonal form)","3.6.1.15","3-cyclohexyl-N-{(2S)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-N~2~-(octylsulfonyl)-L-alaninamide",
,,,,"3.4.22.66",,
,,,,"2.7.7.48",,
"5T6D",,"5T6D","2.10 A resolution structure of Norovirus 3CL protease in complex with the dipeptidyl inhibitor 7l (hexagonal form)","3.6.1.15","3-cyclohexyl-N-{(2S)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-N~2~-{[3-(4-methoxyphenoxy)propyl]sulfonyl}-L-
alaninamide",
,,,,"3.4.22.66",,
,,,,"2.7.7.48",,
"5T6F",,"5T6F","1.90 A resolution structure of Norovirus 3CL protease in complex with the dipeptidyl inhibitor 7l (orthorhombic P form)","3.6.1.15","3-cyclohexyl-N-{(2S)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-N~2~-{[3-(4-methoxyphenoxy)propyl]sulfonyl}-L-
alaninamide",
,,,,"3.4.22.66",,
,,,,"2.7.7.48",,
"5TCA","J55","5TCA","Complement Factor D inhibited with JH3","3.4.21.46","1-(2-{(2S)-2-[(6-bromopyridin-2-yl)carbamoyl]-1,3-thiazolidin-3-yl}-2-oxoethyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide",
,"J55",,,,,
,"J55",,,,,
,"J55",,,,,
"5TCC","J56","5TCC","Complement Factor D inhibited with JH4","3.4.21.46","(2S)-N-(6-bromopyridin-2-yl)-3-[(1H-indazol-1-yl)acetyl]-1,3-thiazolidine-2-carboxamide",
,"J56",,,,,
,"J56",,,,,
"5TG1",,"5TG1","1.40 A resolution structure of Norovirus 3CL protease in complex with the a m-chlorophenyl substituted macrocyclic inhibitor (17-mer)","3.4.22.66","CHLORIDE ION",
,,,,"3.6.1.15","(4S,7S,17S)-17-(3-chlorophenyl)-7-(hydroxymethyl)-4-(2-methylpropyl)-1-oxa-3,6,11-triazacycloheptadecane-2,5,10-trione",
,,,,"2.7.7.48",,
"5TG2",,"5TG2","1.75 A resolution structure of Norovirus 3CL protease in complex with the a n-pentyl substituted macrocyclic inhibitor (17-mer)","3.4.22.66","(4S,7S,17R)-7-(hydroxymethyl)-4-(2-methylpropyl)-17-pentyl-1-oxa-3,6,11-triazacycloheptadecane-2,5,10-trione",
,,,,"3.6.1.15",,
,,,,"2.7.7.48",,
"5ZFI","9C9","5ZFI","Mouse kallikrein 7 in complex with 6-benzyl-1,4-diazepan-7-one derivative","3.4.21.117","2-[(3Z,6R)-6-[(2,6-dichlorophenyl)methyl]-3-(dimethylhydrazinylidene)-7-oxo-1,4-diazepan-1-yl]-N-[3-(1-methyl-1H-pyrazol-4-yl)phenyl]acetamide",
,,,,,"2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL",
"5ZFH",,"5ZFH","Mouse Kallikrein 7","3.4.21.117",
"6AHS","9YO","6AHS","Mouse Kallikrein 7 in complex with imidazolinylindole derivative","3.4.21.117","1-[(2-chlorophenyl)sulfonyl]-5-methyl-3-[(4R)-2-methyl-4,5-dihydro-1H-imidazol-4-yl]-1H-indole",
,,,,,"2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL",
,,,,,"CHLORIDE ION",
"5WEJ",,"5WEJ","1.95 A resolution structure of Norovirus 3CL protease in complex with a dipeptidyl oxazolidinone-based inhibitor","3.6.1.15","(2S)-2-{(5S)-5-[(3-chlorophenyl)methyl]-2-oxo-1,3-oxazolidin-3-yl}-4-methyl-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}pentanamide",
,,,,"3.4.22.66",,
,,,,"2.7.7.48",,
"5WI6",,"5WI6","Human beta-1 tryptase mutant Ile99Cys","3.4.21.59","SULFATE ION",
,,,,,"L-alpha-glutamyl-N-{(1S)-4-{[amino(iminio)methyl]amino}-1-[(1S)-2-chloro-1-hydroxyethyl]butyl}glycinamide",
"6BIB",,"6BIB","1.95 A resolution structure of Norovirus 3CL protease in complex with a triazole-based macrocyclic inhibitor","3.4.22.66","benzyl [(9S,12S,15S)-12-(cyclohexylmethyl)-9-(hydroxymethyl)-6,11,14-trioxo-1,5,10,13,18,19-hexaazabicyclo[15.2.1]icosa-17(20),18-dien-15-yl]carbamate",
,,,,"3.6.1.15",,
,,,,"2.7.7.48",,
"6BID",,"6BID","1.15 A resolution structure of Norovirus 3CL protease in complex with a triazole-based macrocyclic inhibitor","3.4.22.66","benzyl [(8S,11S,14S)-11-(cyclohexylmethyl)-8-(hydroxymethyl)-5,10,13-trioxo-1,4,9,12,17,18-hexaazabicyclo[14.2.1]nonadeca-16(19),17-dien-14-yl]carbamate",
,,,,"3.6.1.15",,
,,,,"2.7.7.48",,
"6BIC",,"6BIC","2.25 A resolution structure of Norovirus 3CL protease in complex with a triazole-based macrocyclic inhibitor","3.4.22.66","(phenylmethyl) ~{N}-[(9~{S},12~{S},15~{S})-9-(hydroxymethyl)-12-(2-methylpropyl)-6,11,14-tris(oxidanylidene)-1,5,10,13,18,19-hexazabicyclo[15.2.1]icosa-17(20),18-dien-15-yl]carbamate",
,,,,"3.6.1.15",,
,,,,"2.7.7.48",,
"5E0J",,"5E0J","1.20 A resolution structure of Norovirus 3CL protease in complex with a triazole-based macrocyclic (21-mer) inhibitor","3.4.22.66","CHLORIDE ION",
,,,,"3.6.1.15","(phenylmethyl) ~{N}-[(12~{S},15~{S},18~{S})-15-(cyclohexylmethyl)-12-(hydroxymethyl)-9,14,17-tris(oxidanylidene)-1,8,13,16,21,22-hexazabicyclo[18.2.1]tricosa-20(23),21-dien-18-yl]carbamate",
,,,,"2.7.7.48",,
"5E0G",,"5E0G","1.20 A resolution structure of Norovirus 3CL protease in complex with a triazole-based macrocyclic (17-mer) inhibitor","3.4.22.66","CHLORIDE ION",
,,,,"3.6.1.15","(phenylmethyl) ~{N}-[(8~{S},11~{S},14~{S})-8-(hydroxymethyl)-11-(2-methylpropyl)-5,10,13-tris(oxidanylidene)-1,4,9,12,17,18-hexazabicyclo[14.2.1]nonadeca-16(19),17-dien-14-yl]carbamate",
,,,,"2.7.7.48",,
"5DG6",,"5DG6","2.35A resolution structure of Norovirus 3CL protease in complex an oxadiazole-based, cell permeable macrocyclic (21-mer) inhibitor","3.4.22.66","CHLORIDE ION",
,,,,"3.6.1.15","tert-butyl [(4S,7S,10S)-7-(cyclohexylmethyl)-10-(hydroxymethyl)-5,8,13-trioxo-23-oxa-6,9,14,21,22-pentaazabicyclo[18.2.1]tricosa-1(22),20-dien-4-yl]carbamate",
,,,,"2.7.7.48",,
"5DGJ",,"5DGJ","1.0A resolution structure of Norovirus 3CL protease in complex an oxadiazole-based, cell permeable macrocyclic (20-mer) inhibitor","3.4.22.66","tert-butyl [(4S,7S,10S)-7-(cyclohexylmethyl)-10-(hydroxymethyl)-5,8,13-trioxo-22-oxa-6,9,14,20,21-pentaazabicyclo[17.2.1]docosa-1(21),19-dien-4-yl]carbamate",
,,,,"3.6.1.15",,
,,,,"2.7.7.48",,
"4ZHA",,"4ZHA","Factor Xa complex with GTC000102","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","MAGNESIUM ION",
,,,,,"4-[(3S)-3-({[(E)-2-(5-chlorothiophen-2-yl)ethenyl]sulfonyl}amino)-2-oxo-2,3-dihydro-1H-pyrrol-1-yl]-3-fluoro-N-methylbenzamide",
"4ZH8",,"4ZH8","Factor Xa complex with GTC000006","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","6-chloro-N-{(3S)-1-[(2S)-1-(morpholin-4-yl)-1-oxopropan-2-yl]-2-oxo-2,3-dihydro-1H-pyrrol-3-yl}-N-(2-oxobutyl)naphthalene-2-sulfonamide",
"4WXI",,"4WXI","FACTOR XIA IN COMPLEX WITH THE INHIBITOR trans-N-{(1S)-1-[4-(3-amino-2H-indazol-6-yl)pyridin-2-yl]-2-phenylethyl}-4-(aminomethyl)cyclohexanecarboxamide","3.4.21.27","trans-N-{(1S)-1-[4-(3-amino-2H-indazol-6-yl)pyridin-2-yl]-2-phenylethyl}-4-(aminomethyl)cyclohexanecarboxamide",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"4Y71",,"4Y71","Factor Xa complex with GTC000398","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","6-chloro-N-{(3S)-1-[(2S)-1-(4-methyl-5-oxo-1,4-diazepan-1-yl)-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulf
onamide",
"4Y6D","48U","4Y6D","Factor Xa complex with GTC000101","3.4.21.6","4-[(3S)-3-({[(E)-2-(5-chlorothiophen-2-yl)ethenyl]sulfonyl}amino)-2-oxopyrrolidin-1-yl]-3-fluoro-N,N-dimethylbenzamide",
,"48U",,,"3.4.21.6",,
"4Y7B",,"4Y7B","Factor Xa complex with GTC000441","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","6-chloro-N-{(3S)-1-[(2S)-1-{(1R,5S)-7-[2-(methylamino)ethyl]-3,7-diazabicyclo[3.3.1]non-3-yl}-1-oxopropan-2-yl]-2-oxopy
rrolidin-3-yl}naphthalene-2-sulfonamide",
"4Y7A",,"4Y7A","Factor Xa complex with GTC000422","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","MAGNESIUM ION",
,,,,,"N-[(3S)-1-{(2S)-1-[(3S)-3-aminopiperidin-1-yl]-1-oxopropan-2-yl}-2-oxopyrrolidin-3-yl]-6-chloronaphthalene-2-sulfonamid
e",
"4XBC",,"4XBC","1.60 A resolution structure of Norovirus 3CL protease complex with a covalently bound dipeptidyl inhibitor (1R,2S)-2-({N-[(benzyloxy)carbonyl]-3-cyclohexyl-L-alanyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid (Hexagonal Form)","3.4.22.66","(1R,2S)-2-({N-[(benzyloxy)carbonyl]-3-cyclohexyl-L-alanyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid",
,,,,"3.6.1.15","TETRAETHYLENE GLYCOL",
,,,,"2.7.7.48",,
"4XOJ",,"4XOJ","Structure of bovine trypsin in complex with analogues of sunflower inhibitor 1 (SFTI-1)","3.4.21.4","SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"CALCIUM ION",
,,,,,"SODIUM ION",
,,,,,"AMMONIUM ION",
"5PTP",,"5PTP","STRUCTURE OF HYDROLASE (SERINE PROTEINASE)","3.4.21.4","CALCIUM ION",
"5MS3",,"5MS3","Kallikrein-related peptidase 8 calcium complex","3.4.21.118","CALCIUM ION",
"5MT4","M7O","5MT4","COMPLEMENT FACTOR D IN COMPLEX WITH A REVERSIBLE BENZOIC ACID BASED INHIBITOR","3.4.21.46","2-[(phenylmethyl)carbamoylamino]benzoic acid",
"6SJU",,"6SJU","Human kallikrein 7 with aromatic coumarinic ester compound 3 covalently bound to H57","3.4.21.117","TRIETHYLENE GLYCOL",
,,,,,"SULFATE ION",
,,,,,"(3-iodanylphenyl) 6-methyl-2-oxidanylidene-chromene-3-carboxylate",
,,,,,"4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID",
"6P0P",,"6P0P","Human beta-tryptase co-crystal structure with 5-{4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl}-2-(3'-{4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl}-[1,1'-biphenyl]-3-yl)-2-hydroxy-2H-1,3,2-benzodioxaborol-2-uide","3.4.21.59","(3'-{4-[3-(aminomethyl)phenyl]piperidine-1-carbonyl}[1,1'-biphenyl]-3-yl){4-[3-(aminomethyl)phenyl]piperidin-1-yl}[3,4-di(hydroxy-kappaO)phenyl]methanonato(2-)hydroxyborate(1-)",
,,,,,"SULFATE ION",
,,,,,"TRIETHYLENE GLYCOL",
,,,,,"2-(N-MORPHOLINO)-ETHANESULFONIC ACID",
"3BSQ",,"3BSQ","Crystal structure of human kallikrein 7 produced as a secretion protein in E.coli","3.4.21.117","SULFATE ION",
"5XLY",,"5XLY","Crystal structure of CheR1 in complex with c-di-GMP-bound MapZ","2.1.1.80","9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one)",
,,,,,,
"5Y4R",,"5Y4R","Structure of a methyltransferase complex","2.1.1.80","SULFATE ION",
,,,,,"9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one)",
"5Y9L","8R3","5Y9L","Human kallikrein 7 in complex with 1,3,6-trisubstituted 1,4-diazepane-7-one","3.4.21.117","3-[2-[(3Z,6R)-6-[(5-chloranyl-2-methoxy-phenyl)methyl]-3-(dimethylhydrazinylidene)-7-oxidanylidene-1,4-diazepan-1-yl]ethanoylamino]benzoic acid",
,,,,,"CHLORIDE ION",
"5YJK","8VX","5YJK","Human kallikrein 7 in complex with 1,4-diazepane-7-one 1-acetamide derivative","3.4.21.117","(R)-2-(6-(5-chloro-2-methoxybenzyl)-3-(2,2-dimethylhydrazono)-7-oxo-1,4-diazepan-1-yl)-N-(3-(methylsulfonyl)phenyl)acetamide",
,,,,,"CHLORIDE ION",
"1DFP",,"1DFP","FACTOR D INHIBITED BY DIISOPROPYL FLUOROPHOSPHATE","3.4.21.46","DIISOPROPYL PHOSPHONATE",
"1DIC",,"1DIC","STRUCTURE OF 3,4-DICHLOROISOCOUMARIN-INHIBITED FACTOR D","3.4.21.46","3,4-DICHLOROISOCOUMARIN",
,,,,,"OXYGEN ATOM",
"1DLE",,"1DLE","FACTOR B SERINE PROTEASE DOMAIN","3.4.21.47",
"1DS2",,"1DS2","CRYSTAL STRUCTURE OF SGPB:OMTKY3-COO-LEU18I","3.4.21.81",
,,,,,
"1DSU",,"1DSU","HUMAN FACTOR D, COMPLEMENT ACTIVATING ENZYME","3.4.21.46",
"1EJA",,"1EJA","STRUCTURE OF PORCINE TRYPSIN COMPLEXED WITH BDELLASTASIN, AN ANTISTASIN-TYPE INHIBITOR","3.4.21.4","SODIUM ION",
,,,,,,
"1EKB",,"1EKB","THE SERINE PROTEASE DOMAIN OF ENTEROPEPTIDASE BOUND TO INHIBITOR VAL-ASP-ASP-ASP-ASP-LYS-CHLOROMETHANE","3.4.21.9","ZINC ION",
,,,,"3.4.21.9",,
,,,,,,
"1F13",,"1F13","RECOMBINANT HUMAN CELLULAR COAGULATION FACTOR XIII","2.3.2.13",
"1EP5",,"1EP5","CRYSTAL STRUCTURE OF THE CONSERVED CORE DOMAIN OF VENEZUALAN EQUINE ENCEPHALITIS CAPSID PROTEIN","3.4.21","UREA",
,,,,"3.4.21.90","SULFATE ION",
"1EUF",,"1EUF","BOVINE DUODENASE(NEW SERINE PROTEASE), CRYSTAL STRUCTURE","3.4.21","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"PHOSPHATE ION",
"6E5M",,"6E5M","Crystallographic structure of the cyclic nonapeptide derived from the BTCI inhibitor bound to beta-trypsin in space group P 32 2 1","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"6DWF",,"6DWF","Crystal structure of complex of BBKI mutant, L55R with Bovine Trypsin","3.4.21.4",
,,,,,
"6DWH",,"6DWH","Crystal structure of complex of BBKI and Bovine Trypsin","3.4.21.4","SODIUM ION",
,,,,,"CHLORIDE ION",
"6EAT",,"6EAT","Crystallographic structure of the cyclic nonapeptide derived from the BTCI inhibitor bound to beta-trypsin in space group P 21 21 21.","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"7LPR",,"7LPR","STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS","3.4.21.12","SULFATE ION",
,,,,,,
"1A5I",,"1A5I","CATALYTIC DOMAIN OF VAMPIRE BAT (DESMODUS ROTUNDUS) SALIVA PLASMINOGEN ACTIVATOR IN COMPLEX WITH EGR-CMK (GLU-GLY-ARG CHLOROMETHYL KETONE)","3.4.21.68","L-alpha-glutamyl-N-{(1S)-4-{[amino(iminio)methyl]amino}-1-[(1S)-2-chloro-1-hydroxyethyl]butyl}glycinamide",
"1AB9",,"1AB9","CRYSTAL STRUCTURE OF BOVINE GAMMA-CHYMOTRYPSIN","3.4.21.1","SULFATE ION",
,,,,"3.4.21.1",,
,,,,"3.4.21.1",,
,,,,,,
"1AFQ",,"1AFQ","CRYSTAL STRUCTURE OF BOVINE GAMMA-CHYMOTRYPSIN COMPLEXED WITH A SYNTHETIC INHIBITOR","3.4.21.1","D-leucyl-N-(4-fluorobenzyl)-L-phenylalaninamide",
,,,,"3.4.21.1","SULFATE ION",
,,,,"3.4.21.1",,
"1AN1",,"1AN1","LEECH-DERIVED TRYPTASE INHIBITOR/TRYPSIN COMPLEX","3.4.21.4","CALCIUM ION",
,,,,"3.4.21.4",,
"1AO5",,"1AO5","MOUSE GLANDULAR KALLIKREIN-13 (PRORENIN CONVERTING ENZYME)","3.4.21.35",
,,,,"3.4.21.119",
"1AVX",,"1AVX","COMPLEX PORCINE PANCREATIC TRYPSIN/SOYBEAN TRYPSIN INHIBITOR, TETRAGONAL CRYSTAL FORM","3.4.21.4","CALCIUM ION",
,,,,,,
"1AVW",,"1AVW","COMPLEX PORCINE PANCREATIC TRYPSIN/SOYBEAN TRYPSIN INHIBITOR, ORTHORHOMBIC CRYSTAL FORM","3.4.21.4","CALCIUM ION",
,,,,,,
"1SLX",,"1SLX","RAT ANIONIC N143H, E151H TRYPSIN COMPLEXED TO A86H ECOTIN; ZINC-BOUND",,"CALCIUM ION",
,,,,"3.4.21.4","ACETATE ION",
,,,,,"ZINC ION",
"1SLW",,"1SLW","RAT ANIONIC N143H, E151H TRYPSIN COMPLEXED TO A86H ECOTIN; NICKEL-BOUND",,"CALCIUM ION",
,,,,"3.4.21.4","ACETATE ION",
,,,,,"NICKEL (II) ION",
"1SLV",,"1SLV","RAT ANIONIC N143H, E151H TRYPSIN COMPLEXED TO A86H ECOTIN; COPPER-BOUND",,"CALCIUM ION",
,,,,"3.4.21.4","ACETATE ION",
,,,,,"COPPER (II) ION",
"1SLU",,"1SLU","RAT ANIONIC N143H, E151H TRYPSIN COMPLEXED TO A86H ECOTIN",,"CALCIUM ION",
,,,,"3.4.21.4","ACETATE ION",
"1TLD",,"1TLD","CRYSTAL STRUCTURE OF BOVINE BETA-TRYPSIN AT 1.5 ANGSTROMS RESOLUTION IN A CRYSTAL FORM WITH LOW MOLECULAR PACKING DENSITY. ACTIVE SITE GEOMETRY, ION PAIRS AND SOLVENT STRUCTURE","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
"1TRN",,"1TRN","CRYSTAL STRUCTURE OF HUMAN TRYPSIN 1: UNEXPECTED PHOSPHORYLATION OF TYROSINE 151","3.4.21.4","PHOSPHORYLISOPROPANE",
"1YF4",,"1YF4","Crystal Structure of trypsin-vasopressin complex","3.4.21.4","CALCIUM ION",
,,,,,,
"1ZHR",,"1ZHR","Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with Benzamidine (S434A-T475A-C482S-K437A Mutant)","3.4.21.27","BENZAMIDINE",
"1ZPC","716","1ZPC","Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 2-[2-(3-Chloro-phenyl)-2-hydroxy-acetylamino]-N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-3-methyl-butyramide","3.4.21.27","SULFATE ION",
,,,,,"2-[2-(3-CHLORO-PHENYL)-2-HYDROXY-ACETYLAMINO]-N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]-3-METHYL-BUTYRAMIDE",
"1ZPB","995","1ZPB","Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 4-Methyl-pentanoic acid {1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-methyl-propyl}-amide","3.4.21.27","SULFATE ION",
,,,,,"4-METHYL-PENTANOIC ACID {1-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYLCARBAMOYL]-2-METHYL-PROPYL}-AMIDE",
"1ZPZ",,"1ZPZ","Factor XI catalytic domain complexed with N-((R)-1-(4-bromophenyl)ethyl)urea-Asn-Val-Arg-alpha-ketothiazole","3.4.21.27","SULFATE ION",
,,,,,"N~2~-({[(1R)-1-(4-BROMOPHENYL)ETHYL]AMINO}CARBONYL)ASPARAGINYL-N~1~-{4-{[AMINO(IMINO)METHYL]AMINO}-1-[2,3-DIHYDRO-1,3-THIAZOL-2-YL(HYDROXY)METHYL]BUTYL}VALINAMIDE",
"1ZRK",,"1ZRK","Factor XI complexed with 3-hydroxypropyl 3-(7-amidinonaphthalene-1-carboxamido)benzenesulfonate","3.4.21.27","SULFATE ION",
,,,,,"3-HYDROXYPROPYL 3-[({7-[AMINO(IMINO)METHYL]-1-NAPHTHYL}AMINO)CARBONYL]BENZENESULFONATE",
"1ZTJ",,"1ZTJ","Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 2-(5-Benzylamino-2-methylsulfanyl-6-oxo-6H-pyrimidin-1-yl)-N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-acetamide","3.4.21.27","SULFATE ION",
,,,,,"BICARBONATE ION",
,,,,,"2-(5-BENZYLAMINO-2-METHYLSULFANYL-6-OXO-6H-PYRIMIDIN-1-YL)-N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]-ACETAMIDE",
"1ZSK",,"1ZSK","Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 6-Carbamimidoyl-4-(3-hydroxy-2-methyl-benzoylamino)-naphthalene-2-carboxylic acid methyl ester","3.4.21.27","SULFATE ION",
,,,,,"BICARBONATE ION",
,,,,,"6-CARBAMIMIDOYL-4-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-NAPHTHALENE-2-CARBOXYLIC ACID METHYL ESTER",
"1ZSJ",,"1ZSJ","Crystal Structure of the Catalytic Domain of Coagulation Factor XI in complex with N-(7-Carbamimidoyl-naphthalen-1-yl)-3-hydroxy-2-methyl-benzamide","3.4.21.27","SULFATE ION",
,,,,,"BICARBONATE ION",
,,,,,"N-(7-CARBAMIMIDOYL-NAPHTHALEN-1-YL)-3-HYDROXY-2-METHYL-BENZAMIDE",
"1Z7K",,"1Z7K","Crystal Structure of Trypsin- Ovomucoid turkey egg white inhibitor complex","3.4.21.4",
,,,,,
,,,,,
"1P11",,"1P11","CRYSTAL STRUCTURES OF ALPHA-LYTIC PROTEASE COMPLEXES WITH IRREVERSIBLY BOUND PHOSPHONATE ESTERS","3.4.21.12","SULFATE ION",
,,,,,,
,,,,,,
"1OP0",,"1OP0","Crystal Structure of AaV-SP-I, a Glycosylated Snake Venom Serine Proteinase from Agkistrodon acutus","3.4.21","SULFATE ION",
"1OP2",,"1OP2","Crystal Structure of AaV-SP-II, a Glycosylated Snake Venom Serine Proteinase from Agkistrodon acutus","3.4.21","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"SULFATE ION",
"1P12",,"1P12","CRYSTAL STRUCTURES OF ALPHA-LYTIC PROTEASE COMPLEXES WITH IRREVERSIBLY BOUND PHOSPHONATE ESTERS","3.4.21.12","SULFATE ION",
,,,,,,
"1OXG",,"1OXG","Crystal structure of a complex formed between organic solvent treated bovine alpha-chymotrypsin and its autocatalytically produced highly potent 14-residue peptide at 2.2 resolution","3.4.21.1","SULFATE ION",
,,,,"3.4.21.1",,
"1Q31",,"1Q31","Crystal Structure of the Tobacco Etch Virus Protease C151A mutant","3.4.22.44","BETA-MERCAPTOETHANOL",
,,,,"3.4",,
,,,,"3.4.22.45",,
,,,,"3.6.4",,
,,,,"2.7.7.48",,
"1WDI",,"1WDI","Crystal Structure Of TT0907 From Thermus Thermophilus HB8","2.4.99.17","CITRIC ACID",
"1WQS",,"1WQS","Crystal structure of Norovirus 3C-like protease","2.7.7.48","MERCURY (II) ION",
,,,,"3.4.22.66","L(+)-TARTARIC ACID",
,,,,"3.6.1.15","D(-)-TARTARIC ACID",
"1X7A","187","1X7A","Porcine Factor IXa Complexed to 1-{3-[amino(imino)methyl]phenyl}-N-[4-(1H-benzimidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide","3.4.21.22","1-{3-[AMINO(IMINO)METHYL]PHENYL}-N-[4-(1H-BENZIMIDAZOL-1-YL)-2-FLUOROPHENYL]-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE",
,"187",,,"3.4.21.22",,
"1RFN",,"1RFN","HUMAN COAGULATION FACTOR IXA IN COMPLEX WITH P-AMINO BENZAMIDINE","3.4.21.22","CALCIUM ION",
,,,,"3.4.21.22","P-AMINO BENZAMIDINE",
,,,,,"TERTIARY-BUTYL ALCOHOL",
"1RS0",,"1RS0","Crystal Structure Analysis of the Bb segment of Factor B complexed with Di-isopropyl-phosphate (DIP)","3.4.21.47","IODIDE ION",
,,,,,"SODIUM ION",
,,,,,"MAGNESIUM ION",
,,,,,"DIISOPROPYL PHOSPHONATE",
"1RRK",,"1RRK","Crystal Structure Analysis of the Bb segment of Factor B","3.4.21.47","IODIDE ION",
,,,,,"SODIUM ION",
,,,,,"COBALT (II) ION",
"1RTK",,"1RTK","Crystal Structure Analysis of the Bb segment of Factor B complexed with 4-guanidinobenzoic acid","3.4.21.47","IODIDE ION",
,,,,,"SODIUM ION",
,,,,,"MAGNESIUM ION",
,,,,,"4-GUANIDINOBENZOIC ACID",
"1SDD",,"1SDD","Crystal Structure of Bovine Factor Vai",,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"CALCIUM ION",
,,,,,"COPPER (II) ION",
"1SFI",,"1SFI","High resolution structure of a potent, cyclic protease inhibitor from sunflower seeds","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
"1SGR",,"1SGR","LEU 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B","3.4.21.81","PHOSPHATE ION",
,,,,,,
"1SGQ",,"1SGQ","GLY 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B","3.4.21.81","PHOSPHATE ION",
,,,,,,
"1SGP",,"1SGP","ALA 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B","3.4.21.81","PHOSPHATE ION",
,,,,,,
"1H4W","BEN","1H4W","Structure of human trypsin IV (brain trypsin)","3.4.21.4","BENZAMIDINE",
,"BEN",,,,"CALCIUM ION",
"1HIA",,"1HIA","KALLIKREIN COMPLEXED WITH HIRUSTASIN","3.4.21.35",
,,,,"3.4.21.35",
,,,,,
"1LO6",,"1LO6","Human Kallikrein 6 (hK6) active form with benzamidine inhibitor at 1.56 A resolution","3.4.21","MAGNESIUM ION",
,,,,,"BENZAMIDINE",
"1LQE","IMA","1LQE","CRYSTAL STRUCTURE OF TRYPSIN IN COMPLEX WITH 79.","3.4.21.4","CALCIUM ION",
,"IMA",,,,"SULFATE ION",
,,,,,"[4-({[5-BENZYLOXY-1-(3-CARBAMIMIDOYL-BENZYL)-1H-INDOLE-2-CARBONYL]-AMINO}-METHYL)-PHENYL]-TRIMETHYL-AMMONIUM",
"1MD8",,"1MD8","Monomeric structure of the active catalytic domain of complement protease C1r","3.4.21.41",
"6TWC",,"6TWC","Crystal Structure of the Catalytic Domain of the Coagulation Factor XIa in Complex with Double Bridged Peptide F21","3.4.21.27","ACETONE",
,,,,"3.4.21.27",,
,,,,,,
"6VLV",,"6VLV","Factor XIa in complex with compound 11","3.4.21.27","CITRATE ANION",
,,,,,"1-carbamimidamido-4-chloro-N-[(2R)-3-methyl-1-(morpholin-4-yl)-1-oxobutan-2-yl]isoquinoline-7-sulfonamide",
"1K9O",,"1K9O","CRYSTAL STRUCTURE OF MICHAELIS SERPIN-TRYPSIN COMPLEX",
,,,,3.4.21.4,
"1KDQ",,"1KDQ","Crystal Structure Analysis of the Mutant S189D Rat Chymotrypsin","3.4.21.1","CALCIUM ION",
,,,,"3.4.21.1",,
"1KSN","FXV","1KSN","Crystal Structure of Human Coagulation Factor XA Complexed with FXV673","3.4.21.6","CALCIUM ION",
,"FXV",,,"3.4.21.6","METHYL-3-(4'-N-OXOPYRIDYLPHENOYL)-3-METHYL-2-(M-AMIDINOBENZYL)-PROPIONATE",
"1KXE",,"1KXE","SINDBIS VIRUS CAPSID (Y180S, E183G DOUBLE MUTANT), TETRAGONAL CRYSTAL FORM","3.4.21",
,,,,"3.4.21.90",
"1KXD",,"1KXD","SINDBIS VIRUS CAPSID (N222L MUTANT), TETRAGONAL CRYSTAL FORM","3.4.21",
,,,,"3.4.21.90",
"1KXC",,"1KXC","SINDBIS VIRUS CAPSID (N190K MUTANT), TETRAGONAL CRYSTAL FORM","3.4.21",
,,,,"3.4.21.90",
"1KXB",,"1KXB","SINDBIS VIRUS CAPSID (S215A MUTANT), TETRAGONAL CRYSTAL FORM","3.4.21",
,,,,"3.4.21.90",
"1KXA",,"1KXA","SINDBIS VIRUS CAPSID, (WILD-TYPE) RESIDUES 106-264, TETRAGONAL CRYSTAL FORM","3.4.21",
,,,,"3.4.21.90",
"1KXF",,"1KXF","SINDBIS VIRUS CAPSID, (WILD-TYPE) RESIDUES 1-264, TETRAGONAL CRYSTAL FORM (FORM II)","3.4.21",
,,,,"3.4.21.90",
"1LDT",,"1LDT","COMPLEX OF LEECH-DERIVED TRYPTASE INHIBITOR WITH PORCINE TRYPSIN","3.4.21.4","CALCIUM ION",
,,,,,,
"1C2G",,"1C2G","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.4","CALCIUM ION",
,,,,,"MAGNESIUM ION",
,,,,,"ZINC ION",
,,,,,"BIS(5-AMIDINO-2-BENZIMIDAZOLYL)METHANE KETONE HYDRATE",
,,,,,"DIMETHYL SULFOXIDE",
"1C2F",,"1C2F","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.4","CALCIUM ION",
,,,,,"MAGNESIUM ION",
,,,,,"ZINC ION",
,,,,,"BIS(5-AMIDINO-2-BENZIMIDAZOLYL)METHANE KETONE HYDRATE",
,,,,,"DIMETHYL SULFOXIDE",
"1C2I",,"1C2I","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.4","CALCIUM ION",
,,,,,"CHLORIDE ION",
,,,,,"ZINC ION",
,,,,,"BIS(5-AMIDINO-2-BENZIMIDAZOLYL)METHANE KETONE",
,,,,,"DIMETHYL SULFOXIDE",
"1C9T",,"1C9T","COMPLEX OF BDELLASTASIN WITH BOVINE TRYPSIN","3.4.21.4",
,,,,,
"1C9P",,"1C9P","COMPLEX OF BDELLASTASIN WITH PORCINE TRYPSIN","3.4.21.4","CALCIUM ION",
,,,,,,
"1CHO",,"1CHO","CRYSTAL AND MOLECULAR STRUCTURES OF THE COMPLEX OF ALPHA-*CHYMOTRYPSIN WITH ITS INHIBITOR TURKEY OVOMUCOID THIRD DOMAIN AT 1.8 ANGSTROMS RESOLUTION","3.4.21.1",
,,,,"3.4.21.1",
,,,,"3.4.21.1",
,,,,,
"1D6R",,"1D6R","CRYSTAL STRUCTURE OF CANCER CHEMOPREVENTIVE BOWMAN-BIRK INHIBITOR IN TERNARY COMPLEX WITH BOVINE TRYPSIN AT 2.3 A RESOLUTION. STRUCTURAL BASIS OF JANUS-FACED SERINE PROTEASE INHIBITOR SPECIFICITY","3.4.21.4",
,,,,,
"9LPR",,"9LPR","STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS","3.4.21.12","SULFATE ION",
,,,,,,
"6Y4S",,"6Y4S","Human kallikrein-related peptidase 7 (KLK7) in the unliganded state","3.4.21.117","TRIETHYLENE GLYCOL",
,,,,,"SULFATE ION",
"1TX6",,"1TX6","trypsin:BBI complex","3.4.21.4","CALCIUM ION",
,,,,,,
"1C1R","BAI","1C1R","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.4","CALCIUM ION",
,"BAI",,,,"MAGNESIUM ION",
,,,,,"SULFATE ION",
,,,,,"ZINC ION",
,,,,,"(5-AMIDINO-2-BENZIMIDAZOLYL)(2-BENZIMIDAZOLYL)METHANE",
,,,,,"DIMETHYL SULFOXIDE",
"1C1P",,"1C1P","RECRUITING ZINC TO MEDIATE POTENT, SPECIFIC INHIBITION OF SERINE PROTEASES","3.4.21.4","CALCIUM ION",
,,,,,"MAGNESIUM ION",
,,,,,"SULFATE ION",
,,,,,"(5-AMIDINO-2-BENZIMIDAZOLYL)(2-BENZIMIDAZOLYL)METHANE",
,,,,,"DIMETHYL SULFOXIDE",
"1PYT",,"1PYT","TERNARY COMPLEX OF PROCARBOXYPEPTIDASE A, PROPROTEINASE E, AND CHYMOTRYPSINOGEN C","3.4.17.1","ZINC ION",
,,,,"3.4.17.1","CALCIUM ION",
,,,,,,
,,,,"3.4.21.2",,
"6I42",,"6I42","Structure of the alpha-Synuclein PreNAC/Cyclophilin A-complex","5.2.1.8",
,,,,,
"2HI9",,"2HI9","Crystal Structure of human native protein C inhibitor",,"CITRIC ACID",
,,,,,"GLYCEROL",
"5NDD",,"5NDD","Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in complex with AZ8838 at 2.8 angstrom resolution","3.2.1.17","(~{S})-(4-fluoranyl-2-propyl-phenyl)-(1~{H}-imidazol-2-yl)methanol",
,,,,,"SODIUM ION",
,,,,,"PHOSPHATE ION",
"5NDZ",,"5NDZ","Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in complex with AZ3451 at 3.6 angstrom resolution","3.2.1.17","2-(6-bromanyl-1,3-benzodioxol-5-yl)-~{N}-(4-cyanophenyl)-1-[(1~{S})-1-cyclohexylethyl]benzimidazole-5-carboxamide",
,,,,,"SODIUM ION",
"2HVX","DRX","2HVX","Discovery of Potent, Orally Active, Nonpeptide Inhibitors of Human Mast Cell Chymase by Using Structure-Based Drug Design","3.4.21.39","[(1S)-1-(5-CHLORO-1-BENZOTHIEN-3-YL)-2-(2-NAPHTHYLAMINO)-2-OXOETHYL]PHOSPHONIC ACID",
,"DRX",,,,,
,"DRX",,,,,
"2IOT",,"2IOT","Clavulanic Acid bound to Elastase","3.4.21.36","SULFATE ION",
,,,,,"N-(3-OXOPROPYL)GLYCINE",
"2J38","GS5","2J38","CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX","3.4.21.6","5-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1-BENZOTHIOPHENE-2-SULFONAMIDE",
,"GS5",,,"3.4.21.6","CALCIUM ION",
"2J34","GS6","2J34","CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX","3.4.21.6","6-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1-BENZOTHIOPHENE-2-SULFONAMIDE",
,"GS6",,,"3.4.21.6","CALCIUM ION",
,"GS6",,,,,
"2J4I","GSJ","2J4I","CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX","3.4.21.6","1-PYRROLIDINEACETAMIDE, 3-[[(6-CHLORO-2-NAPHTHALENYL)SULFONYL]AMINO]-ALPHA-METHYL-N-(1-METHYLETHYL)-N-[2-[(METHYLSULFONYL)AMINO]ETHYL]-2-OXO-, (ALPHAS,3S)-",
,"GSJ",,,"3.4.21.6","CALCIUM ION",
,"GSJ",,,,,
"2J95","GSX","2J95","CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX","3.4.21.6","5'-CHLORO-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-2,2'-BITHIOPHENE-5-SULFONAMIDE",
,"GSX",,,"3.4.21.6","CALCIUM ION",
,"GSX",,,,,
"2J94","G15","2J94","CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX","3.4.21.6","5-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}-1H-1,2,4-TRIAZOLE-3-SULFONAMIDE",
,"G15",,,"3.4.21.6","CALCIUM ION",
"2EI6","D92","2EI6","FACTOR XA IN COMPLEX WITH THE INHIBITOR (-)-cis-N1-[(5-Chloroindol-2-yl)carbonyl]-N2-[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine","3.4.21.6","CALCIUM ION",
,"D92",,,"3.4.21.6","N-((1R,2S)-2-(5-CHLORO-1H-INDOLE-2-CARBOXAMIDO)CYCLOHEXYL)-5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXAMIDE",
,"D92",,,,,
,"D92",,,,,
"2JKH","BI7","2JKH","Factor Xa - cation inhibitor complex","3.4.21.6","3-[(3~{a}~{S},4~{R},8~{a}~{S},8~{b}~{R})-4-[5-(5-chloranylthiophen-2-yl)-1,2-oxazol-3-yl]-1,3-bis(oxidanylidene)-4,6,7,8,8~{a},8~{b}-hexahydro-3~{a}~{H}-pyrrolo[3,4-a]pyrrolizin-2-yl]propyl-trimethyl-azanium",
,"BI7",,,"3.4.21.6","CALCIUM ION",
,,,,,"SODIUM ION",
"2P3F",,"2P3F","Crystal structure of the factor Xa/NAP5 complex","3.4.21.6","SODIUM ION",
,,,,"3.4.21.6",,
,,,,,,
"2P3U",,"2P3U","Crystal structure of human factor XA complexed with 3-chloro-N-(4-chloro-2-{[(5-chloropyridin-2-yl)amino]carbonyl}-6-methoxyphenyl)-4-[(1-methyl-1H-imidazol-2-yl)methyl]thiophene-2-carboxamide {Pfizer 320663}","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","3-CHLORO-N-(4-CHLORO-2-{[(5-CHLOROPYRIDIN-2-YL)AMINO]CARBONYL}-6-METHOXYPHENYL)-4-[(1-METHYL-1H-IMIDAZOL-2-YL)METHYL]THIOPHENE-2-CARBOXAMIDE",
"2P95","ME5","2P95","Factor xa in complex with the inhibitor 5-chloro-N-((1R,2S)-2-(4-(2-oxopyridin-1(2H)-YL)benzamido) cyclopentyl)thiophene-2-carboxamide","3.4.21.6","5-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO) CYCLOPENTYL)THIOPHENE-2-CARBOXAMIDE",
,"ME5",,,"3.4.21.6",,
,"ME5",,,,,
"2P93","ME1","2P93","Factor xa in complex with the inhibitor 5-chloro-N-(2-(4-(2-oxopyridin-1(2H)-yl)benzamido)ethyl)thiophene-2-carboxamide","3.4.21.6","5-CHLORO-N-(2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)ETHYL)THIOPHENE-2-CARBOXAMIDE",
,"ME1",,,"3.4.21.6",,
,"ME1",,,,,
"2PHB","230","2PHB","An Orally Efficacious Factor Xa Inhibitor","3.4.21.6","CALCIUM ION",
,"230",,,"3.4.21.6","(2R,4R)-N~1~-(4-CHLOROPHENYL)-N~2~-[2-FLUORO-4-(2-OXOPYRIDIN-1(2H)-YL)PHENYL]-4-METHOXYPYRROLIDINE-1,2-DICARBOXAMIDE",
,"230",,,,,
,"230",,,,,
"2Q1J","FXI","2Q1J","The discovery of glycine and related amino acid-based factor xa inhibitors","3.4.21.6","CALCIUM ION",
,"FXI",,,"3.4.21.6","1-(butyl{[(4-chlorophenyl)amino]carbonyl}amino)-N-[3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]cyclopropanecarboxamide",
"2PR3","237","2PR3","Factor XA inhibitor","3.4.21.6","CALCIUM ION",
,"237",,,"3.4.21.6","(2R,4R)-N~1~-(4-CHLOROPHENYL)-N~2~-[3-FLUORO-2'-(METHYLSULFONYL)BIPHENYL-4-YL]-4-METHOXYPYRROLIDINE-1,2-DICARBOXAMIDE",
,"237",,,,,
"2Q6F","3IH","2Q6F","Crystal structure of infectious bronchitis virus (IBV) main protease in complex with a Michael acceptor inhibitor N3","3.4.22",
,,,,,
"2H9E",,"2H9E","Crystal Structure of FXa/selectide/NAPC2 ternary complex","3.4.21.6","PHOSPHATE ION",
,,,,"3.4.21.6","ACETATE ION",
,,,,,"SODIUM ION",
,,,,,,
"2GV7","672","2GV7","Structure of Matriptase in Complex with Inhibitor CJ-672","3.4.21","(S)-4-(4-(3-(3-CARBAMIMIDOYLPHENYL)-2-(2,4,6-TRIISOPROPYLPHENYLSULFONAMIDO)PROPANOYL)PIPERAZINE-1-CARBONYL)PIPERIDINE-1-CARBOXIMIDAMIDE",
,"672",,,"3.4.21.109",,
,"672",,,,,
,"672",,,,,
"2GV6","730","2GV6","Crystal Structure of Matriptase with Inhibitor CJ-730","3.4.21","(S)-3-(3-(4-(2-GUANIDINOETHYL)PIPERIDIN-1-YL)-2-(NAPHTHALENE-2-SULFONAMIDO)-3-OXOPROPYL)BENZIMIDAMIDE",
,"730",,,"3.4.21.109",,
"2QXJ",,"2QXJ","Crystal Structure of Human Kallikrein 7 in Complex with Suc-Ala-Ala-Pro-Phe-chloromethylketone and Copper","3.4.21.117","COPPER (II) ION",
,,,,,"N-(3-carboxypropanoyl)-L-alanyl-L-alanyl-N-[(2S,3S)-4-chloro-3-hydroxy-1-phenylbutan-2-yl]-L-prolinamide",
"2QXI",,"2QXI","High resolution structure of Human Kallikrein 7 in Complex with Suc-Ala-Ala-Pro-Phe-chloromethylketone","3.4.21.117","N-(3-carboxypropanoyl)-L-alanyl-L-alanyl-N-[(2S,3S)-4-chloro-3-hydroxy-1-phenylbutan-2-yl]-L-prolinamide",
"2QXH",,"2QXH","Crystal Structure of Human Kallikrein 7 in Complex with Suc-Ala-Ala-Pro-Phe-chloromethylketone","3.4.21.117","N-(3-carboxypropanoyl)-L-alanyl-L-alanyl-N-[(2S,3S)-4-chloro-3-hydroxy-1-phenylbutan-2-yl]-L-prolinamide",
"2QXG",,"2QXG","Crystal Structure of Human Kallikrein 7 in Complex with Ala-Ala-Phe-chloromethylketone","3.4.21.117","L-alanyl-N-[(1S,2R)-1-benzyl-2-hydroxypropyl]-L-alaninamide",
"2RA0","JNJ","2RA0","X-ray Structure of FXa in complex with 7-fluoroindazole","3.4.21.6","1-(3-amino-1,2-benzisoxazol-5-yl)-6-(4-{2-[(dimethylamino)methyl]-1H-imidazol-1-yl}-2-fluorophenyl)-7-fluoro-1H-indazole-3-carboxamide",
,"JNJ",,,"3.4.21.6",,
,"JNJ",,,,,
"2EY4",,"2EY4","Crystal Structure of a Cbf5-Nop10-Gar1 Complex","5.4.99","ZINC ION",
,,,,"5.4.99.25",,
,,,,,,
,,,,,,
"2F9O",,"2F9O","Crystal Structure of the Recombinant Human Alpha I Tryptase Mutant D216G","3.4.21.59",
"1XXF",,"1XXF","Crystal Structure of the FXIa Catalytic Domain in Complex with Ecotin Mutant (EcotinP)","3.4.21.27","SODIUM ION",
,,,,,,
"1XXD",,"1XXD","Crystal Structure of the FXIa Catalytic Domain in Complex with mutated Ecotin","3.4.21.27",
,,,,,
"1YBW",,"1YBW","Protease domain of HGFA with no inhibitor","3.4.21","2-acetamido-2-deoxy-beta-D-glucopyranose",
"2O8W","PL0","2O8W","Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q/S195A) in complex with Inhibitors","3.4.21.73","SULFATE ION",
,"PL0",,,,"TETRAETHYLENE GLYCOL",
,"PL0",,,,"1-phenylguanidine",
"2O8U",,"2O8U","Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q/S195A) in complex with Inhibitors","3.4.21.73","SULFATE ION",
,,,,,"BENZAMIDINE",
,,,,,"TETRAETHYLENE GLYCOL",
,,,,,"DI(HYDROXYETHYL)ETHER",
"2O8T",,"2O8T","Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q) in complex with Inhibitors","3.4.21.73","SULFATE ION",
,,,,,"PENTAETHYLENE GLYCOL",
,,,,,"DI(HYDROXYETHYL)ETHER",
"2ODQ",,"2ODQ","Complement component C2a, the catalytic fragment of C3- and C5-convertase of human complement","3.4.21.43","2-acetamido-2-deoxy-beta-D-glucopyranose",
"2ODP",,"2ODP","Complement component C2a, the catalytic fragment of C3- and C5-convertase of human complement","3.4.21.43","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"MAGNESIUM ION",
"2P16","GG2","2P16","Factor Xa in Complex with the Inhibitor APIXABAN (BMS-562247) AKA 1-(4-METHOXYPHENYL)-7-OXO-6-(4-(2-OXO-1-PIPERIDINYL)PHENYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3, 4-C]PYRIDINE-3-CARBOXAMIDE","3.4.21.6","CALCIUM ION",
,"GG2",,,"3.4.21.6","1-(4-METHOXYPHENYL)-7-OXO-6-[4-(2-OXOPIPERIDIN-1-YL)PHENYL]-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDINE-3-CARBOXAMIDE",
,"GG2",,,,,
,"GG2",,,,,
,"GG2",,,,,
,"GG2",,,,,
,"GG2",,,,,
,"GG2",,,,,
,"GG2",,,,,
,"GG2",,,,,
,"GG2",,,,,
,"GG2",,,,,
"2RFK",,"2RFK","Substrate RNA Positioning in the Archaeal H/ACA Ribonucleoprotein Complex",,"ZINC ION",
,,,,,,
,,,,,,
,,,,"5.4.99",,
,,,,"5.4.99.25",,
,,,,,,
,,,,,,
"3VFE",,"3VFE","Virtual Screening and X-Ray Crystallography for Human Kallikrein 6 Inhibitors with an Amidinothiophene P1 Group","3.4.21","4-{[(3R)-3-{[(7-methoxynaphthalen-2-yl)sulfonyl](thiophen-3-ylmethyl)amino}-2-oxopyrrolidin-1-yl]methyl}thiophene-2-carboximidamide",
"3DGV",,"3DGV","Crystal structure of thrombin activatable fibrinolysis inhibitor (TAFI)","3.4.17.20","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,"ZINC ION",
,,,,,"SULFATE ION",
,,,,,"MALONATE ION",
"4AFQ",,"4AFQ","Human Chymase - Fynomer Complex","3.4.21.39","CITRATE ANION",
,,,,,"3-[(3-CHOLAMIDOPROPYL)DIMETHYLAMMONIO]-1-PROPANESULFONATE",
"4AFU",,"4AFU","Human Chymase - Fynomer Complex","3.4.21.39",
,,,,,
"4AG1",,"4AG1","Human Chymase - Fynomer Complex","3.4.21.39","SULFATE ION",
,,,,,,
"4AFZ",,"4AFZ","Human Chymase - Fynomer Complex","3.4.21.39","D(-)-TARTARIC ACID",
,,,,,,
"4ACA",,"4ACA","CRYSTAL STRUCTURE OF TRANSLATION ELONGATION FACTOR SELB FROM METHANOCOCCUS MARIPALUDIS, APO FORM",,"SULFATE ION",
,,,,,"(3ALPHA,5BETA,12ALPHA)-3,12-DIHYDROXYCHOLAN-24-OIC ACID",
,,,,,"GUANOSINE-5'-MONOPHOSPHATE",
"4ACB",,"4ACB","CRYSTAL STRUCTURE OF TRANSLATION ELONGATION FACTOR SELB FROM METHANOCOCCUS MARIPALUDIS IN COMPLEX WITH THE GTP ANALOGUE GPPNHP",,"PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",
,,,,,"MAGNESIUM ION",
,,,,,"GUANOSINE-5'-DIPHOSPHATE",
,,,,,"SULFATE ION",
,,,,,"(3ALPHA,5BETA,12ALPHA)-3,12-DIHYDROXYCHOLAN-24-OIC ACID",
,,,,,"GUANOSINE-5'-MONOPHOSPHATE",
"4AC9",,"4AC9","CRYSTAL STRUCTURE OF TRANSLATION ELONGATION FACTOR SELB FROM METHANOCOCCUS MARIPALUDIS IN COMPLEX WITH GDP",,"GUANOSINE-5'-DIPHOSPHATE",
,,,,,"MAGNESIUM ION",
,,,,,"SULFATE ION",
,,,,,"(3ALPHA,5BETA,12ALPHA)-3,12-DIHYDROXYCHOLAN-24-OIC ACID",
,,,,,"GUANOSINE-5'-MONOPHOSPHATE",
"3KGP","4AZ","3KGP","Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic Acid and 4-(Aminomethyl-phenyl)-methanol","3.4.21.73","4-(aminomethyl)benzoic acid",
,,,,,"SULFATE ION",
"3KID","2BS","3KID","The Crystal Structures of 2-Aminobenzothiazole-based Inhibitors in Complexes with Urokinase-type Plasminogen Activator","3.4.21.73","ethyl 2-amino-1,3-benzothiazole-6-carboxylate",
"3KHV","4AL","3KHV","Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic Acid and 4-(Aminomethyl-phenyl)-methanol","3.4.21.73","[4-(aminomethyl)phenyl]methanol",
,,,,,"SULFATE ION",
,,,,,"TRIETHYLENE GLYCOL",
"3KL6","443","3KL6","Discovery of Tetrahydropyrimidin-2(1H)-one derivative TAK-442: A potent, selective and orally active factor Xa inhibitor","3.4.21.6","1-(1-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}piperidin-4-yl)tetrahydropyrimidin-2(1H)-one",
,"443",,,"3.4.21.6","1,2-ETHANEDIOL",
,"443",,,,"CALCIUM ION",
,"443",,,,,
,"443",,,,,
"3LC3","IYX","3LC3","Benzothiophene Inhibitors of Factor IXa","3.4.21.22","1-[5-(3,4-dimethoxyphenyl)-1-benzothiophen-2-yl]methanediamine",
,"IYX",,,"3.4.21.22","CALCIUM ION",
"3LC5","IZX","3LC5","Selective Benzothiophine Inhibitors of Factor IXa","3.4.21.22","CALCIUM ION",
,,,,"3.4.21.22","1-{4-[(R)-phenyl(3-phenyl-1,2,4-oxadiazol-5-yl)methoxy]-1-benzothiophen-2-yl}methanediamine",
"3LIW","RUP","3LIW","Factor XA in complex with (R)-2-(1-ADAMANTYLCARBAMOYLAMINO)-3-(3-CARBAMIDOYL-PHENYL)-N-PHENETHYL-PROPIONIC ACID AMIDE","3.4.21.6","CALCIUM ION",
,"RUP",,,"3.4.21.6","(R)-2-(3-ADAMANTAN-1-YL-UREIDO)-3-(3-CARBAMIMIDOYL-PHENYL)-N-PHENETHYL-PROPIONAMIDE",
"4DJZ",,"4DJZ","Catalytic fragment of masp-1 in complex with its specific inhibitor developed by directed evolution on sgci scaffold","3.4.21",
,,,,"3.4.21",
,,,,,
"4DOQ",,"4DOQ","Crystal structure of the complex of Porcine Pancreatic Trypsin with 1/2SLPI","3.4.21.4","3,6,9,12,15,18,21,24,27-NONAOXANONACOSANE-1,29-DIOL",
,,,,,"SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"HEXAETHYLENE GLYCOL",
"3MWI",,"3MWI","The complex crystal Structure of Urokianse and 5-nitro-1H-indole-2-amidine","3.4.21.73","5-nitro-1H-indole-2-carboximidamide",
,,,,,"SULFATE ION",
"3NCL",,"3NCL","Crystal Structure of MT-SP1 bound to Benzamidine Phosphonate Inhibitor","3.4.21.109","phenyl (4-carbamimidoylbenzyl)phosphonate",
,,,,,"FORMIC ACID",
"3NZI",,"3NZI","Substrate induced remodeling of the active site regulates HtrA1 activity","3.4.21",
,,,,,
"3P8G",,"3P8G","Crystal Structure of MT-SP1 in complex with benzamidine","3.4.21.109","SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"BENZAMIDINE",
,,,,,"GLUTATHIONE",
"4CR5","0TU","4CR5","Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design","3.4.21.27","6-chloroquinolin-2(1H)-one",
,"0TU",,,,"SULFATE ION",
,"0TU",,,,,
"4CR9","OTW","4CR9","Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design","3.4.21.27","4-methylquinoline-2,6-diamine",
,,,,,"SULFATE ION",
"4CRC","OTM","4CRC","Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design","3.4.21.27","(2S)-2-[[(E)-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]amino]-3-phenyl-N-[4-(1H-1,2,3,4-tetrazol-5-yl)phenyl]propanamide",
,"OTM",,,,"SULFATE ION",
"4CRD","OTJ","4CRD","Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design","3.4.21.27","Methyl N-[4-[5-chloro-2-[[3-[5-chloro-2-(tetrazol-1-yl)phenyl]propanoylamino]methyl]-1H-imidazol-4-yl]phenyl]carbamate",
,,,,,"SULFATE ION",
"4CRE",,"4CRE","Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design","3.4.21.27","6-chloro-4-methyl-1H-quinolin-2-one",
,,,,,"SULFATE ION",
"4D8N","0HM","4D8N","Human Kallikrein 6 Inhibitors with a para-Amidobenzylanmine P1 Group Carry a High Binding Efficiency","3.4.21","2-{[4-(aminomethyl)phenyl]carbamoyl}-1-[(1-benzyl-1H-imidazol-2-yl)methyl]-3-hydroxypyridinium",
,"0HM",,,,,
"2Y7X","MZA","2Y7X","The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs","3.4.21.6","6-CHLORO-N-[(3S)-1-(5-FLUORO-1,2,3,4-TETRAHYDROISOQUINOLIN-6-YL)-2-OXO-PYRROLIDIN-3-YL]NAPHTHALENE-2-SULFONAMIDE",
,"MZA",,,"3.4.21.6","CALCIUM ION",
,"MZA",,,,"MAGNESIUM ION",
"2Y7Z","C0Z","2Y7Z","Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs","3.4.21.6","6-CHLORO-N-[(3S)-1-[(1S)-1-DIMETHYLAMINO-2,3-DIHYDRO-1H-INDEN-5-YL]-2-OXO-PYRROLIDIN-3-YL]NAPHTHALENE-2-SULFONAMIDE",
,"C0Z",,,"3.4.21.6","CALCIUM ION",
,"C0Z",,,,"MAGNESIUM ION",
"2Y81","931","2Y81","Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs","3.4.21.6","6-CHLORO-N-((3S)-2-OXO-1-{4-[(2R)-2--PYRROLIDINYL] PHENYL}-3-PYRROLIDINYL)-2-NAPHTHALENESULFONAMIDE",
,"931",,,"3.4.21.6","CALCIUM ION",
,"931",,,,"MAGNESIUM ION",
"2Y82","930","2Y82","Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs","3.4.21.6","6-CHLORO-N-((3S)-2-OXO-1-{4-[(2S)-2-PYRROLIDINYL]PHENYL}-3-PYRROLIDINYL)-2-NAPHTHALENESULFONAMIDE",
,"930",,,"3.4.21.6","CALCIUM ION",
,"930",,,,"MAGNESIUM ION",
,"930",,,,,
"2VVC","LZF","2VVC","Aminopyrrolidine Factor Xa inhibitor","3.4.21.6","5-chloro-N-[(3S,4S)-1-(2-{[2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl]amino}-2-oxoethyl)-4-methoxypyrrolidin-3-yl]thiophene-2-carboxamide",
,"LZF",,,"3.4.21.6","CALCIUM ION",
,"LZF",,,,"SODIUM ION",
"2VWL","LZH","2VWL","Aminopyrrolidine Factor Xa inhibitor","3.4.21.6","5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID ((3R,5S)-1-{[2-FLUORO-4-(2-OXO-PYRIDIN-1-YL)-PHENYLCARBAMOYL]-METHYL}-5-HYDROXYMETHYL-PYRROLIDIN-3-YL)-AMIDE",
,"LZH",,,"3.4.21.6","CHLORIDE ION",
,,,,,"CALCIUM ION",
,,,,,"SODIUM ION",
"2VWM","LZI","2VWM","Aminopyrrolidine Factor Xa inhibitor","3.4.21.6","(4R)-4-{[(5-chlorothiophen-2-yl)carbonyl]amino}-N-(cyclopropylmethyl)-1-(2-{[2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl]amino}-2-oxoethyl)-L-prolinamide",
,"LZI",,,"3.4.21.6","SODIUM ION",
"2VWN","H25","2VWN","Aminopyrrolidine Factor Xa inhibitor","3.4.21.6","5-Chloro-thiophene-2-carboxylic acid ((3S,4S)-1-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-methyl}-4-hydroxy-pyrrolidin-3-yl)-amide",
,"H25",,,"3.4.21.6","CALCIUM ION",
,,,,,"SODIUM ION",
,,,,,"CHLORIDE ION",
"2VWO","LZG","2VWO","Aminopyrrolidine Factor Xa inhibitor","3.4.21.6","5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID ((3S,4S)-4-FLUORO- 1-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYLCARBAMOYL]-METHYL}-PYRROLIDIN-3-YL)-AMIDE",
,"LZG",,,"3.4.21.6","CALCIUM ION",
,,,,,"SODIUM ION",
,,,,,"CHLORIDE ION",
"2VVU","H22","2VVU","Aminopyrrolidine Factor Xa inhibitor","3.4.21.6","5-chloro-N-[(3R)-1-(2-{[2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl]amino}-2-oxoethyl)pyrrolidin-3-yl]thiophene-2-carboxamide",
,"H22",,,"3.4.21.6","CALCIUM ION",
,,,,,"SODIUM ION",
"2VVV","H21","2VVV","Aminopyrrolidine-related triazole Factor Xa inhibitor","3.4.21.6","5-chloro-N-[1-(2-{[2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl]amino}-2-oxoethyl)-1H-1,2,4-triazol-3-yl]thiophene-2-carboxamide",
,"H21",,,"3.4.21.6","CALCIUM ION",
,,,,,"SODIUM ION",
"2W26","RIV","2W26","Factor Xa in complex with BAY59-7939","3.4.21.6","5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide",
,"RIV",,,"3.4.21.6","CALCIUM ION",
,"RIV",,,,,
,"RIV",,,,,
,"RIV",,,,,
,"RIV",,,,,
,"RIV",,,,,
,"RIV",,,,,
,"RIV",,,,,
,"RIV",,,,,
,"RIV",,,,,
,"RIV",,,,,
,"RIV",,,,,
"2W3I","L1C","2W3I","Crystal Structure of FXa in complex with 4,4-disubstituted pyrrolidine-1,2-dicarboxamide inhibitor 2","3.4.21.6","CALCIUM ION",
,"L1C",,,"3.4.21.6","(2R,4S)-N^1^-(4-chlorophenyl)-4-(2,4-difluorophenyl)-4-hydroxy-N^2^-(2-oxo-2H-1,3'-bipyridin-6'-yl)pyrrolidine-1,2-dicarboxamide",
,"L1C",,,,,
,"L1C",,,,,
"2W3K","L1D","2W3K","Crystal Structure of FXa in complex with 4,4-disubstituted pyrrolidine-1,2-dicarboxamide inhibitor 1","3.4.21.6","(2R,4S)-N^1^-(4-chlorophenyl)-N^2^-[2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl]-4-hydroxy-4-phenylpyrrolidine-1,2-dicarboxamide",
,"L1D",,,"3.4.21.6","CALCIUM ION",
,"L1D",,,,,
"3QGJ",,"3QGJ","1.3A Structure of alpha-Lytic Protease Bound to Ac-AlaAlaPro-Alanal","3.4.21.12","1,2-ETHANEDIOL",
,,,,,"SULFATE ION",
,,,,,"trifluoroacetic acid",
"3CEN","FXA","3CEN","Factor XA in complex with the inhibitor N-(2-(((5-chloro-2-pyridinyl) amino)sulfonyl)phenyl)-4-(2-oxo-1(2H)-pyridinyl)benzamide","3.4.21.6","N-(2-(((5-CHLORO-2-PYRIDINYL)AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDE",
,"FXA",,,"3.4.21.6",,
,"FXA",,,,,
"3CS7","LG0","3CS7","FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(4-methoxyphenyl)-6-(4-(1-(pyrrolidin-1-ylmethyl)cyclopropyl)phenyl)-3-(trifluoromethyl)-5,6-dihydro-1H-pyrazolo[3,4-c]pyridin-7(4H)-one","3.4.21.6","CALCIUM ION",
,"LG0",,,"3.4.21.6","1-(4-methoxyphenyl)-6-(4-(1-(pyrrolidin-1-ylmethyl)cyclopropyl)phenyl)-3-(trifluoromethyl)-5,6-dihydro-1H-pyrazolo[3,4-c]pyridin-7(4H)-one",
,"LG0",,,,,
"3FFG","FFG","3FFG","Factor XA in complex with the inhibitor (R)-6-(2'-((3- HYDROXYPYRROLIDIN-1-YL)METHYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN- 7(4H)-ONE","3.4.21.6","(R)-6-(2'-((3-hydroxypyrrolidin-1-yl)methyl)biphenyl-4-yl)-1-(3-(5-oxo-4,5-dihydro-1h-1,2,4-triazol-3-yl)phenyl)-3-(trifluoromethyl)-5,6-dihydro-1h-pyrazolo[3,4-c]pyridin-7(4h)-one",
,"FFG",,,"3.4.21.6",,
,"FFG",,,,,
"3IIT","D14","3IIT","Factor XA in complex with a cis-1,2-diaminocyclohexane derivative","3.4.21.6","CALCIUM ION",
,"D14",,,"3.4.21.6","7-chloro-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-{[(5-methyl-5,6-dihydro-4H-pyrrolo[3,4-d][1,3]thiazol-2-yl)carbonyl]amino}cyclohexyl]isoquinoline-3-carboxamide",
,"D14",,,,,
"3MHW","ABV","3MHW","The complex crystal Structure of Urokianse and 2-Aminobenzothiazole","3.4.21.73","SULFATE ION",
,,,,,"1,3-benzothiazol-2-amine",
"3MMG",,"3MMG","Crystal structure of tobacco vein mottling virus protease","3.4","FORMIC ACID",
,,,,"3.4.22.45",,
,,,,"3.6.4",,
,,,,"3.4.22.44",,
,,,,"2.7.7.48",,
,,,,"3.4",,
,,,,"3.4.22.45",,
,,,,"3.6.4",,
,,,,"3.4.22.44",,
,,,,"2.7.7.48",,
"3MQK",,"3MQK","Cbf5-Nop10-Gar1 complex binding with 17mer RNA containing ACA trinucleotide","5.4.99",
,,,,"5.4.99.25",
,,,,,
,,,,,
,,,,,
,,,,,
"4FU7","1UP","4FU7","Crystal Structure of the Urokinase","3.4.21.73","SULFATE ION",
,"1UP",,,,"ACETATE ION",
,"1UP",,,,"2-[(7-carbamimidoyl-2-methoxynaphthalen-1-yl)oxy]acetamide",
"4H42","11E","4H42","Synthesis of a Weak Basic uPA Inhibitor and Crystal Structure of Complex with uPA","3.4.21.73","N-[(2-amino-1,3-benzothiazol-6-yl)carbonyl]glycine",
,,,,,"1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE",
"4K8Y",,"4K8Y","Atomic resolution crystal structures of Kallikrein-Related Peptidase 4 complexed with Sunflower Trypsin Inhibitor (SFTI-1)","3.4.21",
,,,,,
"4KEL",,"4KEL","Atomic resolution crystal structure of Kallikrein-Related Peptidase 4 complexed with a modified SFTI inhibitor FCQR(N)","3.4.21",
,,,,,
"4KKD",,"4KKD","The X-ray crystal structure of Mannose-binding lectin-associated serine proteinase-3 reveals the structural basis for enzyme inactivity associated with the 3MC syndrome","3.4.21","IMIDAZOLE",
"4KP0","KPK","4KP0","Crystal Structure of the human Chymase with TJK002","3.4.21.39","4-({1-[(4-methyl-1-benzothiophen-3-yl)methyl]-1H-benzimidazol-2-yl}sulfanyl)butanoic acid",
,"KPK",,,,,
"4R0I","3KM","4R0I","CRYSTAL STRUCTURE of MATRIPTASE in COMPLEX WITH INHIBITOR","3.4.21.109","3-({(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-[(naphthalen-2-ylsulfonyl)amino]-3-oxopropyl}oxy)benzenecarboximidamide",
,,,,"3.4.21.109",,
"3TJN",,"3TJN","HtrA1 catalytic domain, apo form","3.4.21",
"3TVJ",,"3TVJ","Catalytic fragment of MASP-2 in complex with its specific inhibitor developed by directed evolution on SGCI scaffold","3.4.21.104","SULFATE ION",
,,,,"3.4.21.104",,
,,,,,,
"4X6M","3Y3","4X6M","FACTOR XIA IN COMPLEX WITH THE INHIBITOR 1-{(1S)-1-[4-(3-amino-1H-indazol-6-yl)-5-chloro-1H-imidazol-2-yl]-2-phenylethyl}-3-[2-(aminomethyl)-5-chlorobenzyl]urea","3.4.21.27","1-{(1S)-1-[4-(3-amino-1H-indazol-6-yl)-5-chloro-1H-imidazol-2-yl]-2-phenylethyl}-3-[2-(aminomethyl)-5-chlorobenzyl]urea",
,"3Y3",,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"4X6N","3Y5","4X6N","FACTOR XIA IN COMPLEX WITH THE INHIBITOR 1-{(1S)-1-[4-(3-amino-1H-indazol-6-yl)-5-chloro-1H-imidazol-2-yl]-2-phenylethyl}-3-[5-chloro-2-(1H-tetrazol-1-yl)benzyl]urea","3.4.21.27","1-{(1S)-1-[4-(3-amino-1H-indazol-6-yl)-5-chloro-1H-imidazol-2-yl]-2-phenylethyl}-3-[5-chloro-2-(1H-tetrazol-1-yl)benzyl]urea",
,"3Y5",,,"3.4.21.27","SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"4X6O","3Y4","4X6O","FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl (4-{4-chloro-2-[(1S)-1-({3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]propanoyl}amino)-2-phenylethyl]-1H-imidazol-5-yl}phenyl)carbamate","3.4.21.27","methyl (4-{4-chloro-2-[(1S)-1-({3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]propanoyl}amino)-2-phenylethyl]-1H-imidazol-5-yl}phenyl)carbamate",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"4SGA",,"4SGA","STRUCTURES OF PRODUCT AND INHIBITOR COMPLEXES OF STREPTOMYCES GRISEUS PROTEASE A AT 1.8 ANGSTROMS RESOLUTION. A MODEL FOR SERINE PROTEASE CATALYSIS","3.4.21.80",
,,,,,
"4TY6","39D","4TY6","Factor XIa in complex with the inhibitor 4-{2-[(1S)-1-({[trans-4-(aminomethyl)cyclohexyl]carbonyl}amino)-2-phenylethyl]-1H-imidazol-4-yl}benzamide","3.4.21.27","4-{2-[(1S)-1-({[trans-4-(aminomethyl)cyclohexyl]carbonyl}amino)-2-phenylethyl]-1H-imidazol-4-yl}benzamide",
,,,,"3.4.21.27","SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"4TY7","39F","4TY7","Factor XIa in complex with the inhibitor (2S)-6-amino-N-{(1S)-1-[4-(3-amino-2H-indazol-6-yl)-5-chloro-1H-imidazol-2-yl]-2-phenylethyl}-2-ethylhexanamide","3.4.21.27","trans-N-{(1S)-1-[4-(3-amino-2H-indazol-6-yl)-5-chloro-1H-imidazol-2-yl]-2-phenylethyl}-4-(aminomethyl)cyclohexane-1-carboxamide",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"4K1E",,"4K1E","Atomic resolution crystal structures of Kallikrein-Related Peptidase 4 complexed with a modified SFTI inhibitor FCQR","3.4.21","(4S)-2-METHYL-2,4-PENTANEDIOL",
,,,,,"LITHIUM ION",
"3K2U",,"3K2U","Crystal structure of HGFA in complex with the allosteric inhibitory antibody Fab40","3.4.21",
,,,,"3.4.21",
,,,,,
,,,,,
"4EZA",,"4EZA","Crystal structure of the atypical phosphoinositide (aPI) binding domain of IQGAP2",
"3SGA",,"3SGA","STRUCTURES OF PRODUCT AND INHIBITOR COMPLEXES OF STREPTOMYCES GRISEUS PROTEASE A AT 1.8 ANGSTROMS RESOLUTION. A MODEL FOR SERINE PROTEASE CATALYSIS","3.4.21.80",
,,,,,
"2V0B",,"2V0B","SAD Structure solution porcine pancreatic elastase from a Selenate derivative","3.4.21.36","CALCIUM ION",
,,,,,"SELENATE ION",
"2VH6","GSV","2VH6","Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs","3.4.21.6","2-(5-chlorothiophen-2-yl)-N-{(3S)-1-[3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-2-oxopyrrolidin-3-yl}ethanesulfonamide",
,"GSV",,,"3.4.21.6",,
"2VH0","GSI","2VH0","Structure and property based design of factor Xa inhibitors:biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs","3.4.21.6","CALCIUM ION",
,"GSI",,,"3.4.21.6","MAGNESIUM ION",
,,,,,"2-(5-chlorothiophen-2-yl)-N-[(3S)-1-(4-{2-[(dimethylamino)methyl]-1H-imidazol-1-yl}-2-fluorophenyl)-2-oxopyrrolidin-3-yl]ethanesulfonamide",
"2WPM",,"2WPM","factor IXa superactive mutant, EGR-CMK inhibited","3.4.21.22","CALCIUM ION",
,,,,,,
,,,,"3.4.21.22",,
"2WUB",,"2WUB","Crystal structure of HGFA in complex with the allosteric non- inhibitory antibody Fab40.deltaTrp","3.4.21",
,,,,"3.4.21",
,,,,,
,,,,,
"2WYG","461","2WYG","Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs","3.4.21.6","(E)-2-(5-CHLOROTHIOPHEN-2-YL)-N-[(3S)-1-{4-[(1R)-1-(DIMETHYLAMINO)ETHYL]-2-FLUOROPHENYL}-2-OXOPYRROLIDIN-3-YL]ETHENESULFONAMIDE",
,"461",,,"3.4.21.6",,
,"461",,,,,
"2WYJ","898","2WYJ","Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs","3.4.21.6","(E)-2-(5-CHLOROTHIOPHEN-2-YL)-N-[(3S)-1-{4-[(1S)-1-(DIMETHYLAMINO)ETHYL]-2-FLUOROPHENYL}-2-OXOPYRROLIDIN-3-YL]ETHENESULFONAMIDE",
,"898",,,"3.4.21.6",,
,"898",,,,,
,"898",,,,,
"2XC5","OYJ","2XC5","Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor","3.4.21.6","(3R,4R)-1-METHANESULFONYL-PYRROLIDINE-3,4-DICARBOXYLIC ACID 3-[(4-CHLORO-3-FLUORO-PHENYL)-AMIDE] 4-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYL]-AMIDE}",
,"OYJ",,,"3.4.21.6","CALCIUM ION",
,,,,,"SODIUM ION",
"2XBV","XBV","2XBV","Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor","3.4.21.6","(3R,4R)-1-(2,2-DIFLUORO-ETHYL)-PYRROLIDINE-3,4-DICARBOXYLIC ACID 3-[(5-CHLORO-PYRIDIN-2-YL)-AMIDE]-4-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYL]-AMIDE}",
,"XBV",,,"3.4.21.6","CALCIUM ION",
,"XBV",,,,"SODIUM ION",
"2XBY",,"2XBY","Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor","3.4.21.6","(3R,4R)-1-METHYLCARBAMOYLMETHYL-PYRROLIDINE-3,4-DICARBOXYLIC ACID 3-[(4-CHLORO-PHENYL)-AMIDE] 4-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYL]-AMIDE}",
,,,,"3.4.21.6","CALCIUM ION",
,,,,,"SODIUM ION",
"2XC0","8NC","2XC0","Factor Xa in complex with a pyrrolidine-3,4-dicarboxylic acid inhibitor","3.4.21.6","(3R,4R)-1-METHANESULFONYL-PYRROLIDINE-3,4--DICARBOXYLIC ACID 3-[(3-FLUORO-4-METHOXY-PHENYL)-AMIDE] 4-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYL]-AMIDE}",
,"8NC",,,"3.4.21.6","CALCIUM ION",
,"8NC",,,,"SODIUM ION",
"2XRC",,"2XRC","Human complement factor I","3.4.21.45","CALCIUM ION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"2Y5F","XWG","2Y5F","FACTOR XA - CATION INHIBITOR COMPLEX","3.4.21.6","(3AS,4R,5S,8AS,8BR)-4-[5-(5-CHLOROTHIOPHEN-2-YL)-1,2-OXAZOL-3-YL]-2-[3-[1-(2-HYDROXYETHYL)PYRROLIDIN-1-IUM-1-YL]PROPYL]-4,6,7,8,8A,8B-HEXAHYDRO-3AH-PYRROLO[3,4-A]PYRROLIZINE-1,3-DIONE",
,"XWG",,,"3.4.21.6","SODIUM ION",
"2Y5G","FJD","2Y5G","FACTOR XA - CATION INHIBITOR COMPLEX","3.4.21.6","3-[(3AS,4R,5S,8AS,8BR)-4-[5-(5-CHLOROTHIOPHEN-2-YL)-1,3-OXAZOL-2-YL]-1,3-DIOXO-4,6,7,8,8A,8B-HEXAHYDRO-3AH-PYRROLO[3,4-A]PYRROLIZIN-2-YL]PROPYL-TRIMETHYL-AZANIUM",
,"FJD",,,"3.4.21.6","SODIUM ION",
"2Y5H","Y5H","2Y5H","FACTOR XA - CATION INHIBITOR COMPLEX","3.4.21.6","3-[(3AS,4R,5S,8AS,8BR)-4-[2-(5-CHLOROTHIOPHEN-2-YL)-1,3-OXAZOL-4-YL]-1,3-DIOXO-4,6,7,8,8A,8B-HEXAHYDRO-3AH-PYRROLO[3,4-A]PYRROLIZIN-2-YL]PROPYL-TRIMETHYL-AZANIUM",
,"Y5H",,,"3.4.21.6","SODIUM ION",
"2Y80","439","2Y80","Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs","3.4.21.6","6-CHLORO-N-{(3S)-1-[(1S)-1-(DIMETHYLAMINO)-2,3-DIHYDRO-1H-INDEN-5-YL]-2-OXO-3-PYRROLIDINYL}-2-NAPHTHALENESULFONAMIDE",
,"439",,,"3.4.21.6","CALCIUM ION",
,"439",,,,"MAGNESIUM ION",
,"439",,,,,
"2BOH","IIA","2BOH","Crystal structure of factor Xa in complex with compound ""1""","3.4.21.6","CALCIUM ION",
,"IIA",,,"3.4.21.6","1-{[5-(5-CHLORO-2-THIENYL)ISOXAZOL-3-YL]METHYL}-N-(1-ISOPROPYLPIPERIDIN-4-YL)-1H-INDOLE-2-CARBOXAMIDE",
,"IIA",,,,,
"2BQ7","IID","2BQ7","Crystal structure of factor Xa in complex with 43","3.4.21.6","N-(1-ISOPROPYLPIPERIDIN-4-YL)-1-(3-METHOXYBENZYL)-1H-INDOLE-2-CARBOXAMIDE",
,"IID",,,"3.4.21.6","CALCIUM ION",
,"IID",,,,,
"2BQ6","IIB","2BQ6","Crystal structure of factor Xa in complex with 21","3.4.21.6","CALCIUM ION",
,"IIB",,,"3.4.21.6","1-{[5-(5-CHLORO-2-THIENYL)ISOXAZOL-3-YL]METHYL}-3-CYANO-N-(1-ISOPROPYLPIPERIDIN-4-YL)-7-METHYL-1H-INDOLE-2-CARBOXAMIDE",
"2BQW","IIE","2BQW","CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND 45","3.4.21.6","CALCIUM ION",
,"IIE",,,"3.4.21.6","1-{2-[(4-CHLOROPHENYL)AMINO]-2-OXOETHYL}-N-(1-ISOPROPYLPIPERIDIN-4-YL)-1H-INDOLE-2-CARBOXAMIDE",
"1JIM",,"1JIM","STEREOSPECIFIC REACTION OF 3-METHOXY-4-CHLORO-7-AMINOISOCOUMARIN WITH CRYSTALLINE PORCINE PANCREATIC ELASTASE","3.4.21.36","SULFATE ION",
,,,,,"METHYL(2-ACETOXY-2-(2-CARBOXY-4-AMINO-PHENYL))ACETATE",
"1VCP",,"1VCP","SEMLIKI FOREST VIRUS CAPSID PROTEIN (CRYSTAL FORM I)","3.4.21.90","MERCURY (II) ION",
"1V3X","D76","1V3X","Factor Xa in complex with the inhibitor 1-[6-methyl-4,5,6,7-tetrahydrothiazolo(5,4-c)pyridin-2-yl] carbonyl-2-carbamoyl-4-(6-chloronaphth-2-ylsulphonyl)piperazine","3.4.21.6","CALCIUM ION",
,"D76",,,"3.4.21.6","(2R)-4-[(6-CHLORO-2-NAPHTHYL)SULFONYL]-1-[(5-METHYL-4,5,6,7-TETRAHYDRO[1,3]THIAZOLO[5,4-C]PYRIDIN-2-YL)CARBONYL]PIPERAZ
INE-2-CARBOXAMIDE",
,"D76",,,,,
"2BDI",,"2BDI","Human Kallikrein 4 complex with cobalt and p-aminobenzamidine","3.4.21","COBALT (II) ION",
,,,,,"P-AMINO BENZAMIDINE",
"1FDP",,"1FDP","PROENZYME OF HUMAN COMPLEMENT FACTOR D, RECOMBINANT PROFACTOR D","3.4.21.46",
"1FIZ",,"1FIZ","THREE DIMENSIONAL STRUCTURE OF BETA-ACROSIN FROM BOAR SPERMATOZOA","3.4.21.10","SULFATE ION",
,,,,"3.4.21.10","P-AMINO BENZAMIDINE",
"1FIW",,"1FIW","THREE-DIMENSIONAL STRUCTURE OF BETA-ACROSIN FROM RAM SPERMATOZOA","3.4.21.10","P-AMINO BENZAMIDINE",
,,,,"3.4.21.10",,
"2FZZ","5QC","2FZZ","Factor Xa in complex with the inhibitor 1-(3-amino-1,2-benzisoxazol-5-yl)-6-(2'-(((3r)-3-hydroxy-1-pyrrolidinyl)methyl)-4-biphenylyl)-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7h-pyrazolo[3,4-c]pyridin-7-one","3.4.21.6","1-(3-AMINO-1,2-BENZISOXAZOL-5-YL)-6-(2'-{[(3R)-3-HYDROXYPYRROLIDIN-1-YL]METHYL}BIPHENYL-4-YL)-3-(TRIFLUOROMETHYL)-1,4,5,6-TETRAHYDRO-7H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE",
,"5QC",,,"3.4.21.6",,
,"5QC",,,,,
"2D1J",,"2D1J","Factor Xa in complex with the inhibitor 2-[[4-[(5-chloroindol-2-yl)sulfonyl]piperazin-1-yl] carbonyl]thieno[3,2-b]pyridine n-oxide","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","2-({4-[(5-CHLORO-1H-INDOL-2-YL)SULFONYL]PIPERAZIN-1-YL}CARBONYL)THIENO[3,2-B]PYRIDINE 4-OXIDE",
"2CH6",,"2CH6","Crystal structure of human N-acetylglucosamine kinase in complex with ADP and glucose","2.7.1.59","ADENOSINE-5'-DIPHOSPHATE",
,,,,,"alpha-D-glucopyranose",
"4O97","NTX","4O97","Crystal structure of matriptase in complex with inhibitor","3.4.21.109","N-(trans-4-aminocyclohexyl)-3,5-bis[(3-carbamimidoylbenzyl)oxy]benzamide",
,"NTX",,,"3.4.21.109",,
"4O9V","NT4","4O9V","Crystal structure of matriptase in complex with inhibitor","3.4.21.109","N-(trans-4-aminocyclohexyl)-3,5-bis(4-carbamimidoylphenoxy)benzamide",
,"NT4",,,"3.4.21.109",,
"6JYP",,"6JYP","Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-[bis(azanyl)methylidene]-6-chloranyl-pyrazine-2-carboxamide","3.4.21.73","3-azanyl-5-(azepan-1-yl)-N-[bis(azanyl)methylidene]-6-chloranyl-pyrazine-2-carboxamide",
,,,,,"SULFATE ION",
"6JYQ",,"6JYQ","Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-2-yl)pyrazine-2-carboxamide","3.4.21.73","3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-2-yl)pyrazine-2-carboxamide",
,,,,,"SULFATE ION",
"6O1F",,"6O1F","Complex between soybean trypsin inhibitor beta1-tryptase and a humanized fab","3.4.21.59","1,2-ETHANEDIOL",
,,,,,,
,,,,,,
,,,,,,
"5TP0","BRN","5TP0","Human mesotrypsin in complex with diminazene","3.4.21.4","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"BERENIL",
"5TNO",,"5TNO","Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors","3.4.21.22","Unknown ligand",
,,,,"3.4.21.22","SODIUM ION",
,,,,,"2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID",
"5TNT","7GQ","5TNT","Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors","3.4.21.22","N-[(1S,4S,7R)-2-(3-amino-4-chloro[1,2]oxazolo[5,4-c]pyridin-7-yl)-2-azabicyclo[2.2.1]heptan-7-yl]-2-chloro-4-(3-methyl-1H-1,2,4-triazol-1-yl)benzamide",
,,,,"3.4.21.22","SODIUM ION",
,,,,,"2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID",
"5SGA",,"5SGA","Structures of product and inhibitor complexes of Streptomyces griseus protease a at 1.8 Angstroms resolution. a model for serine protease catalysis","3.4.21.80",
,,,,,
"5TJX","GBT","5TJX","Structure of human plasma kallikrein","3.4.21.34","(8E)-3-amino-1-methyl-15-[(1H-pyrazol-1-yl)methyl]-7,10,11,12,24,25-hexahydro-6H,18H,23H-19,22-(metheno)pyrido[4,3-j][1,9,13,17,18]benzodioxatriazacyclohenicosin-23-one",
,"GBT",,,,"PHOSPHATE ION",
"5TKU","7DK","5TKU","FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((15S)-15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)-2-PROPENOYL)AMINO)-9-OXO-8,17,19-TRIAZATRICYCLO[14.2.1.0~2,7~]NONADECA-1(18),2,4,6,16(19)-PENTAEN-5-YL)CARBAMATE","3.4.21.27","METHYL
((15S)-15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)-2-PROPENOYL)AMINO)-9-OXO-8,17,19-TRIAZATRICYCLO[14.2.1.0~2,7~]N
ONADECA-1(18),2,4,6,16(19)-PENTAEN-5-YL)CARBAMATE",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"5TKT","7DS","5TKT","FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((12E,15S)-15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)-2-PROPENOYL)AMINO)-9-OXO-8,17,19-TRIAZATRICYCLO[14.2.1.0~2,7~]NONADECA-1(18),2,4,6,12,16(19)-HEXAEN-5-YL)CARBAMATE","3.4.21.27","METHYL
((12E,15S)-15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)-2-PROPENOYL)AMINO)-9-OXO-8,17,19-TRIAZATRICYCLO[14.2.1.0~2,
7~]NONADECA-1(18),2,4,6,12,16(19)-HEXAEN-5-YL)CARBAMATE",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"5TKS","7DL","5TKS","FACTOR XIA IN COMPLEX WITH THE INHIBITOR ((15S)-18-CHLORO- 15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)-2- PROPENOYL)AMINO)-17,19-DIAZATRICYCLO[14.2.1.0~2,7~]NONADECA-1(18),2,4,6,16(19)-PENTAEN-5-YL)CARBAMATE","3.4.21.27","((15S)-18-CHLORO- 15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)-2- PROPENOYL)AMINO)-17,19-DIAZATRICYCLO[14.2.1.0~2,7~]NONADECA-1(18),2,4,6,16(19)-PENTAEN-5-YL)CARBAMATE",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"6AG7",,"6AG7","The crystal structure of uPA in complex with HMA-55F","3.4.21.73","3,5-diamino-N-carbamimidoyl-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carboxamide",
"6AG9",,"6AG9","Crystal structure of uPA in complex with 3,5-bis(azanyl)-6-(1-benzofuran-2-yl)-N-carbamimidoyl-pyrazine-2- carboxamide","3.4.21.73","3,5-bis(azanyl)-6-(1-benzofuran-2-yl)-N-carbamimidoyl-pyrazine-2-carboxamide",
,,,,,"SULFATE ION",
"6AG3",,"6AG3","Crystal structure of uPA in complex with 3,5-bis(azanyl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide","3.4.21.73","3,5-bis(azanyl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide",
"6AG2",,"6AG2","uPA-HMA","3.4.21.73","3,5-bis(azanyl)-N-carbamimidoyl-6-(2-methoxypyrimidin-5-yl)pyrazine-2-carboxamide",
,,,,,"SULFATE ION",
"5WB6","9ZM","5WB6","FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(11S)-11-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-6-fluoro-2-oxo-1,3,4,10,11,13-hexahydro-2H-5,9:15,12-di(azeno)-1,13-benzodiazacycloheptadecin-18-yl]carbamate","3.4.21.27","methyl [(11S)-11-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-6-fluoro-2-oxo-1,3,4,10,11,13-hexahydro-2H-5,9:15,12-di(azeno)-1,13-benzodiazacycloheptadecin-18-yl]carbamate",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"5VOE",,"5VOE","DesGla-XaS195A Bound to Aptamer 11F7t","3.4.21.6","SODIUM ION",
,,,,"3.4.21.6","CALCIUM ION",
,,,,,"MAGNESIUM ION",
"5E2O","5JM","5E2O","FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[(N-{(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}-L-phenylalanyl)amino]benzoic acid","3.4.21.27","4-[(N-{(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}-L-phenylalanyl)amino]benzoic acid",
,"5JM",,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"5E2P","7P0","5E2P","FACTOR XIA IN COMPLEX WITH THE INHIBITOR N-[(1S)-1-benzyl-2-[2-[5-chloro-2-(tetrazol-1-yl)phenyl]ethylamino]-2-oxo-ethyl]-4-hydroxy-2-oxo-1H-quinoline-6-carboxamide","3.4.21.27","N-[(1S)-1-benzyl-2-[2-[5-chloro-2-(tetrazol-1-yl)phenyl]ethylamino]-2-oxo-ethyl]-4-hydroxy-2-oxo-1H-quinoline-6-carboxamide",
,"7P0",,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"5EXM","5ST","5EXM","FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[2-[(1~{S})-1-[[4-(aminomethyl)cyclohexyl]carbonylamino]-2-phenyl-ethyl]pyridin-4-yl]phenyl]carbamate","3.4.21.27","methyl ~{N}-[4-[2-[(1~{S})-1-[[4-(aminomethyl)cyclohexyl]carbonylamino]-2-phenyl-ethyl]pyridin-4-yl]phenyl]carbamate",
,"5ST",,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"5EXL","5SS","5EXL","FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-(aminomethyl)-~{N}-[(1~{S})-1-[4-(3-oxidanyl-1~{H}-indazol-5-yl)pyridin-2-yl]-2-phenyl-ethyl]cyclohexane-1-carboxamide","3.4.21.27","4-(aminomethyl)-~{N}-[(1~{S})-1-[4-(3-oxidanyl-1~{H}-indazol-5-yl)pyridin-2-yl]-2-phenyl-ethyl]cyclohexane-1-carboxamide",
,"5SS",,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"5FAH","5VT","5FAH","KALLIKREIN-7 IN COMPLEX WITH COMPOUND1","3.4.21.117","ACETATE ION",
,"5VT",,,,"(2~{S})-~{N}2-[2-(4-methoxyphenyl)ethyl]-~{N}1-(naphthalen-1-ylmethyl)pyrrolidine-1,2-dicarboxamide",
"5FCK","5WC","5FCK","COMPLEMENT FACTOR D IN COMPLEX WITH COMPOUND 5","3.4.21.46","1-[2-[(1~{R},3~{S},5~{R})-3-[[(1~{R})-1-(3-chloranyl-2-fluoranyl-phenyl)ethyl]carbamoyl]-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxidanylidene-ethyl]pyrazolo[3,4-c]pyridine-3-carboxamide",
,"5WC",,,,"SULFATE ION",
,"5WC",,,,,
,"5WC",,,,,
,"5WC",,,,,
,"5WC",,,,,
"5F8X",,"5F8X","The crystal structure of human plasma kallikrein in complex with its peptide inhibitor pkalin-3","3.4.21.34","SULFATE ION",
,,,,,"piperidine-1-carboximidamide",
"5F8Z",,"5F8Z","The crystal structure of human Plasma Kallikrein in complex with its peptide inhibitor pkalin-1","3.4.21.34","SULFATE ION",
,,,,,"piperidine-1-carboximidamide",
"5F8T",,"5F8T","The crystal structure of human Plasma Kallikrein in complex with its peptide inhibitor pkalin-2","3.4.21.34","SULFATE ION",
,,,,,"piperidine-1-carboximidamide",
"4YZU","4K6","4YZU","Rapid development of two Factor IXa inhibitors from Hit to Lead","3.4.21.22","N-[2-(5,6-dimethyl-1H-benzimidazol-2-yl)ethyl]-4-(4H-1,2,4-triazol-4-yl)benzamide",
,"4K6",,,"3.4.21.22","SODIUM ION",
,,,,,"2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID",
,,,,,"CHLORIDE ION",
"4ZKN",,"4ZKN","The crystal structure of upain-1-W3A in complex with uPA at pH5.5","3.4.21.73","SULFATE ION",
,,,,,"TETRAETHYLENE GLYCOL",
"4ZKO",,"4ZKO","The crystal structure of upain-1-W3A in complex with uPA at pH7.4","3.4.21.73","SULFATE ION",
,,,,,"HEXAETHYLENE GLYCOL",
,,,,,,
"4ZKR",,"4ZKR","The crystal structure of upain-1-W3A in complex with uPA at pH9.0","3.4.21.73","SULFATE ION",
,,,,,"HEXAETHYLENE GLYCOL",
"4ZKS",,"4ZKS","The crystal structure of upain-1-W3A in complex with inactive uPA (uPA-S195A) at pH7.4","3.4.21.73",
,,,,,
"4Y76",,"4Y76","Factor Xa complex with GTC000401","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","N~2~-[(6-chloronaphthalen-2-yl)sulfonyl]-N~2~-{(3S)-1-[(2S)-1-(4-methyl-1,4-diazepan-1-yl)-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl}glycinamide",
"4Y79","4O6","4Y79","Factor Xa complex with GTC000406","3.4.21.6","CALCIUM ION",
,"4O6",,,"3.4.21.6","MAGNESIUM ION",
,,,,,"(E)-2-(4-chlorophenyl)-N-{(3S)-1-[(2S)-1-(morpholin-4-yl)-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl}ethenesulfonamide",
"4Y8X",,"4Y8X","Factor XIa in complex with the inhibitor methyl (4-{4-chloro-2-[(1S)-1-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-2-phenylethyl]-1H-imidazol-5-yl}phenyl)carbamate","3.4.21.27","methyl (4-{4-chloro-2-[(1S)-1-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-2-phenylethyl]-1H-imidazol-5-yl}phenyl)carbamate",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"4Y8Y",,"4Y8Y","Factor XIa in complex with the inhibitor methyl (4-{4-chloro-2-[(1S)-1-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-3-(morpholin-4-yl)-3-oxopropyl]-1H-imidazol-5-yl}phenyl)carbamate","3.4.21.27","methyl (4-{4-chloro-2-[(1S)-1-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-3-(morpholin-4-yl)-3-oxopropyl]-1H-imidazol-5-yl}phenyl)carbamate",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"4Y8Z","4CE","4Y8Z","Factor XIa in complex with the inhibitor (2E)-N-[(1S)-1-[5-chloro-4-(4-hydroxy-2-oxo-1,2-dihydroquinolin-6-yl)-1H-imidazol-2-yl]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enamide","3.4.21.27","(2E)-N-[(1S)-1-[5-chloro-4-(4-hydroxy-2-oxo-1,2-dihydroquinolin-6-yl)-1H-imidazol-2-yl]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enamide",
,"4CE",,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"4Z0K","4LN","4Z0K","Rapid development of two Factor IXa inhibitors from Hit to Lead","3.4.21.22","N-[(2R)-10-hydroxy-2,7-dimethyl-1,2,3,4-tetrahydropyrido[1,2-b]indazol-2-yl]-4-(4H-1,2,4-triazol-4-yl)benzamide",
,,,,"3.4.21.22","SODIUM ION",
,,,,,"2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID",
,,,,,"CHLORIDE ION",
"4XBB",,"4XBB","1.85A resolution structure of Norovirus 3CL protease complex with a covalently bound dipeptidyl inhibitor diethyl [(1R,2S)-2-[(N-{[(3-chlorobenzyl)oxy]carbonyl}-3-cyclohexyl-L-alanyl)amino]-1-hydroxy-3-(2-oxo-2H-pyrrol-3-yl)propyl]phosphonate","3.4.22.66","diethyl [(1R,2S)-2-[(N-{[(3-chlorobenzyl)oxy]carbonyl}-3-cyclohexyl-L-alanyl)amino]-1-hydroxy-3-(2-oxo-2H-pyrrol-3-yl)propyl]phosphonate",
,,,,"3.6.1.15","SULFATE ION",
,,,,"2.7.7.48",,
"4XBD",,"4XBD","1.45A resolution structure of Norovirus 3CL protease complex with a covalently bound dipeptidyl inhibitor (1R,2S)-2-({N-[(benzyloxy)carbonyl]-3-cyclohexyl-L-alanyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid (Orthorhombic P Form)","3.4.22.66","(1R,2S)-2-({N-[(benzyloxy)carbonyl]-3-cyclohexyl-L-alanyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid",
,,,,"3.6.1.15",,
,,,,"2.7.7.48",,
"4XD7",,"4XD7","Structure of thermophilic F1-ATPase inhibited by epsilon subunit","3.6.3.14","SULFATE ION",
,,,,"7.1.2.2","ADENOSINE-5'-DIPHOSPHATE",
,,,,"3.6.3.14",,
,,,,"7.1.2.2",,
,,,,,,
,,,,,,
"5K0H",,"5K0H","Human factor Xa in complex with synthetic inhibitor benzylsulfonyl-dSer(Benzyl)-Gly-4-amidinobenzylamide","3.4.21.6","CALCIUM ION",
,,,,"3.4.21.6","O-benzyl-N-(benzylsulfonyl)-D-seryl-N-[(4-carbamimidoylphenyl)methyl]glycinamide",
"5LYO",,"5LYO","Crystal structure of the zymogen matriptase catalytic domain","3.4.21.109","SULFATE ION",
"5MT0","QJS","5MT0","COMPLEMENT FACTOR D IN COMPLEX WITH A REVERSIBLE INDOLE CARBOXYLIC ACID BASED INHIBITOR","3.4.21.46","5-fluoranyl-3-[[(1~{S},2~{S})-2-phenylcyclopropyl]carbonylamino]-1~{H}-indole-2-carboxylic acid",
,,,,,"SULFATE ION",
"5JBB",,"5JBB","Crystal structure of factor IXa variant V16I K98T Y177T I213V in complex with EGR-chloromethylketone","3.4.21.22","CALCIUM ION",
,,,,"3.4.21.22","L-alpha-glutamyl-N-{(1S)-4-{[amino(iminio)methyl]amino}-1-[(1S)-2-chloro-1-hydroxyethyl]butyl}glycinamide",
,,,,,"DIMETHYL SULFOXIDE",
"5JBA",,"5JBA","Crystal structure of factor IXa variant V16I K98T Y177T I212V in complex with PPACK","3.4.21.22","CALCIUM ION",
,,,,"3.4.21.22","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,,"DIMETHYL SULFOXIDE",
"5JBC",,"5JBC","Crystal structure of factor IXa variant V16I K98T Y177T I213V in complex with PPACK","3.4.21.22","CALCIUM ION",
,,,,"3.4.21.22","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
"5JB8",,"5JB8","Crystal structure of factor IXa variant K98T in complex with EGR-chloromethylketone","3.4.21.22","CALCIUM ION",
,,,,"3.4.21.22","L-alpha-glutamyl-N-{(1S)-4-{[amino(iminio)methyl]amino}-1-[(1S)-2-chloro-1-hydroxyethyl]butyl}glycinamide",
,,,,,"DIMETHYL SULFOXIDE",
"5JB9",,"5JB9","Crystal structure of factor IXa K98T variant in complex with PPACK","3.4.21.22","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.22","CALCIUM ION",
,,,,,"DIMETHYL SULFOXIDE",
"5NBA","8S5","5NBA","Complement factor D in complex with the inhibitor (2S,4R)-4-Fluoro-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide]","3.4.21.46","(2~{S},4~{R})-~{N}1-(1-aminocarbonylindol-3-yl)-4-fluoranyl-~{N}2-[3-(trifluoromethyloxy)phenyl]pyrrolidine-1,2-dicarboxamide",
"5NAR","8RW","5NAR","Complement factor D in complex with the inhibitor (S)-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide]","3.4.21.46","SULFATE ION",
,,,,,"(2~{S})-~{N}1-(1-aminocarbonylindol-3-yl)-~{N}2-[3-(trifluoromethyloxy)phenyl]pyrrolidine-1,2-dicarboxamide",
"5NB6","8S2","5NB6","Complement factor D in complex with the inhibitor (2S,4S)-4-Amino-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide]","3.4.21.46","(2~{S},4~{S})-~{N}1-(1-aminocarbonylindol-3-yl)-4-azanyl-~{N}2-[3-(trifluoromethyloxy)phenyl]pyrrolidine-1,2-dicarboxamide",
"5NAW","8RZ","5NAW","Complement factor D in complex with the inhibitor (1R,3S,5R)-2-Aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-[(1-carbamoyl-1H-indol-3-yl)-amide] 3-[(3-trifluoromethoxy-phenyl)-amide]","3.4.21.46","(1~{R},3~{S},5~{R})-~{N}2-(1-aminocarbonylindol-3-yl)-~{N}3-[3-(trifluoromethyloxy)phenyl]-2-azabicyclo[3.1.0]hexane-2,3-dicarboxamide",
"5NB7","8NQ","5NB7","Complement factor D","3.4.21.46","DIMETHYL SULFOXIDE",
,,,,,"1-[2-[(1~{R},3~{S},5~{R})-3-[(6-bromanylpyridin-2-yl)carbamoyl]-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxidanylidene-ethyl]indazole-3-carboxamide",
"6Q8S",,"6Q8S","Elastase (PPE) under 2 kbar of argon","3.4.21.36","SODIUM ION",
,,,,,"SULFATE ION",
,,,,,"ARGON",
"6QMR","J6T","6QMR","Complement factor D in complex with the inhibitor (S)-2-(2-((3'-(1-amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid","3.4.21.46","2-[2-[[3-[3-[(1~{S})-1-azanyl-2-oxidanyl-ethyl]phenyl]phenyl]methoxy]phenyl]ethanoic acid",
"6QMT","J7B","6QMT","Complement factor D in complex with the inhibitor 2-(2-(3'-(aminomethyl)-[1,1'-biphenyl]-3-carboxamido)phenyl)acetic acid","3.4.21.46","2-[2-[[3-[3-(aminomethyl)phenyl]phenyl]carbonylamino]phenyl]ethanoic acid",
"6SHH",,"6SHH","Human kallikrein 7 with aromatic coumarinic ester compound 1 covalently bound to H57","3.4.21.117","TRIETHYLENE GLYCOL",
,,,,,"SULFATE ION",
,,,,,"(3-chlorophenyl) 6-methyl-2-oxidanylidene-chromene-3-carboxylate",
,,,,,"4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID",
"6SHI",,"6SHI","Human kallikrein 7 with aromatic coumarinic ester compound 2 covalently bound to H57","3.4.21.117","TRIETHYLENE GLYCOL",
,,,,,"6-methyl-2-oxidanylidene-chromene-3-carboxylic acid",
,,,,,"SULFATE ION",
,,,,,"4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID",
"6TS4",,"6TS4","Coagulation factor XI protease domain in complex with active site inhibitor","3.4.21.27","SULFATE ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"SODIUM ION",
,,,,,"2-[2-[[3-[3-(aminomethyl)phenyl]phenyl]carbonylamino]phenyl]ethanoic acid",
"6TS6",,"6TS6","Coagulation factor XI protease domain in complex with active site inhibitor","3.4.21.27","SULFATE ION",
,,,,,"DIMETHYL SULFOXIDE",
,,,,,"2-[2-[[3-[(3~{S})-3-azanyl-2,3-dihydro-1-benzofuran-5-yl]-5-(2-cyanopropan-2-yl)phenyl]methoxy]phenyl]ethanoic acid",
"6TS5",,"6TS5","Coagulation factor XI protease domain in complex with active site inhibitor","3.4.21.27","2-[2-[3-[(3~{S})-3-azanyl-2,3-dihydro-1-benzofuran-5-yl]-5-propan-2-yl-phenyl]ethoxy]-3-methoxy-benzoic acid",
,,,,,"SULFATE ION",
,,,,,"DIMETHYL SULFOXIDE",
"6TS7",,"6TS7","Coagulation factor XI protease domain in complex with active site inhibitor","3.4.21.27","2-[2-[[3-(1,2,3,4-tetrahydroisoquinolin-7-yl)phenyl]methoxy]phenyl]ethanoic acid",
"5WXQ",,"5WXQ","Crystal structure of uPA in complex with upain-2-4","3.4.21.73",
,,,,,
"5WXS",,"5WXS","Crystal structure of uPA in complex with S2444","3.4.21.73","(2R)-N-[2-[[(2S)-5-carbamimidamido-1-oxidanylidene-pentan-2-yl]amino]-2-oxidanylidene-ethyl]-5-oxidanylidene-1,2-dihydropyrrole-2-carboxamide",
"5WXR",,"5WXR","Crystal structure of uPA in complex with upain-2-4-W3A","3.4.21.73",
,,,,,
"5WXT",,"5WXT","Crystal structure of uPA-S195A in complex with S2444","3.4.21.73","(2R)-N-[2-[[(2S)-1-[[4-[bis(oxidanyl)amino]phenyl]amino]-5-carbamimidamido-1-oxidanylidene-pentan-2-yl]amino]-2-oxidanylidene-ethyl]-5-oxidanylidene-pyrrolidine-2-carboxamide",
"5XW1",,"5XW1","Crystal Structure of Porcine pancreatic trypsin with tripeptide inhibitor, PRN, at pH10","3.4.21.4","CALCIUM ION",
,,,,"3.4.21.4","(4S)-2-METHYL-2,4-PENTANEDIOL",
,,,,,,
"5YC7",,"5YC7","The crystal structure of uPA in complex with 4-Bromobenzylamirne at pH7.4","3.4.21.73","1-(4-BROMOPHENYL)METHANAMINE",
,,,,,"SULFATE ION",
"5YC6",,"5YC6","The crystal structure of uPA in complex with 4-Bromobenzylamirne at pH4.6","3.4.21.73","1-(4-BROMOPHENYL)METHANAMINE",
,,,,,"SULFATE ION",
,,,,,"TRIETHYLENE GLYCOL",
"5YM6",,"5YM6","Crystal Structure of porcine delta coronavirus nsp9","2.7.7.48",
,,,,"3.6.4.12",
,,,,"3.6.4.13",
"5YM8",,"5YM8","Crystal Structure of porcine delta coronavirus nsp9-N7","2.7.7.48",
,,,,"3.6.4.12",
,,,,"3.6.4.13",
"5Z1C",,"5Z1C","The crystal structure of uPA in complex with 4-Iodobenzylamine at pH7.4","3.4.21.73","1-(4-iodophenyl)methanamine",
"1EAX",,"1EAX","Crystal structure of MTSP1 (matriptase)","3.4.21","SULFATE ION",
,,,,"3.4.21.109","BENZAMIDINE",
"1DST",,"1DST","MUTANT OF FACTOR D WITH ENHANCED CATALYTIC ACTIVITY","3.4.21.46",
"1ELV",,"1ELV","CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN COMPLEMENT C1S PROTEASE","3.4.21.42","SULFATE ION",
,,,,,"2-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-ETHANESULFONIC ACID",
"1NFY","RTR","1NFY","CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR200095","3.4.21.6","CALCIUM ION",
,"RTR",,,"3.4.21.6","4-({4-[(6-CHLORO-1-BENZOTHIEN-2-YL)SULFONYL]-2-OXOPIPERAZIN-1-YL}METHYL)BENZENECARBOXIMIDAMIDE",
,"RTR",,,,,
,"RTR",,,,,
"1NFX","RDR","1NFX","CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208944","3.4.21.6","CALCIUM ION",
,"RDR",,,"3.4.21.6","4-[(6-CHLORO-1-BENZOTHIEN-2-YL)SULFONYL]-1-{[1-(2-HYDROXYETHYL)-1H-PYRROLO[3,2-C]PYRIDIN-2-YL]METHYL}PIPERAZIN-2-ONE",
,"RDR",,,,,
"1NFW","RRR","1NFW","CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR209685","3.4.21.6","CALCIUM ION",
,"RRR",,,"3.4.21.6","4-{[(E)-2-(5-CHLOROTHIEN-2-YL)VINYL]SULFONYL}-1-(1H-PYRROLO[3,2-C]PYRIDIN-2-YLMETHYL)PIPERAZIN-2-ONE",
,"RRR",,,,,
"1NFU","RRP","1NFU","CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR132747","3.4.21.6","CALCIUM ION",
,"RRP",,,"3.4.21.6","3-({4-[(6-CHLORO-1-BENZOTHIEN-2-YL)SULFONYL]-2-OXOPIPERAZIN-1-YL}METHYL)BENZENECARBOXIMIDAMIDE",
,"RRP",,,,,
,"RRP",,,,,
"1YM0",,"1YM0","Crystal Structure of Earthworm Fibrinolytic Enzyme Component B: a Novel, Glycosylated Two-chained Trypsin","3.4.21","MAGNESIUM ION",
,,,,"3.4.21","SULFATE ION",
"1ZHP",,"1ZHP","Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with Benzamidine (S434A-T475A-K505 Mutant)","3.4.21.27","BENZAMIDINE",
,,,,,"GLUTATHIONE",
"1ZHM",,"1ZHM","Crystal Structure of the Catalytic Domain of the Coagulation Factor XIa in Complex with Benzamidine (S434A-T475A-K437 Mutant)","3.4.21.27","BENZAMIDINE",
,,,,,"GLUTATHIONE",
"1ZJK",,"1ZJK","Crystal structure of the zymogen catalytic region of human MASP-2","3.4.21",
,,,,"3.4.21.104",
"1ZR0",,"1ZR0","Crystal Structure of Kunitz Domain 1 of Tissue Factor Pathway Inhibitor-2 with Bovine Trypsin","3.4.21.4","CALCIUM ION",
,,,,,,
"1Z6E","IK8","1Z6E","Factor XA in complex with the inhibitor 1-(3'-amino-1,2-benzisoxazol-5'-yl)-n-(4-(2'-((dimethylamino)methyl)-1h-imidazol-1-yl)-2-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazole-5-carboxamide (razaxaban; DPC906; BMS-561389)","3.4.21.6","1-(3-AMINO-1,2-BENZISOXAZOL-5-YL)-N-(4-{2-[(DIMETHYLAMINO)METHYL]-1H-IMIDAZOL-1-YL}-2-FLUOROPHENYL)-3-(TRIFLUOROMETHYL)
-1H-PYRAZOLE-5-CARBOXAMIDE",
,"IK8",,,"3.4.21.6",,
,"IK8",,,,,
,"IK8",,,,,
"1OP8",,"1OP8","Crystal Structure of Human Granzyme A","3.4.21.78","SULFATE ION",
"1ORF",,"1ORF","The Oligomeric Structure of Human Granzyme A Reveals the Molecular Determinants of Substrate Specificity","3.4.21.78","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,,"SULFATE ION",
"1PFX",,"1PFX","PORCINE FACTOR IXA","3.4.21.22","D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide",
,,,,"3.4.21.22",,
"1PQ8",,"1PQ8","Trypsin at pH 4 at atomic resolution","3.4.21.4","SULFATE ION",
,,,,,"LYSINE",
,,,,,"CITRIC ACID",
"1WTH",,"1WTH","Crystal structure of gp5-S351L mutant and gp27 complex","3.2.1.17","POTASSIUM ION",
,,,,,"PHOSPHATE ION",
"1WU1","D91","1WU1","Factor Xa in complex with the inhibitor 4-[(5-chloroindol-2-yl)sulfonyl]-2-(2-methylpropyl)-1-[[5-(pyridin-4-yl) pyrimidin-2-yl]carbonyl]piperazine","3.4.21.6","CALCIUM ION",
,"D91",,,"3.4.21.6","5-CHLORO-2-({3-ISOBUTYL-4-[(5-PYRIDIN-4-YLPYRIMIDIN-2-YL)CARBONYL]PIPERAZIN-1-YL}SULFONYL)-1H-INDOLE",
"1SKY",,"1SKY","CRYSTAL STRUCTURE OF THE NUCLEOTIDE FREE ALPHA3BETA3 SUB-COMPLEX OF F1-ATPASE FROM THE THERMOPHILIC BACILLUS PS3","7.1.2.2","SULFATE ION",
,,,,"7.1.2.2",,
"1GVL",,"1GVL","Human prokallikrein 6 (hK6)/ prozyme/ proprotease M/ proneurosin","3.4.21",
"1LPK","CBB","1LPK","CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 125.","3.4.21.6","CALCIUM ION",
,"CBB",,,"3.4.21.6","1-(3-CARBAMIMIDOYL-BENZYL)-1H-INDOLE-2-CARBOXYLIC ACID 3-CARBAMIMIDOYL-BENZYLESTER",
"1LPG","IMA","1LPG","CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 79.","3.4.21.6","CALCIUM ION",
,"IMA",,,"3.4.21.6","[4-({[5-BENZYLOXY-1-(3-CARBAMIMIDOYL-BENZYL)-1H-INDOLE-2-CARBONYL]-AMINO}-METHYL)-PHENYL]-TRIMETHYL-AMMONIUM",
,"IMA",,,,,
"1M0Z",,"1M0Z","Crystal Structure of the von Willebrand Factor Binding Domain of Glycoprotein Ib alpha",
"1LPZ","CMB","1LPZ","CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 41.","3.4.21.6","CALCIUM ION",
,"CMB",,,"3.4.21.6","1-(3-carbamimidoylbenzyl)-N-(3,5-dichlorobenzyl)-4-methyl-1H-indole-2-carboxamide",
,"CMB",,,,,
"1LQD","CMI","1LQD","CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 45.","3.4.21.6","CALCIUM ION",
,"CMI",,,"3.4.21.6","1-(3-CARBAMIMIDOYL-BENZYL)-4-METHYL-1H-INDOLE-2-CARBOXYLIC ACID 3,5-DIMETHYL-BENZYLAMIDE",
"1MD7",,"1MD7","Monomeric structure of the zymogen of complement protease C1r","3.4.21.41","2-acetamido-2-deoxy-beta-D-glucopyranose",
"6R8X",,"6R8X","COAGULATION FACTOR XI CATALYTIC DOMAIN IN COMPLEX WITH FAB-PORTION OF MAA868","3.4.21.27",
,,,,,
,,,,,
"6USY",,"6USY","COAGULATION FACTOR XI CATALYTIC DOMAIN (C123S) IN COMPLEX WITH NVP-XIV936","3.4.21.27","1-[(2S)-2-{3-[(3S)-3-amino-2,3-dihydro-1-benzofuran-5-yl]-5-(propan-2-yl)phenyl}-2-hydroxyethyl]-1H-indole-7-carboxylic acid",
"1KLT",,"1KLT","CRYSTAL STRUCTURE OF PMSF-TREATED HUMAN CHYMASE AT 1.9 ANGSTROMS RESOLUTION","3.4.21.39","phenylmethanesulfonic acid",
"1L0Z",,"1L0Z","THE STRUCTURE OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH XENON AND BROMIDE, CRYOPROTECTED WITH DRY PARAFFIN OIL","3.4.21.36","SODIUM ION",
,,,,,"BROMIDE ION",
,,,,,"XENON",
"1L2E",,"1L2E","Human Kallikrein 6 (hK6) Active Form with benzamidine inhibitor","3.4.21","MAGNESIUM ION",
,,,,,"BENZAMIDINE",
"1L8J",,"1L8J","Crystal Structure of the Endothelial Protein C Receptor and Bound Phospholipid Molecule",,"PHOSPHATIDYLETHANOLAMINE",
"1K28",,"1K28","The Structure of the Bacteriophage T4 Cell-Puncturing Device","3.2.1.17","POTASSIUM ION",
,,,,,"PHOSPHATE ION",
"3M36","M35","3M36","Factor XA in complex with the inhibitor 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423)","3.4.21.6","1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide",
,"M35",,,"3.4.21.6","CALCIUM ION",
,"M35",,,,,
,"M35",,,,,
,"M35",,,,,
"3M37","M37","3M37","Factor XA in complex with the inhibitor 1-[2-(aminomethyl)phenyl]-N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC602)","3.4.21.6","1-[2-(aminomethyl)phenyl]-N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide",
,"M37",,,"3.4.21.6","CALCIUM ION",
,"M37",,,,,
"3M61",,"3M61","Crystal structure of complex of urokinase and a upain-1 variant(W3A) in pH4.6 condition","3.4.21.73",
,,,,,
"6KK4",,"6KK4","Crystal structure of Zika NS2B-NS3 protease with compound 9","3.4.21.91","1-[(9~{R},16~{S},19~{S})-16,19-bis(4-azanylbutyl)-4,8,15,18,21-pentakis(oxidanylidene)-3,7,14,17,20-pentazabicyclo[21.3.1]heptacosa-1(26),23(27),24-trien-9-yl]guanidine",
,,,,"3.6.1.15","GLYCEROL",
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
"6KK6",,"6KK6","Crystal structure of Zika NS2B-NS3 protease with compound 16","3.4.21.91","SULFATE ION",
,,,,"3.6.1.15","GLYCEROL",
,,,,"3.6.4.13","1-[(5~{R},8~{R},15~{S},18~{S})-15,18-bis(4-azanylbutyl)-5-methyl-4,7,14,17,20-pentakis(oxidanylidene)-3,6,13,16,19-pentazabicyclo[20.3.1]hexacosa-1(25),22(26),23-trien-8-yl]guanidine",
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
"6Y3B",,"6Y3B","Crystal Structure of Unlinked NS2B-NS3 Protease from Zika Virus in Complex with Inhibitor MI-2110","3.4.21.91","GLYCEROL",
,,,,"3.6.1.15","1-[(8~{R},15~{S},18~{S})-15,18-bis(4-azanylbutyl)-4,7,14,17,20-pentakis(oxidanylidene)-3,6,13,16,19-pentazabicyclo[20.3.1]hexacosa-1(25),22(26),23-trien-8-yl]guanidine",
,,,,"3.6.4.13","SULFATE ION",
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
,,,,"3.4.21.91",,
,,,,"3.6.1.15",,
,,,,"3.6.4.13",,
,,,,"2.1.1.56",,
,,,,"2.1.1.57",,
,,,,"2.7.7.48",,
"3Q25",,"3Q25","Crystal structure of human alpha-synuclein (1-19) fused to maltose binding protein (MBP)",,"SULFATE ION",
,,,,,"GLYCEROL",
"3Q26",,"3Q26","Cyrstal structure of human alpha-synuclein (10-42) fused to maltose binding protein (MBP)",,"GLYCEROL",
,,,,,"SULFATE ION",
"3Q27",,"3Q27","Cyrstal structure of human alpha-synuclein (32-57) fused to maltose binding protein (MBP)",,"SULFATE ION",
,,,,,"GLYCEROL",
"3Q29",,"3Q29","Cyrstal structure of human alpha-synuclein (1-19) fused to maltose binding protein (MBP)",,"GLYCEROL",
,,,,,"SULFATE ION",
"2I6S",,"2I6S","Complement component C2a","3.4.21.43","2-acetamido-2-deoxy-beta-D-glucopyranose",
"2DE9",,"2DE9","Crystal structure of porcine pancreatic elastase complexed with Tris after soaking a tris-free solution","3.4.21.36","SULFATE ION",
"2DE8",,"2DE8","Crystal structure of porcine pancreatic elastase with a unique conformation induced by Tris","3.4.21.36","CHLORIDE ION",
,,,,,"2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL",
"2P3T","993","2P3T","Crystal structure of human factor XA complexed with 3-Chloro-4-(2-methylamino-imidazol-1-ylmethyl)-thiophene-2-carboxylic acid [4-chloro-2-(5-chloro-pyridin-2-ylcarbamoyl)-6-methoxy-phenyl]-amide","3.4.21.6","CALCIUM ION",
,"993",,,"3.4.21.6","CHLORIDE ION",
,"993",,,,"3-CHLORO-4-(2-METHYLAMINO-IMIDAZOL-1-YLMETHYL)-THIOPHENE-2-CARBOXYLIC ACID [4-CHLORO-2-(5-CHLORO-PYRIDIN-2-YLCARBAMOYL)-6-METHOXY-PHENYL]-AMIDE",
"2OQU",,"2OQU","High Pressure Cryocooling of Capillary Sample Cryoprotection and Diffraction Phasing at Long Wavelengths","3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"XENON",
"2Q6D",,"2Q6D","Crystal structure of infectious bronchitis virus (IBV) main protease","3.4.22",
,,,,"2.7.7.48",
,,,,"3.6.4.12",
,,,,"3.6.4.13",
,,,,"3.1.13",
,,,,"3.1",
,,,,"2.1.1",
"2H1U",,"2H1U","Porcine pancreatic elastase complexed with MetPheLeuGlu at pH 5.0",,"CALCIUM ION",
,,,,"3.4.21.36","SULFATE ION",
"2R2W","4PG","2R2W","Urokinase plasminogen activator B-chain-GPPE complex","3.4.21.73","SULFATE ION",
,"4PG",,,,"1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine",
"2EQN",,"2EQN","Solution structure of the NAF1 domain of Hypothetical protein BC008207 [Homo sapiens]",
"2EST",,"2EST","Crystallographic study of the binding of a trifluoroacetyl dipeptide anilide inhibitor with elastase","3.4.21.36","6-ammonio-N-(trifluoroacetyl)-L-norleucyl-N-[4-(trifluoromethyl)phenyl]-L-alaninamide",
,,,,,"SULFATE ION",
"2EYQ",,"2EYQ","Crystal structure of Escherichia coli transcription-repair coupling factor","3.6.4","SULFATE ION",
,,,,,"4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID",
"2FO9",,"2FO9","Structure of porcine pancreatic elastase in 95% acetone","3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"ACETONE",
"2FOH",,"2FOH","Structure of porcine pancreatic elastase in 40% trifluoroethanol","3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"TRIFLUOROETHANOL",
"2FOG",,"2FOG","Structure of porcine pancreatic elastase in 40% trifluoroethanol","3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"TRIFLUOROETHANOL",
"2FOE",,"2FOE","Structure of porcine pancreatic elastase in 80% hexane","3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"(2S)-HEX-5-ENE-1,2-DIOL",
"2FOC",,"2FOC","Structure of porcine pancreatic elastase in 55% dimethylformamide","3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"DIMETHYLFORMAMIDE",
"1XX9",,"1XX9","Crystal Structure of the FXIa Catalytic Domain in Complex with EcotinM84R","3.4.21.27","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,,
"1YC0",,"1YC0","short form HGFA with first Kunitz domain from HAI-1","3.4.21","PHOSPHATE ION",
,,,,,,
"2NWN",,"2NWN","New Pharmacophore for Serine Protease Inhibition Revealed by Crystal Structure of Human Urokinase-type Plasminogen Activator Complexed with a Cyclic Peptidyl Inhibitor, upain-1","3.4.21.73",
,,,,,
"3E3T",,"3E3T","Structure of porcine pancreatic elastase with the magic triangle I3C","3.4.21.36","SULFATE ION",
,,,,,"SODIUM ION",
,,,,,"IODIDE ION",
,,,,,"5-amino-2,4,6-triiodobenzene-1,3-dicarboxylic acid",
"3QN7",,"3QN7","Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA)","3.4.21.73","1,3,5-tris(bromomethyl)benzene",
,,,,,,
"4AG2",,"4AG2","Human Chymase - Fynomer Complex","3.4.21.39","2-(N-MORPHOLINO)-ETHANESULFONIC ACID",
,,,,,"(2S)-2-hydroxybutanedioic acid",
,,,,,"SODIUM ION",
"3L3T",,"3L3T","Human mesotrypsin complexed with amyloid precursor protein inhibitor variant (APPIR15K)","3.4.21.4","FORMIC ACID",
,,,,,"CALCIUM ION",
"4DVA",,"4DVA","The crystal structure of human urokinase-type plasminogen activator catalytic domain","3.4.21.73","SULFATE ION",
,,,,,"HEXAETHYLENE GLYCOL",
"4DW2",,"4DW2","The crystal structure of uPA in complex with the Fab fragment of mAb-112","3.4.21.73","SULFATE ION",
,,,,,,
,,,,,,
"3MU4",,"3MU4","Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region B of the crystal. First step of radiation damage","3.4.21.36","SODIUM ION",
,,,,,"SULFATE ION",
"3MU5",,"3MU5","Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region B of the crystal. Third step of radiation damage","3.4.21.36","SODIUM ION",
,,,,,"SULFATE ION",
"3MU8",,"3MU8","Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region B of the crystal. Fifth step of radiation damage","3.4.21.36","SODIUM ION",
,,,,,"SULFATE ION",
"3MTY",,"3MTY","Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region A of the crystal. First step of radiation damage","3.4.21.36","SODIUM ION",
,,,,,"SULFATE ION",
"3MU0",,"3MU0","Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region A of the crystal. Third step of radiation damage","3.4.21.36","SODIUM ION",
,,,,,"SULFATE ION",
"3MU1",,"3MU1","Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region A of the crystal. Fifth step of radiation damage","3.4.21.36","SODIUM ION",
,,,,,"SULFATE ION",
"3N7O","N7O","3N7O","X-ray structure of human chymase in complex with small molecule inhibitor.","3.4.21.39","(S)-[(1S)-1-(5-chloro-1-benzothiophen-3-yl)-2-{[(E)-2-(3,4-difluorophenyl)ethenyl]amino}-2-oxoethyl]methylphosphinic acid",
,"N7O",,,,"Unknown ligand",
,"N7O",,,,,
"3NPS",,"3NPS","Crystal structure of membrane-type serine protease 1 (MT-SP1) in complex with the Fab Inhibitor S4","3.4.21.109","1,2-ETHANEDIOL",
,,,,,"SODIUM ION",
,,,,,"CHLORIDE ION",
"3ODD",,"3ODD","Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region B of the crystal. Second step of radiation damage","3.4.21.36","SODIUM ION",
,,,,,"SULFATE ION",
"3ODF",,"3ODF","Comparison of the character and the speed of X-ray-induced structural changes of porcine pancreatic elastase at two temperatures, 100 and 15K. The data set was collected from region A of the crystal. Second step of radiation damage","3.4.21.36","SODIUM ION",
,,,,,"SULFATE ION",
"3P72",,"3P72","structure of platelet Glycoprotein 1b alpha with a bound peptide inhibitor",,"CHLORIDE ION",
,,,,,,
"3OX7",,"3OX7","The crystal structure of uPA complex with peptide inhibitor MH027 at pH4.6","3.4.21.73","SULFATE ION",
,,,,,"TETRAETHYLENE GLYCOL",
"3P8F",,"3P8F","Crystal Structure of MT-SP1 in complex with SFTI-1","3.4.21.109","GLUTATHIONE",
,,,,,,
"3OY5",,"3OY5","The crystal structure of uPA complex with peptide inhibitor MH027 at pH7.4","3.4.21.73","SULFATE ION",
,,,,,,
"3OY6",,"3OY6","The crystal structure of uPA complex with peptide inhibitor MH036 at pH4.6","3.4.21.73",
,,,,,
"2ZCK",,"2ZCK","Crystal structure of a ternary complex between PSA, a substrat-acyl intermediate and an activating antibody","3.4.21.77",
,,,,,
,,,,,
,,,,,
"2ZCL",,"2ZCL","Crystal structure of human prostate specific antigen complexed with an activating antibody","3.4.21.77","2-acetamido-2-deoxy-beta-D-glucopyranose",
,,,,,,
,,,,,,
"2ZCH",,"2ZCH","Crystal structure of human prostate specific antigen complexed with an activating antibody","3.4.21.77","2-acetamido-2-deoxy-alpha-D-glucopyranose",
,,,,,"CHLORIDE ION",
,,,,,"PHOSPHATE ION",
"2ZKS",,"2ZKS","Structural insights into the proteolytic machinery of apoptosis-inducing Granzyme M","3.4.21","SULFATE ION",
,,,,,,
"2VIV","VG2","2VIV","Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator","3.4.21.73","ACETATE ION",
,"VG2",,,,"4-(2-aminoethoxy)-N-(3-chloro-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide",
,"VG2",,,,,
"2VIW","D56","2VIW","Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator","3.4.21.73","ACETATE ION",
,"D56",,,,"4-(2-aminoethoxy)-N-(3-chloro-2-ethoxy-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide",
,"D56",,,,,
"2VIN","505","2VIN","Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator","3.4.21.73","ACETATE ION",
,"505",,,,"SULFATE ION",
,"505",,,,"(2R)-1-(2,6-dimethylphenoxy)propan-2-amine",
"2VIO","L1O","2VIO","Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator","3.4.21.73","ACETATE ION",
,"L1O",,,,"4-(2-aminoethoxy)-3,5-dichlorobenzoic acid",
,"L1O",,,,,
"2VIP","L1R","2VIP","Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator","3.4.21.73","ACETATE ION",
,"L1R",,,,"SULFATE ION",
,"L1R",,,,"4-(2-AMINOETHOXY)-3,5-DICHLORO-N-[3-(1-METHYLETHOXY)PHENYL]BENZAMIDE",
"2VIQ","D55","2VIQ","Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator","3.4.21.73","ACETATE ION",
,"D55",,,,"4-(2-aminoethoxy)-N-(2,5-diethoxyphenyl)-3,5-dimethylbenzamide",
,"D55",,,,,
"2VNT","QGG","2VNT","UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX WITH A 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANIDINE","3.4.21.73","1-({4-CHLORO-1-[(DIAMINOMETHYLIDENE)AMINO]ISOQUINOLIN-7-YL}SULFONYL)-D-PROLINE",
,"QGG",,,,"SULFATE ION",
,"QGG",,,,,
"2ZU2",,"2ZU2","complex structure of CoV 229E 3CL protease with EPDTC","3.4.22","(4S)-2-METHYL-2,4-PENTANEDIOL",
,,,,"3.4.19.12","zinc(II)hydrogensulfide",
"3S0N","0BB","3S0N","Crystal Structure of Human Chymase with Benzimidazolone Inhibitor","3.4.21.39","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"0BB",,,,"ZINC ION",
,"0BB",,,,"4-{3-[(4-methyl-1-benzothiophen-3-yl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}butanoic acid",
,"0BB",,,,,
"3HGN",,"3HGN","Structure of porcine pancreatic elastase complexed with a potent peptidyl inhibitor FR130180 determined by neutron crystallography","3.4.21.36","4-[[(2S)-3-methyl-1-oxo-1-[(2S)-2-[[(3S)-1,1,1-trifluoro-4-methyl-2-oxo-pentan-3-yl]carbamoyl]pyrrolidin-1-yl]butan-2-yl]carbamoyl]benzoic acid",
,,,,,"CALCIUM ION",
,,,,,"SULFATE ION",
"3HGP",,"3HGP","Structure of porcine pancreatic elastase complexed with a potent peptidyl inhibitor FR130180 determined by high resolution crystallography","3.4.21.36","4-[[(2S)-3-methyl-1-oxo-1-[(2S)-2-[[(3S)-1,1,1-trifluoro-4-methyl-2-oxo-pentan-3-yl]carbamoyl]pyrrolidin-1-yl]butan-2-yl]carbamoyl]benzoic acid",
,,,,,"CALCIUM ION",
,,,,,"SULFATE ION",
"3IG6","438","3IG6","Low molecular weigth human Urokinase type Plasminogen activator 2-[6-(3'-Aminomethyl-biphenyl-3-yloxy)-4-(3-dimethylamino-pyrrolidin-1-yl)-3,5-difluoro-pyridin-2-yloxy]-4-dimethylamino-benzoic acid complex","3.4.21.73","2-[(6-{[3'-(aminomethyl)biphenyl-3-yl]oxy}-4-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-3,5-difluoropyridin-2-yl)oxy]-4-(dimethylamino)benzoic acid",
,"438",,,"3.4.21.73","PHOSPHATE ION",
,"438",,,,,
"3MO3",,"3MO3","Investigation of global and local effects of radiation damage on porcine pancreatic elastase. Fifth stage of radiation damage","3.4.21.36","SODIUM ION",
,,,,,"SULFATE ION",
"3MNS",,"3MNS","Investigation of global and local effects of radiation damage on porcine pancreatic elastase. Third stage of radiation damage","3.4.21.36","SODIUM ION",
,,,,,"SULFATE ION",
"3MNB",,"3MNB","Investigation of global and local effects of radiation damage on porcine pancreatic elastase. First stage of radiation damage","3.4.21.36","SODIUM ION",
,,,,,"SULFATE ION",
"3MNC",,"3MNC","Investigation of global and local effects of radiation damage on porcine pancreatic elastase. Second stage of radiation damage","3.4.21.36","SODIUM ION",
,,,,,"SULFATE ION",
"3MOC",,"3MOC","Investigation of global and local effects of radiation damage on porcine pancreatic elastase. Eighth stage of radiation damage","3.4.21.36","SODIUM ION",
,,,,,"SULFATE ION",
"3MO6",,"3MO6","Investigation of global and local effects of radiation damage on porcine pancreatic elastase. Sixth stage of radiation damage","3.4.21.36","SODIUM ION",
,,,,,"SULFATE ION",
"3MNX",,"3MNX","Investigation of global and local effects of radiation damage on porcine pancreatic elastase. Fourth stage of radiation damage","3.4.21.36","SODIUM ION",
,,,,,"SULFATE ION",
"3MO9",,"3MO9","Investigation of global and local effects of radiation damage on porcine pancreatic elastase. Seventh stage of radiation damage","3.4.21.36","SODIUM ION",
,,,,,"SULFATE ION",
"4HG6",,"4HG6","Structure of a cellulose synthase - cellulose translocation intermediate","2.4.1.12","URIDINE-5'-DIPHOSPHATE",
,,,,,"LAURYL DIMETHYLAMINE-N-OXIDE",
"4FU8","2UP","4FU8","Crystal Structure of the Urokinase","3.4.21.73","naphthalene-2-carboximidamide",
,"2UP",,,,"ACETATE ION",
,"2UP",,,,"SUCCINIC ACID",
,"2UP",,,,"SULFATE ION",
"4FUD","6UP","4FUD","Crystal Structure of the Urokinase","3.4.21.73","8-aminonaphthalene-2-carboximidamide",
,"6UP",,,,"SUCCINIC ACID",
,"6UP",,,,"SULFATE ION",
,,,,,"SODIUM ION",
"4K5Z","1P7","4K5Z","Crystal Structure of Human Chymase in Complex with Fragment Inhibitor 6-chloro-2,3-dihydro-1H-isoindol-1-one","3.4.21.39","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"1P7",,,,"ZINC ION",
,,,,,"6-chloro-2,3-dihydro-1H-isoindol-1-one",
"4K60","1P8","4K60","Crystal Structure of Human Chymase in Complex with Fragment 6-bromo-1,3-dihydro-2H-indol-2-one","3.4.21.39","2-acetamido-2-deoxy-beta-D-glucopyranose",
,"1P8",,,,"ZINC ION",
,"1P8",,,,"6-bromo-1,3-dihydro-2H-indol-2-one",
"3TJU",,"3TJU","Crystal structure of human granzyme H with an inhibitor","3.4.21","SULFATE ION",
,,,,,,
"4X1N",,"4X1N","The crystal structure of mupain-1-16 in complex with murinised human uPA at pH7.4",,"piperidine-1-carboximidamide",
,,,,"3.4.21.73",,
"4X1Q",,"4X1Q","The crystal structure of mupain-1 in complex with murinised human uPA at pH7.4",
,,,,3.4.21.73,
"4X1R","PL0","4X1R","The crystal structure of mupain-1-12 in complex with murinised human uPA at pH7.4",,"1-phenylguanidine",
,"PL0",,,"3.4.21.73",,
,"PL0",,,,,
"4X1S",,"4X1S","The crystal structure of mupain-1-16-D9A in complex with murinised human uPA at pH7.4",,"piperidine-1-carboximidamide",
,,,,"3.4.21.73",,
"4K2Y","ES2","4K2Y","Crystal Structure of Human Chymase in Complex with Fragment Inhibitor 6-chloro-1,3-dihydro-2H-indol-2-one","3.4.21.39","ZINC ION",
,"ES2",,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,"ES2",,,,"6-chloro-1,3-dihydro-2H-indol-2-one",
"4K69","1P9","4K69","Crystal Structure of Human Chymase in Complex with Fragment Linked Benzimidazolone Inhibitor: (3S)-3-{3-[(6-bromo-2-oxo-2,3-dihydro-1H-indol-4-yl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}hexanoic acid","3.4.21.39","ZINC ION",
,"1P9",,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
,"1P9",,,,"(3S)-3-{3-[(6-bromo-2-oxo-2,3-dihydro-1H-indol-4-yl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}hexanoic acid",
"3SOR",,"3SOR","Factor XIa in complex with a clorophenyl-tetrazole inhibitor","3.4.21.27","CITRIC ACID",
,,,,,"{4-[(N-{3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]propanoyl}-L-phenylalanyl)amino]phenyl}acetic acid",
"4KTU",,"4KTU","Bovine trypsin in complex with microviridin J at pH 6.5","3.4.21.4","CALCIUM ION",
,,,,,,
"4KTS",,"4KTS","Bovine trypsin in complex with microviridin J at pH 8.5","3.4.21.4","CALCIUM ION",
,,,,,"DI(HYDROXYETHYL)ETHER",
"5AVD",,"5AVD","The 0.86 angstrom structure of elastase crystallized in high-strength agarose hydrogel","3.4.21.36","SULFATE ION",
"4P00",,"4P00","Bacterial Cellulose Synthase in complex with cyclic-di-GMP and UDP","2.4.1.12","URIDINE-5'-DIPHOSPHATE",
,,,,,"9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one)",
,,,,,"MAGNESIUM ION",
,,,,,"DIUNDECYL PHOSPHATIDYL CHOLINE",
,,,,,"1,2-DIACYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE",
"4P02",,"4P02","Structure of Bacterial Cellulose Synthase with cyclic-di-GMP bound.","2.4.1.12","9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one)",
,,,,,"DIUNDECYL PHOSPHATIDYL CHOLINE",
,,,,,"1,2-DIACYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE",
,,,,,"MAGNESIUM ION",
"2BLQ",,"2BLQ","Elastase After A High Dose X-Ray ""Burn""","3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
"2BLO",,"2BLO","Elastase before a high dose x-ray ""burn""","3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
"1INC","ICL","1INC","CRYSTAL STRUCTURES OF THE COMPLEX OF PORCINE PANCREATIC ELASTASE WITH TWO VALINE-DERIVED BENZOXAZINONE INHIBITORS","3.4.21.36","SULFATE ION",
,,,,,"CALCIUM ION",
,,,,,"[1-(3-CHLORO-2-FORMYL-PHENYLCARBAMOYL)-2-METHYL-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER",
"1QGF",,"1QGF","PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3R, 4S)N-PARA-TOLUENESULPHONYL-3-ETHYL-4-(CARBOXYLIC ACID)PYRROLIDIN-2-ONE","3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"(2S,3S)-3-FORMYL-2-({[(4-METHYLPHENYL)SULFONYL]AMINO}METHYL)PENTANOIC ACID",
"1QIX",,"1QIX","Porcine pancreatic elastase complexed with human beta-casomorphin-7",,"CALCIUM ION",
,,,,"3.4.21.11","SULFATE ION",
,,,,"3.4.21.36",,
"1QNJ",,"1QNJ","THE STRUCTURE OF NATIVE PORCINE PANCREATIC ELASTASE AT ATOMIC RESOLUTION (1.1 A)","3.4.21.36","SODIUM ION",
,,,,,"SULFATE ION",
"2ANY",,"2ANY","Expression, Crystallization and the Three-dimensional Structure of the Catalytic Domain of Human Plasma Kallikrein: Implications for Structure-Based Design of Protease Inhibitors","3.4.21.34","PHOSPHATE ION",
,,,,,"BENZAMIDINE",
"2ANW",,"2ANW","Expression, crystallization and three-dimensional structure of the catalytic domain of human plasma kallikrein: Implications for structure-based design of protease inhibitors","3.4.21.34","BENZAMIDINE",
"2A7J",,"2A7J","On the Routine Use of Soft X-Rays in Macromolecular Crystallography, Part III- The Optimal Data Collection Wavelength","3.4.21.36","ACETATE ION",
,,,,,"CALCIUM ION",
,,,,,"CHLORIDE ION",
"2AGI",,"2AGI","The leupeptin-trypsin covalent complex at 1.14 A resolution","3.4.21.4","SULFATE ION",
,,,,,"CALCIUM ION",
"1FZZ",,"1FZZ","THE CRYSTAL STRUCTURE OF THE COMPLEX OF NON-PEPTIDIC INHIBITOR ONO-6818 AND PORCINE PANCREATIC ELASTASE.","3.4.21.36","2-(5-AMINO-6-OXO-2-PHENYL-6H-PYRIMIDIN-1-YL)-N-[2-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)-1-(METHYLETHYL)-2-HYDROXYETHYL]ACETAMIDE",
"1GPZ",,"1GPZ","THE CRYSTAL STRUCTURE OF THE ZYMOGEN CATALYTIC DOMAIN OF COMPLEMENT PROTEASE C1R","3.4.21.41","2-acetamido-2-deoxy-beta-D-glucopyranose",
"1FX0",,"1FX0","Crystal structure of the chloroplast F1-ATPase from spinach","7.1.2.2",
,,,,"7.1.2.2",
"2ASU",,"2ASU","Crystal Structure of the beta-chain of HGFl/MSP",
,,,,
"2BB4",,"2BB4","Porcine pancreatic elastase complexed with beta-casomorphin-7 and Asp-Phe at pH 5.0",,"ASPARTIC ACID",
,,,,"3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"PHENYLALANINE",
"2BD3",,"2BD3","Porcine pancreatic elastase complexed with beta-casomorphin-7 and Lys-Ala-NH2 at pH 5.0",,"LYSINE",
,,,,"3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"ALANINE",
"2BD2",,"2BD2","Porcine pancreatic elastase complexed with beta-casomorphin-7 and Arg-Phe at pH 5.0",,"ARGININE",
,,,,"3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"PHENYLALANINE",
"2BD9",,"2BD9","Porcine pancreatic elastase complexed with beta-casomorphin-7 and Arg-Phe at pH 5.0 (50 min soak) and immersed in pH 9 buffer for 28 seconds (2nd pH jump)","3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
"2BD8",,"2BD8","Porcine pancreatic elastase complexed with beta-casomorphin-7 and Arg-Phe at pH 5.0 (50 min soak) and immersed in pH 9 buffer for 30 seconds",,"ARGININE",
,,,,"3.4.21.36","PHENYLALANINE",
,,,,,"CALCIUM ION",
,,,,,"SULFATE ION",
"2BD7",,"2BD7","Porcine pancreatic elastase complexed with beta-casomorphin-7 and Arg-Phe at pH 5.0 (50 min soak)",,"ARGININE",
,,,,"3.4.21.36","PHENYLALANINE",
,,,,,"CALCIUM ION",
,,,,,"SULFATE ION",
"2BD5",,"2BD5","Porcine pancreatic elastase complexed with beta-casomorphin-7 and Lys-Ser at pH 5 and immersed in pH 9 buffer for 30 seconds",,"LYSINE",
,,,,"3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
"2BD4",,"2BD4","Porcine pancreatic elastase complexed with beta-casomorphin-7 and Lys-Ser at pH 5.0",,"LYSINE",
,,,,"3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
"2BDC",,"2BDC","Porcine pancreatic elastase complexed with Asn-Pro-Ile at pH 5.0","3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
"2BDB",,"2BDB","Porcine pancreatic elastase complexed with Asn-Pro-Ile and Ala-Ala at pH 5.0","3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
,,,,,"ALANINE",
"2BDA",,"2BDA","Porcine pancreatic elastase complexed with N-acetyl-NPI and Ala-Ala at pH 5.0",,"ALANINE",
,,,,"3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
"1FI8",,"1FI8","RAT GRANZYME B [N66Q] COMPLEXED TO ECOTIN [81-84 IEPD]","3.4.21",
,,,,"3.4.21.79",
,,,,,
,,,,,
"1FV9","172","1FV9","Crystal structure of human microurokinase in complex with 2-amino-5-hydroxy-benzimidazole","3.4.21.73","SULFATE ION",
,,,,,"2-AMINO-5-HYDROXY-BENZIMIDAZOLE",
"2G4U",,"2G4U","Anomalous substructure of porcine pancreatic elastaase (Ca)","3.4.21.36","CALCIUM ION",
,,,,,"CITRATE ANION",
"2G4T",,"2G4T","anomalous substructure of porcine pancreatic elastase (Na)","3.4.21.36","SODIUM ION",
,,,,,"SULFATE ION",
"2GDZ",,"2GDZ","Crystal structure of 15-hydroxyprostaglandin dehydrogenase type1, complexed with NAD+","1.1.1.141","NICOTINAMIDE-ADENINE-DINUCLEOTIDE",
"2CV3","FRN","2CV3","Crystal structure of porcine pancreatic elastase complexed with a macroclyclic peptide inhibitor","3.4.21.36",
,,,,,
"4MGX",,"4MGX","Crystal structure of human filamin C domains 4-5 and GPIB alpha cytoplasmic domain complex",
,,,,
"3F1S",,"3F1S","Crystal structure of Protein Z complexed with protein Z-dependent inhibitor",,"CHLORIDE ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"CITRATE ANION",
,,,,,"2-acetamido-2-deoxy-beta-D-glucopyranose",
"3EST",,"3EST","STRUCTURE OF NATIVE PORCINE PANCREATIC ELASTASE AT 1.65 ANGSTROMS RESOLUTION","3.4.21.36","CALCIUM ION",
,,,,,"SULFATE ION",
"6FOC",,"6FOC","F1-ATPase from Mycobacterium smegmatis","3.6.3.14","ADENOSINE-5'-DIPHOSPHATE",
,,,,"7.1.2.2","MAGNESIUM ION",
,,,,"3.6.3.14","PHOSPHATE ION",
,,,,"7.1.2.2",,
,,,,,,
,,,,,,
"6NMB","AMH","6NMB","Tranexamic Acid is an Active Site Inhibitor of Urokinase Plasminogen Activator","3.4.21.73","NITRATE ION",
,,,,,"TRANS-4-AMINOMETHYLCYCLOHEXANE-1-CARBOXYLIC ACID",
"6O1S",,"6O1S","Structure of human plasma kallikrein protease domain with inhibitor","3.4.21.34","PHOSPHATE ION",
,,,,,"1,2-ETHANEDIOL",
,,,,,"N-[(6-amino-2,4-dimethylpyridin-3-yl)methyl]-1-({4-[(1H-pyrazol-1-yl)methyl]phenyl}methyl)-1H-pyrazole-4-carboxamide",
"5UBM",,"5UBM","Crystal structure of human C1s in complex with inhibitor gigastasin","3.4.21.42",
,,,,"3.4.21.42",
,,,,,
"5QQP","NR7","5QQP","FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(5E,8S)-8-[(4S)-4-(3-chlorophenyl)-2-oxopiperidin-1-yl]-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate","3.4.21.27","methyl [(5E,8S)-8-[(4S)-4-(3-chlorophenyl)-2-oxopiperidin-1-yl]-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"5QQO","NRJ","5QQO","FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(5E,8S)-8-[(6R)-6-(3-chlorophenyl)-2-oxo-1,3-oxazinan-3-yl]-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate","3.4.21.27","methyl [(5E,8S)-8-[(6R)-6-(3-chlorophenyl)-2-oxo-1,3-oxazinan-3-yl]-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate",
,,,,"3.4.21.27","SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"5QTT","QEY","5QTT","FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(3R,7S)-7-{[5-amino-1-(3-chloro-2-fluorophenyl)-1H-pyrazole-4-carbonyl]amino}-3-methyl-2-oxo-2,3,4,5,6,7-hexahydro-1H-12,8-(metheno)-1,9-benzodiazacyclotetradecin-15-yl]carbamate","3.4.21.27","methyl [(3R,7S)-7-{[5-amino-1-(3-chloro-2-fluorophenyl)-1H-pyrazole-4-carbonyl]amino}-3-methyl-2-oxo-2,3,4,5,6,7-hexahydro-1H-12,8-(metheno)-1,9-benzodiazacyclotetradecin-15-yl]carbamate",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"5QTW",,"5QTW","FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-14-[(methoxycarbonyl)amino]-2,3,4,5,6,7-hexahydro-1H-8,11-epimino-1,9-benzodiazacyclotridecine-2-carboxylate","3.4.21.27","methyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-14-[(methoxycarbonyl)amino]-2,3,4,5,6,7-hexahydro-1H-8,11-epimino-1,9-benzodiazacyclotridecine-2-carboxylate",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
"5QTV",,"5QTV","FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-2-(trifluoromethyl)-2,3,4,5,6,7-hexahydro-1H-8,11-epimino-1,9-benzodiazacyclotridecin-14-yl]carbamate","3.4.21.27","methyl [(2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-2-(trifluoromethyl)-2,3,4,5,6,7-hexahydro-1H-8,11-epimino-1,9-benzodiazacyclotridecin-14-yl]carbamate",
,,,,,"SULFATE ION",
,,,,,"1,2-ETHANEDIOL",
